[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fbqxyig8ktovixGupAVwP56SdnjxvDh8jDlIxRll6rPQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":35,"phaseBuckets":46,"rows":53},"Organon and Co",[4],505,false,2,297,1737417,15,[13,16,19,22,25,27,30,32],{"name":14,"count":15},"Hypercholesterolemia",85,{"name":17,"count":18},"Asthma",55,{"name":20,"count":21},"Seasonal Allergic Rhinitis",25,{"name":23,"count":24},"Contraception",23,{"name":26,"count":24},"Hypertension",{"name":28,"count":29},"Schizophrenia",19,{"name":31,"count":11},"Allergic Rhinitis",{"name":33,"count":34},"Rhinitis, Allergic, Seasonal",12,[36,41],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT05172726","Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects","2026-10","tapinarof cream, 1%",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT07265479","A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to \u003C 24 Months With Atopic Dermatitis","2028-01","Tapinarof cream, 1%",[47,48,49,50,51,52],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[54,147,195,411,596,726,826,920,1012,1101,1188,1249,1325,1365,1413,1443,1491,1547,1587,1613,1648,1690,1716,1758,1789,1821,1843,1877,1906,1938,1973,2008,2030,2059,2077,2095,2113,2131,2149,2167,2185,2203,2221,2245,2269,2287,2305,2331,2349,2367,2385,2408,2426,2444,2462,2487,2505,2526,2551,2569,2587,2605,2629,2653,2671,2695,2713,2737,2755,2777,2802,2829,2847,2871,2889,2912,2938,2956,2974,3000,3018,3041,3059,3082,3107,3132,3156,3179,3197,3222,3240,3258,3276,3294,3312,3334,3358,3376,3394,3412,3503,3588,3666,3743,3809,3858,3905,3964,3998,4028,4078,4112,4146,4172,4214,4240,4266,4299,4325,4368,4410,4444,4474,4501,4529,4564,4597,4619,4641,4670,4710,4732,4754,4781,4803,4825,4862,4894,4916,4950,4982,5010,5032,5067,5089,5111,5145,5167,5208,5235,5269,5291,5313,5331,5349,5367,5385,5403,5421,5445,5471,5492,5516,5534,5558,5576,5594,5612,5630,5655,5673,5697,5715,5733,5751,5769,5787,5805,5823,5846,5873,5891,5916,5938,5960,5989,6007,6025,6043,6061,6079,6097,6121,6139,6157,6181,6203,6221,6239,6263,6281,6305,6323,6341,6359,6384,6402,6424,6442,6460,6478,6496,6518,6536,6560,6578,6599,6624,6642,6664,6682,6706,6724,6750,6768,6791,6809,6833,6857,6875,6898,6916,6943,6961,6979,7003,7025,7049,7067,7102,7120,7138,7156,7174,7192,7210,7228,7246,7264,7282,7300,7330,7348,7366,7391,7416,7434,7452,7470,7493,7511,7536,7554,7572,7590,7608,7626,7644,7662,7680,7698,7716,7737,7755,7773,7798,7816,7834,7857,7875,7897,7915,7937,7955,7977,8001,8026,8044,8068,8086,8104,8122,8147,8165,8183,8209,8227,8245,8263,8281,8299,8324,8342,8363,8388,8411,8433,8451,8469,8487,8509,8534,8552,8570,8594,8612,8630,8648,8666,8684,8702,8720,8738,8756,8774,8792,8818,8836,8858,8876,8901,8919,8947,8965,8983,9001,9019,9042,9060,9078,9102,9128,9146,9164,9182,9206,9224,9248,9266,9284,9309,9327,9345,9367,9385,9408,9426,9449,9473,9498,9516,9534,9552,9585,9612,9637,9655,9679,9701,9719,9745,9763,9781,9799,9817,9835,9853,9875,9897,9924,9942,9960,9978,10004,10022,10040,10065,10088,10111,10129,10147,10171,10189,10214,10232,10256,10274,10292,10310,10340,10358,10376,10394,10412,10430,10456,10474,10492,10513,10541,10559,10577,10595,10613,10631,10649,10676,10694,10712,10730,10756,10781,10799,10817,10835,10856,10874,10892,10910,10928,10946,10969,10987,11010,11028,11046,11064,11090,11108,11126,11144,11162,11180,11203,11225,11484,11703,11835,12050,12205,12279,12407,12493,12572,12637,12687,12744,12790,12824,12857,12891,12917,12943,12978,13021,13043,13068,13090,13112,13134,13156,13181,13203,13225,13247,13269,13287,13305,13327,13349,13372,13390,13408,13426,13444,13462,13480,13498,13516,13534,13552,13570,13588,13606,13624,13642,13660,13678,13696,13714,13732,13750,13768,13790,13812,13834,13856,13880,13898,13920,13942],{"intervention":45,"totalTrials":55,"cells":56},8,{"EARLY_PHASE1":57,"PHASE1":60,"PHASE2":62,"PHASE3":85,"PHASE4":143,"NA":145},{"trials":58,"activeCount":59},[],0,{"trials":61,"activeCount":59},[],{"trials":63,"activeCount":59},[64,75],{"nctId":65,"briefTitle":66,"status":67,"phases":68,"primaryCompletion":69,"completion":69,"start":70,"enrollment":71,"conditions":72,"interventions":74},"NCT04042103","Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis","COMPLETED",[49],"2020-01-09","2019-07-23",21,[73],"Plaque Psoriasis",[45],{"nctId":76,"briefTitle":77,"status":67,"phases":78,"primaryCompletion":79,"completion":79,"start":80,"enrollment":81,"conditions":82,"interventions":84},"NCT05186805","Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis",[49],"2022-08-24","2021-11-15",36,[83],"Atopic Dermatitis",[45],{"trials":86,"activeCount":8,"soonestReadout":39},[87,97,104,113,124,135],{"nctId":88,"briefTitle":89,"status":67,"phases":90,"primaryCompletion":91,"completion":92,"start":93,"enrollment":94,"conditions":95,"interventions":96},"NCT05142774","Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis",[50],"2024-02-29","2024-03-07","2021-10-28",728,[83],[45],{"nctId":37,"briefTitle":38,"status":98,"phases":99,"primaryCompletion":39,"completion":39,"start":100,"enrollment":101,"conditions":102,"interventions":103},"ACTIVE_NOT_RECRUITING",[50],"2021-12-02",58,[73],[40],{"nctId":105,"briefTitle":106,"status":67,"phases":107,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":112},"NCT04053387","Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)",[50],"2021-04-06","2019-08-13",763,[73],[40],{"nctId":114,"briefTitle":115,"status":67,"phases":116,"primaryCompletion":117,"completion":118,"start":119,"enrollment":120,"conditions":121,"interventions":122},"NCT05014568","Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults",[50],"2023-03-30","2023-04-07","2021-09-01",407,[83],[40,123],"Vehicle cream",{"nctId":125,"briefTitle":126,"status":67,"phases":127,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":133},"NCT05032859","Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)",[50],"2023-02-03","2023-02-08","2021-09-23",406,[83],[40,134],"vehicle cream",{"nctId":42,"briefTitle":43,"status":136,"phases":137,"primaryCompletion":44,"completion":44,"start":138,"enrollment":139,"conditions":140,"interventions":141},"RECRUITING",[50],"2025-12-29",180,[83],[45,142],"Vehicle Cream",{"trials":144,"activeCount":59},[],{"trials":146,"activeCount":59},[],{"intervention":142,"totalTrials":148,"cells":149},5,{"EARLY_PHASE1":150,"PHASE1":152,"PHASE2":154,"PHASE3":156,"PHASE4":191,"NA":193},{"trials":151,"activeCount":59},[],{"trials":153,"activeCount":59},[],{"trials":155,"activeCount":59},[],{"trials":157,"activeCount":190,"soonestReadout":44},[158,169,173,177,186],{"nctId":159,"briefTitle":160,"status":67,"phases":161,"primaryCompletion":162,"completion":163,"start":164,"enrollment":165,"conditions":166,"interventions":167},"NCT03983980","Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)",[50],"2020-05-13","2020-05-29","2019-06-06",515,[73],[168,142],"Tapinarof",{"nctId":114,"briefTitle":115,"status":67,"phases":170,"primaryCompletion":117,"completion":118,"start":119,"enrollment":120,"conditions":171,"interventions":172},[50],[83],[40,123],{"nctId":125,"briefTitle":126,"status":67,"phases":174,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":175,"interventions":176},[50],[83],[40,134],{"nctId":178,"briefTitle":179,"status":67,"phases":180,"primaryCompletion":181,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":185},"NCT03956355","Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)",[50],"2020-05-26","2019-05-21",510,[73],[168,142],{"nctId":42,"briefTitle":43,"status":136,"phases":187,"primaryCompletion":44,"completion":44,"start":138,"enrollment":139,"conditions":188,"interventions":189},[50],[83],[45,142],1,{"trials":192,"activeCount":59},[],{"trials":194,"activeCount":59},[],{"intervention":196,"totalTrials":71,"cells":197},"Mometasone furoate nasal spray",{"EARLY_PHASE1":198,"PHASE1":200,"PHASE2":202,"PHASE3":217,"PHASE4":342,"NA":409},{"trials":199,"activeCount":59},[],{"trials":201,"activeCount":59},[],{"trials":203,"activeCount":59},[204],{"nctId":205,"briefTitle":206,"status":67,"phases":207,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":213},"NCT00750750","Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Study P02683)",[49],"2003-09-01","2003-01-01",981,[212],"Acute Rhinosinusitis",[214,215,216],"mometasone furoate nasal spray","MFNS","Amoxicillin",{"trials":218,"activeCount":59},[219,230,240,249,259,270,279,288,297,308,317,326,333],{"nctId":220,"briefTitle":221,"status":67,"phases":222,"primaryCompletion":223,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":228},"NCT03855228","Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)",[50],"1995-08-07","1995-03-01",704,[227],"Rhinitis, Allergic",[196,229],"Loratadine",{"nctId":231,"briefTitle":232,"status":67,"phases":233,"primaryCompletion":234,"completion":235,"start":236,"enrollment":237,"conditions":238,"interventions":239},"NCT03861559","Onset of Action of Mometasone Furoate (MK-0887\u002FSCH 032088) Nasal Spray Compared With Placebo in Seasonal Allergic Rhinitis (C93-184)",[50],"1994-06-27","1994-07-07","1994-03-30",201,[33],[214],{"nctId":241,"briefTitle":242,"status":67,"phases":243,"primaryCompletion":244,"completion":245,"start":246,"enrollment":210,"conditions":247,"interventions":248},"NCT00751075","Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Phase 3 Study)(Study P02692)",[50],"2004-05-06","2004-06-22","2003-12-01",[212],[214,215,216],{"nctId":250,"briefTitle":251,"status":67,"phases":252,"primaryCompletion":253,"completion":253,"start":208,"enrollment":254,"conditions":255,"interventions":257},"NCT00731185","Mometasone Furoate Nasal Spray for Treatment of Nasal Polyposis After Surgery (Study P03218)",[50],"2005-09-01",162,[256],"Nasal Polyps",[258],"Mometasone Furoate Nasal Spray",{"nctId":260,"briefTitle":261,"status":67,"phases":262,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":266,"interventions":268},"NCT00552032","Efficacy and Safety of Mometasone Furoate Nasal Spray in Children With Adenoid Hypertrophy. SNORE Study (P05155)",[50],"2010-01-01","2007-08-01",132,[267],"Adenoids Hypertrophy",[269],"Mometasone Furoate nasal spray",{"nctId":271,"briefTitle":272,"status":67,"phases":273,"primaryCompletion":274,"completion":274,"start":275,"enrollment":276,"conditions":277,"interventions":278},"NCT00732381","Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05529)",[50],"2008-11","2008-08",351,[31],[196],{"nctId":280,"briefTitle":281,"status":67,"phases":282,"primaryCompletion":283,"completion":283,"start":284,"enrollment":285,"conditions":286,"interventions":287},"NCT00468312","Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis (Study P05106)(COMPLETED)",[50],"2007-07","2007-03",429,[20],[196],{"nctId":289,"briefTitle":290,"status":67,"phases":291,"primaryCompletion":292,"completion":292,"start":293,"enrollment":294,"conditions":295,"interventions":296},"NCT00733005","Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05528)(COMPLETED)",[50],"2008-10","2008-07",324,[31],[196],{"nctId":298,"briefTitle":299,"status":67,"phases":300,"primaryCompletion":301,"completion":301,"start":302,"enrollment":303,"conditions":304,"interventions":305},"NCT03879772","Dose-Ranging Study of Mometasone Furoate (MK-0887\u002FSCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)",[50],"1996-07-01","1996-03-12",679,[33],[196,306,307],"Beclomethasone dipropionate nasal spray","Chlorpheniramine maleate syrup",{"nctId":309,"briefTitle":310,"status":67,"phases":311,"primaryCompletion":312,"completion":312,"start":313,"enrollment":314,"conditions":315,"interventions":316},"NCT00378378","Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old (P04292)",[50],"2008-06","2006-07",127,[256],[258],{"nctId":318,"briefTitle":319,"status":67,"phases":320,"primaryCompletion":321,"completion":321,"start":322,"enrollment":323,"conditions":324,"interventions":325},"NCT01386125","A Study of the Effectiveness and Safety of Mometasone Furoate Nasal Spray (MFNS, SCH 032088) for the Treatment of Nasal Polyps (P05604)",[50],"2013-02","2011-06",748,[256],[258],{"nctId":327,"briefTitle":328,"status":67,"phases":329,"primaryCompletion":292,"completion":292,"start":275,"enrollment":330,"conditions":331,"interventions":332},"NCT00728416","Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05583)",[50],333,[31],[196],{"nctId":334,"briefTitle":335,"status":67,"phases":336,"primaryCompletion":337,"completion":337,"start":338,"enrollment":339,"conditions":340,"interventions":341},"NCT00599027","An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma",[50],"2009-05","2008-05",51,[31,17],[196],{"trials":343,"activeCount":59},[344,355,364,372,382,388,398],{"nctId":345,"briefTitle":346,"status":347,"phases":348,"primaryCompletion":349,"completion":349,"start":350,"enrollment":59,"conditions":351,"interventions":354},"NCT00553891","Placebo-controlled Trial With Nasonex for Nasal Obstruction Secondary to Adenoids Hypertrophy in Children (P04367)(TERMINATED)","WITHDRAWN",[51],"2009-10","2006-05",[352,267,353],"Nasal Obstruction","Adenoidectomy",[214],{"nctId":356,"briefTitle":357,"status":67,"phases":358,"primaryCompletion":359,"completion":360,"start":350,"enrollment":361,"conditions":362,"interventions":363},"NCT00358527","Mometasone Furoate on Sleep Disturbances in Subjects With Seasonal Allergic Rhinitis (Study P04608) (COMPLETED)",[51],"2006-10","2006-11",401,[20],[258],{"nctId":365,"briefTitle":366,"status":67,"phases":367,"primaryCompletion":283,"completion":283,"start":368,"enrollment":369,"conditions":370,"interventions":371},"NCT00491504","This Study Contains an Active Drug Treatment Group With Mometasone Furoate Nasal Spray and a Placebo (Dummy) Treatment Group for Seasonal Allergic Rhinitis (SAR). (Study P05073)(COMPLETED)",[51],"2007-02",310,[20],[258],{"nctId":373,"briefTitle":374,"status":67,"phases":375,"primaryCompletion":376,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":380},"NCT00783458","Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented Flonase® Nasal Spray (Study P04208)",[51],"2005-01-01","2004-12-01",100,[31],[258,381],"fluticasone nasal spray",{"nctId":383,"briefTitle":384,"status":67,"phases":385,"primaryCompletion":376,"completion":376,"start":377,"enrollment":378,"conditions":386,"interventions":387},"NCT00817050","Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented Flonase® Nasal Spray (Study P04207)",[51],[31],[258,381],{"nctId":389,"briefTitle":390,"status":67,"phases":391,"primaryCompletion":392,"completion":392,"start":393,"enrollment":394,"conditions":395,"interventions":397},"NCT01098071","Nasonex (Mometasone Furoate Nasal Spray) in Adenoids Hypertrophy in Children (P04367)",[51],"2009-09-01","2008-08-01",34,[396],"Adenoids",[214],{"nctId":399,"briefTitle":400,"status":67,"phases":401,"primaryCompletion":402,"completion":402,"start":350,"enrollment":403,"conditions":404,"interventions":408},"NCT00359216","The Effects of Mometasone Furoate Nasal Spray in Subjects With Sleep-disordered Breathing (SDB) Associated With Perennial Allergic Rhinitis (Study P04726)",[51],"2008-01",30,[405,406,407],"Perennial Allergic Rhinitis","Obstructive Sleep Apnea","Sleep Disorder",[196],{"trials":410,"activeCount":59},[],{"intervention":412,"totalTrials":413,"cells":414},"Atorvastatin",17,{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":419,"PHASE3":421,"PHASE4":545,"NA":594},{"trials":416,"activeCount":59},[],{"trials":418,"activeCount":59},[],{"trials":420,"activeCount":59},[],{"trials":422,"activeCount":59},[423,433,445,457,469,479,489,501,510,520,529,536],{"nctId":424,"briefTitle":425,"status":67,"phases":426,"primaryCompletion":427,"completion":427,"start":428,"enrollment":429,"conditions":430,"interventions":431},"NCT03867318","Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693\u002FMK-0653-030)",[50],"2001-11-16","2000-04-24",621,[14],[412,432],"Ezetimibe",{"nctId":434,"briefTitle":435,"status":67,"phases":436,"primaryCompletion":437,"completion":438,"start":439,"enrollment":440,"conditions":441,"interventions":442},"NCT00276484","To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090)",[50],"2008-02","2008-03","2006-02",579,[14],[443,443,444],"atorvastatin","ezetimibe",{"nctId":446,"briefTitle":447,"status":67,"phases":448,"primaryCompletion":449,"completion":450,"start":451,"enrollment":452,"conditions":453,"interventions":454},"NCT01154036","MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)",[50],"2012-09","2012-10","2010-07",1547,[14],[455,443,456],"ezetimibe 10 mg","Comparator: rosuvastatin",{"nctId":458,"briefTitle":459,"status":67,"phases":460,"primaryCompletion":461,"completion":461,"start":462,"enrollment":463,"conditions":464,"interventions":467},"NCT00650689","Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396)",[50],"2004-12","2003-05",122,[14,465,466],"Atherosclerosis","Coronary Artery Disease",[468,412],"Ezetimibe + Atorvastatin",{"nctId":470,"briefTitle":471,"status":67,"phases":472,"primaryCompletion":473,"completion":473,"start":474,"enrollment":475,"conditions":476,"interventions":477},"NCT03885921","Safety and Tolerability Study of Ezetimibe (SCH 058235\u002FMK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417\u002FMK-0653-019)",[50],"2003-07-08","2000-10-25",44,[14],[432,412,478],"Simvastatin",{"nctId":480,"briefTitle":481,"status":67,"phases":482,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":486,"interventions":488},"NCT03884452","Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)",[50],"2001-05-24","2000-05-03",50,[487],"Familial Hypercholesterolemia",[412,478,432],{"nctId":490,"briefTitle":491,"status":67,"phases":492,"primaryCompletion":493,"completion":494,"start":495,"enrollment":496,"conditions":497,"interventions":498},"NCT03768427","Ezetimibe (EZ)\u002FAtorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)",[50],"2021-03-17","2021-04-01","2019-05-27",454,[14],[499,500,412],"EZ 10 mg\u002FAtor 10 mg","EZ 10 mg\u002FAtor 20 mg",{"nctId":502,"briefTitle":503,"status":67,"phases":504,"primaryCompletion":505,"completion":505,"start":506,"enrollment":507,"conditions":508,"interventions":509},"NCT03882996","A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418\u002FMK-0653-032)",[50],"2003-02-04","2000-10-06",432,[14],[432,412],{"nctId":511,"briefTitle":512,"status":67,"phases":513,"primaryCompletion":514,"completion":514,"start":515,"enrollment":516,"conditions":517,"interventions":518},"NCT01370603","A Study to Evaluate the Effectiveness of Ezetimibe\u002FAtorvastatin 10 mg\u002F40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)",[50],"2012-05","2011-09",328,[14],[412,432,519],"Ezetimibe\u002Fatorvastatin",{"nctId":521,"briefTitle":522,"status":67,"phases":523,"primaryCompletion":524,"completion":524,"start":525,"enrollment":526,"conditions":527,"interventions":528},"NCT00654095","Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)",[50],"2009-06-01","2007-12-01",146,[14],[432,443],{"nctId":530,"briefTitle":531,"status":67,"phases":532,"primaryCompletion":533,"completion":533,"start":515,"enrollment":131,"conditions":534,"interventions":535},"NCT01370590","A Study to Evaluate the Effectiveness of Ezetimibe\u002FAtorvastatin 10 mg\u002F20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)",[50],"2012-04",[14],[412,432,519],{"nctId":537,"briefTitle":538,"status":67,"phases":539,"primaryCompletion":292,"completion":292,"start":540,"enrollment":541,"conditions":542,"interventions":543},"NCT00418834","Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)",[50],"2007-01",1053,[14],[544,443],"ezetimibe and atorvastatin",{"trials":546,"activeCount":59},[547,555,566,576,585],{"nctId":548,"briefTitle":549,"status":67,"phases":550,"primaryCompletion":551,"completion":551,"start":208,"enrollment":552,"conditions":553,"interventions":554},"NCT00653796","Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434)",[51],"2004-08-01",148,[14,465],[468,412],{"nctId":556,"briefTitle":557,"status":67,"phases":558,"primaryCompletion":559,"completion":559,"start":560,"enrollment":561,"conditions":562,"interventions":564},"NCT00871351","Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027)(COMPLETED)",[51],"2010-05-01","2009-02-01",125,[563],"Primary Hypercholesterolemia",[432,412,412,565],"Rosuvastatin",{"nctId":567,"briefTitle":568,"status":67,"phases":569,"primaryCompletion":368,"completion":368,"start":570,"enrollment":571,"conditions":572,"interventions":573},"NCT00166530","EASEGO Study: Doubling of Atorvastatin\u002FSimvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)",[51],"2005-11",367,[465],[574,575,443],"ezetimibe (+) simvastatin","simvastatin",{"nctId":577,"briefTitle":578,"status":67,"phases":579,"primaryCompletion":580,"completion":580,"start":581,"enrollment":582,"conditions":583,"interventions":584},"NCT00166504","Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)",[51],"2007-10","2005-10",203,[14],[574,443],{"nctId":586,"briefTitle":587,"status":67,"phases":588,"primaryCompletion":589,"completion":589,"start":570,"enrollment":590,"conditions":591,"interventions":592},"NCT00157924","Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic Syndrome Patients (0653A-093)",[51],"2007-09",190,[14],[593,443],"simvastatin (+) ezetimibe",{"trials":595,"activeCount":59},[],{"intervention":478,"totalTrials":597,"cells":598},14,{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":603,"PHASE3":605,"PHASE4":674,"NA":724},{"trials":600,"activeCount":59},[],{"trials":602,"activeCount":59},[],{"trials":604,"activeCount":59},[],{"trials":606,"activeCount":59},[607,618,629,638,642,653,657,664],{"nctId":608,"briefTitle":609,"status":610,"phases":611,"primaryCompletion":612,"completion":612,"start":613,"enrollment":614,"conditions":615,"interventions":616},"NCT00651391","Effect of Ezetimibe Plus Simvastatin on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (Study P03336)","TERMINATED",[50],"2004-09-01","2003-10-01",28,[14,465],[617,478],"Ezetimibe + Simvastatin",{"nctId":619,"briefTitle":620,"status":67,"phases":621,"primaryCompletion":622,"completion":622,"start":623,"enrollment":624,"conditions":625,"interventions":627},"NCT00202878","IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe\u002FSimvastatin) vs Simvastatin (P04103)",[50],"2014-09-18","2005-10-17",18144,[14,626],"Myocardial Infarction",[628,575],"ezetimibe\u002Fsimvastatin",{"nctId":630,"briefTitle":631,"status":67,"phases":632,"primaryCompletion":633,"completion":633,"start":634,"enrollment":635,"conditions":636,"interventions":637},"NCT00650819","Comparison of Ezetimibe Plus Simvastatin Versus Ezetimibe or Simvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03757)(COMPLETED)",[50],"2005-02-01","2004-06-01",240,[14],[617,478,432],{"nctId":470,"briefTitle":471,"status":67,"phases":639,"primaryCompletion":473,"completion":473,"start":474,"enrollment":475,"conditions":640,"interventions":641},[50],[14],[432,412,478],{"nctId":643,"briefTitle":644,"status":67,"phases":645,"primaryCompletion":646,"completion":646,"start":647,"enrollment":648,"conditions":649,"interventions":651},"NCT00652301","A Research Study to Evaluate MK0653 (Ezetimibe) and Simvastatin, Given Together and Alone, on Intestinal Absorption of Cholesterol (0653-050)(COMPLETED)",[50],"2004-04","2003-07",40,[650],"Cholesterol",[444,652,575],"Comparator: Placebo",{"nctId":480,"briefTitle":481,"status":67,"phases":654,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":655,"interventions":656},[50],[487],[412,478,432],{"nctId":658,"briefTitle":659,"status":67,"phases":660,"primaryCompletion":524,"completion":524,"start":525,"enrollment":661,"conditions":662,"interventions":663},"NCT00653523","Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)",[50],151,[14],[432,478],{"nctId":665,"briefTitle":666,"status":67,"phases":667,"primaryCompletion":668,"completion":668,"start":669,"enrollment":670,"conditions":671,"interventions":672},"NCT00129402","Effects of Ezetimibe With Simvastatin in the Therapy of Adolescents With HeFH (Study P02579)",[50],"2007-06","2005-08",248,[14],[673,575],"ezetimibe with simvastatin",{"trials":675,"activeCount":59},[676,686,695,705,709,717],{"nctId":677,"briefTitle":678,"status":610,"phases":679,"primaryCompletion":680,"completion":680,"start":681,"enrollment":682,"conditions":683,"interventions":685},"NCT00739050","Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED)",[51],"2008-02-01","2007-09-19",4,[684],"Systemic Lupus Erythematosus",[575,652],{"nctId":687,"briefTitle":688,"status":67,"phases":689,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":693,"interventions":694},"NCT00652444","Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial (0653-151)",[51],"2004-08","2003-09",120,[14],[444,575],{"nctId":696,"briefTitle":697,"status":67,"phases":698,"primaryCompletion":699,"completion":700,"start":633,"enrollment":701,"conditions":702,"interventions":704},"NCT00652717","Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins In Patients After Myocardial Infarction (MI)(0653A-150)",[51],"2005-02-15","2005-08-04",280,[703],"Cardiovascular Disorder",[432,575],{"nctId":567,"briefTitle":568,"status":67,"phases":706,"primaryCompletion":368,"completion":368,"start":570,"enrollment":571,"conditions":707,"interventions":708},[51],[465],[574,575,443],{"nctId":710,"briefTitle":711,"status":67,"phases":712,"primaryCompletion":551,"completion":551,"start":208,"enrollment":713,"conditions":714,"interventions":716},"NCT00653835","Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)",[51],153,[715,465],"Hypercholesterolaemia",[617,478],{"nctId":718,"briefTitle":719,"status":67,"phases":720,"primaryCompletion":612,"completion":612,"start":613,"enrollment":721,"conditions":722,"interventions":723},"NCT00650663","Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377)",[51],247,[14,465],[617,478],{"trials":725,"activeCount":59},[],{"intervention":574,"totalTrials":727,"cells":728},10,{"EARLY_PHASE1":729,"PHASE1":731,"PHASE2":733,"PHASE3":735,"PHASE4":806,"NA":824},{"trials":730,"activeCount":59},[],{"trials":732,"activeCount":59},[],{"trials":734,"activeCount":59},[],{"trials":736,"activeCount":59},[737,748,756,765,775,785,797],{"nctId":738,"briefTitle":739,"status":67,"phases":740,"primaryCompletion":741,"completion":741,"start":742,"enrollment":743,"conditions":744,"interventions":747},"NCT00093899","A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED)",[50],"2005-09","2004-11",611,[745,14,746],"Hyperlipidemia","Hypertriglyceridemia",[574],{"nctId":749,"briefTitle":750,"status":67,"phases":751,"primaryCompletion":312,"completion":312,"start":284,"enrollment":752,"conditions":753,"interventions":754},"NCT00462748","A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121)",[50],786,[14],[574,755,456],"Comparator: atorvastatin",{"nctId":757,"briefTitle":758,"status":67,"phases":759,"primaryCompletion":760,"completion":760,"start":761,"enrollment":762,"conditions":763,"interventions":764},"NCT00651560","Vytorin As Strategy To Reduce Dislipidemia In Adults (0653A-148)",[50],"2005-12-23","2005-11-01",167,[745],[574],{"nctId":766,"briefTitle":767,"status":67,"phases":768,"primaryCompletion":769,"completion":769,"start":770,"enrollment":771,"conditions":772,"interventions":774},"NCT00092677","An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)",[50],"2008-04","2001-01",1873,[773],"Aortic Stenosis",[574,652],{"nctId":776,"briefTitle":777,"status":67,"phases":778,"primaryCompletion":779,"completion":779,"start":780,"enrollment":781,"conditions":782,"interventions":783},"NCT00479713","A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe\u002FSimvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)",[50],"2008-03-01","2007-02-01",618,[14],[574,784,652,652],"Comparator : rosuvastatin calcium",{"nctId":786,"briefTitle":787,"status":67,"phases":788,"primaryCompletion":789,"completion":789,"start":790,"enrollment":791,"conditions":792,"interventions":794},"NCT00862251","Ezetimibe\u002FSimvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)",[50],"2011-03","2009-04",808,[703,793],"Diabetes Mellitus",[574,795,565,796],"simvastatin 40 mg or atorvastatin 20 mg","atorvastatin 10 mg or simvastatin 20 mg",{"nctId":798,"briefTitle":799,"status":67,"phases":800,"primaryCompletion":293,"completion":293,"start":540,"enrollment":801,"conditions":802,"interventions":804},"NCT00409773","Ezetimibe\u002FSimvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)",[50],1143,[14,803],"Metabolic Syndrome",[574,805,652],"Comparator: atorvastatin calcium",{"trials":807,"activeCount":59},[808,816,820],{"nctId":809,"briefTitle":810,"status":67,"phases":811,"primaryCompletion":812,"completion":812,"start":264,"enrollment":813,"conditions":814,"interventions":815},"NCT00654628","Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED)",[51],"2009-07-01",173,[14],[574],{"nctId":567,"briefTitle":568,"status":67,"phases":817,"primaryCompletion":368,"completion":368,"start":570,"enrollment":571,"conditions":818,"interventions":819},[51],[465],[574,575,443],{"nctId":577,"briefTitle":578,"status":67,"phases":821,"primaryCompletion":580,"completion":580,"start":581,"enrollment":582,"conditions":822,"interventions":823},[51],[14],[574,443],{"trials":825,"activeCount":59},[],{"intervention":827,"totalTrials":828,"cells":829},"Desloratadine 5 mg",9,{"EARLY_PHASE1":830,"PHASE1":832,"PHASE2":834,"PHASE3":836,"PHASE4":869,"NA":918},{"trials":831,"activeCount":59},[],{"trials":833,"activeCount":59},[],{"trials":835,"activeCount":59},[],{"trials":837,"activeCount":59},[838,851,860],{"nctId":839,"briefTitle":840,"status":67,"phases":841,"primaryCompletion":842,"completion":843,"start":844,"enrollment":845,"conditions":846,"interventions":850},"NCT01916980","Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema\u002FDermatitis and Dermal Pruritus (MK-4117-202)",[50],"2014-03-08","2014-03-22","2013-08-27",94,[847,848,849],"Eczema","Dermatitis","Dermal Pruritus",[827],{"nctId":852,"briefTitle":853,"status":67,"phases":854,"primaryCompletion":855,"completion":855,"start":856,"enrollment":857,"conditions":858,"interventions":859},"NCT02320396","Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Seasonal Allergic Rhinitis (MK-4117-204)",[50],"2015-04-27","2015-01-09",449,[20],[827],{"nctId":861,"briefTitle":862,"status":67,"phases":863,"primaryCompletion":864,"completion":864,"start":865,"enrollment":866,"conditions":867,"interventions":868},"NCT01918033","A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200)",[50],"2014-01-26","2013-08-20",608,[405],[827],{"trials":870,"activeCount":59},[871,879,888,896,902,911],{"nctId":872,"briefTitle":873,"status":67,"phases":874,"primaryCompletion":647,"completion":647,"start":875,"enrollment":463,"conditions":876,"interventions":877},"NCT00794495","Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181)",[51],"2002-12",[20,405],[827,878],"Cetirizine",{"nctId":880,"briefTitle":881,"status":67,"phases":882,"primaryCompletion":462,"completion":462,"start":883,"enrollment":463,"conditions":884,"interventions":885},"NCT00794248","Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03179)",[51],"2002-11",[20],[886,887],"desloratadine 5 mg","fexofenadine",{"nctId":889,"briefTitle":890,"status":67,"phases":891,"primaryCompletion":892,"completion":892,"start":875,"enrollment":893,"conditions":894,"interventions":895},"NCT00794599","Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03182)",[51],"2003-08",118,[20,405],[827,878],{"nctId":897,"briefTitle":898,"status":67,"phases":899,"primaryCompletion":647,"completion":647,"start":883,"enrollment":893,"conditions":900,"interventions":901},"NCT00794768","Preference for Clarinex Tablets vs Allegra Tablets in Patients With Seasonal Allergies (P03178)",[51],[20],[886,887],{"nctId":903,"briefTitle":904,"status":67,"phases":905,"primaryCompletion":906,"completion":906,"start":907,"enrollment":908,"conditions":909,"interventions":910},"NCT00783133","Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03177)",[51],"2003-06-01","2002-11-01",131,[20],[827,887],{"nctId":912,"briefTitle":913,"status":67,"phases":914,"primaryCompletion":462,"completion":462,"start":875,"enrollment":915,"conditions":916,"interventions":917},"NCT00794846","Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03180)",[51],124,[20,405],[827,878],{"trials":919,"activeCount":59},[],{"intervention":921,"totalTrials":55,"cells":922},"losartan potassium",{"EARLY_PHASE1":923,"PHASE1":925,"PHASE2":948,"PHASE3":950,"PHASE4":991,"NA":1010},{"trials":924,"activeCount":59},[],{"trials":926,"activeCount":59},[927,937],{"nctId":928,"briefTitle":929,"status":67,"phases":930,"primaryCompletion":931,"completion":932,"start":646,"enrollment":933,"conditions":934,"interventions":935},"NCT00953680","Bioequivalence of Losartan and Hydrochlorothiazide (HCTZ) Combination Tablet and Coadministration of Its Components (0954A-306)",[48],"2004-05","2004-07",77,[26],[921,921,936],"hydrochlorothiazide",{"nctId":938,"briefTitle":939,"status":67,"phases":940,"primaryCompletion":941,"completion":941,"start":942,"enrollment":943,"conditions":944,"interventions":945},"NCT00943852","The Effect of Losartan and Losartan Plus Isosorbide Mononitrate on Central Blood Pressure Measurements (0954-317)",[48],"2006-12","2006-08",13,[26],[921,946,947,947,652],"Comparator: isosorbide mononitrate","Comparator: losartan + ISMN",{"trials":949,"activeCount":59},[],{"trials":951,"activeCount":59},[952,961,968,982],{"nctId":953,"briefTitle":954,"status":67,"phases":955,"primaryCompletion":956,"completion":956,"start":957,"enrollment":958,"conditions":959,"interventions":960},"NCT00756938","Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337)",[50],"2012-08-14","2009-03-01",101,[26],[921],{"nctId":962,"briefTitle":963,"status":67,"phases":964,"primaryCompletion":812,"completion":263,"start":680,"enrollment":965,"conditions":966,"interventions":967},"NCT00739674","SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)",[50],992,[26],[921],{"nctId":969,"briefTitle":970,"status":67,"phases":971,"primaryCompletion":972,"completion":973,"start":974,"enrollment":975,"conditions":976,"interventions":978},"NCT00568178","An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))",[50],"2008-09-01","2011-03-01","2007-06-01",306,[977],"Proteinuria",[979,980,981],"Losartan Potassium","Comparator: amlodipine besylate","Enalapril Maleate",{"nctId":983,"briefTitle":984,"status":610,"phases":985,"primaryCompletion":986,"completion":986,"start":987,"enrollment":648,"conditions":988,"interventions":989},"NCT00447603","A Study of Losartan Compared to Losartan\u002FHCTZ in Pediatric Patients With Hypertension (0954A-327)",[50],"2007-10-22","2007-05-24",[26],[990,921],"hydrochlorothiazide (+) losartan potassium",{"trials":992,"activeCount":59},[993,1002],{"nctId":994,"briefTitle":995,"status":67,"phases":996,"primaryCompletion":392,"completion":392,"start":680,"enrollment":237,"conditions":997,"interventions":998},"NCT00496834","LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)",[51],[26],[921,999,1000,1001],"Comparator: carvedilol","Comparator: losartan","Comparator: carvedilol (+) hydrochlorothiazide",{"nctId":1003,"briefTitle":1004,"status":67,"phases":1005,"primaryCompletion":376,"completion":376,"start":1006,"enrollment":571,"conditions":1007,"interventions":1009},"NCT00140907","ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)",[51],"2000-03-14",[1008],"High Blood Pressure",[921,652],{"trials":1011,"activeCount":59},[],{"intervention":755,"totalTrials":55,"cells":1013},{"EARLY_PHASE1":1014,"PHASE1":1016,"PHASE2":1018,"PHASE3":1020,"PHASE4":1089,"NA":1099},{"trials":1015,"activeCount":59},[],{"trials":1017,"activeCount":59},[],{"trials":1019,"activeCount":59},[],{"trials":1021,"activeCount":59},[1022,1026,1040,1049,1061,1071,1078],{"nctId":749,"briefTitle":750,"status":67,"phases":1023,"primaryCompletion":312,"completion":312,"start":284,"enrollment":752,"conditions":1024,"interventions":1025},[50],[14],[574,755,456],{"nctId":1027,"briefTitle":1028,"status":67,"phases":1029,"primaryCompletion":1030,"completion":1031,"start":1032,"enrollment":1033,"conditions":1034,"interventions":1037},"NCT00090168","Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED)",[50],"2004-10-20","2004-11-10","2004-01-27",435,[14,1035,1036],"Atherosclerotic Disease","Coronary Disease",[1038,755,1039],"MK0653A , ezetimibe (+) simvastatin","Duration of Treatment: 6 weeks",{"nctId":1041,"briefTitle":1042,"status":67,"phases":1043,"primaryCompletion":402,"completion":402,"start":439,"enrollment":1044,"conditions":1045,"interventions":1046},"NCT00276458","To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)",[50],196,[14],[755,652,1047,1048],"Comparator: ezetimibe","Comparator: Placebo.",{"nctId":1050,"briefTitle":1051,"status":67,"phases":1052,"primaryCompletion":974,"completion":974,"start":376,"enrollment":1053,"conditions":1054,"interventions":1055},"NCT00132717","A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)",[50],450,[14],[1056,755,1057,1058,1059,456,1060],"MK0653A","Comparator: fluvastatin","Comparator: lovastatin","Comparator: pravastatin","Comparator: simvastatin",{"nctId":1062,"briefTitle":1063,"status":67,"phases":1064,"primaryCompletion":1065,"completion":1065,"start":1066,"enrollment":1067,"conditions":1068,"interventions":1069},"NCT00092690","MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)",[50],"2004-03","2003-06",1902,[14],[1070,755],"MK0653A, ezetimibe (+) simvastatin",{"nctId":1072,"briefTitle":1073,"status":67,"phases":1074,"primaryCompletion":275,"completion":275,"start":283,"enrollment":1075,"conditions":1076,"interventions":1077},"NCT00496730","A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10\u002F20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)",[50],256,[14],[593,755],{"nctId":1079,"briefTitle":1080,"status":67,"phases":1081,"primaryCompletion":1082,"completion":1082,"start":1083,"enrollment":1084,"conditions":1085,"interventions":1087},"NCT00110435","A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)",[50],"2005-12","2005-05",1229,[1086,14],"Type 2 Diabetes Mellitus",[1070,1088,755],"Duration of Treatment: 4 wk placebo run in then 6 wk active",{"trials":1090,"activeCount":59},[1091],{"nctId":1092,"briefTitle":1093,"status":67,"phases":1094,"primaryCompletion":292,"completion":292,"start":1095,"enrollment":1096,"conditions":1097,"interventions":1098},"NCT00442897","Vytorin (10\u002F20 Or 10\u002F40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)",[51],"2006-09",229,[14],[593,755],{"trials":1100,"activeCount":59},[],{"intervention":1102,"totalTrials":1103,"cells":1104},"tibolone",7,{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1111,"PHASE4":1165,"NA":1186},{"trials":1106,"activeCount":59},[],{"trials":1108,"activeCount":59},[],{"trials":1110,"activeCount":59},[],{"trials":1112,"activeCount":59},[1113,1123,1133,1142,1154],{"nctId":1114,"briefTitle":1115,"status":67,"phases":1116,"primaryCompletion":942,"completion":942,"start":1117,"enrollment":1118,"conditions":1119,"interventions":1121},"NCT00519857","Trial to Evaluate Tibolone in the Treatment of Osteoporosis (P06468)",[50],"2001-07",4534,[1120],"Osteoporosis",[1122],"Tibolone",{"nctId":1124,"briefTitle":1125,"status":67,"phases":1126,"primaryCompletion":580,"completion":580,"start":1127,"enrollment":1128,"conditions":1129,"interventions":1132},"NCT00408863","Livial Intervention Following Breast Cancer; Efficacy, Recurrence and Tolerability Endpoints (LIBERATE)(COMPLETED)(P05885)",[50],"2002-05",3148,[1130,1131],"Breast Cancer","Climacteric Symptoms",[1102],{"nctId":1134,"briefTitle":1135,"status":67,"phases":1136,"primaryCompletion":1137,"completion":1137,"start":1138,"enrollment":1139,"conditions":1140,"interventions":1141},"NCT00725374","A Study to Investigate the Effects of Tibolone (Livial®) on Breast Tissue in Postmenopausal Women With Breast Cancer (Study 32971)(P06469)",[50],"2005-04-15","2002-12-15",102,[1130],[1102],{"nctId":1143,"briefTitle":1144,"status":67,"phases":1145,"primaryCompletion":1146,"completion":1146,"start":1147,"enrollment":1148,"conditions":1149,"interventions":1151},"NCT00745108","Tibolone Endometrium Study (Study 32972)(P06470)",[50],"2005-07-21","2001-10-01",32,[1150],"Postmenopausal Women",[1102,1152,1153],"Tibolone 2.5 mg","CE\u002FMPA",{"nctId":1155,"briefTitle":1156,"status":67,"phases":1157,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":1160,"conditions":1161,"interventions":1163},"NCT00413764","Efficacy of Tibolone Versus Transdermal E2\u002FNETA on Sexual Function in Naturally Postmenopausal Women (P06089)",[50],"2005-11-15","2004-03-23",358,[1162],"Sexual Dysfunction",[1102,1164],"estradiol-norethisterone",{"trials":1166,"activeCount":59},[1167,1176],{"nctId":1168,"briefTitle":1169,"status":67,"phases":1170,"primaryCompletion":699,"completion":699,"start":1171,"enrollment":294,"conditions":1172,"interventions":1174},"NCT00431431","Comparison of Tibolone and Raloxifene on Bone Mineral Density in Osteopenic Postmenopausal Women (P06090)",[51],"2000-07-31",[1173],"Osteopenia",[1102,1175],"raloxifen",{"nctId":1177,"briefTitle":1178,"status":67,"phases":1179,"primaryCompletion":1180,"completion":1180,"start":883,"enrollment":1181,"conditions":1182,"interventions":1184},"NCT00431093","Trial to Compare the Effects of Tibolone (Livial®) and Continuous Combined Low-Dose Estradiol\u002FNoresterone (Activelle®)",[51],"2005-03",570,[1183],"Menopause",[1102,1185],"low-dose estradiol\u002Fnoresterone",{"trials":1187,"activeCount":59},[],{"intervention":878,"totalTrials":1103,"cells":1189},{"EARLY_PHASE1":1190,"PHASE1":1192,"PHASE2":1194,"PHASE3":1196,"PHASE4":1213,"NA":1247},{"trials":1191,"activeCount":59},[],{"trials":1193,"activeCount":59},[],{"trials":1195,"activeCount":59},[],{"trials":1197,"activeCount":59},[1198,1206],{"nctId":1199,"briefTitle":1200,"status":67,"phases":1201,"primaryCompletion":742,"completion":742,"start":742,"enrollment":1202,"conditions":1203,"interventions":1204},"NCT00794378","Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03829)(COMPLETED)",[50],202,[31],[1205,878],"Desloratadine",{"nctId":1207,"briefTitle":1208,"status":67,"phases":1209,"primaryCompletion":742,"completion":742,"start":742,"enrollment":1210,"conditions":1211,"interventions":1212},"NCT00794794","Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03826)",[50],204,[31],[1205,878],{"trials":1214,"activeCount":59},[1215,1219,1229,1233,1237],{"nctId":872,"briefTitle":873,"status":67,"phases":1216,"primaryCompletion":647,"completion":647,"start":875,"enrollment":463,"conditions":1217,"interventions":1218},[51],[20,405],[827,878],{"nctId":1220,"briefTitle":1221,"status":610,"phases":1222,"primaryCompletion":1223,"completion":1223,"start":1224,"enrollment":1225,"conditions":1226,"interventions":1228},"NCT00751166","A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736)",[51],"2005-05-01","2004-03-01",149,[1227],"Urticaria",[1205,878],{"nctId":889,"briefTitle":890,"status":67,"phases":1230,"primaryCompletion":892,"completion":892,"start":875,"enrollment":893,"conditions":1231,"interventions":1232},[51],[20,405],[827,878],{"nctId":912,"briefTitle":913,"status":67,"phases":1234,"primaryCompletion":462,"completion":462,"start":875,"enrollment":915,"conditions":1235,"interventions":1236},[51],[20,405],[827,878],{"nctId":1238,"briefTitle":1239,"status":67,"phases":1240,"primaryCompletion":1241,"completion":1241,"start":244,"enrollment":1242,"conditions":1243,"interventions":1244},"NCT00751218","A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735)",[51],"2005-05-24",174,[1227],[1245,1246],"desloratadine","cetirizine",{"trials":1248,"activeCount":59},[],{"intervention":1250,"totalTrials":1103,"cells":1251},"montelukast",{"EARLY_PHASE1":1252,"PHASE1":1254,"PHASE2":1266,"PHASE3":1268,"PHASE4":1303,"NA":1323},{"trials":1253,"activeCount":59},[],{"trials":1255,"activeCount":59},[1256],{"nctId":1257,"briefTitle":1258,"status":67,"phases":1259,"primaryCompletion":1260,"completion":292,"start":1261,"enrollment":1262,"conditions":1263,"interventions":1264},"NCT00636207","A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) in Participants With Mild or Moderate Asthma (MK-0476-380 AM3)(COMPLETED)",[48],"2008-09","2007-08",46,[17],[1265],"Montelukast",{"trials":1267,"activeCount":59},[],{"trials":1269,"activeCount":59},[1270,1277,1286,1295],{"nctId":1271,"briefTitle":1272,"status":67,"phases":1273,"primaryCompletion":875,"completion":875,"start":770,"enrollment":1274,"conditions":1275,"interventions":1276},"NCT00700661","A Study of MK0476 in the Treatment of Asthma Patients Aged 2-5 Years (0476-907)",[50],500,[17],[1250],{"nctId":1278,"briefTitle":1279,"status":67,"phases":1280,"primaryCompletion":1281,"completion":1281,"start":1282,"enrollment":1283,"conditions":1284,"interventions":1285},"NCT01857063","Study of the Efficacy and Safety of MK-0476 in Japanese Pediatric Participants With Seasonal Allergic Rhinitis (MK-0476-519)",[50],"2013-09-01","2013-06-10",220,[20],[1265],{"nctId":1287,"briefTitle":1288,"status":67,"phases":1289,"primaryCompletion":931,"completion":931,"start":1290,"enrollment":1291,"conditions":1292,"interventions":1294},"NCT00092118","The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265)",[50],"2003-10",1992,[1293],"Rhinitis, Allergic, Perennial",[1265,652],{"nctId":1296,"briefTitle":1297,"status":67,"phases":1298,"primaryCompletion":360,"completion":360,"start":1299,"enrollment":1300,"conditions":1301,"interventions":1302},"NCT00461032","Montelukast Back to School Asthma Study (0476-340)",[50],"2006-06",1162,[17],[1250,652],{"trials":1304,"activeCount":59},[1305,1314],{"nctId":1306,"briefTitle":1307,"status":67,"phases":1308,"primaryCompletion":1309,"completion":1309,"start":906,"enrollment":1310,"conditions":1311,"interventions":1312},"NCT00756418","Montelukast Post-marketing Comparative Study With Theophyline Added to Inhaled Corticosteroid (0476-396)",[51],"2004-08-28",84,[17],[1250,1313],"Theophylline",{"nctId":1315,"briefTitle":1316,"status":67,"phases":1317,"primaryCompletion":349,"completion":349,"start":1095,"enrollment":1318,"conditions":1319,"interventions":1320},"NCT00394355","Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)",[51],566,[17],[1321,1321,1322,1250],"mometasone furoate dry powder inhaler","fluticasone propionate hydrofluoroalkane",{"trials":1324,"activeCount":59},[],{"intervention":887,"totalTrials":148,"cells":1326},{"EARLY_PHASE1":1327,"PHASE1":1329,"PHASE2":1331,"PHASE3":1333,"PHASE4":1335,"NA":1363},{"trials":1328,"activeCount":59},[],{"trials":1330,"activeCount":59},[],{"trials":1332,"activeCount":59},[],{"trials":1334,"activeCount":59},[],{"trials":1336,"activeCount":59},[1337,1341,1345,1349,1356],{"nctId":880,"briefTitle":881,"status":67,"phases":1338,"primaryCompletion":462,"completion":462,"start":883,"enrollment":463,"conditions":1339,"interventions":1340},[51],[20],[886,887],{"nctId":897,"briefTitle":898,"status":67,"phases":1342,"primaryCompletion":647,"completion":647,"start":883,"enrollment":893,"conditions":1343,"interventions":1344},[51],[20],[886,887],{"nctId":903,"briefTitle":904,"status":67,"phases":1346,"primaryCompletion":906,"completion":906,"start":907,"enrollment":908,"conditions":1347,"interventions":1348},[51],[20],[827,887],{"nctId":1350,"briefTitle":1351,"status":67,"phases":1352,"primaryCompletion":1353,"completion":1353,"start":551,"enrollment":94,"conditions":1354,"interventions":1355},"NCT00783146","Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054)",[51],"2004-10-01",[20],[1245,887],{"nctId":1357,"briefTitle":1358,"status":67,"phases":1359,"primaryCompletion":1353,"completion":1353,"start":551,"enrollment":1360,"conditions":1361,"interventions":1362},"NCT00783211","Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED)",[51],722,[20],[1245,887],{"trials":1364,"activeCount":59},[],{"intervention":565,"totalTrials":148,"cells":1366},{"EARLY_PHASE1":1367,"PHASE1":1369,"PHASE2":1379,"PHASE3":1381,"PHASE4":1396,"NA":1411},{"trials":1368,"activeCount":59},[],{"trials":1370,"activeCount":59},[1371],{"nctId":1372,"briefTitle":1373,"status":67,"phases":1374,"primaryCompletion":462,"completion":462,"start":1375,"enrollment":648,"conditions":1376,"interventions":1377},"NCT00651144","Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)",[48],"2003-03",[14,465],[1378,565,432],"Ezetimibe + Rosuvastatin",{"trials":1380,"activeCount":59},[],{"trials":1382,"activeCount":59},[1383,1392],{"nctId":1384,"briefTitle":1385,"status":67,"phases":1386,"primaryCompletion":1387,"completion":1387,"start":1388,"enrollment":1389,"conditions":1390,"interventions":1391},"NCT02748057","A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)",[50],"2017-12-11","2016-05-18",135,[14,487],[432,565],{"nctId":786,"briefTitle":787,"status":67,"phases":1393,"primaryCompletion":789,"completion":789,"start":790,"enrollment":791,"conditions":1394,"interventions":1395},[50],[703,793],[574,795,565,796],{"trials":1397,"activeCount":59},[1398,1402],{"nctId":556,"briefTitle":557,"status":67,"phases":1399,"primaryCompletion":559,"completion":559,"start":560,"enrollment":561,"conditions":1400,"interventions":1401},[51],[563],[432,412,412,565],{"nctId":1403,"briefTitle":1404,"status":610,"phases":1405,"primaryCompletion":1406,"completion":1406,"start":612,"enrollment":1407,"conditions":1408,"interventions":1409},"NCT00651378","Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)",[51],"2005-06-01",87,[14,465,466],[565,468,1410],"Double Atorvastatin",{"trials":1412,"activeCount":59},[],{"intervention":617,"totalTrials":682,"cells":1414},{"EARLY_PHASE1":1415,"PHASE1":1417,"PHASE2":1419,"PHASE3":1421,"PHASE4":1431,"NA":1441},{"trials":1416,"activeCount":59},[],{"trials":1418,"activeCount":59},[],{"trials":1420,"activeCount":59},[],{"trials":1422,"activeCount":59},[1423,1427],{"nctId":608,"briefTitle":609,"status":610,"phases":1424,"primaryCompletion":612,"completion":612,"start":613,"enrollment":614,"conditions":1425,"interventions":1426},[50],[14,465],[617,478],{"nctId":630,"briefTitle":631,"status":67,"phases":1428,"primaryCompletion":633,"completion":633,"start":634,"enrollment":635,"conditions":1429,"interventions":1430},[50],[14],[617,478,432],{"trials":1432,"activeCount":59},[1433,1437],{"nctId":710,"briefTitle":711,"status":67,"phases":1434,"primaryCompletion":551,"completion":551,"start":208,"enrollment":713,"conditions":1435,"interventions":1436},[51],[715,465],[617,478],{"nctId":718,"briefTitle":719,"status":67,"phases":1438,"primaryCompletion":612,"completion":612,"start":613,"enrollment":721,"conditions":1439,"interventions":1440},[51],[14,465],[617,478],{"trials":1442,"activeCount":59},[],{"intervention":1444,"totalTrials":682,"cells":1445},"Mometasone",{"EARLY_PHASE1":1446,"PHASE1":1448,"PHASE2":1450,"PHASE3":1452,"PHASE4":1461,"NA":1489},{"trials":1447,"activeCount":59},[],{"trials":1449,"activeCount":59},[],{"trials":1451,"activeCount":59},[],{"trials":1453,"activeCount":59},[1454],{"nctId":1455,"briefTitle":1456,"status":67,"phases":1457,"primaryCompletion":570,"completion":1082,"start":741,"enrollment":276,"conditions":1458,"interventions":1459},"NCT00783224","A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)",[50],[405],[1444,1460],"Fluticasone",{"trials":1462,"activeCount":59},[1463,1471,1479],{"nctId":1464,"briefTitle":1465,"status":67,"phases":1466,"primaryCompletion":376,"completion":376,"start":209,"enrollment":1467,"conditions":1468,"interventions":1470},"NCT00763529","Elocon vs Fluticasone in Localized Psoriasis (P03197)",[51],245,[1469],"Psoriasis",[1444,1460],{"nctId":1472,"briefTitle":1473,"status":67,"phases":1474,"primaryCompletion":1475,"completion":1475,"start":246,"enrollment":1476,"conditions":1477,"interventions":1478},"NCT00783237","Onset of Effect of Mometasone Nasal Spray in Induced Allergic Rhinitis (Study P03431)",[51],"2004-02-21",340,[31],[1444],{"nctId":1480,"briefTitle":1481,"status":67,"phases":1482,"primaryCompletion":1483,"completion":1483,"start":1484,"enrollment":1485,"conditions":1486,"interventions":1487},"NCT00070707","Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)",[51],"2003-11-26","2003-04-03",188,[33,17],[1444,1488],"Albuterol\u002FSalbutamol",{"trials":1490,"activeCount":59},[],{"intervention":1492,"totalTrials":682,"cells":1493},"Atorvastatin 10 mg",{"EARLY_PHASE1":1494,"PHASE1":1496,"PHASE2":1498,"PHASE3":1500,"PHASE4":1535,"NA":1545},{"trials":1495,"activeCount":59},[],{"trials":1497,"activeCount":59},[],{"trials":1499,"activeCount":59},[],{"trials":1501,"activeCount":59},[1502,1515,1524],{"nctId":1503,"briefTitle":1504,"status":67,"phases":1505,"primaryCompletion":1506,"completion":1506,"start":1507,"enrollment":1508,"conditions":1509,"interventions":1510},"NCT03867110","An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)",[50],"2001-07-27","2000-03-06",628,[14],[1511,1492,1512,1513,1514],"Ezetimibe 10 mg","Atorvastatin 20 mg","Atorvastatin 40 mg","Atorvastatin 80 mg",{"nctId":1516,"briefTitle":1517,"status":67,"phases":1518,"primaryCompletion":1519,"completion":1519,"start":1520,"enrollment":1521,"conditions":1522,"interventions":1523},"NCT02550288","A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)",[50],"2016-05-30","2015-09-29",309,[14],[1511,1492],{"nctId":1525,"briefTitle":1526,"status":67,"phases":1527,"primaryCompletion":1528,"completion":1528,"start":1529,"enrollment":1530,"conditions":1531,"interventions":1532},"NCT00535405","A Study to Assess the Cholesterol Lowering Effect of Ezetimibe\u002FSimvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)",[50],"2009-03","2007-11",1289,[14],[1492,1533,1512,1534,1513],"Ezetimibe 10 mg\u002Fsimvastatin 20 mg","Ezetimibe 10 mg\u002Fsimvastatin 40 mg",{"trials":1536,"activeCount":59},[1537],{"nctId":1538,"briefTitle":1539,"status":67,"phases":1540,"primaryCompletion":359,"completion":359,"start":741,"enrollment":1541,"conditions":1542,"interventions":1544},"NCT00319449","Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)",[51],22,[14,1543],"Coronary Arteriosclerosis",[432,1492],{"trials":1546,"activeCount":59},[],{"intervention":1548,"totalTrials":1549,"cells":1550},"5-mg Desloratadine",3,{"EARLY_PHASE1":1551,"PHASE1":1553,"PHASE2":1555,"PHASE3":1557,"PHASE4":1573,"NA":1585},{"trials":1552,"activeCount":59},[],{"trials":1554,"activeCount":59},[],{"trials":1556,"activeCount":59},[],{"trials":1558,"activeCount":59},[1559,1566],{"nctId":1560,"briefTitle":1561,"status":67,"phases":1562,"primaryCompletion":1529,"completion":1529,"start":942,"enrollment":1563,"conditions":1564,"interventions":1565},"NCT00406783","Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)",[50],547,[33,1293],[1548],{"nctId":1567,"briefTitle":1568,"status":67,"phases":1569,"primaryCompletion":769,"completion":769,"start":1095,"enrollment":1570,"conditions":1571,"interventions":1572},"NCT00405964","Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)",[50],716,[31],[1548],{"trials":1574,"activeCount":59},[1575],{"nctId":1576,"briefTitle":1577,"status":67,"phases":1578,"primaryCompletion":790,"completion":790,"start":589,"enrollment":1579,"conditions":1580,"interventions":1582},"NCT00536380","Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849)",[51],314,[1581],"Chronic Idiopathic Urticaria",[1548,1583,1584],"10-mg Desloratadine","20-mg Desloratadine",{"trials":1586,"activeCount":59},[],{"intervention":468,"totalTrials":1549,"cells":1588},{"EARLY_PHASE1":1589,"PHASE1":1591,"PHASE2":1593,"PHASE3":1595,"PHASE4":1601,"NA":1611},{"trials":1590,"activeCount":59},[],{"trials":1592,"activeCount":59},[],{"trials":1594,"activeCount":59},[],{"trials":1596,"activeCount":59},[1597],{"nctId":458,"briefTitle":459,"status":67,"phases":1598,"primaryCompletion":461,"completion":461,"start":462,"enrollment":463,"conditions":1599,"interventions":1600},[50],[14,465,466],[468,412],{"trials":1602,"activeCount":59},[1603,1607],{"nctId":548,"briefTitle":549,"status":67,"phases":1604,"primaryCompletion":551,"completion":551,"start":208,"enrollment":552,"conditions":1605,"interventions":1606},[51],[14,465],[468,412],{"nctId":1403,"briefTitle":1404,"status":610,"phases":1608,"primaryCompletion":1406,"completion":1406,"start":612,"enrollment":1407,"conditions":1609,"interventions":1610},[51],[14,465,466],[565,468,1410],{"trials":1612,"activeCount":59},[],{"intervention":1321,"totalTrials":1549,"cells":1614},{"EARLY_PHASE1":1615,"PHASE1":1617,"PHASE2":1619,"PHASE3":1621,"PHASE4":1631,"NA":1646},{"trials":1616,"activeCount":59},[],{"trials":1618,"activeCount":59},[],{"trials":1620,"activeCount":59},[],{"trials":1622,"activeCount":59},[1623],{"nctId":1624,"briefTitle":1625,"status":67,"phases":1626,"primaryCompletion":1627,"completion":1627,"start":668,"enrollment":139,"conditions":1628,"interventions":1629},"NCT00442117","A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Budesonide DPI in Asthmatics (Study P04880)",[50],"2009-07",[17],[1321,1630],"Budesonide DPI",{"trials":1632,"activeCount":59},[1633,1642],{"nctId":1634,"briefTitle":1635,"status":67,"phases":1636,"primaryCompletion":1528,"completion":1528,"start":1637,"enrollment":1638,"conditions":1639,"interventions":1640},"NCT00521599","A Study of the Equivalent Effectiveness of 400 mcg Mometasone Furoate Using Two Different Dry Powder Inhalers in Moderate Asthmatics (Study P04828)",[51],"2007-05",672,[17],[1641],"Mometasone furoate dry powder inhaler",{"nctId":1315,"briefTitle":1316,"status":67,"phases":1643,"primaryCompletion":349,"completion":349,"start":1095,"enrollment":1318,"conditions":1644,"interventions":1645},[51],[17],[1321,1321,1322,1250],{"trials":1647,"activeCount":59},[],{"intervention":1649,"totalTrials":1549,"cells":1650},"alendronate sodium (+) cholecalciferol",{"EARLY_PHASE1":1651,"PHASE1":1653,"PHASE2":1671,"PHASE3":1673,"PHASE4":1675,"NA":1688},{"trials":1652,"activeCount":59},[],{"trials":1654,"activeCount":59},[1655,1662],{"nctId":1656,"briefTitle":1657,"status":67,"phases":1658,"primaryCompletion":669,"completion":669,"start":931,"enrollment":1659,"conditions":1660,"interventions":1661},"NCT00641771","4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230)",[48],56,[1120],[1649,652],{"nctId":1663,"briefTitle":1664,"status":67,"phases":1665,"primaryCompletion":892,"completion":1666,"start":462,"enrollment":1667,"conditions":1668,"interventions":1669},"NCT00806416","A Study of the Bioequivalence of 70 mg Alendronate and 70 mg Alendronate in Combination With 2800 IU Vitamin D",[48],"2004-01",244,[1120],[1649,1670],"Comparator: alendronate",{"trials":1672,"activeCount":59},[],{"trials":1674,"activeCount":59},[],{"trials":1676,"activeCount":59},[1677],{"nctId":1678,"briefTitle":1679,"status":67,"phases":1680,"primaryCompletion":1681,"completion":1681,"start":1682,"enrollment":1683,"conditions":1684,"interventions":1686},"NCT00729651","Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)",[51],"2009-04-10","2008-03-20",343,[1685],"Osteoporosis Postmenopausal",[1649,1687],"Comparator: Alendronate sodium",{"trials":1689,"activeCount":59},[],{"intervention":593,"totalTrials":1549,"cells":1691},{"EARLY_PHASE1":1692,"PHASE1":1694,"PHASE2":1696,"PHASE3":1698,"PHASE4":1704,"NA":1714},{"trials":1693,"activeCount":59},[],{"trials":1695,"activeCount":59},[],{"trials":1697,"activeCount":59},[],{"trials":1699,"activeCount":59},[1700],{"nctId":1072,"briefTitle":1073,"status":67,"phases":1701,"primaryCompletion":275,"completion":275,"start":283,"enrollment":1075,"conditions":1702,"interventions":1703},[50],[14],[593,755],{"trials":1705,"activeCount":59},[1706,1710],{"nctId":1092,"briefTitle":1093,"status":67,"phases":1707,"primaryCompletion":292,"completion":292,"start":1095,"enrollment":1096,"conditions":1708,"interventions":1709},[51],[14],[593,755],{"nctId":586,"briefTitle":587,"status":67,"phases":1711,"primaryCompletion":589,"completion":589,"start":570,"enrollment":590,"conditions":1712,"interventions":1713},[51],[14],[593,443],{"trials":1715,"activeCount":59},[],{"intervention":1717,"totalTrials":8,"cells":1718},"Prednisone\u002Fprednisolone",{"EARLY_PHASE1":1719,"PHASE1":1721,"PHASE2":1723,"PHASE3":1725,"PHASE4":1740,"NA":1756},{"trials":1720,"activeCount":59},[],{"trials":1722,"activeCount":59},[],{"trials":1724,"activeCount":59},[],{"trials":1726,"activeCount":59},[1727],{"nctId":1728,"briefTitle":1729,"status":67,"phases":1730,"primaryCompletion":1731,"completion":1731,"start":1732,"enrollment":1733,"conditions":1734,"interventions":1735},"NCT02741271","Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)",[50],"2017-12-04","2016-05-11",181,[17],[1736,1737,1736,1738,1739],"MF MDI 100 mcg BID","MF\u002FF MDI 100\u002F10 mcg BID","Albuterol\u002FSalbutamol PRN","Prednisone\u002FPrednisolone",{"trials":1741,"activeCount":59},[1742],{"nctId":1743,"briefTitle":1744,"status":67,"phases":1745,"primaryCompletion":1746,"completion":1746,"start":1747,"enrollment":1748,"conditions":1749,"interventions":1750},"NCT01471340","A Serious Asthma Outcome Study With Mometasone Furoate\u002FFormoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)",[51],"2016-11-30","2012-01-09",11744,[17],[1751,1752,1753,1754,1755,1717],"Mometasone Furoate\u002FFormoterol MDI 100\u002F5 mcg","Mometasone Furoate\u002FFormoterol MDI 200\u002F5 mcg","Mometasone Furoate MDI 100 mcg","Mometasone Furoate MDI 200 mcg","Albuterol 90 mcg \u002Fsalbutamol 100 mcg HFA MDI",{"trials":1757,"activeCount":59},[],{"intervention":1759,"totalTrials":8,"cells":1760},"MK0663, etoricoxib \u002F Duration of Treatment: 4 weeks",{"EARLY_PHASE1":1761,"PHASE1":1763,"PHASE2":1765,"PHASE3":1774,"PHASE4":1776,"NA":1787},{"trials":1762,"activeCount":59},[],{"trials":1764,"activeCount":59},[],{"trials":1766,"activeCount":59},[1767],{"nctId":1768,"briefTitle":1769,"status":347,"phases":1770,"start":742,"enrollment":59,"conditions":1771,"interventions":1773},"NCT00095017","Safety and Efficacy of an Investigational Drug Versus Placebo in the Treatment of Cancer Pain (0663-083)",[49],[1772],"Bone Neoplasms",[1759],{"trials":1775,"activeCount":59},[],{"trials":1777,"activeCount":59},[1778],{"nctId":1779,"briefTitle":1780,"status":67,"phases":1781,"primaryCompletion":1180,"completion":1180,"start":1782,"enrollment":361,"conditions":1783,"interventions":1785},"NCT00090181","Study of MK0663 in Patients With Chronic Low Back Pain (0663-806)(COMPLETED)",[51],"2004-06",[1784],"Chronic Low Back Pain",[1759,1786],"Comparator: diclofenac \u002F Duration of Treatment: 4 weeks",{"trials":1788,"activeCount":59},[],{"intervention":1790,"totalTrials":8,"cells":1791},"levocetirizine",{"EARLY_PHASE1":1792,"PHASE1":1794,"PHASE2":1796,"PHASE3":1798,"PHASE4":1808,"NA":1819},{"trials":1793,"activeCount":59},[],{"trials":1795,"activeCount":59},[],{"trials":1797,"activeCount":59},[],{"trials":1799,"activeCount":59},[1800],{"nctId":1801,"briefTitle":1802,"status":67,"phases":1803,"primaryCompletion":1804,"completion":1804,"start":246,"enrollment":1805,"conditions":1806,"interventions":1807},"NCT00789152","The Effect of Desloratadine and Levocetirizine on Nasal Obstruction (Study P03609)",[50],"2004-05-01",81,[31],[1245,1790],{"trials":1809,"activeCount":59},[1810],{"nctId":1811,"briefTitle":1812,"status":67,"phases":1813,"primaryCompletion":350,"completion":350,"start":439,"enrollment":81,"conditions":1814,"interventions":1816},"NCT00359138","The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441)",[51],[1815],"Hypersensitivity",[1245,1790,1817,1818],"Desloratadine placebo","Levocetirizine placebo",{"trials":1820,"activeCount":59},[],{"intervention":1460,"totalTrials":8,"cells":1822},{"EARLY_PHASE1":1823,"PHASE1":1825,"PHASE2":1827,"PHASE3":1829,"PHASE4":1835,"NA":1841},{"trials":1824,"activeCount":59},[],{"trials":1826,"activeCount":59},[],{"trials":1828,"activeCount":59},[],{"trials":1830,"activeCount":59},[1831],{"nctId":1455,"briefTitle":1456,"status":67,"phases":1832,"primaryCompletion":570,"completion":1082,"start":741,"enrollment":276,"conditions":1833,"interventions":1834},[50],[405],[1444,1460],{"trials":1836,"activeCount":59},[1837],{"nctId":1464,"briefTitle":1465,"status":67,"phases":1838,"primaryCompletion":376,"completion":376,"start":209,"enrollment":1467,"conditions":1839,"interventions":1840},[51],[1469],[1444,1460],{"trials":1842,"activeCount":59},[],{"intervention":1844,"totalTrials":8,"cells":1845},"MK0476, montelukast sodium \u002F Duration of Treatment: 4 Weeks",{"EARLY_PHASE1":1846,"PHASE1":1848,"PHASE2":1850,"PHASE3":1852,"PHASE4":1864,"NA":1875},{"trials":1847,"activeCount":59},[],{"trials":1849,"activeCount":59},[],{"trials":1851,"activeCount":59},[],{"trials":1853,"activeCount":59},[1854],{"nctId":1855,"briefTitle":1856,"status":67,"phases":1857,"primaryCompletion":1858,"completion":1858,"start":1859,"enrollment":1274,"conditions":1860,"interventions":1861},"NCT00092144","Study of an Approved Drug in Patients With Asthma (0476-289)(COMPLETED)",[50],"2004-06-15","2004-02-26",[17],[1862,1863],"MK0476, montelukast sodium \u002F Duration of Treatment: 4 weeks","Comparator: placebo \u002F Duration of Treatment: 4 weeks",{"trials":1865,"activeCount":59},[1866],{"nctId":1867,"briefTitle":1868,"status":67,"phases":1869,"primaryCompletion":1870,"completion":1870,"start":1871,"enrollment":1485,"conditions":1872,"interventions":1873},"NCT00446056","Montelukast Post-Marketing Comparative Study With Ketotifen (0476-379)",[51],"2004-06-16","2003-09-25",[17],[1844,1874],"Comparator: ketotifen \u002F Duration of Treatment: 4 Weeks",{"trials":1876,"activeCount":59},[],{"intervention":1878,"totalTrials":8,"cells":1879},"Ezetimibe\u002Fsimvastatin",{"EARLY_PHASE1":1880,"PHASE1":1882,"PHASE2":1884,"PHASE3":1886,"PHASE4":1892,"NA":1904},{"trials":1881,"activeCount":59},[],{"trials":1883,"activeCount":59},[],{"trials":1885,"activeCount":59},[],{"trials":1887,"activeCount":59},[1888],{"nctId":619,"briefTitle":620,"status":67,"phases":1889,"primaryCompletion":622,"completion":622,"start":623,"enrollment":624,"conditions":1890,"interventions":1891},[50],[14,626],[628,575],{"trials":1893,"activeCount":59},[1894],{"nctId":1895,"briefTitle":1896,"status":347,"phases":1897,"primaryCompletion":1898,"completion":1898,"start":1899,"enrollment":59,"conditions":1900,"interventions":1902},"NCT01587235","A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406)",[51],"2014-05","2013-03",[1901],"Dyslipidemia",[1878,1903],"Other Statin",{"trials":1905,"activeCount":59},[],{"intervention":1907,"totalTrials":8,"cells":1908},"MK0663, Arcoxia, etoricoxib \u002F Duration of Treatment: 3 Days",{"EARLY_PHASE1":1909,"PHASE1":1911,"PHASE2":1913,"PHASE3":1915,"PHASE4":1917,"NA":1936},{"trials":1910,"activeCount":59},[],{"trials":1912,"activeCount":59},[],{"trials":1914,"activeCount":59},[],{"trials":1916,"activeCount":59},[],{"trials":1918,"activeCount":59},[1919,1928],{"nctId":1920,"briefTitle":1921,"status":67,"phases":1922,"primaryCompletion":1083,"completion":1083,"start":1923,"enrollment":1924,"conditions":1925,"interventions":1927},"NCT00380523","Analgesic Treatment Mediated by Arcoxia (0663-093)",[51],"2005-04",237,[1926],"Pain",[1907],{"nctId":1929,"briefTitle":1930,"status":67,"phases":1931,"primaryCompletion":1932,"completion":1932,"start":253,"enrollment":1933,"conditions":1934,"interventions":1935},"NCT00380627","Quality of Life With Arcoxia in Women With Dysmenorrhea (0663-094)",[51],"2006-01-31",337,[1926],[1907],{"trials":1937,"activeCount":59},[],{"intervention":1939,"totalTrials":8,"cells":1940},"MK0476; montelukast sodium\u002FDuration of Treatment: 16 weeks",{"EARLY_PHASE1":1941,"PHASE1":1943,"PHASE2":1945,"PHASE3":1947,"PHASE4":1949,"NA":1971},{"trials":1942,"activeCount":59},[],{"trials":1944,"activeCount":59},[],{"trials":1946,"activeCount":59},[],{"trials":1948,"activeCount":59},[],{"trials":1950,"activeCount":59},[1951,1961],{"nctId":1952,"briefTitle":1953,"status":67,"phases":1954,"primaryCompletion":1955,"completion":1955,"start":1956,"enrollment":1957,"conditions":1958,"interventions":1959},"NCT00157937","A Study to Compare Effectiveness of Montelukast Sodium With Comparator in Mild to Moderate Persistent Asthmatics (0476-329)",[51],"2005-06","2003-02",31,[17,31],[1939,1960],"Comparator: theophylline ER\u002FDuration of Treatment: 16 weeks",{"nctId":1962,"briefTitle":1963,"status":67,"phases":1964,"primaryCompletion":1965,"completion":1965,"start":1966,"enrollment":1967,"conditions":1968,"interventions":1969},"NCT00140946","A Study to Assess the Effect of Montelukast Sodium With Concomitant Administration of Inhaled Budesonide in Asthmatic Patients (0476-075)",[51],"2000-10","1998-03",546,[17],[1939,1970],"Comparator: placebo \u002F Duration of Treatment: 16 weeks",{"trials":1972,"activeCount":59},[],{"intervention":1974,"totalTrials":8,"cells":1975},"Montelukast chewable",{"EARLY_PHASE1":1976,"PHASE1":1978,"PHASE2":1980,"PHASE3":1982,"PHASE4":1994,"NA":2006},{"trials":1977,"activeCount":59},[],{"trials":1979,"activeCount":59},[],{"trials":1981,"activeCount":59},[],{"trials":1983,"activeCount":59},[1984],{"nctId":1985,"briefTitle":1986,"status":67,"phases":1987,"primaryCompletion":1988,"completion":1988,"start":1989,"enrollment":1407,"conditions":1990,"interventions":1991},"NCT01852812","Study of the Safety and Pharmacokinetics of Montelukast (MK-0476) in the Treatment of Japanese Pediatric Participants With Perennial Allergic Rhinitis (MK-0476-520)",[50],"2013-12-24","2013-06-07",[405],[1992,1993],"Montelukast Oral Granules","Montelukast Chewable",{"trials":1995,"activeCount":59},[1996],{"nctId":1997,"briefTitle":1998,"status":67,"phases":1999,"primaryCompletion":1782,"completion":1782,"start":2000,"enrollment":2001,"conditions":2002,"interventions":2004},"NCT00092092","Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma (MK-0476-254)",[51],"2002-10",71,[2003],"Asthma, Bronchial",[1974,2005],"Budesonide inhaler",{"trials":2007,"activeCount":59},[],{"intervention":381,"totalTrials":8,"cells":2009},{"EARLY_PHASE1":2010,"PHASE1":2012,"PHASE2":2014,"PHASE3":2016,"PHASE4":2018,"NA":2028},{"trials":2011,"activeCount":59},[],{"trials":2013,"activeCount":59},[],{"trials":2015,"activeCount":59},[],{"trials":2017,"activeCount":59},[],{"trials":2019,"activeCount":59},[2020,2024],{"nctId":373,"briefTitle":374,"status":67,"phases":2021,"primaryCompletion":376,"completion":376,"start":377,"enrollment":378,"conditions":2022,"interventions":2023},[51],[31],[258,381],{"nctId":383,"briefTitle":384,"status":67,"phases":2025,"primaryCompletion":376,"completion":376,"start":377,"enrollment":378,"conditions":2026,"interventions":2027},[51],[31],[258,381],{"trials":2029,"activeCount":59},[],{"intervention":2031,"totalTrials":8,"cells":2032},"Zyrtec®",{"EARLY_PHASE1":2033,"PHASE1":2035,"PHASE2":2037,"PHASE3":2039,"PHASE4":2041,"NA":2057},{"trials":2034,"activeCount":59},[],{"trials":2036,"activeCount":59},[],{"trials":2038,"activeCount":59},[],{"trials":2040,"activeCount":59},[],{"trials":2042,"activeCount":59},[2043,2050],{"nctId":2044,"briefTitle":2045,"status":67,"phases":2046,"primaryCompletion":581,"completion":581,"start":669,"enrollment":1283,"conditions":2047,"interventions":2049},"NCT00780403","Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications (Study P04573) (Completed)",[51],[2048],"Allergies",[1205,2031],{"nctId":2051,"briefTitle":2052,"status":67,"phases":2053,"primaryCompletion":581,"completion":581,"start":741,"enrollment":2054,"conditions":2055,"interventions":2056},"NCT00779116","Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications (Study P04574)(COMPLETED)",[51],217,[2048],[1205,2031],{"trials":2058,"activeCount":59},[],{"intervention":999,"totalTrials":190,"cells":2060},{"EARLY_PHASE1":2061,"PHASE1":2063,"PHASE2":2065,"PHASE3":2067,"PHASE4":2069,"NA":2075},{"trials":2062,"activeCount":59},[],{"trials":2064,"activeCount":59},[],{"trials":2066,"activeCount":59},[],{"trials":2068,"activeCount":59},[],{"trials":2070,"activeCount":59},[2071],{"nctId":994,"briefTitle":995,"status":67,"phases":2072,"primaryCompletion":392,"completion":392,"start":680,"enrollment":237,"conditions":2073,"interventions":2074},[51],[26],[921,999,1000,1001],{"trials":2076,"activeCount":59},[],{"intervention":1000,"totalTrials":190,"cells":2078},{"EARLY_PHASE1":2079,"PHASE1":2081,"PHASE2":2083,"PHASE3":2085,"PHASE4":2087,"NA":2093},{"trials":2080,"activeCount":59},[],{"trials":2082,"activeCount":59},[],{"trials":2084,"activeCount":59},[],{"trials":2086,"activeCount":59},[],{"trials":2088,"activeCount":59},[2089],{"nctId":994,"briefTitle":995,"status":67,"phases":2090,"primaryCompletion":392,"completion":392,"start":680,"enrollment":237,"conditions":2091,"interventions":2092},[51],[26],[921,999,1000,1001],{"trials":2094,"activeCount":59},[],{"intervention":1001,"totalTrials":190,"cells":2096},{"EARLY_PHASE1":2097,"PHASE1":2099,"PHASE2":2101,"PHASE3":2103,"PHASE4":2105,"NA":2111},{"trials":2098,"activeCount":59},[],{"trials":2100,"activeCount":59},[],{"trials":2102,"activeCount":59},[],{"trials":2104,"activeCount":59},[],{"trials":2106,"activeCount":59},[2107],{"nctId":994,"briefTitle":995,"status":67,"phases":2108,"primaryCompletion":392,"completion":392,"start":680,"enrollment":237,"conditions":2109,"interventions":2110},[51],[26],[921,999,1000,1001],{"trials":2112,"activeCount":59},[],{"intervention":1175,"totalTrials":190,"cells":2114},{"EARLY_PHASE1":2115,"PHASE1":2117,"PHASE2":2119,"PHASE3":2121,"PHASE4":2123,"NA":2129},{"trials":2116,"activeCount":59},[],{"trials":2118,"activeCount":59},[],{"trials":2120,"activeCount":59},[],{"trials":2122,"activeCount":59},[],{"trials":2124,"activeCount":59},[2125],{"nctId":1168,"briefTitle":1169,"status":67,"phases":2126,"primaryCompletion":699,"completion":699,"start":1171,"enrollment":294,"conditions":2127,"interventions":2128},[51],[1173],[1102,1175],{"trials":2130,"activeCount":59},[],{"intervention":1751,"totalTrials":190,"cells":2132},{"EARLY_PHASE1":2133,"PHASE1":2135,"PHASE2":2137,"PHASE3":2139,"PHASE4":2141,"NA":2147},{"trials":2134,"activeCount":59},[],{"trials":2136,"activeCount":59},[],{"trials":2138,"activeCount":59},[],{"trials":2140,"activeCount":59},[],{"trials":2142,"activeCount":59},[2143],{"nctId":1743,"briefTitle":1744,"status":67,"phases":2144,"primaryCompletion":1746,"completion":1746,"start":1747,"enrollment":1748,"conditions":2145,"interventions":2146},[51],[17],[1751,1752,1753,1754,1755,1717],{"trials":2148,"activeCount":59},[],{"intervention":1752,"totalTrials":190,"cells":2150},{"EARLY_PHASE1":2151,"PHASE1":2153,"PHASE2":2155,"PHASE3":2157,"PHASE4":2159,"NA":2165},{"trials":2152,"activeCount":59},[],{"trials":2154,"activeCount":59},[],{"trials":2156,"activeCount":59},[],{"trials":2158,"activeCount":59},[],{"trials":2160,"activeCount":59},[2161],{"nctId":1743,"briefTitle":1744,"status":67,"phases":2162,"primaryCompletion":1746,"completion":1746,"start":1747,"enrollment":1748,"conditions":2163,"interventions":2164},[51],[17],[1751,1752,1753,1754,1755,1717],{"trials":2166,"activeCount":59},[],{"intervention":1753,"totalTrials":190,"cells":2168},{"EARLY_PHASE1":2169,"PHASE1":2171,"PHASE2":2173,"PHASE3":2175,"PHASE4":2177,"NA":2183},{"trials":2170,"activeCount":59},[],{"trials":2172,"activeCount":59},[],{"trials":2174,"activeCount":59},[],{"trials":2176,"activeCount":59},[],{"trials":2178,"activeCount":59},[2179],{"nctId":1743,"briefTitle":1744,"status":67,"phases":2180,"primaryCompletion":1746,"completion":1746,"start":1747,"enrollment":1748,"conditions":2181,"interventions":2182},[51],[17],[1751,1752,1753,1754,1755,1717],{"trials":2184,"activeCount":59},[],{"intervention":1754,"totalTrials":190,"cells":2186},{"EARLY_PHASE1":2187,"PHASE1":2189,"PHASE2":2191,"PHASE3":2193,"PHASE4":2195,"NA":2201},{"trials":2188,"activeCount":59},[],{"trials":2190,"activeCount":59},[],{"trials":2192,"activeCount":59},[],{"trials":2194,"activeCount":59},[],{"trials":2196,"activeCount":59},[2197],{"nctId":1743,"briefTitle":1744,"status":67,"phases":2198,"primaryCompletion":1746,"completion":1746,"start":1747,"enrollment":1748,"conditions":2199,"interventions":2200},[51],[17],[1751,1752,1753,1754,1755,1717],{"trials":2202,"activeCount":59},[],{"intervention":1755,"totalTrials":190,"cells":2204},{"EARLY_PHASE1":2205,"PHASE1":2207,"PHASE2":2209,"PHASE3":2211,"PHASE4":2213,"NA":2219},{"trials":2206,"activeCount":59},[],{"trials":2208,"activeCount":59},[],{"trials":2210,"activeCount":59},[],{"trials":2212,"activeCount":59},[],{"trials":2214,"activeCount":59},[2215],{"nctId":1743,"briefTitle":1744,"status":67,"phases":2216,"primaryCompletion":1746,"completion":1746,"start":1747,"enrollment":1748,"conditions":2217,"interventions":2218},[51],[17],[1751,1752,1753,1754,1755,1717],{"trials":2220,"activeCount":59},[],{"intervention":2222,"totalTrials":190,"cells":2223},"Ethinylestradiol + Etonogestrel Vaginal Ring",{"EARLY_PHASE1":2224,"PHASE1":2226,"PHASE2":2228,"PHASE3":2230,"PHASE4":2232,"NA":2243},{"trials":2225,"activeCount":59},[],{"trials":2227,"activeCount":59},[],{"trials":2229,"activeCount":59},[],{"trials":2231,"activeCount":59},[],{"trials":2233,"activeCount":59},[2234],{"nctId":2235,"briefTitle":2236,"status":67,"phases":2237,"primaryCompletion":2238,"completion":2238,"start":2239,"enrollment":2240,"conditions":2241,"interventions":2242},"NCT01490190","Study of the Use of a Contraceptive Vaginal Ring (NuvaRing) in Normal Daily Practice in Indian Women (P07733)",[51],"2012-12-05","2011-12-26",252,[23],[2222],{"trials":2244,"activeCount":59},[],{"intervention":2246,"totalTrials":190,"cells":2247},"Levonorgestrel (LNG)\u002FEthinylestradiol (EE) oral contraceptive",{"EARLY_PHASE1":2248,"PHASE1":2250,"PHASE2":2252,"PHASE3":2254,"PHASE4":2256,"NA":2267},{"trials":2249,"activeCount":59},[],{"trials":2251,"activeCount":59},[],{"trials":2253,"activeCount":59},[],{"trials":2255,"activeCount":59},[],{"trials":2257,"activeCount":59},[2258],{"nctId":2259,"briefTitle":2260,"status":67,"phases":2261,"primaryCompletion":1782,"completion":1782,"start":1065,"enrollment":2262,"conditions":2263,"interventions":2264},"NCT01044056","A Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30) (Study 34237 (P06650)) (COMPLETED)",[51],24,[23],[2246,2265,2266],"norelgestrominum and ethinylestradiol patch oral contraceptive patch","Nuvaring ™",{"trials":2268,"activeCount":59},[],{"intervention":2265,"totalTrials":190,"cells":2270},{"EARLY_PHASE1":2271,"PHASE1":2273,"PHASE2":2275,"PHASE3":2277,"PHASE4":2279,"NA":2285},{"trials":2272,"activeCount":59},[],{"trials":2274,"activeCount":59},[],{"trials":2276,"activeCount":59},[],{"trials":2278,"activeCount":59},[],{"trials":2280,"activeCount":59},[2281],{"nctId":2259,"briefTitle":2260,"status":67,"phases":2282,"primaryCompletion":1782,"completion":1782,"start":1065,"enrollment":2262,"conditions":2283,"interventions":2284},[51],[23],[2246,2265,2266],{"trials":2286,"activeCount":59},[],{"intervention":2266,"totalTrials":190,"cells":2288},{"EARLY_PHASE1":2289,"PHASE1":2291,"PHASE2":2293,"PHASE3":2295,"PHASE4":2297,"NA":2303},{"trials":2290,"activeCount":59},[],{"trials":2292,"activeCount":59},[],{"trials":2294,"activeCount":59},[],{"trials":2296,"activeCount":59},[],{"trials":2298,"activeCount":59},[2299],{"nctId":2259,"briefTitle":2260,"status":67,"phases":2300,"primaryCompletion":1782,"completion":1782,"start":1065,"enrollment":2262,"conditions":2301,"interventions":2302},[51],[23],[2246,2265,2266],{"trials":2304,"activeCount":59},[],{"intervention":2306,"totalTrials":190,"cells":2307},"MK0954, losartan potassium\u002FDuration of Treatment: 20 weeks",{"EARLY_PHASE1":2308,"PHASE1":2310,"PHASE2":2312,"PHASE3":2314,"PHASE4":2316,"NA":2329},{"trials":2309,"activeCount":59},[],{"trials":2311,"activeCount":59},[],{"trials":2313,"activeCount":59},[],{"trials":2315,"activeCount":59},[],{"trials":2317,"activeCount":59},[2318],{"nctId":2319,"briefTitle":2320,"status":67,"phases":2321,"primaryCompletion":2322,"completion":2322,"start":2323,"enrollment":2324,"conditions":2325,"interventions":2327},"NCT00140985","Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)",[51],"2002-01","2000-02",97,[2326],"Renal Disorder",[2306,2328],"Comparator: amlodipine \u002F Duration of Treatment: 20 weeks",{"trials":2330,"activeCount":59},[],{"intervention":2328,"totalTrials":190,"cells":2332},{"EARLY_PHASE1":2333,"PHASE1":2335,"PHASE2":2337,"PHASE3":2339,"PHASE4":2341,"NA":2347},{"trials":2334,"activeCount":59},[],{"trials":2336,"activeCount":59},[],{"trials":2338,"activeCount":59},[],{"trials":2340,"activeCount":59},[],{"trials":2342,"activeCount":59},[2343],{"nctId":2319,"briefTitle":2320,"status":67,"phases":2344,"primaryCompletion":2322,"completion":2322,"start":2323,"enrollment":2324,"conditions":2345,"interventions":2346},[51],[2326],[2306,2328],{"trials":2348,"activeCount":59},[],{"intervention":1874,"totalTrials":190,"cells":2350},{"EARLY_PHASE1":2351,"PHASE1":2353,"PHASE2":2355,"PHASE3":2357,"PHASE4":2359,"NA":2365},{"trials":2352,"activeCount":59},[],{"trials":2354,"activeCount":59},[],{"trials":2356,"activeCount":59},[],{"trials":2358,"activeCount":59},[],{"trials":2360,"activeCount":59},[2361],{"nctId":1867,"briefTitle":1868,"status":67,"phases":2362,"primaryCompletion":1870,"completion":1870,"start":1871,"enrollment":1485,"conditions":2363,"interventions":2364},[51],[17],[1844,1874],{"trials":2366,"activeCount":59},[],{"intervention":1903,"totalTrials":190,"cells":2368},{"EARLY_PHASE1":2369,"PHASE1":2371,"PHASE2":2373,"PHASE3":2375,"PHASE4":2377,"NA":2383},{"trials":2370,"activeCount":59},[],{"trials":2372,"activeCount":59},[],{"trials":2374,"activeCount":59},[],{"trials":2376,"activeCount":59},[],{"trials":2378,"activeCount":59},[2379],{"nctId":1895,"briefTitle":1896,"status":347,"phases":2380,"primaryCompletion":1898,"completion":1898,"start":1899,"enrollment":59,"conditions":2381,"interventions":2382},[51],[1901],[1878,1903],{"trials":2384,"activeCount":59},[],{"intervention":2386,"totalTrials":190,"cells":2387},"Ezetimibe\u002FSimvastatin 10\u002F20 mg",{"EARLY_PHASE1":2388,"PHASE1":2390,"PHASE2":2392,"PHASE3":2394,"PHASE4":2396,"NA":2406},{"trials":2389,"activeCount":59},[],{"trials":2391,"activeCount":59},[],{"trials":2393,"activeCount":59},[],{"trials":2395,"activeCount":59},[],{"trials":2397,"activeCount":59},[2398],{"nctId":2399,"briefTitle":2400,"status":67,"phases":2401,"primaryCompletion":779,"completion":779,"start":2402,"enrollment":692,"conditions":2403,"interventions":2404},"NCT00423579","The Effects of Ezetimibe\u002FSimvastatin 10\u002F20 mg Versus Simvastatin 40 mg in High Cholesterol and Coronary Heart Disease Study (P04039AM2)(COMPLETED)",[51],"2006-07-01",[14,1036],[2386,2405],"simvastatin 40 mg",{"trials":2407,"activeCount":59},[],{"intervention":2405,"totalTrials":190,"cells":2409},{"EARLY_PHASE1":2410,"PHASE1":2412,"PHASE2":2414,"PHASE3":2416,"PHASE4":2418,"NA":2424},{"trials":2411,"activeCount":59},[],{"trials":2413,"activeCount":59},[],{"trials":2415,"activeCount":59},[],{"trials":2417,"activeCount":59},[],{"trials":2419,"activeCount":59},[2420],{"nctId":2399,"briefTitle":2400,"status":67,"phases":2421,"primaryCompletion":779,"completion":779,"start":2402,"enrollment":692,"conditions":2422,"interventions":2423},[51],[14,1036],[2386,2405],{"trials":2425,"activeCount":59},[],{"intervention":1817,"totalTrials":190,"cells":2427},{"EARLY_PHASE1":2428,"PHASE1":2430,"PHASE2":2432,"PHASE3":2434,"PHASE4":2436,"NA":2442},{"trials":2429,"activeCount":59},[],{"trials":2431,"activeCount":59},[],{"trials":2433,"activeCount":59},[],{"trials":2435,"activeCount":59},[],{"trials":2437,"activeCount":59},[2438],{"nctId":1811,"briefTitle":1812,"status":67,"phases":2439,"primaryCompletion":350,"completion":350,"start":439,"enrollment":81,"conditions":2440,"interventions":2441},[51],[1815],[1245,1790,1817,1818],{"trials":2443,"activeCount":59},[],{"intervention":1818,"totalTrials":190,"cells":2445},{"EARLY_PHASE1":2446,"PHASE1":2448,"PHASE2":2450,"PHASE3":2452,"PHASE4":2454,"NA":2460},{"trials":2447,"activeCount":59},[],{"trials":2449,"activeCount":59},[],{"trials":2451,"activeCount":59},[],{"trials":2453,"activeCount":59},[],{"trials":2455,"activeCount":59},[2456],{"nctId":1811,"briefTitle":1812,"status":67,"phases":2457,"primaryCompletion":350,"completion":350,"start":439,"enrollment":81,"conditions":2458,"interventions":2459},[51],[1815],[1245,1790,1817,1818],{"trials":2461,"activeCount":59},[],{"intervention":2463,"totalTrials":190,"cells":2464},"MK0476, montelukast sodium \u002F Duration of Treatment : 56 Weeks",{"EARLY_PHASE1":2465,"PHASE1":2467,"PHASE2":2469,"PHASE3":2471,"PHASE4":2473,"NA":2485},{"trials":2466,"activeCount":59},[],{"trials":2468,"activeCount":59},[],{"trials":2470,"activeCount":59},[],{"trials":2472,"activeCount":59},[],{"trials":2474,"activeCount":59},[2475],{"nctId":2476,"briefTitle":2477,"status":67,"phases":2478,"primaryCompletion":2479,"completion":2479,"start":2480,"enrollment":2481,"conditions":2482,"interventions":2483},"NCT00395408","Linear Growth Study (0476-097)(COMPLETED)",[51],"2003-12","2000-06",360,[17],[2463,2484],"Comparator : beclomethasone dipropionate \u002F Duration of Treatment : 56 Weeks",{"trials":2486,"activeCount":59},[],{"intervention":2484,"totalTrials":190,"cells":2488},{"EARLY_PHASE1":2489,"PHASE1":2491,"PHASE2":2493,"PHASE3":2495,"PHASE4":2497,"NA":2503},{"trials":2490,"activeCount":59},[],{"trials":2492,"activeCount":59},[],{"trials":2494,"activeCount":59},[],{"trials":2496,"activeCount":59},[],{"trials":2498,"activeCount":59},[2499],{"nctId":2476,"briefTitle":2477,"status":67,"phases":2500,"primaryCompletion":2479,"completion":2479,"start":2480,"enrollment":2481,"conditions":2501,"interventions":2502},[51],[17],[2463,2484],{"trials":2504,"activeCount":59},[],{"intervention":2506,"totalTrials":190,"cells":2507},"Losartan 50 mg \u002F HCTZ 12.5 mg",{"EARLY_PHASE1":2508,"PHASE1":2510,"PHASE2":2512,"PHASE3":2514,"PHASE4":2516,"NA":2524},{"trials":2509,"activeCount":59},[],{"trials":2511,"activeCount":59},[],{"trials":2513,"activeCount":59},[],{"trials":2515,"activeCount":59},[],{"trials":2517,"activeCount":59},[2518],{"nctId":2519,"briefTitle":2520,"status":67,"phases":2521,"primaryCompletion":524,"completion":524,"start":264,"enrollment":11,"conditions":2522,"interventions":2523},"NCT01431508","A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3)",[51],[26],[2506],{"trials":2525,"activeCount":59},[],{"intervention":2527,"totalTrials":190,"cells":2528},"Losartan (+) amlodipine",{"EARLY_PHASE1":2529,"PHASE1":2531,"PHASE2":2533,"PHASE3":2535,"PHASE4":2537,"NA":2549},{"trials":2530,"activeCount":59},[],{"trials":2532,"activeCount":59},[],{"trials":2534,"activeCount":59},[],{"trials":2536,"activeCount":59},[],{"trials":2538,"activeCount":59},[2539],{"nctId":2540,"briefTitle":2541,"status":67,"phases":2542,"primaryCompletion":2543,"completion":2543,"start":2544,"enrollment":2545,"conditions":2546,"interventions":2547},"NCT01277822","Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399)",[51],"2013-04-22","2011-05-30",334,[26],[2527,2548],"Amlodipine camsylate",{"trials":2550,"activeCount":59},[],{"intervention":2548,"totalTrials":190,"cells":2552},{"EARLY_PHASE1":2553,"PHASE1":2555,"PHASE2":2557,"PHASE3":2559,"PHASE4":2561,"NA":2567},{"trials":2554,"activeCount":59},[],{"trials":2556,"activeCount":59},[],{"trials":2558,"activeCount":59},[],{"trials":2560,"activeCount":59},[],{"trials":2562,"activeCount":59},[2563],{"nctId":2540,"briefTitle":2541,"status":67,"phases":2564,"primaryCompletion":2543,"completion":2543,"start":2544,"enrollment":2545,"conditions":2565,"interventions":2566},[51],[26],[2527,2548],{"trials":2568,"activeCount":59},[],{"intervention":1960,"totalTrials":190,"cells":2570},{"EARLY_PHASE1":2571,"PHASE1":2573,"PHASE2":2575,"PHASE3":2577,"PHASE4":2579,"NA":2585},{"trials":2572,"activeCount":59},[],{"trials":2574,"activeCount":59},[],{"trials":2576,"activeCount":59},[],{"trials":2578,"activeCount":59},[],{"trials":2580,"activeCount":59},[2581],{"nctId":1952,"briefTitle":1953,"status":67,"phases":2582,"primaryCompletion":1955,"completion":1955,"start":1956,"enrollment":1957,"conditions":2583,"interventions":2584},[51],[17,31],[1939,1960],{"trials":2586,"activeCount":59},[],{"intervention":1185,"totalTrials":190,"cells":2588},{"EARLY_PHASE1":2589,"PHASE1":2591,"PHASE2":2593,"PHASE3":2595,"PHASE4":2597,"NA":2603},{"trials":2590,"activeCount":59},[],{"trials":2592,"activeCount":59},[],{"trials":2594,"activeCount":59},[],{"trials":2596,"activeCount":59},[],{"trials":2598,"activeCount":59},[2599],{"nctId":1177,"briefTitle":1178,"status":67,"phases":2600,"primaryCompletion":1180,"completion":1180,"start":883,"enrollment":1181,"conditions":2601,"interventions":2602},[51],[1183],[1102,1185],{"trials":2604,"activeCount":59},[],{"intervention":2606,"totalTrials":190,"cells":2607},"inhaled corticosteroid",{"EARLY_PHASE1":2608,"PHASE1":2610,"PHASE2":2612,"PHASE3":2614,"PHASE4":2616,"NA":2627},{"trials":2609,"activeCount":59},[],{"trials":2611,"activeCount":59},[],{"trials":2613,"activeCount":59},[],{"trials":2615,"activeCount":59},[],{"trials":2617,"activeCount":59},[2618],{"nctId":2619,"briefTitle":2620,"status":67,"phases":2621,"primaryCompletion":580,"completion":580,"start":2622,"enrollment":2623,"conditions":2624,"interventions":2625},"NCT00442559","Montelukast in Mild Asthmatic Children With Allergic Rhinitis (0476-367)",[51],"2005-01",191,[17,31],[2626,2606],"montelukast sodium",{"trials":2628,"activeCount":59},[],{"intervention":2630,"totalTrials":190,"cells":2631},"MK0954, losartan potassium\u002FDuration of Treatment: 18 weeks",{"EARLY_PHASE1":2632,"PHASE1":2634,"PHASE2":2636,"PHASE3":2638,"PHASE4":2640,"NA":2651},{"trials":2633,"activeCount":59},[],{"trials":2635,"activeCount":59},[],{"trials":2637,"activeCount":59},[],{"trials":2639,"activeCount":59},[],{"trials":2641,"activeCount":59},[2642],{"nctId":2643,"briefTitle":2644,"status":67,"phases":2645,"primaryCompletion":2646,"completion":2646,"start":2647,"enrollment":692,"conditions":2648,"interventions":2649},"NCT00140959","Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)",[51],"2004-06-30","2003-02-01",[26],[2630,2650],"Comparator: losartan, HCTZ, amlodipine, atenolol\u002FDuration of Treatment: 18 weeks",{"trials":2652,"activeCount":59},[],{"intervention":2650,"totalTrials":190,"cells":2654},{"EARLY_PHASE1":2655,"PHASE1":2657,"PHASE2":2659,"PHASE3":2661,"PHASE4":2663,"NA":2669},{"trials":2656,"activeCount":59},[],{"trials":2658,"activeCount":59},[],{"trials":2660,"activeCount":59},[],{"trials":2662,"activeCount":59},[],{"trials":2664,"activeCount":59},[2665],{"nctId":2643,"briefTitle":2644,"status":67,"phases":2666,"primaryCompletion":2646,"completion":2646,"start":2647,"enrollment":692,"conditions":2667,"interventions":2668},[51],[26],[2630,2650],{"trials":2670,"activeCount":59},[],{"intervention":2672,"totalTrials":190,"cells":2673},"MK0954A; hydrochlorothiazide (+) losartan potassium \u002F Duration of Treatment: 12 weeks",{"EARLY_PHASE1":2674,"PHASE1":2676,"PHASE2":2678,"PHASE3":2680,"PHASE4":2682,"NA":2693},{"trials":2675,"activeCount":59},[],{"trials":2677,"activeCount":59},[],{"trials":2679,"activeCount":59},[],{"trials":2681,"activeCount":59},[],{"trials":2683,"activeCount":59},[2684],{"nctId":2685,"briefTitle":2686,"status":67,"phases":2687,"primaryCompletion":2688,"completion":2688,"start":2689,"enrollment":1242,"conditions":2690,"interventions":2692},"NCT00157963","Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)",[51],"2006-02-08","2005-02-05",[2691],"Essential Hypertension",[2672],{"trials":2694,"activeCount":59},[],{"intervention":2005,"totalTrials":190,"cells":2696},{"EARLY_PHASE1":2697,"PHASE1":2699,"PHASE2":2701,"PHASE3":2703,"PHASE4":2705,"NA":2711},{"trials":2698,"activeCount":59},[],{"trials":2700,"activeCount":59},[],{"trials":2702,"activeCount":59},[],{"trials":2704,"activeCount":59},[],{"trials":2706,"activeCount":59},[2707],{"nctId":1997,"briefTitle":1998,"status":67,"phases":2708,"primaryCompletion":1782,"completion":1782,"start":2000,"enrollment":2001,"conditions":2709,"interventions":2710},[51],[2003],[1974,2005],{"trials":2712,"activeCount":59},[],{"intervention":2714,"totalTrials":190,"cells":2715},"MK0476 (singulair), montelukast sodium \u002F Duration of Treatment: 6 Weeks",{"EARLY_PHASE1":2716,"PHASE1":2718,"PHASE2":2720,"PHASE3":2722,"PHASE4":2724,"NA":2735},{"trials":2717,"activeCount":59},[],{"trials":2719,"activeCount":59},[],{"trials":2721,"activeCount":59},[],{"trials":2723,"activeCount":59},[],{"trials":2725,"activeCount":59},[2726],{"nctId":2727,"briefTitle":2728,"status":67,"phases":2729,"primaryCompletion":2479,"completion":2479,"start":2730,"enrollment":2731,"conditions":2732,"interventions":2733},"NCT00545324","First Step With Singulair® Therapy (0476-323)",[51],"2002-09",399,[17],[2714,2734],"Comparator: Fluticasone \u002F Duration of Treatment: 6 Weeks",{"trials":2736,"activeCount":59},[],{"intervention":2734,"totalTrials":190,"cells":2738},{"EARLY_PHASE1":2739,"PHASE1":2741,"PHASE2":2743,"PHASE3":2745,"PHASE4":2747,"NA":2753},{"trials":2740,"activeCount":59},[],{"trials":2742,"activeCount":59},[],{"trials":2744,"activeCount":59},[],{"trials":2746,"activeCount":59},[],{"trials":2748,"activeCount":59},[2749],{"nctId":2727,"briefTitle":2728,"status":67,"phases":2750,"primaryCompletion":2479,"completion":2479,"start":2730,"enrollment":2731,"conditions":2751,"interventions":2752},[51],[17],[2714,2734],{"trials":2754,"activeCount":59},[],{"intervention":2756,"totalTrials":190,"cells":2757},"MK0733, simvastatin \u002F Duration of Treatment: 12 Weeks",{"EARLY_PHASE1":2758,"PHASE1":2760,"PHASE2":2762,"PHASE3":2764,"PHASE4":2766,"NA":2775},{"trials":2759,"activeCount":59},[],{"trials":2761,"activeCount":59},[],{"trials":2763,"activeCount":59},[],{"trials":2765,"activeCount":59},[],{"trials":2767,"activeCount":59},[2768],{"nctId":2769,"briefTitle":2770,"status":67,"phases":2771,"primaryCompletion":2772,"completion":2772,"start":1223,"enrollment":403,"conditions":2773,"interventions":2774},"NCT00398294","To Evaluate the Lipid-Lowering Efficacy and Safety of Simvastatin 40 Mg Tablet In Patients With Hypercholesterolemia (0733-264)",[51],"2006-04-04",[14],[2756],{"trials":2776,"activeCount":59},[],{"intervention":2778,"totalTrials":190,"cells":2779},"Cream",{"EARLY_PHASE1":2780,"PHASE1":2782,"PHASE2":2784,"PHASE3":2786,"PHASE4":2788,"NA":2800},{"trials":2781,"activeCount":59},[],{"trials":2783,"activeCount":59},[],{"trials":2785,"activeCount":59},[],{"trials":2787,"activeCount":59},[],{"trials":2789,"activeCount":59},[2790],{"nctId":2791,"briefTitle":2792,"status":610,"phases":2793,"primaryCompletion":2794,"completion":2794,"start":1627,"enrollment":1549,"conditions":2795,"interventions":2799},"NCT00671528","Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4)",[51],"2010-05",[2796,2797,2798],"Dermatitis, Atopic","Eczema, Atopic","Skin Diseases, Eczematous",[2778,2778,2778],{"trials":2801,"activeCount":59},[],{"intervention":2803,"totalTrials":190,"cells":2804},"Atozet 10\u002F40 mg or 10\u002F80 mg",{"EARLY_PHASE1":2805,"PHASE1":2807,"PHASE2":2809,"PHASE3":2811,"PHASE4":2813,"NA":2827},{"trials":2806,"activeCount":59},[],{"trials":2808,"activeCount":59},[],{"trials":2810,"activeCount":59},[],{"trials":2812,"activeCount":59},[],{"trials":2814,"activeCount":59},[2815],{"nctId":2816,"briefTitle":2817,"status":67,"phases":2818,"primaryCompletion":2819,"completion":2820,"start":2821,"enrollment":2822,"conditions":2823,"interventions":2825},"NCT05761444","Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients",[51],"2024-09-04","2024-10-15","2023-07-26",137,[2824],"Atherosclerotic Cardiovascular Disease",[2803,2826],"Lipitor 40 mg or 80 mg",{"trials":2828,"activeCount":59},[],{"intervention":2826,"totalTrials":190,"cells":2830},{"EARLY_PHASE1":2831,"PHASE1":2833,"PHASE2":2835,"PHASE3":2837,"PHASE4":2839,"NA":2845},{"trials":2832,"activeCount":59},[],{"trials":2834,"activeCount":59},[],{"trials":2836,"activeCount":59},[],{"trials":2838,"activeCount":59},[],{"trials":2840,"activeCount":59},[2841],{"nctId":2816,"briefTitle":2817,"status":67,"phases":2842,"primaryCompletion":2819,"completion":2820,"start":2821,"enrollment":2822,"conditions":2843,"interventions":2844},[51],[2824],[2803,2826],{"trials":2846,"activeCount":59},[],{"intervention":2848,"totalTrials":190,"cells":2849},"VTAMA® (tapinarof) Cream 1%",{"EARLY_PHASE1":2850,"PHASE1":2852,"PHASE2":2854,"PHASE3":2856,"PHASE4":2858,"NA":2869},{"trials":2851,"activeCount":59},[],{"trials":2853,"activeCount":59},[],{"trials":2855,"activeCount":59},[],{"trials":2857,"activeCount":59},[],{"trials":2859,"activeCount":59},[2860],{"nctId":2861,"briefTitle":2862,"status":67,"phases":2863,"primaryCompletion":2864,"completion":2865,"start":2866,"enrollment":394,"conditions":2867,"interventions":2868},"NCT05680740","A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis",[51],"2023-05-18","2023-05-25","2022-12-27",[1469],[2848],{"trials":2870,"activeCount":59},[],{"intervention":1687,"totalTrials":190,"cells":2872},{"EARLY_PHASE1":2873,"PHASE1":2875,"PHASE2":2877,"PHASE3":2879,"PHASE4":2881,"NA":2887},{"trials":2874,"activeCount":59},[],{"trials":2876,"activeCount":59},[],{"trials":2878,"activeCount":59},[],{"trials":2880,"activeCount":59},[],{"trials":2882,"activeCount":59},[2883],{"nctId":1678,"briefTitle":1679,"status":67,"phases":2884,"primaryCompletion":1681,"completion":1681,"start":1682,"enrollment":1683,"conditions":2885,"interventions":2886},[51],[1685],[1649,1687],{"trials":2888,"activeCount":59},[],{"intervention":2890,"totalTrials":190,"cells":2891},"etonogestrel implant",{"EARLY_PHASE1":2892,"PHASE1":2894,"PHASE2":2896,"PHASE3":2898,"PHASE4":2900,"NA":2910},{"trials":2893,"activeCount":59},[],{"trials":2895,"activeCount":59},[],{"trials":2897,"activeCount":59},[],{"trials":2899,"activeCount":59},[],{"trials":2901,"activeCount":59},[2902],{"nctId":2903,"briefTitle":2904,"status":67,"phases":2905,"primaryCompletion":570,"completion":570,"start":2906,"enrollment":2907,"conditions":2908,"interventions":2909},"NCT00725413","A Study to Investigate the Contraceptive Efficacy and Safety of a Subdermal Etonogestrel Implant (Implanon®)(P06473)(COMPLETED)",[51],"2001-11",210,[23],[2890],{"trials":2911,"activeCount":59},[],{"intervention":2913,"totalTrials":190,"cells":2914},"alendronate 70-mg\u002Fvitamin D3 5600 IU combination",{"EARLY_PHASE1":2915,"PHASE1":2917,"PHASE2":2919,"PHASE3":2921,"PHASE4":2923,"NA":2936},{"trials":2916,"activeCount":59},[],{"trials":2918,"activeCount":59},[],{"trials":2920,"activeCount":59},[],{"trials":2922,"activeCount":59},[],{"trials":2924,"activeCount":59},[2925],{"nctId":2926,"briefTitle":2927,"status":67,"phases":2928,"primaryCompletion":2929,"completion":2929,"start":2930,"enrollment":2931,"conditions":2932,"interventions":2934},"NCT01350934","A Study to Evaluate Alendronate Sodium \u002FVitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264)",[51],"2013-01-10","2011-06-19",219,[2933],"Osteoporosis, Postmenopausal",[2913,2935],"Calcitriol",{"trials":2937,"activeCount":59},[],{"intervention":2935,"totalTrials":190,"cells":2939},{"EARLY_PHASE1":2940,"PHASE1":2942,"PHASE2":2944,"PHASE3":2946,"PHASE4":2948,"NA":2954},{"trials":2941,"activeCount":59},[],{"trials":2943,"activeCount":59},[],{"trials":2945,"activeCount":59},[],{"trials":2947,"activeCount":59},[],{"trials":2949,"activeCount":59},[2950],{"nctId":2926,"briefTitle":2927,"status":67,"phases":2951,"primaryCompletion":2929,"completion":2929,"start":2930,"enrollment":2931,"conditions":2952,"interventions":2953},[51],[2933],[2913,2935],{"trials":2955,"activeCount":59},[],{"intervention":1970,"totalTrials":190,"cells":2957},{"EARLY_PHASE1":2958,"PHASE1":2960,"PHASE2":2962,"PHASE3":2964,"PHASE4":2966,"NA":2972},{"trials":2959,"activeCount":59},[],{"trials":2961,"activeCount":59},[],{"trials":2963,"activeCount":59},[],{"trials":2965,"activeCount":59},[],{"trials":2967,"activeCount":59},[2968],{"nctId":1962,"briefTitle":1963,"status":67,"phases":2969,"primaryCompletion":1965,"completion":1965,"start":1966,"enrollment":1967,"conditions":2970,"interventions":2971},[51],[17],[1939,1970],{"trials":2973,"activeCount":59},[],{"intervention":2975,"totalTrials":190,"cells":2976},"MK0663; etoricoxib \u002F Duration of Treatment:4 Weeks",{"EARLY_PHASE1":2977,"PHASE1":2979,"PHASE2":2981,"PHASE3":2983,"PHASE4":2985,"NA":2998},{"trials":2978,"activeCount":59},[],{"trials":2980,"activeCount":59},[],{"trials":2982,"activeCount":59},[],{"trials":2984,"activeCount":59},[],{"trials":2986,"activeCount":59},[2987],{"nctId":2988,"briefTitle":2989,"status":67,"phases":2990,"primaryCompletion":2991,"completion":2991,"start":2992,"enrollment":2993,"conditions":2994,"interventions":2996},"NCT00140972","A Study to Assess Etoricoxib Versus Diclofenac in Chinese Patients With Osteoarthritis of the Knee or Hip (0663-080)(COMPLETED)",[51],"2005-06-27","2004-12-03",160,[2995],"Osteoarthritis",[2975,2997],"Comparator: diclofenac sodium tablet 75 mg \u002F Duration of Treatment:4 Weeks",{"trials":2999,"activeCount":59},[],{"intervention":2997,"totalTrials":190,"cells":3001},{"EARLY_PHASE1":3002,"PHASE1":3004,"PHASE2":3006,"PHASE3":3008,"PHASE4":3010,"NA":3016},{"trials":3003,"activeCount":59},[],{"trials":3005,"activeCount":59},[],{"trials":3007,"activeCount":59},[],{"trials":3009,"activeCount":59},[],{"trials":3011,"activeCount":59},[3012],{"nctId":2988,"briefTitle":2989,"status":67,"phases":3013,"primaryCompletion":2991,"completion":2991,"start":2992,"enrollment":2993,"conditions":3014,"interventions":3015},[51],[2995],[2975,2997],{"trials":3017,"activeCount":59},[],{"intervention":3019,"totalTrials":190,"cells":3020},"Ezetimibe + Statin",{"EARLY_PHASE1":3021,"PHASE1":3023,"PHASE2":3025,"PHASE3":3027,"PHASE4":3029,"NA":3039},{"trials":3022,"activeCount":59},[],{"trials":3024,"activeCount":59},[],{"trials":3026,"activeCount":59},[],{"trials":3028,"activeCount":59},[],{"trials":3030,"activeCount":59},[3031],{"nctId":3032,"briefTitle":3033,"status":67,"phases":3034,"primaryCompletion":283,"completion":283,"start":1082,"enrollment":3035,"conditions":3036,"interventions":3037},"NCT00652327","Comparison of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Statin in the Treatment of Hypercholesterolemia (P04355)",[51],83,[14],[3019,3038],"Double Statin",{"trials":3040,"activeCount":59},[],{"intervention":3038,"totalTrials":190,"cells":3042},{"EARLY_PHASE1":3043,"PHASE1":3045,"PHASE2":3047,"PHASE3":3049,"PHASE4":3051,"NA":3057},{"trials":3044,"activeCount":59},[],{"trials":3046,"activeCount":59},[],{"trials":3048,"activeCount":59},[],{"trials":3050,"activeCount":59},[],{"trials":3052,"activeCount":59},[3053],{"nctId":3032,"briefTitle":3033,"status":67,"phases":3054,"primaryCompletion":283,"completion":283,"start":1082,"enrollment":3035,"conditions":3055,"interventions":3056},[51],[14],[3019,3038],{"trials":3058,"activeCount":59},[],{"intervention":3060,"totalTrials":190,"cells":3061},"Asmanex twisthaler",{"EARLY_PHASE1":3062,"PHASE1":3064,"PHASE2":3066,"PHASE3":3068,"PHASE4":3070,"NA":3080},{"trials":3063,"activeCount":59},[],{"trials":3065,"activeCount":59},[],{"trials":3067,"activeCount":59},[],{"trials":3069,"activeCount":59},[],{"trials":3071,"activeCount":59},[3072],{"nctId":3073,"briefTitle":3074,"status":610,"phases":3075,"primaryCompletion":3076,"completion":3076,"start":1095,"enrollment":3077,"conditions":3078,"interventions":3079},"NCT00442351","Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild\u002FModerate Persistent Asthmatics (Study P04654)(TERMINATED)",[51],"2007-04",26,[17],[3060],{"trials":3081,"activeCount":59},[],{"intervention":3083,"totalTrials":190,"cells":3084},"MK0476, Singulair, montelukast sodium \u002F Duration of Treatment: 8 Weeks",{"EARLY_PHASE1":3085,"PHASE1":3087,"PHASE2":3089,"PHASE3":3091,"PHASE4":3093,"NA":3105},{"trials":3086,"activeCount":59},[],{"trials":3088,"activeCount":59},[],{"trials":3090,"activeCount":59},[],{"trials":3092,"activeCount":59},[],{"trials":3094,"activeCount":59},[3095],{"nctId":3096,"briefTitle":3097,"status":67,"phases":3098,"primaryCompletion":3099,"completion":3099,"start":3100,"enrollment":3101,"conditions":3102,"interventions":3104},"NCT00380705","Quality of Life in Asthma and Rhinitis Allergic With Singulair (0476-365)",[51],"2005-07-29","2005-03-18",91,[17,3103],"Rhinitis Allergic",[3083],{"trials":3106,"activeCount":59},[],{"intervention":3108,"totalTrials":190,"cells":3109},"Marvelon",{"EARLY_PHASE1":3110,"PHASE1":3112,"PHASE2":3114,"PHASE3":3116,"PHASE4":3118,"NA":3130},{"trials":3111,"activeCount":59},[],{"trials":3113,"activeCount":59},[],{"trials":3115,"activeCount":59},[],{"trials":3117,"activeCount":59},[],{"trials":3119,"activeCount":59},[3120],{"nctId":3121,"briefTitle":3122,"status":67,"phases":3123,"primaryCompletion":3124,"completion":3124,"start":3125,"enrollment":3126,"conditions":3127,"interventions":3129},"NCT00778999","Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696)",[51],"2008-07-24","2006-10-01",442,[3128],"Infertility",[3108],{"trials":3131,"activeCount":59},[],{"intervention":3133,"totalTrials":190,"cells":3134},"VTAMA (tapinarof) cream, 1%",{"EARLY_PHASE1":3135,"PHASE1":3137,"PHASE2":3139,"PHASE3":3141,"PHASE4":3143,"NA":3154},{"trials":3136,"activeCount":59},[],{"trials":3138,"activeCount":59},[],{"trials":3140,"activeCount":59},[],{"trials":3142,"activeCount":59},[],{"trials":3144,"activeCount":59},[3145],{"nctId":3146,"briefTitle":3147,"status":67,"phases":3148,"primaryCompletion":3149,"completion":3150,"start":3151,"enrollment":1957,"conditions":3152,"interventions":3153},"NCT05789576","A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region",[51],"2023-06-30","2023-07-19","2023-03-13",[1469],[3133],{"trials":3155,"activeCount":59},[],{"intervention":3157,"totalTrials":190,"cells":3158},"MK0663; etoricoxib \u002F Duration of Treatment: 5 Days",{"EARLY_PHASE1":3159,"PHASE1":3161,"PHASE2":3163,"PHASE3":3165,"PHASE4":3167,"NA":3177},{"trials":3160,"activeCount":59},[],{"trials":3162,"activeCount":59},[],{"trials":3164,"activeCount":59},[],{"trials":3166,"activeCount":59},[],{"trials":3168,"activeCount":59},[3169],{"nctId":3170,"briefTitle":3171,"status":67,"phases":3172,"primaryCompletion":1223,"completion":1223,"start":376,"enrollment":139,"conditions":3173,"interventions":3175},"NCT00142558","A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED)",[51],[3174],"Acute Gout",[3157,3176],"Comparator: indomethacin 75 mg sustained release capsule \u002F Duration of Treatment: 5 Days",{"trials":3178,"activeCount":59},[],{"intervention":3176,"totalTrials":190,"cells":3180},{"EARLY_PHASE1":3181,"PHASE1":3183,"PHASE2":3185,"PHASE3":3187,"PHASE4":3189,"NA":3195},{"trials":3182,"activeCount":59},[],{"trials":3184,"activeCount":59},[],{"trials":3186,"activeCount":59},[],{"trials":3188,"activeCount":59},[],{"trials":3190,"activeCount":59},[3191],{"nctId":3170,"briefTitle":3171,"status":67,"phases":3192,"primaryCompletion":1223,"completion":1223,"start":376,"enrollment":139,"conditions":3193,"interventions":3194},[51],[3174],[3157,3176],{"trials":3196,"activeCount":59},[],{"intervention":3198,"totalTrials":190,"cells":3199},"Comparator: montelukast sodium",{"EARLY_PHASE1":3200,"PHASE1":3202,"PHASE2":3204,"PHASE3":3206,"PHASE4":3208,"NA":3220},{"trials":3201,"activeCount":59},[],{"trials":3203,"activeCount":59},[],{"trials":3205,"activeCount":59},[],{"trials":3207,"activeCount":59},[],{"trials":3209,"activeCount":59},[3210],{"nctId":3211,"briefTitle":3212,"status":67,"phases":3213,"primaryCompletion":3214,"completion":3214,"start":437,"enrollment":3215,"conditions":3216,"interventions":3218},"NCT00534976","The Effect of Montelukast on Difficulty in Breathing After Exercise in Pediatric Patients (MK0476-377)(COMPLETED)",[51],"2010-03",364,[3217],"Exercise-induced Bronchoconstriction (EIB)",[3198,3219],"Comparator: Comparator: placebo",{"trials":3221,"activeCount":59},[],{"intervention":3219,"totalTrials":190,"cells":3223},{"EARLY_PHASE1":3224,"PHASE1":3226,"PHASE2":3228,"PHASE3":3230,"PHASE4":3232,"NA":3238},{"trials":3225,"activeCount":59},[],{"trials":3227,"activeCount":59},[],{"trials":3229,"activeCount":59},[],{"trials":3231,"activeCount":59},[],{"trials":3233,"activeCount":59},[3234],{"nctId":3211,"briefTitle":3212,"status":67,"phases":3235,"primaryCompletion":3214,"completion":3214,"start":437,"enrollment":3215,"conditions":3236,"interventions":3237},[51],[3217],[3198,3219],{"trials":3239,"activeCount":59},[],{"intervention":1313,"totalTrials":190,"cells":3241},{"EARLY_PHASE1":3242,"PHASE1":3244,"PHASE2":3246,"PHASE3":3248,"PHASE4":3250,"NA":3256},{"trials":3243,"activeCount":59},[],{"trials":3245,"activeCount":59},[],{"trials":3247,"activeCount":59},[],{"trials":3249,"activeCount":59},[],{"trials":3251,"activeCount":59},[3252],{"nctId":1306,"briefTitle":1307,"status":67,"phases":3253,"primaryCompletion":1309,"completion":1309,"start":906,"enrollment":1310,"conditions":3254,"interventions":3255},[51],[17],[1250,1313],{"trials":3257,"activeCount":59},[],{"intervention":1410,"totalTrials":190,"cells":3259},{"EARLY_PHASE1":3260,"PHASE1":3262,"PHASE2":3264,"PHASE3":3266,"PHASE4":3268,"NA":3274},{"trials":3261,"activeCount":59},[],{"trials":3263,"activeCount":59},[],{"trials":3265,"activeCount":59},[],{"trials":3267,"activeCount":59},[],{"trials":3269,"activeCount":59},[3270],{"nctId":1403,"briefTitle":1404,"status":610,"phases":3271,"primaryCompletion":1406,"completion":1406,"start":612,"enrollment":1407,"conditions":3272,"interventions":3273},[51],[14,465,466],[565,468,1410],{"trials":3275,"activeCount":59},[],{"intervention":1583,"totalTrials":190,"cells":3277},{"EARLY_PHASE1":3278,"PHASE1":3280,"PHASE2":3282,"PHASE3":3284,"PHASE4":3286,"NA":3292},{"trials":3279,"activeCount":59},[],{"trials":3281,"activeCount":59},[],{"trials":3283,"activeCount":59},[],{"trials":3285,"activeCount":59},[],{"trials":3287,"activeCount":59},[3288],{"nctId":1576,"briefTitle":1577,"status":67,"phases":3289,"primaryCompletion":790,"completion":790,"start":589,"enrollment":1579,"conditions":3290,"interventions":3291},[51],[1581],[1548,1583,1584],{"trials":3293,"activeCount":59},[],{"intervention":1584,"totalTrials":190,"cells":3295},{"EARLY_PHASE1":3296,"PHASE1":3298,"PHASE2":3300,"PHASE3":3302,"PHASE4":3304,"NA":3310},{"trials":3297,"activeCount":59},[],{"trials":3299,"activeCount":59},[],{"trials":3301,"activeCount":59},[],{"trials":3303,"activeCount":59},[],{"trials":3305,"activeCount":59},[3306],{"nctId":1576,"briefTitle":1577,"status":67,"phases":3307,"primaryCompletion":790,"completion":790,"start":589,"enrollment":1579,"conditions":3308,"interventions":3309},[51],[1581],[1548,1583,1584],{"trials":3311,"activeCount":59},[],{"intervention":3313,"totalTrials":190,"cells":3314},"statins",{"EARLY_PHASE1":3315,"PHASE1":3317,"PHASE2":3319,"PHASE3":3321,"PHASE4":3323,"NA":3332},{"trials":3316,"activeCount":59},[],{"trials":3318,"activeCount":59},[],{"trials":3320,"activeCount":59},[],{"trials":3322,"activeCount":59},[],{"trials":3324,"activeCount":59},[3325],{"nctId":3326,"briefTitle":3327,"status":67,"phases":3328,"primaryCompletion":1637,"completion":1637,"start":1083,"enrollment":3329,"conditions":3330,"interventions":3331},"NCT00652847","Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152)(COMPLETED)",[51],1140,[14],[444,3313],{"trials":3333,"activeCount":59},[],{"intervention":3335,"totalTrials":190,"cells":3336},"MK0476; montelukast sodium",{"EARLY_PHASE1":3337,"PHASE1":3339,"PHASE2":3341,"PHASE3":3343,"PHASE4":3345,"NA":3356},{"trials":3338,"activeCount":59},[],{"trials":3340,"activeCount":59},[],{"trials":3342,"activeCount":59},[],{"trials":3344,"activeCount":59},[],{"trials":3346,"activeCount":59},[3347],{"nctId":3348,"briefTitle":3349,"status":67,"phases":3350,"primaryCompletion":3351,"completion":3351,"start":3352,"enrollment":1283,"conditions":3353,"interventions":3354},"NCT00140881","A Study to Determine the Effect of Montelukast Sodium as an Episode Modifier in the Treatment of Infrequent Episodic Asthma in Children (0476-165)",[51],"2003-02-14","2000-06-01",[17],[3335,3355],"Comparator: placebo",{"trials":3357,"activeCount":59},[],{"intervention":1786,"totalTrials":190,"cells":3359},{"EARLY_PHASE1":3360,"PHASE1":3362,"PHASE2":3364,"PHASE3":3366,"PHASE4":3368,"NA":3374},{"trials":3361,"activeCount":59},[],{"trials":3363,"activeCount":59},[],{"trials":3365,"activeCount":59},[],{"trials":3367,"activeCount":59},[],{"trials":3369,"activeCount":59},[3370],{"nctId":1779,"briefTitle":1780,"status":67,"phases":3371,"primaryCompletion":1180,"completion":1180,"start":1782,"enrollment":361,"conditions":3372,"interventions":3373},[51],[1784],[1759,1786],{"trials":3375,"activeCount":59},[],{"intervention":1488,"totalTrials":190,"cells":3377},{"EARLY_PHASE1":3378,"PHASE1":3380,"PHASE2":3382,"PHASE3":3384,"PHASE4":3386,"NA":3392},{"trials":3379,"activeCount":59},[],{"trials":3381,"activeCount":59},[],{"trials":3383,"activeCount":59},[],{"trials":3385,"activeCount":59},[],{"trials":3387,"activeCount":59},[3388],{"nctId":1480,"briefTitle":1481,"status":67,"phases":3389,"primaryCompletion":1483,"completion":1483,"start":1484,"enrollment":1485,"conditions":3390,"interventions":3391},[51],[33,17],[1444,1488],{"trials":3393,"activeCount":59},[],{"intervention":1322,"totalTrials":190,"cells":3395},{"EARLY_PHASE1":3396,"PHASE1":3398,"PHASE2":3400,"PHASE3":3402,"PHASE4":3404,"NA":3410},{"trials":3397,"activeCount":59},[],{"trials":3399,"activeCount":59},[],{"trials":3401,"activeCount":59},[],{"trials":3403,"activeCount":59},[],{"trials":3405,"activeCount":59},[3406],{"nctId":1315,"briefTitle":1316,"status":67,"phases":3407,"primaryCompletion":349,"completion":349,"start":1095,"enrollment":1318,"conditions":3408,"interventions":3409},[51],[17],[1321,1321,1322,1250],{"trials":3411,"activeCount":59},[],{"intervention":3413,"totalTrials":727,"cells":3414},"MK0653, ezetimibe",{"EARLY_PHASE1":3415,"PHASE1":3417,"PHASE2":3419,"PHASE3":3421,"PHASE4":3499,"NA":3501},{"trials":3416,"activeCount":59},[],{"trials":3418,"activeCount":59},[],{"trials":3420,"activeCount":59},[],{"trials":3422,"activeCount":59},[3423,3431,3440,3450,3456,3464,3470,3476,3484,3491],{"nctId":3424,"briefTitle":3425,"status":67,"phases":3426,"primaryCompletion":1782,"completion":1782,"start":462,"enrollment":3427,"conditions":3428,"interventions":3429},"NCT00092612","Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED)",[50],372,[14,1036],[3413,3430],"Comparator: ezetimibe, placebo",{"nctId":3432,"briefTitle":3433,"status":67,"phases":3434,"primaryCompletion":741,"completion":581,"start":3435,"enrollment":403,"conditions":3436,"interventions":3439},"NCT00092898","An Investigational Drug Study to Lower Non-Cholesterol Sterol Levels Associated With Sitosterolemia (0653-062)(COMPLETED)",[50],"2004-10",[3437,3438],"Lipid Metabolism, Inborn Errors","Heart Disease",[3413,3355],{"nctId":3441,"briefTitle":3442,"status":67,"phases":3443,"primaryCompletion":3444,"completion":3445,"start":3446,"enrollment":3447,"conditions":3448,"interventions":3449},"NCT00092807","Sitosterolemia Extension Study (0653-003)(COMPLETED)",[50],"2001-09-18","2004-11-30","2001-02-12",37,[3437,3438],[3413,3355],{"nctId":3451,"briefTitle":3452,"status":67,"phases":3453,"primaryCompletion":932,"completion":690,"start":462,"enrollment":1053,"conditions":3454,"interventions":3455},"NCT00092638","An Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-804)(COMPLETED)",[50],[14,1036],[3413,3430],{"nctId":3457,"briefTitle":3458,"status":67,"phases":3459,"primaryCompletion":1290,"completion":1290,"start":2730,"enrollment":3460,"conditions":3461,"interventions":3462},"NCT00092586","Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040)",[50],2904,[14],[3413,3463],"Comparator: statins",{"nctId":3465,"briefTitle":3466,"status":67,"phases":3467,"primaryCompletion":932,"completion":690,"start":1375,"enrollment":3126,"conditions":3468,"interventions":3469},"NCT00092625","Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)",[50],[14,1036],[3413,3430],{"nctId":3471,"briefTitle":3472,"status":67,"phases":3473,"primaryCompletion":3444,"completion":3445,"start":3446,"enrollment":101,"conditions":3474,"interventions":3475},"NCT00092820","Sitosterolemia Extension Study (0653-004)(COMPLETED)",[50],[3437,3438],[3413,3355],{"nctId":3477,"briefTitle":3478,"status":67,"phases":3479,"primaryCompletion":2479,"completion":2479,"start":875,"enrollment":3480,"conditions":3481,"interventions":3482},"NCT00092560","Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036)",[50],587,[14,746],[3413,3483],"Comparator: fenofibrate monotherapy",{"nctId":3485,"briefTitle":3486,"status":67,"phases":3487,"primaryCompletion":1782,"completion":932,"start":1956,"enrollment":3488,"conditions":3489,"interventions":3490},"NCT00092599","Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801)",[50],410,[14,1036],[3413,3430],{"nctId":3492,"briefTitle":3493,"status":67,"phases":3494,"primaryCompletion":742,"completion":742,"start":3495,"enrollment":3496,"conditions":3497,"interventions":3498},"NCT00092573","Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)",[50],"2003-04",576,[14,746],[3413,3483],{"trials":3500,"activeCount":59},[],{"trials":3502,"activeCount":59},[],{"intervention":3504,"totalTrials":1103,"cells":3505},"rizatriptan benzoate",{"EARLY_PHASE1":3506,"PHASE1":3508,"PHASE2":3521,"PHASE3":3523,"PHASE4":3584,"NA":3586},{"trials":3507,"activeCount":59},[],{"trials":3509,"activeCount":59},[3510],{"nctId":3511,"briefTitle":3512,"status":67,"phases":3513,"primaryCompletion":3514,"completion":3514,"start":3515,"enrollment":1957,"conditions":3516,"interventions":3518},"NCT00604812","Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)",[48],"2010-09-17","2007-12-17",[3517],"Migraine Disorders",[3504,3504,3519,3520],"Rizatriptan 5 mg Placebo","Rizatriptan 10 mg Placebo",{"trials":3522,"activeCount":59},[],{"trials":3524,"activeCount":59},[3525,3536,3547,3557,3565,3575],{"nctId":3526,"briefTitle":3527,"status":67,"phases":3528,"primaryCompletion":3529,"completion":3530,"start":3531,"enrollment":3532,"conditions":3533,"interventions":3535},"NCT00899379","Treatment of Multiple Attacks of Acute Migraine (0462-025)",[50],"1996-01","1996-04","1995-04",473,[3534],"Migraine Headache",[3504,652],{"nctId":3537,"briefTitle":3538,"status":67,"phases":3539,"primaryCompletion":3540,"completion":3541,"start":3542,"enrollment":3543,"conditions":3544,"interventions":3545},"NCT00897104","MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)",[50],"1996-05","1996-09","1995-08",933,[3534],[3504,3546,652],"Comparator: sumatriptan",{"nctId":3548,"briefTitle":3549,"status":67,"phases":3550,"primaryCompletion":3551,"completion":3551,"start":3552,"enrollment":3553,"conditions":3554,"interventions":3556},"NCT00812006","A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis",[50],"2009-10-22","2009-03-24",108,[3555],"Migraine",[3504,3355],{"nctId":3558,"briefTitle":3559,"status":67,"phases":3560,"primaryCompletion":3540,"completion":3541,"start":3561,"enrollment":3562,"conditions":3563,"interventions":3564},"NCT00898677","Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)",[50],"1995-09",1268,[3534],[3504,3504,3546,652],{"nctId":3566,"briefTitle":3567,"status":67,"phases":3568,"primaryCompletion":3569,"completion":3569,"start":3570,"enrollment":3571,"conditions":3572,"interventions":3574},"NCT01004263","A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)",[50],"2011-04-18","2009-12-01",674,[3573],"Acute Migraine With or Without Aura in Adolescents",[3504],{"nctId":3576,"briefTitle":3577,"status":67,"phases":3578,"primaryCompletion":3529,"completion":3579,"start":3580,"enrollment":3581,"conditions":3582,"interventions":3583},"NCT00897949","MK0462 in Treatment of Migraine With Recurrence (MK0462-022)",[50],"1996-07","1995-03",1473,[3534],[3504,3355],{"trials":3585,"activeCount":59},[],{"trials":3587,"activeCount":59},[],{"intervention":3589,"totalTrials":1103,"cells":3590},"NOMAC-E2",{"EARLY_PHASE1":3591,"PHASE1":3593,"PHASE2":3605,"PHASE3":3607,"PHASE4":3662,"NA":3664},{"trials":3592,"activeCount":59},[],{"trials":3594,"activeCount":59},[3595],{"nctId":3596,"briefTitle":3597,"status":67,"phases":3598,"primaryCompletion":274,"completion":274,"start":338,"enrollment":3599,"conditions":3600,"interventions":3601},"NCT00779532","Thorough QT\u002FQTc Study of Multiple Oral Doses of NOMAC-E2 (Org 10486 0 + Org 2317) in Healthy Women (Study 292011)(P05802)",[48],189,[23],[3602,3589,3603,3604],"Moxifloxacin","Moxifloxacin placebo","NOMAC-E2 placebo",{"trials":3606,"activeCount":59},[],{"trials":3608,"activeCount":59},[3609,3617,3627,3634,3643,3650],{"nctId":3610,"briefTitle":3611,"status":67,"phases":3612,"primaryCompletion":402,"completion":402,"start":359,"enrollment":3613,"conditions":3614,"interventions":3615},"NCT00511355","Effects on Hemostasis, Lipids, Carbohydrate Metabolism, Adrenal & Thyroid Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG-EE (292004)(COMPLETED)(P05764)",[50],121,[23],[3589,3616],"Levonorgestrel and Ethinyl Estradiol",{"nctId":3618,"briefTitle":3619,"status":67,"phases":3620,"primaryCompletion":3621,"completion":3621,"start":3622,"enrollment":3623,"conditions":3624,"interventions":3625},"NCT00511199","Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared to a COC Containing DRSP\u002FEE (292001)(COMPLETED)(P05724)",[50],"2008-04-01","2006-05-01",2152,[23],[3589,3626],"DRSP-EE",{"nctId":3628,"briefTitle":3629,"status":67,"phases":3630,"primaryCompletion":402,"completion":402,"start":359,"enrollment":3631,"conditions":3632,"interventions":3633},"NCT00511433","Effects on Ovarian Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP\u002FEE (292003)(COMPLETED)(P05723)",[50],48,[23],[3589,3626],{"nctId":3635,"briefTitle":3636,"status":67,"phases":3637,"primaryCompletion":3638,"completion":3638,"start":1095,"enrollment":3639,"conditions":3640,"interventions":3641},"NCT00511342","Effects on Bone Mineral Density (BMD) of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG\u002FEE (292005)(P05765)(COMPLETED)",[50],"2009-06",110,[23],[3589,3642],"LNG-EE",{"nctId":3644,"briefTitle":3645,"status":67,"phases":3646,"primaryCompletion":275,"completion":275,"start":1299,"enrollment":3647,"conditions":3648,"interventions":3649},"NCT00413062","Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP\u002FEE (292002)(P05722)",[50],2281,[23],[3589,3626],{"nctId":3651,"briefTitle":3652,"status":610,"phases":3653,"primaryCompletion":3654,"completion":3654,"start":3655,"enrollment":3656,"conditions":3657,"interventions":3658},"NCT01656434","Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)",[50],"2014-02-12","2012-11-02",3173,[23],[3589,3659,3660,3661],"NETA-EE","ethinylestradiol","ferrous fumarate",{"trials":3663,"activeCount":59},[],{"trials":3665,"activeCount":59},[],{"intervention":3667,"totalTrials":1103,"cells":3668},"Comparator: montelukast",{"EARLY_PHASE1":3669,"PHASE1":3671,"PHASE2":3682,"PHASE3":3693,"PHASE4":3739,"NA":3741},{"trials":3670,"activeCount":59},[],{"trials":3672,"activeCount":59},[3673],{"nctId":3674,"briefTitle":3675,"status":67,"phases":3676,"primaryCompletion":3677,"completion":3677,"start":293,"enrollment":3678,"conditions":3679,"interventions":3681},"NCT00739297","The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388)",[48],"2008-12",68,[3680],"Chronic Asthma",[3667,3355],{"trials":3683,"activeCount":59},[3684],{"nctId":3685,"briefTitle":3686,"status":67,"phases":3687,"primaryCompletion":3688,"completion":3688,"start":338,"enrollment":3689,"conditions":3690,"interventions":3691},"NCT00666679","Study of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma (0476-386)",[49],"2009-02",134,[17],[3692,3667,3355],"Comparator: mometasone",{"trials":3694,"activeCount":59},[3695,3704,3712,3719,3730],{"nctId":3696,"briefTitle":3697,"status":67,"phases":3698,"primaryCompletion":3699,"completion":3699,"start":1066,"enrollment":339,"conditions":3700,"interventions":3702},"NCT00092131","Montelukast in Exercise-Induced Bronchospasm - 2003 (0476-270)",[50],"2003-11",[3701],"Asthma, Exercise-Induced",[3703,652],"Comparator: Montelukast",{"nctId":3705,"briefTitle":3706,"status":67,"phases":3707,"primaryCompletion":1095,"completion":1095,"start":1082,"enrollment":3708,"conditions":3709,"interventions":3710},"NCT00245570","Montelukast Compared With Placebo and Salmeterol in Exercise-Induced Bronchoconstriction (0476-316)",[50],47,[3701],[3703,3711,652,652],"Comparator: Salmeterol",{"nctId":3713,"briefTitle":3714,"status":67,"phases":3715,"primaryCompletion":3435,"completion":3435,"start":931,"enrollment":3716,"conditions":3717,"interventions":3718},"NCT00090142","Montelukast in Exercise-Induced Bronchospasm - 2004 (0476-275)",[50],62,[3701],[3703,652],{"nctId":3720,"briefTitle":3721,"status":67,"phases":3722,"primaryCompletion":3723,"completion":3723,"start":3724,"enrollment":3725,"conditions":3726,"interventions":3727},"NCT00979901","Montelukast in Patients With Seasonal Allergic Rhinitis - Spring 2000 Study (MK-0476A-162)(COMPLETED)",[50],"2000-05","2000-03",1577,[20],[3667,3728,3355,3729],"Comparator: loratadine","Comparator: montelukast\u002Floratadine",{"nctId":3731,"briefTitle":3732,"status":67,"phases":3733,"primaryCompletion":3734,"completion":3734,"start":3735,"enrollment":3736,"conditions":3737,"interventions":3738},"NCT00963599","Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)",[50],"1999-11","1999-09",907,[20],[3729,3667,3728,3355],{"trials":3740,"activeCount":59},[],{"trials":3742,"activeCount":59},[],{"intervention":3744,"totalTrials":3745,"cells":3746},"MK0663, etoricoxib",6,{"EARLY_PHASE1":3747,"PHASE1":3749,"PHASE2":3751,"PHASE3":3753,"PHASE4":3805,"NA":3807},{"trials":3748,"activeCount":59},[],{"trials":3750,"activeCount":59},[],{"trials":3752,"activeCount":59},[],{"trials":3754,"activeCount":59},[3755,3764,3774,3781,3790,3799],{"nctId":3756,"briefTitle":3757,"status":67,"phases":3758,"primaryCompletion":1082,"completion":1082,"start":1956,"enrollment":3759,"conditions":3760,"interventions":3762},"NCT00092742","Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)",[50],4086,[3761],"Rheumatoid Arthritis",[3744,3763],"Comparator: Diclofenac sodium",{"nctId":3765,"briefTitle":3766,"status":67,"phases":3767,"primaryCompletion":3768,"completion":3768,"start":3769,"enrollment":3770,"conditions":3771,"interventions":3772},"NCT00092755","An Investigational Drug in Patients With Osteoarthritis (0663-073)",[50],"2003-11-13","2003-04-09",548,[2995],[3744,3773],"Comparators: ibuprofen and placebo",{"nctId":3775,"briefTitle":3776,"status":67,"phases":3777,"primaryCompletion":633,"completion":633,"start":1224,"enrollment":1274,"conditions":3778,"interventions":3779},"NCT00092768","A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED)",[50],[2995],[3744,3780],"Comparator: celecoxib",{"nctId":3782,"briefTitle":3783,"status":67,"phases":3784,"primaryCompletion":3785,"completion":3785,"start":3786,"enrollment":3787,"conditions":3788,"interventions":3789},"NCT00092703","Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)",[50],"2003-11-01","2002-06-27",6000,[2995],[3744,3763],{"nctId":3791,"briefTitle":3792,"status":67,"phases":3793,"primaryCompletion":350,"completion":350,"start":3794,"enrollment":3795,"conditions":3796,"interventions":3798},"NCT00250445","A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066)",[50],"2003-01",23498,[3797],"Rheumatoid Arthritis,Osteoarthritis",[3744,3763],{"nctId":3800,"briefTitle":3801,"status":67,"phases":3802,"primaryCompletion":633,"completion":633,"start":1224,"enrollment":1274,"conditions":3803,"interventions":3804},"NCT00092781","A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-077)(COMPLETED)",[50],[2995],[3744,3780],{"trials":3806,"activeCount":59},[],{"trials":3808,"activeCount":59},[],{"intervention":1511,"totalTrials":148,"cells":3810},{"EARLY_PHASE1":3811,"PHASE1":3813,"PHASE2":3815,"PHASE3":3817,"PHASE4":3854,"NA":3856},{"trials":3812,"activeCount":59},[],{"trials":3814,"activeCount":59},[],{"trials":3816,"activeCount":59},[],{"trials":3818,"activeCount":59},[3819,3823,3827,3837,3841],{"nctId":446,"briefTitle":447,"status":67,"phases":3820,"primaryCompletion":449,"completion":450,"start":451,"enrollment":452,"conditions":3821,"interventions":3822},[50],[14],[455,443,456],{"nctId":1503,"briefTitle":1504,"status":67,"phases":3824,"primaryCompletion":1506,"completion":1506,"start":1507,"enrollment":1508,"conditions":3825,"interventions":3826},[50],[14],[1511,1492,1512,1513,1514],{"nctId":3828,"briefTitle":3829,"status":67,"phases":3830,"primaryCompletion":3831,"completion":3831,"start":3832,"enrollment":3833,"conditions":3834,"interventions":3835},"NCT02741245","A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)",[50],"2017-01-18","2016-06-09",321,[14],[1511,3836],"Rosuvastatin 2.5 mg",{"nctId":1516,"briefTitle":1517,"status":67,"phases":3838,"primaryCompletion":1519,"completion":1519,"start":1520,"enrollment":1521,"conditions":3839,"interventions":3840},[50],[14],[1511,1492],{"nctId":3842,"briefTitle":3843,"status":67,"phases":3844,"primaryCompletion":3845,"completion":3845,"start":3846,"enrollment":3847,"conditions":3848,"interventions":3850},"NCT00423488","Ezetimibe and Simvastatin in Primary Hypercholesterolemia, Diabetes Mellitus Type 2, and Coronary Heart Disease (COMPLETED)",[50],"2007-02-16","2005-07-12",93,[14,3849,1036],"Diabetes Mellitus, Type 2",[1511,3851,3852,3851,3853],"Simvastatin 20 mg","Ezetimibe Placebo","Simvastatin Placebo",{"trials":3855,"activeCount":59},[],{"trials":3857,"activeCount":59},[],{"intervention":3728,"totalTrials":148,"cells":3859},{"EARLY_PHASE1":3860,"PHASE1":3862,"PHASE2":3864,"PHASE3":3866,"PHASE4":3901,"NA":3903},{"trials":3861,"activeCount":59},[],{"trials":3863,"activeCount":59},[],{"trials":3865,"activeCount":59},[],{"trials":3867,"activeCount":59},[3868,3877,3885,3889,3897],{"nctId":3869,"briefTitle":3870,"status":67,"phases":3871,"primaryCompletion":1965,"completion":3872,"start":3873,"enrollment":3874,"conditions":3875,"interventions":3876},"NCT00960141","A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)",[50],"2000-11","2000-08",829,[20],[2626,3728,3355],{"nctId":3878,"briefTitle":3879,"status":67,"phases":3880,"primaryCompletion":2906,"completion":2906,"start":3881,"enrollment":3882,"conditions":3883,"interventions":3884},"NCT00963469","Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240)",[50],"2001-08",1079,[20],[2626,3728,3355],{"nctId":3720,"briefTitle":3721,"status":67,"phases":3886,"primaryCompletion":3723,"completion":3723,"start":3724,"enrollment":3725,"conditions":3887,"interventions":3888},[50],[20],[3667,3728,3355,3729],{"nctId":3890,"briefTitle":3891,"status":67,"phases":3892,"primaryCompletion":1117,"completion":1117,"start":3893,"enrollment":3894,"conditions":3895,"interventions":3896},"NCT00972738","Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235)",[50],"2001-04",1214,[20],[2626,3728,652],{"nctId":3731,"briefTitle":3732,"status":67,"phases":3898,"primaryCompletion":3734,"completion":3734,"start":3735,"enrollment":3736,"conditions":3899,"interventions":3900},[50],[20],[3729,3667,3728,3355],{"trials":3902,"activeCount":59},[],{"trials":3904,"activeCount":59},[],{"intervention":3906,"totalTrials":682,"cells":3907},"Ibuprofen",{"EARLY_PHASE1":3908,"PHASE1":3910,"PHASE2":3912,"PHASE3":3927,"PHASE4":3960,"NA":3962},{"trials":3909,"activeCount":59},[],{"trials":3911,"activeCount":59},[],{"trials":3913,"activeCount":59},[3914],{"nctId":3915,"briefTitle":3916,"status":67,"phases":3917,"primaryCompletion":3918,"completion":3919,"start":3920,"enrollment":3921,"conditions":3922,"interventions":3924},"NCT01670656","A Study to Evaluate the Effect of Contraceptive Vaginal Rings on Primary Dysmenorrhea (P08257\u002FMK-8175A\u002FMK-8342B-057)",[49],"2013-09-11","2013-09-12","2013-01-21",439,[3923],"Dysmenorrhea",[3925,3926,3906],"Nomegestrol acetate contraceptive vaginal ring","Etonogestrel containing contraceptive vaginal ring",{"trials":3928,"activeCount":59},[3929,3940,3950],{"nctId":3930,"briefTitle":3931,"status":67,"phases":3932,"primaryCompletion":3933,"completion":3933,"start":3934,"enrollment":3935,"conditions":3936,"interventions":3937},"NCT01462370","Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)",[50],"2012-06","2011-11",139,[3923],[3938,3906,3939],"Etoricoxib","Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg",{"nctId":3941,"briefTitle":3942,"status":610,"phases":3943,"primaryCompletion":3944,"completion":3944,"start":3945,"enrollment":3946,"conditions":3947,"interventions":3948},"NCT02668822","Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in the Treatment of Women With Primary Dysmenorrhea (MK-8342B-060)",[50],"2016-09-12","2016-02-09",18,[3923],[3949,3906],"ENG 125 μg + E2 300 μg vaginal ring",{"nctId":3951,"briefTitle":3952,"status":610,"phases":3953,"primaryCompletion":3954,"completion":3954,"start":3955,"enrollment":21,"conditions":3956,"interventions":3958},"NCT02668783","Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in Women With Primary Dysmenorrhea (With Optional Extension) (MK-8342B-059)",[50],"2016-09-07","2016-02-11",[3957],"Moderate to Severe Primary Dysmenorrhea",[3959,3906],"Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring",{"trials":3961,"activeCount":59},[],{"trials":3963,"activeCount":59},[],{"intervention":456,"totalTrials":682,"cells":3965},{"EARLY_PHASE1":3966,"PHASE1":3968,"PHASE2":3970,"PHASE3":3972,"PHASE4":3994,"NA":3996},{"trials":3967,"activeCount":59},[],{"trials":3969,"activeCount":59},[],{"trials":3971,"activeCount":59},[],{"trials":3973,"activeCount":59},[3974,3978,3982,3986],{"nctId":446,"briefTitle":447,"status":67,"phases":3975,"primaryCompletion":449,"completion":450,"start":451,"enrollment":452,"conditions":3976,"interventions":3977},[50],[14],[455,443,456],{"nctId":749,"briefTitle":750,"status":67,"phases":3979,"primaryCompletion":312,"completion":312,"start":284,"enrollment":752,"conditions":3980,"interventions":3981},[50],[14],[574,755,456],{"nctId":1050,"briefTitle":1051,"status":67,"phases":3983,"primaryCompletion":974,"completion":974,"start":376,"enrollment":1053,"conditions":3984,"interventions":3985},[50],[14],[1056,755,1057,1058,1059,456,1060],{"nctId":3987,"briefTitle":3988,"status":67,"phases":3989,"primaryCompletion":461,"completion":461,"start":646,"enrollment":3990,"conditions":3991,"interventions":3992},"NCT00090298","Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058)",[50],2815,[14],[1070,3993],"Comparator: Rosuvastatin",{"trials":3995,"activeCount":59},[],{"trials":3997,"activeCount":59},[],{"intervention":3430,"totalTrials":682,"cells":3999},{"EARLY_PHASE1":4000,"PHASE1":4002,"PHASE2":4004,"PHASE3":4006,"PHASE4":4024,"NA":4026},{"trials":4001,"activeCount":59},[],{"trials":4003,"activeCount":59},[],{"trials":4005,"activeCount":59},[],{"trials":4007,"activeCount":59},[4008,4012,4016,4020],{"nctId":3424,"briefTitle":3425,"status":67,"phases":4009,"primaryCompletion":1782,"completion":1782,"start":462,"enrollment":3427,"conditions":4010,"interventions":4011},[50],[14,1036],[3413,3430],{"nctId":3451,"briefTitle":3452,"status":67,"phases":4013,"primaryCompletion":932,"completion":690,"start":462,"enrollment":1053,"conditions":4014,"interventions":4015},[50],[14,1036],[3413,3430],{"nctId":3465,"briefTitle":3466,"status":67,"phases":4017,"primaryCompletion":932,"completion":690,"start":1375,"enrollment":3126,"conditions":4018,"interventions":4019},[50],[14,1036],[3413,3430],{"nctId":3485,"briefTitle":3486,"status":67,"phases":4021,"primaryCompletion":1782,"completion":932,"start":1956,"enrollment":3488,"conditions":4022,"interventions":4023},[50],[14,1036],[3413,3430],{"trials":4025,"activeCount":59},[],{"trials":4027,"activeCount":59},[],{"intervention":4029,"totalTrials":682,"cells":4030},"Mometasone furoate MDI",{"EARLY_PHASE1":4031,"PHASE1":4033,"PHASE2":4035,"PHASE3":4037,"PHASE4":4074,"NA":4076},{"trials":4032,"activeCount":59},[],{"trials":4034,"activeCount":59},[],{"trials":4036,"activeCount":59},[],{"trials":4038,"activeCount":59},[4039,4048,4057,4064],{"nctId":4040,"briefTitle":4041,"status":67,"phases":4042,"primaryCompletion":4043,"completion":4043,"start":2402,"enrollment":4044,"conditions":4045,"interventions":4046},"NCT00381485","Effects of Mometasone Furoate\u002FFormoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED)",[50],"2008-01-01",834,[17],[4047,4047,4029],"Mometasone furoate\u002Fformoterol (MF\u002FF) combination",{"nctId":4049,"briefTitle":4050,"status":67,"phases":4051,"primaryCompletion":451,"completion":451,"start":1095,"enrollment":4052,"conditions":4053,"interventions":4055},"NCT00383721","Effects of Mometasone Furoate\u002FFormoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED)",[50],1196,[4054],"Chronic Obstructive Pulmonary Disease (COPD)",[4047,4047,4029,4056],"Formoterol MDI",{"nctId":4058,"briefTitle":4059,"status":67,"phases":4060,"primaryCompletion":451,"completion":451,"start":359,"enrollment":4061,"conditions":4062,"interventions":4063},"NCT00383435","Effects of Mometasone Furoate\u002FFormoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED)",[50],1055,[4054],[4047,4047,4029,4056],{"nctId":4065,"briefTitle":4066,"status":67,"phases":4067,"primaryCompletion":275,"completion":275,"start":1095,"enrollment":4068,"conditions":4069,"interventions":4070},"NCT00383552","Effects of Mometasone Furoate\u002FFormoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED)",[50],746,[17],[4071,4072,4073],"Mometasone Furoate\u002FFormoterol Fumarate Combination MDI 100\u002F10 mcg BID","Mometasone Furoate MDI","Formoterol Fumarate 10 mcg",{"trials":4075,"activeCount":59},[],{"trials":4077,"activeCount":59},[],{"intervention":1070,"totalTrials":682,"cells":4079},{"EARLY_PHASE1":4080,"PHASE1":4082,"PHASE2":4084,"PHASE3":4086,"PHASE4":4108,"NA":4110},{"trials":4081,"activeCount":59},[],{"trials":4083,"activeCount":59},[],{"trials":4085,"activeCount":59},[],{"trials":4087,"activeCount":59},[4088,4096,4100,4104],{"nctId":4089,"briefTitle":4090,"status":67,"phases":4091,"primaryCompletion":1066,"completion":1066,"start":2730,"enrollment":4092,"conditions":4093,"interventions":4094},"NCT00092651","A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038)",[50],1398,[14],[1070,4095],"Comparators: simvastatin and ezetimibe",{"nctId":1062,"briefTitle":1063,"status":67,"phases":4097,"primaryCompletion":1065,"completion":1065,"start":1066,"enrollment":1067,"conditions":4098,"interventions":4099},[50],[14],[1070,755],{"nctId":3987,"briefTitle":3988,"status":67,"phases":4101,"primaryCompletion":461,"completion":461,"start":646,"enrollment":3990,"conditions":4102,"interventions":4103},[50],[14],[1070,3993],{"nctId":1079,"briefTitle":1080,"status":67,"phases":4105,"primaryCompletion":1082,"completion":1082,"start":1083,"enrollment":1084,"conditions":4106,"interventions":4107},[50],[1086,14],[1070,1088,755],{"trials":4109,"activeCount":59},[],{"trials":4111,"activeCount":59},[],{"intervention":3546,"totalTrials":1549,"cells":4113},{"EARLY_PHASE1":4114,"PHASE1":4116,"PHASE2":4118,"PHASE3":4120,"PHASE4":4142,"NA":4144},{"trials":4115,"activeCount":59},[],{"trials":4117,"activeCount":59},[],{"trials":4119,"activeCount":59},[],{"trials":4121,"activeCount":59},[4122,4126,4138],{"nctId":3537,"briefTitle":3538,"status":67,"phases":4123,"primaryCompletion":3540,"completion":3541,"start":3542,"enrollment":3543,"conditions":4124,"interventions":4125},[50],[3534],[3504,3546,652],{"nctId":4127,"briefTitle":4128,"status":67,"phases":4129,"primaryCompletion":4130,"completion":4130,"start":4131,"enrollment":4132,"conditions":4133,"interventions":4135},"NCT00894556","A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)",[50],"2010-01-12","2009-06-10",109,[4134],"Acute Migraine",[4136,652,4137],"rizatriptan","Comparator: Sumatriptan",{"nctId":3558,"briefTitle":3559,"status":67,"phases":4139,"primaryCompletion":3540,"completion":3541,"start":3561,"enrollment":3562,"conditions":4140,"interventions":4141},[50],[3534],[3504,3504,3546,652],{"trials":4143,"activeCount":59},[],{"trials":4145,"activeCount":59},[],{"intervention":3763,"totalTrials":1549,"cells":4147},{"EARLY_PHASE1":4148,"PHASE1":4150,"PHASE2":4152,"PHASE3":4154,"PHASE4":4168,"NA":4170},{"trials":4149,"activeCount":59},[],{"trials":4151,"activeCount":59},[],{"trials":4153,"activeCount":59},[],{"trials":4155,"activeCount":59},[4156,4160,4164],{"nctId":3756,"briefTitle":3757,"status":67,"phases":4157,"primaryCompletion":1082,"completion":1082,"start":1956,"enrollment":3759,"conditions":4158,"interventions":4159},[50],[3761],[3744,3763],{"nctId":3782,"briefTitle":3783,"status":67,"phases":4161,"primaryCompletion":3785,"completion":3785,"start":3786,"enrollment":3787,"conditions":4162,"interventions":4163},[50],[2995],[3744,3763],{"nctId":3791,"briefTitle":3792,"status":67,"phases":4165,"primaryCompletion":350,"completion":350,"start":3794,"enrollment":3795,"conditions":4166,"interventions":4167},[50],[3797],[3744,3763],{"trials":4169,"activeCount":59},[],{"trials":4171,"activeCount":59},[],{"intervention":4173,"totalTrials":1549,"cells":4174},"losartan potassium (+) hydrochlorothiazide",{"EARLY_PHASE1":4175,"PHASE1":4177,"PHASE2":4179,"PHASE3":4181,"PHASE4":4210,"NA":4212},{"trials":4176,"activeCount":59},[],{"trials":4178,"activeCount":59},[],{"trials":4180,"activeCount":59},[],{"trials":4182,"activeCount":59},[4183,4193,4201],{"nctId":4184,"briefTitle":4185,"status":67,"phases":4186,"primaryCompletion":4187,"completion":4188,"start":4189,"enrollment":791,"conditions":4190,"interventions":4191},"NCT00546754","BP-EASE -Effectiveness of Losartan 50 mg\u002FHydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg\u002FHCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)",[50],"2009-04-01","2009-05-01","2007-05-01",[26],[4173,4192],"Comparator: Valsartan (+) Hydrochlorothiazide",{"nctId":4194,"briefTitle":4195,"status":67,"phases":4196,"primaryCompletion":4043,"completion":4043,"start":253,"enrollment":4197,"conditions":4198,"interventions":4200},"NCT00546052","A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)",[50],1738,[26,4199],"Metabolic Disorder",[4173],{"nctId":4202,"briefTitle":4203,"status":67,"phases":4204,"primaryCompletion":4205,"completion":974,"start":4206,"enrollment":4207,"conditions":4208,"interventions":4209},"NCT00398541","Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients (0954A-322)",[50],"2007-04-10","2005-03-01",41,[26],[4173],{"trials":4211,"activeCount":59},[],{"trials":4213,"activeCount":59},[],{"intervention":4047,"totalTrials":1549,"cells":4215},{"EARLY_PHASE1":4216,"PHASE1":4218,"PHASE2":4220,"PHASE3":4222,"PHASE4":4236,"NA":4238},{"trials":4217,"activeCount":59},[],{"trials":4219,"activeCount":59},[],{"trials":4221,"activeCount":59},[],{"trials":4223,"activeCount":59},[4224,4228,4232],{"nctId":4040,"briefTitle":4041,"status":67,"phases":4225,"primaryCompletion":4043,"completion":4043,"start":2402,"enrollment":4044,"conditions":4226,"interventions":4227},[50],[17],[4047,4047,4029],{"nctId":4049,"briefTitle":4050,"status":67,"phases":4229,"primaryCompletion":451,"completion":451,"start":1095,"enrollment":4052,"conditions":4230,"interventions":4231},[50],[4054],[4047,4047,4029,4056],{"nctId":4058,"briefTitle":4059,"status":67,"phases":4233,"primaryCompletion":451,"completion":451,"start":359,"enrollment":4061,"conditions":4234,"interventions":4235},[50],[4054],[4047,4047,4029,4056],{"trials":4237,"activeCount":59},[],{"trials":4239,"activeCount":59},[],{"intervention":3626,"totalTrials":1549,"cells":4241},{"EARLY_PHASE1":4242,"PHASE1":4244,"PHASE2":4246,"PHASE3":4248,"PHASE4":4262,"NA":4264},{"trials":4243,"activeCount":59},[],{"trials":4245,"activeCount":59},[],{"trials":4247,"activeCount":59},[],{"trials":4249,"activeCount":59},[4250,4254,4258],{"nctId":3618,"briefTitle":3619,"status":67,"phases":4251,"primaryCompletion":3621,"completion":3621,"start":3622,"enrollment":3623,"conditions":4252,"interventions":4253},[50],[23],[3589,3626],{"nctId":3628,"briefTitle":3629,"status":67,"phases":4255,"primaryCompletion":402,"completion":402,"start":359,"enrollment":3631,"conditions":4256,"interventions":4257},[50],[23],[3589,3626],{"nctId":3644,"briefTitle":3645,"status":67,"phases":4259,"primaryCompletion":275,"completion":275,"start":1299,"enrollment":3647,"conditions":4260,"interventions":4261},[50],[23],[3589,3626],{"trials":4263,"activeCount":59},[],{"trials":4265,"activeCount":59},[],{"intervention":1512,"totalTrials":1549,"cells":4267},{"EARLY_PHASE1":4268,"PHASE1":4270,"PHASE2":4272,"PHASE3":4274,"PHASE4":4295,"NA":4297},{"trials":4269,"activeCount":59},[],{"trials":4271,"activeCount":59},[],{"trials":4273,"activeCount":59},[],{"trials":4275,"activeCount":59},[4276,4280,4284],{"nctId":1503,"briefTitle":1504,"status":67,"phases":4277,"primaryCompletion":1506,"completion":1506,"start":1507,"enrollment":1508,"conditions":4278,"interventions":4279},[50],[14],[1511,1492,1512,1513,1514],{"nctId":1525,"briefTitle":1526,"status":67,"phases":4281,"primaryCompletion":1528,"completion":1528,"start":1529,"enrollment":1530,"conditions":4282,"interventions":4283},[50],[14],[1492,1533,1512,1534,1513],{"nctId":4285,"briefTitle":4286,"status":67,"phases":4287,"primaryCompletion":4288,"completion":4288,"start":274,"enrollment":4289,"conditions":4290,"interventions":4291},"NCT00782184","Ezetimibe\u002FSimvastatin (10 mg\u002F40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)",[50],"2010-09",250,[14],[4292,4293,4294],"ezetimibe\u002Fsimvastatin 10\u002F40","atorvastatin 40 mg","atorvastatin 20 mg",{"trials":4296,"activeCount":59},[],{"trials":4298,"activeCount":59},[],{"intervention":1513,"totalTrials":1549,"cells":4300},{"EARLY_PHASE1":4301,"PHASE1":4303,"PHASE2":4305,"PHASE3":4307,"PHASE4":4321,"NA":4323},{"trials":4302,"activeCount":59},[],{"trials":4304,"activeCount":59},[],{"trials":4306,"activeCount":59},[],{"trials":4308,"activeCount":59},[4309,4313,4317],{"nctId":1503,"briefTitle":1504,"status":67,"phases":4310,"primaryCompletion":1506,"completion":1506,"start":1507,"enrollment":1508,"conditions":4311,"interventions":4312},[50],[14],[1511,1492,1512,1513,1514],{"nctId":1525,"briefTitle":1526,"status":67,"phases":4314,"primaryCompletion":1528,"completion":1528,"start":1529,"enrollment":1530,"conditions":4315,"interventions":4316},[50],[14],[1492,1533,1512,1534,1513],{"nctId":4285,"briefTitle":4286,"status":67,"phases":4318,"primaryCompletion":4288,"completion":4288,"start":274,"enrollment":4289,"conditions":4319,"interventions":4320},[50],[14],[4292,4293,4294],{"trials":4322,"activeCount":59},[],{"trials":4324,"activeCount":59},[],{"intervention":4326,"totalTrials":1549,"cells":4327},"Fluticasone propionate",{"EARLY_PHASE1":4328,"PHASE1":4330,"PHASE2":4332,"PHASE3":4334,"PHASE4":4364,"NA":4366},{"trials":4329,"activeCount":59},[],{"trials":4331,"activeCount":59},[],{"trials":4333,"activeCount":59},[],{"trials":4335,"activeCount":59},[4336,4343,4355],{"nctId":4337,"briefTitle":4338,"status":347,"phases":4339,"primaryCompletion":438,"start":1529,"enrollment":59,"conditions":4340,"interventions":4341},"NCT00540839","A Study of Montelukast (MK-0476) Compared With Fluticasone in Pediatric Participants With Chronic Asthma (MK-0476-303)",[50],[2003],[4342,4326],"Montelukast sodium",{"nctId":4344,"briefTitle":4345,"status":67,"phases":4346,"primaryCompletion":4347,"completion":4347,"start":4348,"enrollment":4349,"conditions":4350,"interventions":4351},"NCT03882047","Mometasone Furoate Aqueous (MK-0887\u002FSCH 032088) Nasal Spray vs Placebo and FLONASE® in Seasonal Allergic Rhinitis Patients (I94-001)",[50],"1994-09-16","1994-08-11",313,[33],[4352,4326,4353,4354],"Mometasone furoate","Mometasone furoate placebo","Fluticasone propionate placebo",{"nctId":4356,"briefTitle":4357,"status":67,"phases":4358,"primaryCompletion":274,"completion":274,"start":1082,"enrollment":4359,"conditions":4360,"interventions":4362},"NCT00127166","Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)",[50],154,[4361],"Exercise Induced Asthma",[4342,4363,4326],"Salmeterol xinafoate",{"trials":4365,"activeCount":59},[],{"trials":4367,"activeCount":59},[],{"intervention":4369,"totalTrials":8,"cells":4370},"Etoricoxib 90 mg",{"EARLY_PHASE1":4371,"PHASE1":4373,"PHASE2":4375,"PHASE3":4377,"PHASE4":4406,"NA":4408},{"trials":4372,"activeCount":59},[],{"trials":4374,"activeCount":59},[],{"trials":4376,"activeCount":59},[],{"trials":4378,"activeCount":59},[4379,4394],{"nctId":4380,"briefTitle":4381,"status":67,"phases":4382,"primaryCompletion":4383,"completion":4384,"start":4385,"enrollment":4386,"conditions":4387,"interventions":4389},"NCT00820027","Study of MK-0663\u002FEtoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK-0663-098)",[50],"2010-12-13","2010-12-14","2008-12-15",776,[4388],"Pain, Postoperative",[4369,4390,4391,4392,4393],"Etoricoxib 120 mg","Ibuprofen 600 mg","Morphine","Oxycodone",{"nctId":4395,"briefTitle":4396,"status":67,"phases":4397,"primaryCompletion":4398,"completion":4399,"start":4400,"enrollment":4401,"conditions":4402,"interventions":4404},"NCT01208181","A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)",[50],"2014-06-09","2014-07-29","2010-09-27",1404,[4403],"Arthritis, Rheumatoid",[4405,4369],"Etoricoxib 60 mg",{"trials":4407,"activeCount":59},[],{"trials":4409,"activeCount":59},[],{"intervention":4411,"totalTrials":8,"cells":4412},"ENG-E2 125 μg\u002F300 μg vaginal ring",{"EARLY_PHASE1":4413,"PHASE1":4415,"PHASE2":4417,"PHASE3":4419,"PHASE4":4440,"NA":4442},{"trials":4414,"activeCount":59},[],{"trials":4416,"activeCount":59},[],{"trials":4418,"activeCount":59},[],{"trials":4420,"activeCount":59},[4421,4431],{"nctId":4422,"briefTitle":4423,"status":610,"phases":4424,"primaryCompletion":4425,"completion":4425,"start":4426,"enrollment":4427,"conditions":4428,"interventions":4429},"NCT02616146","Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)",[50],"2016-10-06","2015-12-01",2016,[23],[4411,4430],"LNG-EE 150 μg\u002F30 μg COC",{"nctId":4432,"briefTitle":4433,"status":610,"phases":4434,"primaryCompletion":4435,"completion":4435,"start":4436,"enrollment":4437,"conditions":4438,"interventions":4439},"NCT02524288","Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring in Women at Risk for Pregnancy (MK-8342B-061)",[50],"2016-09-16","2015-08-31",1941,[23],[4411],{"trials":4441,"activeCount":59},[],{"trials":4443,"activeCount":59},[],{"intervention":4445,"totalTrials":8,"cells":4446},"MK0476, montelukast sodium",{"EARLY_PHASE1":4447,"PHASE1":4449,"PHASE2":4451,"PHASE3":4453,"PHASE4":4470,"NA":4472},{"trials":4448,"activeCount":59},[],{"trials":4450,"activeCount":59},[],{"trials":4452,"activeCount":59},[],{"trials":4454,"activeCount":59},[4455,4462],{"nctId":4456,"briefTitle":4457,"status":67,"phases":4458,"primaryCompletion":1290,"completion":1290,"start":1375,"enrollment":4459,"conditions":4460,"interventions":4461},"NCT00092885","An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269)",[50],831,[33,2003],[4445,3355],{"nctId":4463,"briefTitle":4464,"status":67,"phases":4465,"primaryCompletion":209,"completion":4466,"start":4467,"enrollment":101,"conditions":4468,"interventions":4469},"NCT00092105","Study of MK0476 (Montelukast Sodium) and Effects on Asthma and Nasal Symptoms Upon Exposure to Cats (0476-256)",[50],"2003-01-28","2002-04-01",[2003,1293],[4445,3355],{"trials":4471,"activeCount":59},[],{"trials":4473,"activeCount":59},[],{"intervention":1047,"totalTrials":8,"cells":4475},{"EARLY_PHASE1":4476,"PHASE1":4478,"PHASE2":4480,"PHASE3":4482,"PHASE4":4497,"NA":4499},{"trials":4477,"activeCount":59},[],{"trials":4479,"activeCount":59},[],{"trials":4481,"activeCount":59},[],{"trials":4483,"activeCount":59},[4484,4493],{"nctId":4485,"briefTitle":4486,"status":610,"phases":4487,"primaryCompletion":1083,"completion":1083,"start":4488,"enrollment":4489,"conditions":4490,"interventions":4492},"NCT00092833","Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED)",[50],"2002-07",49,[4491,3437],"Hypercholesterolemia, Familial",[1047],{"nctId":1041,"briefTitle":1042,"status":67,"phases":4494,"primaryCompletion":402,"completion":402,"start":439,"enrollment":1044,"conditions":4495,"interventions":4496},[50],[14],[755,652,1047,1048],{"trials":4498,"activeCount":59},[],{"trials":4500,"activeCount":59},[],{"intervention":4136,"totalTrials":8,"cells":4502},{"EARLY_PHASE1":4503,"PHASE1":4505,"PHASE2":4507,"PHASE3":4509,"PHASE4":4525,"NA":4527},{"trials":4504,"activeCount":59},[],{"trials":4506,"activeCount":59},[],{"trials":4508,"activeCount":59},[],{"trials":4510,"activeCount":59},[4511,4521],{"nctId":4512,"briefTitle":4513,"status":67,"phases":4514,"primaryCompletion":4515,"completion":4515,"start":4516,"enrollment":4517,"conditions":4518,"interventions":4520},"NCT01001234","A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)",[50],"2011-04-21","2009-11-30",1382,[4519],"Migraine, Acute",[4136,4136],{"nctId":4127,"briefTitle":4128,"status":67,"phases":4522,"primaryCompletion":4130,"completion":4130,"start":4131,"enrollment":4132,"conditions":4523,"interventions":4524},[50],[4134],[4136,652,4137],{"trials":4526,"activeCount":59},[],{"trials":4528,"activeCount":59},[],{"intervention":4530,"totalTrials":8,"cells":4531},"Comparator: placebo \u002F Duration of Treatment - 1 day",{"EARLY_PHASE1":4532,"PHASE1":4534,"PHASE2":4536,"PHASE3":4538,"PHASE4":4560,"NA":4562},{"trials":4533,"activeCount":59},[],{"trials":4535,"activeCount":59},[],{"trials":4537,"activeCount":59},[],{"trials":4539,"activeCount":59},[4540,4551],{"nctId":4541,"briefTitle":4542,"status":67,"phases":4543,"primaryCompletion":4544,"completion":4545,"start":4546,"enrollment":4547,"conditions":4548,"interventions":4549},"NCT00111722","Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)",[50],"2006-02-15","2006-02-23","2005-05-27",393,[3555],[4550,4530],"MK0462, rizatriptan benzoate \u002F Duration of Treatment -1day",{"nctId":4552,"briefTitle":4553,"status":67,"phases":4554,"primaryCompletion":4555,"completion":4556,"start":4546,"enrollment":4547,"conditions":4557,"interventions":4558},"NCT00111709","Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071)",[50],"2006-02-24","2006-02-26",[3555],[4559,4530],"MK0462, rizatriptan benzoate \u002F Duration of Treatment -1 day",{"trials":4561,"activeCount":59},[],{"trials":4563,"activeCount":59},[],{"intervention":4565,"totalTrials":8,"cells":4566},"Comparator: etoricoxib",{"EARLY_PHASE1":4567,"PHASE1":4569,"PHASE2":4578,"PHASE3":4580,"PHASE4":4593,"NA":4595},{"trials":4568,"activeCount":59},[],{"trials":4570,"activeCount":59},[4571],{"nctId":4572,"briefTitle":4573,"status":67,"phases":4574,"primaryCompletion":875,"completion":875,"start":883,"enrollment":81,"conditions":4575,"interventions":4576},"NCT00945035","Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (0663-070)",[48],[1926],[4577,4565],"etoricoxib",{"trials":4579,"activeCount":59},[],{"trials":4581,"activeCount":59},[4582],{"nctId":4583,"briefTitle":4584,"status":67,"phases":4585,"primaryCompletion":3677,"completion":4586,"start":312,"enrollment":4587,"conditions":4588,"interventions":4590},"NCT00694369","A Study to Asses the Effect of MK0663 in the Treatment of Patients With Postoperative Dental Pain (0663-092)",[50],"2009-01",588,[4589],"Postoperative Dental Pain",[4565,4591,4592,3355],"Comparator: ibuprofen","Comparator: acetaminophen + codeine",{"trials":4594,"activeCount":59},[],{"trials":4596,"activeCount":59},[],{"intervention":215,"totalTrials":8,"cells":4598},{"EARLY_PHASE1":4599,"PHASE1":4601,"PHASE2":4603,"PHASE3":4609,"PHASE4":4615,"NA":4617},{"trials":4600,"activeCount":59},[],{"trials":4602,"activeCount":59},[],{"trials":4604,"activeCount":59},[4605],{"nctId":205,"briefTitle":206,"status":67,"phases":4606,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":4607,"interventions":4608},[49],[212],[214,215,216],{"trials":4610,"activeCount":59},[4611],{"nctId":241,"briefTitle":242,"status":67,"phases":4612,"primaryCompletion":244,"completion":245,"start":246,"enrollment":210,"conditions":4613,"interventions":4614},[50],[212],[214,215,216],{"trials":4616,"activeCount":59},[],{"trials":4618,"activeCount":59},[],{"intervention":216,"totalTrials":8,"cells":4620},{"EARLY_PHASE1":4621,"PHASE1":4623,"PHASE2":4625,"PHASE3":4631,"PHASE4":4637,"NA":4639},{"trials":4622,"activeCount":59},[],{"trials":4624,"activeCount":59},[],{"trials":4626,"activeCount":59},[4627],{"nctId":205,"briefTitle":206,"status":67,"phases":4628,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":4629,"interventions":4630},[49],[212],[214,215,216],{"trials":4632,"activeCount":59},[4633],{"nctId":241,"briefTitle":242,"status":67,"phases":4634,"primaryCompletion":244,"completion":245,"start":246,"enrollment":210,"conditions":4635,"interventions":4636},[50],[212],[214,215,216],{"trials":4638,"activeCount":59},[],{"trials":4640,"activeCount":59},[],{"intervention":1060,"totalTrials":8,"cells":4642},{"EARLY_PHASE1":4643,"PHASE1":4645,"PHASE2":4647,"PHASE3":4649,"PHASE4":4666,"NA":4668},{"trials":4644,"activeCount":59},[],{"trials":4646,"activeCount":59},[],{"trials":4648,"activeCount":59},[],{"trials":4650,"activeCount":59},[4651,4662],{"nctId":4652,"briefTitle":4653,"status":67,"phases":4654,"primaryCompletion":4655,"completion":4656,"start":4657,"enrollment":4658,"conditions":4659,"interventions":4660},"NCT00092157","Effectiveness of Two Approved Drugs in Lowering High Cholesterol (0733-224)",[50],"2003-03-03","2003-03-04","2002-05-01",571,[14],[4661,1060],"MK0733, simvastatin",{"nctId":1050,"briefTitle":1051,"status":67,"phases":4663,"primaryCompletion":974,"completion":974,"start":376,"enrollment":1053,"conditions":4664,"interventions":4665},[50],[14],[1056,755,1057,1058,1059,456,1060],{"trials":4667,"activeCount":59},[],{"trials":4669,"activeCount":59},[],{"intervention":4671,"totalTrials":8,"cells":4672},"asenapine 2.5 mg",{"EARLY_PHASE1":4673,"PHASE1":4675,"PHASE2":4689,"PHASE3":4691,"PHASE4":4706,"NA":4708},{"trials":4674,"activeCount":59},[],{"trials":4676,"activeCount":59},[4677],{"nctId":4678,"briefTitle":4679,"status":67,"phases":4680,"primaryCompletion":4681,"completion":4681,"start":4682,"enrollment":403,"conditions":4683,"interventions":4685},"NCT01206517","A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)",[48],"2011-08-04","2010-07-18",[28,4684],"Bipolar I Disorder",[4686,4687,4688],"Asenapine 2.5 mg","Asenapine 5 mg","Asenapine 10 mg",{"trials":4690,"activeCount":59},[],{"trials":4692,"activeCount":59},[4693],{"nctId":4694,"briefTitle":4695,"status":67,"phases":4696,"primaryCompletion":4697,"completion":4698,"start":4699,"enrollment":975,"conditions":4700,"interventions":4704},"NCT01190254","Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)",[50],"2013-03-10","2013-04-01","2010-09-28",[4701,4702,4703],"Schizophrenia, Paranoid","Schizophrenia, Disorganized","Schizophrenia, Undifferentiated",[4671,4705],"asenapine 5.0 mg",{"trials":4707,"activeCount":59},[],{"trials":4709,"activeCount":59},[],{"intervention":3729,"totalTrials":8,"cells":4711},{"EARLY_PHASE1":4712,"PHASE1":4714,"PHASE2":4716,"PHASE3":4718,"PHASE4":4728,"NA":4730},{"trials":4713,"activeCount":59},[],{"trials":4715,"activeCount":59},[],{"trials":4717,"activeCount":59},[],{"trials":4719,"activeCount":59},[4720,4724],{"nctId":3720,"briefTitle":3721,"status":67,"phases":4721,"primaryCompletion":3723,"completion":3723,"start":3724,"enrollment":3725,"conditions":4722,"interventions":4723},[50],[20],[3667,3728,3355,3729],{"nctId":3731,"briefTitle":3732,"status":67,"phases":4725,"primaryCompletion":3734,"completion":3734,"start":3735,"enrollment":3736,"conditions":4726,"interventions":4727},[50],[20],[3729,3667,3728,3355],{"trials":4729,"activeCount":59},[],{"trials":4731,"activeCount":59},[],{"intervention":4056,"totalTrials":8,"cells":4733},{"EARLY_PHASE1":4734,"PHASE1":4736,"PHASE2":4738,"PHASE3":4740,"PHASE4":4750,"NA":4752},{"trials":4735,"activeCount":59},[],{"trials":4737,"activeCount":59},[],{"trials":4739,"activeCount":59},[],{"trials":4741,"activeCount":59},[4742,4746],{"nctId":4049,"briefTitle":4050,"status":67,"phases":4743,"primaryCompletion":451,"completion":451,"start":1095,"enrollment":4052,"conditions":4744,"interventions":4745},[50],[4054],[4047,4047,4029,4056],{"nctId":4058,"briefTitle":4059,"status":67,"phases":4747,"primaryCompletion":451,"completion":451,"start":359,"enrollment":4061,"conditions":4748,"interventions":4749},[50],[4054],[4047,4047,4029,4056],{"trials":4751,"activeCount":59},[],{"trials":4753,"activeCount":59},[],{"intervention":4687,"totalTrials":8,"cells":4755},{"EARLY_PHASE1":4756,"PHASE1":4758,"PHASE2":4764,"PHASE3":4766,"PHASE4":4777,"NA":4779},{"trials":4757,"activeCount":59},[],{"trials":4759,"activeCount":59},[4760],{"nctId":4678,"briefTitle":4679,"status":67,"phases":4761,"primaryCompletion":4681,"completion":4681,"start":4682,"enrollment":403,"conditions":4762,"interventions":4763},[48],[28,4684],[4686,4687,4688],{"trials":4765,"activeCount":59},[],{"trials":4767,"activeCount":59},[4768],{"nctId":4769,"briefTitle":4770,"status":67,"phases":4771,"primaryCompletion":4772,"completion":4772,"start":4773,"enrollment":4774,"conditions":4775,"interventions":4776},"NCT01098110","6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)",[50],"2014-04-14","2010-05-25",532,[28],[4687,4688],{"trials":4778,"activeCount":59},[],{"trials":4780,"activeCount":59},[],{"intervention":4688,"totalTrials":8,"cells":4782},{"EARLY_PHASE1":4783,"PHASE1":4785,"PHASE2":4791,"PHASE3":4793,"PHASE4":4799,"NA":4801},{"trials":4784,"activeCount":59},[],{"trials":4786,"activeCount":59},[4787],{"nctId":4678,"briefTitle":4679,"status":67,"phases":4788,"primaryCompletion":4681,"completion":4681,"start":4682,"enrollment":403,"conditions":4789,"interventions":4790},[48],[28,4684],[4686,4687,4688],{"trials":4792,"activeCount":59},[],{"trials":4794,"activeCount":59},[4795],{"nctId":4769,"briefTitle":4770,"status":67,"phases":4796,"primaryCompletion":4772,"completion":4772,"start":4773,"enrollment":4774,"conditions":4797,"interventions":4798},[50],[28],[4687,4688],{"trials":4800,"activeCount":59},[],{"trials":4802,"activeCount":59},[],{"intervention":3780,"totalTrials":8,"cells":4804},{"EARLY_PHASE1":4805,"PHASE1":4807,"PHASE2":4809,"PHASE3":4811,"PHASE4":4821,"NA":4823},{"trials":4806,"activeCount":59},[],{"trials":4808,"activeCount":59},[],{"trials":4810,"activeCount":59},[],{"trials":4812,"activeCount":59},[4813,4817],{"nctId":3775,"briefTitle":3776,"status":67,"phases":4814,"primaryCompletion":633,"completion":633,"start":1224,"enrollment":1274,"conditions":4815,"interventions":4816},[50],[2995],[3744,3780],{"nctId":3800,"briefTitle":3801,"status":67,"phases":4818,"primaryCompletion":633,"completion":633,"start":1224,"enrollment":1274,"conditions":4819,"interventions":4820},[50],[2995],[3744,3780],{"trials":4822,"activeCount":59},[],{"trials":4824,"activeCount":59},[],{"intervention":4826,"totalTrials":8,"cells":4827},"Rescue medication",{"EARLY_PHASE1":4828,"PHASE1":4830,"PHASE2":4832,"PHASE3":4834,"PHASE4":4858,"NA":4860},{"trials":4829,"activeCount":59},[],{"trials":4831,"activeCount":59},[],{"trials":4833,"activeCount":59},[],{"trials":4835,"activeCount":59},[4836,4847],{"nctId":4837,"briefTitle":4838,"status":67,"phases":4839,"primaryCompletion":4840,"completion":4840,"start":4841,"enrollment":4842,"conditions":4843,"interventions":4845},"NCT01349907","Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898)",[50],"2014-09-05","2011-06-16",322,[4844],"Bipolar Disorder",[4846,4826],"Asenapine",{"nctId":4848,"briefTitle":4849,"status":67,"phases":4850,"primaryCompletion":4851,"completion":4852,"start":4841,"enrollment":4853,"conditions":4854,"interventions":4856},"NCT01244815","Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)",[50],"2013-08-28","2013-09-17",404,[4855],"Bipolar Disorder, Pediatric",[4857,4826],"asenapine",{"trials":4859,"activeCount":59},[],{"trials":4861,"activeCount":59},[],{"intervention":4863,"totalTrials":8,"cells":4864},"MK0663, Etoricoxib \u002F Duration of Treatment : 12 Weeks",{"EARLY_PHASE1":4865,"PHASE1":4867,"PHASE2":4869,"PHASE3":4871,"PHASE4":4890,"NA":4892},{"trials":4866,"activeCount":59},[],{"trials":4868,"activeCount":59},[],{"trials":4870,"activeCount":59},[],{"trials":4872,"activeCount":59},[4873,4883],{"nctId":4874,"briefTitle":4875,"status":67,"phases":4876,"primaryCompletion":3872,"completion":3872,"start":4877,"enrollment":4878,"conditions":4879,"interventions":4881},"NCT00393354","Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-041)",[50],"2000-04",325,[4880],"Recurrent Low Back Pain",[4863,4882],"Comparator : placebo (unspecified) \u002FDuration of Treatment : 12 Weeks",{"nctId":4884,"briefTitle":4885,"status":67,"phases":4886,"primaryCompletion":3872,"completion":3872,"start":4877,"enrollment":4887,"conditions":4888,"interventions":4889},"NCT00393211","Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-042)",[50],319,[4880],[4863,4882],{"trials":4891,"activeCount":59},[],{"trials":4893,"activeCount":59},[],{"intervention":4882,"totalTrials":8,"cells":4895},{"EARLY_PHASE1":4896,"PHASE1":4898,"PHASE2":4900,"PHASE3":4902,"PHASE4":4912,"NA":4914},{"trials":4897,"activeCount":59},[],{"trials":4899,"activeCount":59},[],{"trials":4901,"activeCount":59},[],{"trials":4903,"activeCount":59},[4904,4908],{"nctId":4874,"briefTitle":4875,"status":67,"phases":4905,"primaryCompletion":3872,"completion":3872,"start":4877,"enrollment":4878,"conditions":4906,"interventions":4907},[50],[4880],[4863,4882],{"nctId":4884,"briefTitle":4885,"status":67,"phases":4909,"primaryCompletion":3872,"completion":3872,"start":4877,"enrollment":4887,"conditions":4910,"interventions":4911},[50],[4880],[4863,4882],{"trials":4913,"activeCount":59},[],{"trials":4915,"activeCount":59},[],{"intervention":4917,"totalTrials":8,"cells":4918},"MK-0954A",{"EARLY_PHASE1":4919,"PHASE1":4921,"PHASE2":4923,"PHASE3":4925,"PHASE4":4946,"NA":4948},{"trials":4920,"activeCount":59},[],{"trials":4922,"activeCount":59},[],{"trials":4924,"activeCount":59},[],{"trials":4926,"activeCount":59},[4927,4937],{"nctId":4928,"briefTitle":4929,"status":67,"phases":4930,"primaryCompletion":4931,"completion":4931,"start":4932,"enrollment":4933,"conditions":4934,"interventions":4935},"NCT01307046","MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)",[50],"2012-02-07","2011-03-29",336,[26],[4917,4936],"Losartan",{"nctId":4938,"briefTitle":4939,"status":67,"phases":4940,"primaryCompletion":4941,"completion":4941,"start":4932,"enrollment":4942,"conditions":4943,"interventions":4944},"NCT01307033","A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)",[50],"2012-12-04",278,[26],[4917,4945],"MK-954H",{"trials":4947,"activeCount":59},[],{"trials":4949,"activeCount":59},[],{"intervention":4951,"totalTrials":8,"cells":4952},"Haloperidol",{"EARLY_PHASE1":4953,"PHASE1":4955,"PHASE2":4957,"PHASE3":4959,"PHASE4":4978,"NA":4980},{"trials":4954,"activeCount":59},[],{"trials":4956,"activeCount":59},[],{"trials":4958,"activeCount":59},[],{"trials":4960,"activeCount":59},[4961,4971],{"nctId":4962,"briefTitle":4963,"status":67,"phases":4964,"primaryCompletion":4965,"completion":4966,"start":4967,"enrollment":4968,"conditions":4969,"interventions":4970},"NCT00156104","Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)",[50],"2006-08-18","2006-09-16","2005-07-01",460,[28],[4846,4846,4951],{"nctId":4972,"briefTitle":4973,"status":67,"phases":4974,"primaryCompletion":589,"completion":580,"start":741,"enrollment":4975,"conditions":4976,"interventions":4977},"NCT00156065","Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)",[50],187,[28],[4951,4846,4846],{"trials":4979,"activeCount":59},[],{"trials":4981,"activeCount":59},[],{"intervention":4983,"totalTrials":8,"cells":4984},"formoterol fumarate 10 mcg",{"EARLY_PHASE1":4985,"PHASE1":4987,"PHASE2":4989,"PHASE3":4991,"PHASE4":5006,"NA":5008},{"trials":4986,"activeCount":59},[],{"trials":4988,"activeCount":59},[],{"trials":4990,"activeCount":59},[],{"trials":4992,"activeCount":59},[4993,5002],{"nctId":4994,"briefTitle":4995,"status":67,"phases":4996,"primaryCompletion":1260,"completion":1260,"start":1095,"enrollment":4997,"conditions":4998,"interventions":4999},"NCT00383240","Effects of Mometasone Furoate\u002FFormoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04334AM1)(COMPLETED)",[50],781,[17],[5000,5001,4983],"mometasone furoate\u002Fformoterol fumarate combination MDI 200\u002F10 mcg BID","Mometasone furoate MDI (MF MDI) 200 mcg",{"nctId":4065,"briefTitle":4066,"status":67,"phases":5003,"primaryCompletion":275,"completion":275,"start":1095,"enrollment":4068,"conditions":5004,"interventions":5005},[50],[17],[4071,4072,4073],{"trials":5007,"activeCount":59},[],{"trials":5009,"activeCount":59},[],{"intervention":168,"totalTrials":8,"cells":5011},{"EARLY_PHASE1":5012,"PHASE1":5014,"PHASE2":5016,"PHASE3":5018,"PHASE4":5028,"NA":5030},{"trials":5013,"activeCount":59},[],{"trials":5015,"activeCount":59},[],{"trials":5017,"activeCount":59},[],{"trials":5019,"activeCount":59},[5020,5024],{"nctId":159,"briefTitle":160,"status":67,"phases":5021,"primaryCompletion":162,"completion":163,"start":164,"enrollment":165,"conditions":5022,"interventions":5023},[50],[73],[168,142],{"nctId":178,"briefTitle":179,"status":67,"phases":5025,"primaryCompletion":181,"completion":181,"start":182,"enrollment":183,"conditions":5026,"interventions":5027},[50],[73],[168,142],{"trials":5029,"activeCount":59},[],{"trials":5031,"activeCount":59},[],{"intervention":5033,"totalTrials":8,"cells":5034},"Nomegestrol acetate",{"EARLY_PHASE1":5035,"PHASE1":5037,"PHASE2":5039,"PHASE3":5053,"PHASE4":5063,"NA":5065},{"trials":5036,"activeCount":59},[],{"trials":5038,"activeCount":59},[],{"trials":5040,"activeCount":59},[5041],{"nctId":5042,"briefTitle":5043,"status":67,"phases":5044,"primaryCompletion":5045,"completion":5045,"start":5046,"enrollment":5047,"conditions":5048,"interventions":5049},"NCT01709318","A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109\u002FMK-8175A\u002FMK-8342B-012)",[49],"2013-10-22","2012-12-12",666,[23],[5033,5050,5051,5052],"Etonogestrel","Ethinyl estradiol","Estradiol",{"trials":5054,"activeCount":59},[5055],{"nctId":5056,"briefTitle":5057,"status":347,"phases":5058,"primaryCompletion":5059,"completion":5059,"start":5060,"enrollment":59,"conditions":5061,"interventions":5062},"NCT01723579","Efficacy and Safety of Oral NOMAC-E2 in Indian Women (P07057\u002FMK-8175A-017)",[50],"2015-05","2013-07",[23],[5033,5052],{"trials":5064,"activeCount":59},[],{"trials":5066,"activeCount":59},[],{"intervention":5052,"totalTrials":8,"cells":5068},{"EARLY_PHASE1":5069,"PHASE1":5071,"PHASE2":5073,"PHASE3":5079,"PHASE4":5085,"NA":5087},{"trials":5070,"activeCount":59},[],{"trials":5072,"activeCount":59},[],{"trials":5074,"activeCount":59},[5075],{"nctId":5042,"briefTitle":5043,"status":67,"phases":5076,"primaryCompletion":5045,"completion":5045,"start":5046,"enrollment":5047,"conditions":5077,"interventions":5078},[49],[23],[5033,5050,5051,5052],{"trials":5080,"activeCount":59},[5081],{"nctId":5056,"briefTitle":5057,"status":347,"phases":5082,"primaryCompletion":5059,"completion":5059,"start":5060,"enrollment":59,"conditions":5083,"interventions":5084},[50],[23],[5033,5052],{"trials":5086,"activeCount":59},[],{"trials":5088,"activeCount":59},[],{"intervention":519,"totalTrials":8,"cells":5090},{"EARLY_PHASE1":5091,"PHASE1":5093,"PHASE2":5095,"PHASE3":5097,"PHASE4":5107,"NA":5109},{"trials":5092,"activeCount":59},[],{"trials":5094,"activeCount":59},[],{"trials":5096,"activeCount":59},[],{"trials":5098,"activeCount":59},[5099,5103],{"nctId":511,"briefTitle":512,"status":67,"phases":5100,"primaryCompletion":514,"completion":514,"start":515,"enrollment":516,"conditions":5101,"interventions":5102},[50],[14],[412,432,519],{"nctId":530,"briefTitle":531,"status":67,"phases":5104,"primaryCompletion":533,"completion":533,"start":515,"enrollment":131,"conditions":5105,"interventions":5106},[50],[14],[412,432,519],{"trials":5108,"activeCount":59},[],{"trials":5110,"activeCount":59},[],{"intervention":5112,"totalTrials":8,"cells":5113},"MK0462, rizatriptan benzoate \u002F Duration of Treatment: 1day",{"EARLY_PHASE1":5114,"PHASE1":5116,"PHASE2":5118,"PHASE3":5120,"PHASE4":5141,"NA":5143},{"trials":5115,"activeCount":59},[],{"trials":5117,"activeCount":59},[],{"trials":5119,"activeCount":59},[],{"trials":5121,"activeCount":59},[5122,5132],{"nctId":5123,"briefTitle":5124,"status":67,"phases":5125,"primaryCompletion":5126,"completion":5127,"start":5128,"enrollment":762,"conditions":5129,"interventions":5130},"NCT00095004","Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)",[50],"2005-04-01","2005-04-04","2004-10-21",[3555],[5112,5131],"Comparator: placebo \u002F Duration of Treatment: 1 day",{"nctId":5133,"briefTitle":5134,"status":67,"phases":5135,"primaryCompletion":5136,"completion":5136,"start":5137,"enrollment":5138,"conditions":5139,"interventions":5140},"NCT00092963","Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)",[50],"2005-01-14","2004-08-17",529,[3555],[5112,5131],{"trials":5142,"activeCount":59},[],{"trials":5144,"activeCount":59},[],{"intervention":5131,"totalTrials":8,"cells":5146},{"EARLY_PHASE1":5147,"PHASE1":5149,"PHASE2":5151,"PHASE3":5153,"PHASE4":5163,"NA":5165},{"trials":5148,"activeCount":59},[],{"trials":5150,"activeCount":59},[],{"trials":5152,"activeCount":59},[],{"trials":5154,"activeCount":59},[5155,5159],{"nctId":5123,"briefTitle":5124,"status":67,"phases":5156,"primaryCompletion":5126,"completion":5127,"start":5128,"enrollment":762,"conditions":5157,"interventions":5158},[50],[3555],[5112,5131],{"nctId":5133,"briefTitle":5134,"status":67,"phases":5160,"primaryCompletion":5136,"completion":5136,"start":5137,"enrollment":5138,"conditions":5161,"interventions":5162},[50],[3555],[5112,5131],{"trials":5164,"activeCount":59},[],{"trials":5166,"activeCount":59},[],{"intervention":5168,"totalTrials":8,"cells":5169},"RecFSH \u002F follitropin beta",{"EARLY_PHASE1":5170,"PHASE1":5172,"PHASE2":5174,"PHASE3":5176,"PHASE4":5204,"NA":5206},{"trials":5171,"activeCount":59},[],{"trials":5173,"activeCount":59},[],{"trials":5175,"activeCount":59},[],{"trials":5177,"activeCount":59},[5178,5188],{"nctId":5179,"briefTitle":5180,"status":67,"phases":5181,"primaryCompletion":5182,"completion":533,"start":5183,"enrollment":5184,"conditions":5185,"interventions":5186},"NCT01144416","Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029)",[50],"2011-07","2010-06",1424,[3128],[5187,5168],"SCH 900962 \u002F Corifollitropin alfa \u002F Org 36286",{"nctId":5189,"briefTitle":5190,"status":67,"phases":5191,"primaryCompletion":5192,"completion":5193,"start":5194,"enrollment":5195,"conditions":5196,"interventions":5198},"NCT00696800","A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)",[50],"2007-11-19","2008-01-15","2006-06-27",1509,[5197],"In Vitro Fertilization",[5199,5200,5200,5201,5202,5203],"Corifollitropin alfa","RecFSH \u002F Follitropin beta","Ganirelix","hCG","Progesterone",{"trials":5205,"activeCount":59},[],{"trials":5207,"activeCount":59},[],{"intervention":673,"totalTrials":8,"cells":5209},{"EARLY_PHASE1":5210,"PHASE1":5212,"PHASE2":5214,"PHASE3":5216,"PHASE4":5231,"NA":5233},{"trials":5211,"activeCount":59},[],{"trials":5213,"activeCount":59},[],{"trials":5215,"activeCount":59},[],{"trials":5217,"activeCount":59},[5218,5227],{"nctId":5219,"briefTitle":5220,"status":67,"phases":5221,"primaryCompletion":360,"completion":360,"start":5222,"enrollment":5223,"conditions":5224,"interventions":5225},"NCT00413972","Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia (Study P04420)",[50],"2006-04",392,[14],[673,5226,5226],"Ezetimibe with Simvastatin",{"nctId":665,"briefTitle":666,"status":67,"phases":5228,"primaryCompletion":668,"completion":668,"start":669,"enrollment":670,"conditions":5229,"interventions":5230},[50],[14],[673,575],{"trials":5232,"activeCount":59},[],{"trials":5234,"activeCount":59},[],{"intervention":5236,"totalTrials":8,"cells":5237},"MK0653A, ezetimibe (+) simvastatin \u002F Duration of Treatment: 6 Weeks",{"EARLY_PHASE1":5238,"PHASE1":5240,"PHASE2":5242,"PHASE3":5244,"PHASE4":5265,"NA":5267},{"trials":5239,"activeCount":59},[],{"trials":5241,"activeCount":59},[],{"trials":5243,"activeCount":59},[],{"trials":5245,"activeCount":59},[5246,5257],{"nctId":5247,"briefTitle":5248,"status":67,"phases":5249,"primaryCompletion":5250,"completion":5251,"start":5252,"enrollment":5253,"conditions":5254,"interventions":5255},"NCT00541697","Eze\u002FSimva Switch Study in Diabetics (0653A-807)",[50],"2005-09-28","2005-10-14","2005-01-19",648,[3849],[5236,5256],"Comparator: atorvastatin \u002F Duration of Treatment: 6 Weeks",{"nctId":5258,"briefTitle":5259,"status":610,"phases":5260,"primaryCompletion":668,"completion":668,"start":1095,"enrollment":5261,"conditions":5262,"interventions":5264},"NCT00395603","Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122)",[50],550,[5263,793],"Cardiovascular Diseases",[5236,5256],{"trials":5266,"activeCount":59},[],{"trials":5268,"activeCount":59},[],{"intervention":5256,"totalTrials":8,"cells":5270},{"EARLY_PHASE1":5271,"PHASE1":5273,"PHASE2":5275,"PHASE3":5277,"PHASE4":5287,"NA":5289},{"trials":5272,"activeCount":59},[],{"trials":5274,"activeCount":59},[],{"trials":5276,"activeCount":59},[],{"trials":5278,"activeCount":59},[5279,5283],{"nctId":5247,"briefTitle":5248,"status":67,"phases":5280,"primaryCompletion":5250,"completion":5251,"start":5252,"enrollment":5253,"conditions":5281,"interventions":5282},[50],[3849],[5236,5256],{"nctId":5258,"briefTitle":5259,"status":610,"phases":5284,"primaryCompletion":668,"completion":668,"start":1095,"enrollment":5261,"conditions":5285,"interventions":5286},[50],[5263,793],[5236,5256],{"trials":5288,"activeCount":59},[],{"trials":5290,"activeCount":59},[],{"intervention":3483,"totalTrials":8,"cells":5292},{"EARLY_PHASE1":5293,"PHASE1":5295,"PHASE2":5297,"PHASE3":5299,"PHASE4":5309,"NA":5311},{"trials":5294,"activeCount":59},[],{"trials":5296,"activeCount":59},[],{"trials":5298,"activeCount":59},[],{"trials":5300,"activeCount":59},[5301,5305],{"nctId":3477,"briefTitle":3478,"status":67,"phases":5302,"primaryCompletion":2479,"completion":2479,"start":875,"enrollment":3480,"conditions":5303,"interventions":5304},[50],[14,746],[3413,3483],{"nctId":3492,"briefTitle":3493,"status":67,"phases":5306,"primaryCompletion":742,"completion":742,"start":3495,"enrollment":3496,"conditions":5307,"interventions":5308},[50],[14,746],[3413,3483],{"trials":5310,"activeCount":59},[],{"trials":5312,"activeCount":59},[],{"intervention":3939,"totalTrials":190,"cells":5314},{"EARLY_PHASE1":5315,"PHASE1":5317,"PHASE2":5319,"PHASE3":5321,"PHASE4":5327,"NA":5329},{"trials":5316,"activeCount":59},[],{"trials":5318,"activeCount":59},[],{"trials":5320,"activeCount":59},[],{"trials":5322,"activeCount":59},[5323],{"nctId":3930,"briefTitle":3931,"status":67,"phases":5324,"primaryCompletion":3933,"completion":3933,"start":3934,"enrollment":3935,"conditions":5325,"interventions":5326},[50],[3923],[3938,3906,3939],{"trials":5328,"activeCount":59},[],{"trials":5330,"activeCount":59},[],{"intervention":4390,"totalTrials":190,"cells":5332},{"EARLY_PHASE1":5333,"PHASE1":5335,"PHASE2":5337,"PHASE3":5339,"PHASE4":5345,"NA":5347},{"trials":5334,"activeCount":59},[],{"trials":5336,"activeCount":59},[],{"trials":5338,"activeCount":59},[],{"trials":5340,"activeCount":59},[5341],{"nctId":4380,"briefTitle":4381,"status":67,"phases":5342,"primaryCompletion":4383,"completion":4384,"start":4385,"enrollment":4386,"conditions":5343,"interventions":5344},[50],[4388],[4369,4390,4391,4392,4393],{"trials":5346,"activeCount":59},[],{"trials":5348,"activeCount":59},[],{"intervention":4391,"totalTrials":190,"cells":5350},{"EARLY_PHASE1":5351,"PHASE1":5353,"PHASE2":5355,"PHASE3":5357,"PHASE4":5363,"NA":5365},{"trials":5352,"activeCount":59},[],{"trials":5354,"activeCount":59},[],{"trials":5356,"activeCount":59},[],{"trials":5358,"activeCount":59},[5359],{"nctId":4380,"briefTitle":4381,"status":67,"phases":5360,"primaryCompletion":4383,"completion":4384,"start":4385,"enrollment":4386,"conditions":5361,"interventions":5362},[50],[4388],[4369,4390,4391,4392,4393],{"trials":5364,"activeCount":59},[],{"trials":5366,"activeCount":59},[],{"intervention":4392,"totalTrials":190,"cells":5368},{"EARLY_PHASE1":5369,"PHASE1":5371,"PHASE2":5373,"PHASE3":5375,"PHASE4":5381,"NA":5383},{"trials":5370,"activeCount":59},[],{"trials":5372,"activeCount":59},[],{"trials":5374,"activeCount":59},[],{"trials":5376,"activeCount":59},[5377],{"nctId":4380,"briefTitle":4381,"status":67,"phases":5378,"primaryCompletion":4383,"completion":4384,"start":4385,"enrollment":4386,"conditions":5379,"interventions":5380},[50],[4388],[4369,4390,4391,4392,4393],{"trials":5382,"activeCount":59},[],{"trials":5384,"activeCount":59},[],{"intervention":4393,"totalTrials":190,"cells":5386},{"EARLY_PHASE1":5387,"PHASE1":5389,"PHASE2":5391,"PHASE3":5393,"PHASE4":5399,"NA":5401},{"trials":5388,"activeCount":59},[],{"trials":5390,"activeCount":59},[],{"trials":5392,"activeCount":59},[],{"trials":5394,"activeCount":59},[5395],{"nctId":4380,"briefTitle":4381,"status":67,"phases":5396,"primaryCompletion":4383,"completion":4384,"start":4385,"enrollment":4386,"conditions":5397,"interventions":5398},[50],[4388],[4369,4390,4391,4392,4393],{"trials":5400,"activeCount":59},[],{"trials":5402,"activeCount":59},[],{"intervention":4430,"totalTrials":190,"cells":5404},{"EARLY_PHASE1":5405,"PHASE1":5407,"PHASE2":5409,"PHASE3":5411,"PHASE4":5417,"NA":5419},{"trials":5406,"activeCount":59},[],{"trials":5408,"activeCount":59},[],{"trials":5410,"activeCount":59},[],{"trials":5412,"activeCount":59},[5413],{"nctId":4422,"briefTitle":4423,"status":610,"phases":5414,"primaryCompletion":4425,"completion":4425,"start":4426,"enrollment":4427,"conditions":5415,"interventions":5416},[50],[23],[4411,4430],{"trials":5418,"activeCount":59},[],{"trials":5420,"activeCount":59},[],{"intervention":5422,"totalTrials":190,"cells":5423},"SCH No. 418131",{"EARLY_PHASE1":5424,"PHASE1":5426,"PHASE2":5428,"PHASE3":5430,"PHASE4":5441,"NA":5443},{"trials":5425,"activeCount":59},[],{"trials":5427,"activeCount":59},[],{"trials":5429,"activeCount":59},[],{"trials":5431,"activeCount":59},[5432],{"nctId":5433,"briefTitle":5434,"status":67,"phases":5435,"primaryCompletion":5436,"completion":5436,"start":779,"enrollment":5437,"conditions":5438,"interventions":5440},"NCT00604500","A Patient Handling Study of Mometasone Furoate\u002FFormortoral Fumarate (MF\u002FF) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1)",[50],"2008-11-01",272,[17,5439],"COPD",[5422],{"trials":5442,"activeCount":59},[],{"trials":5444,"activeCount":59},[],{"intervention":5446,"totalTrials":190,"cells":5447},"Beclomethasone Dipropionate",{"EARLY_PHASE1":5448,"PHASE1":5450,"PHASE2":5452,"PHASE3":5454,"PHASE4":5467,"NA":5469},{"trials":5449,"activeCount":59},[],{"trials":5451,"activeCount":59},[],{"trials":5453,"activeCount":59},[],{"trials":5455,"activeCount":59},[5456],{"nctId":5457,"briefTitle":5458,"status":67,"phases":5459,"primaryCompletion":5460,"completion":5461,"start":5462,"enrollment":5463,"conditions":5464,"interventions":5465},"NCT03855189","Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)",[50],"1993-10-08","1993-10-22","1993-08-23",345,[20],[5466,5446],"Mometasone Furoate",{"trials":5468,"activeCount":59},[],{"trials":5470,"activeCount":59},[],{"intervention":5472,"totalTrials":190,"cells":5473},"aminophylline hydrate",{"EARLY_PHASE1":5474,"PHASE1":5476,"PHASE2":5478,"PHASE3":5480,"PHASE4":5488,"NA":5490},{"trials":5475,"activeCount":59},[],{"trials":5477,"activeCount":59},[],{"trials":5479,"activeCount":59},[],{"trials":5481,"activeCount":59},[5482],{"nctId":5483,"briefTitle":5484,"status":67,"phases":5485,"primaryCompletion":1261,"completion":1261,"start":284,"enrollment":3101,"conditions":5486,"interventions":5487},"NCT00442338","Study of MK-0476 in Adult Patients With Acute Asthma (0476-334)",[50],[17],[2626,2626,5472],{"trials":5489,"activeCount":59},[],{"trials":5491,"activeCount":59},[],{"intervention":5493,"totalTrials":190,"cells":5494},"etoricoxib (MK0663) 120 mg",{"EARLY_PHASE1":5495,"PHASE1":5497,"PHASE2":5499,"PHASE3":5501,"PHASE4":5512,"NA":5514},{"trials":5496,"activeCount":59},[],{"trials":5498,"activeCount":59},[],{"trials":5500,"activeCount":59},[],{"trials":5502,"activeCount":59},[5503],{"nctId":5504,"briefTitle":5505,"status":67,"phases":5506,"primaryCompletion":451,"completion":451,"start":292,"enrollment":5507,"conditions":5508,"interventions":5510},"NCT00788710","A Study of MK0663\u002FEtoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED)",[50],430,[5509],"Acute Pain Following a Total Abdominal Hysterectomy",[5493,652,5511],"etoricoxib (MK0663) 90 mg",{"trials":5513,"activeCount":59},[],{"trials":5515,"activeCount":59},[],{"intervention":5511,"totalTrials":190,"cells":5517},{"EARLY_PHASE1":5518,"PHASE1":5520,"PHASE2":5522,"PHASE3":5524,"PHASE4":5530,"NA":5532},{"trials":5519,"activeCount":59},[],{"trials":5521,"activeCount":59},[],{"trials":5523,"activeCount":59},[],{"trials":5525,"activeCount":59},[5526],{"nctId":5504,"briefTitle":5505,"status":67,"phases":5527,"primaryCompletion":451,"completion":451,"start":292,"enrollment":5507,"conditions":5528,"interventions":5529},[50],[5509],[5493,652,5511],{"trials":5531,"activeCount":59},[],{"trials":5533,"activeCount":59},[],{"intervention":5535,"totalTrials":190,"cells":5536},"mometasone furoate combination MDI 200\u002F10 mcg BID",{"EARLY_PHASE1":5537,"PHASE1":5539,"PHASE2":5541,"PHASE3":5543,"PHASE4":5554,"NA":5556},{"trials":5538,"activeCount":59},[],{"trials":5540,"activeCount":59},[],{"trials":5542,"activeCount":59},[],{"trials":5544,"activeCount":59},[5545],{"nctId":5546,"briefTitle":5547,"status":67,"phases":5548,"primaryCompletion":1529,"completion":1529,"start":1299,"enrollment":4853,"conditions":5549,"interventions":5550},"NCT00379288","Study of Mometasone Furoate\u002FFormoterol Combination and Fluticasone\u002FSalmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)",[50],[17],[5535,5551,5552,5553],"mometasone furoate combination MDI 400\u002F10 mcg BID","Fluticasone\u002FSalmeterol 250\u002F50 mcg BID","Fluticasone\u002FSalmeterol 500\u002F50 mcg BID",{"trials":5555,"activeCount":59},[],{"trials":5557,"activeCount":59},[],{"intervention":5551,"totalTrials":190,"cells":5559},{"EARLY_PHASE1":5560,"PHASE1":5562,"PHASE2":5564,"PHASE3":5566,"PHASE4":5572,"NA":5574},{"trials":5561,"activeCount":59},[],{"trials":5563,"activeCount":59},[],{"trials":5565,"activeCount":59},[],{"trials":5567,"activeCount":59},[5568],{"nctId":5546,"briefTitle":5547,"status":67,"phases":5569,"primaryCompletion":1529,"completion":1529,"start":1299,"enrollment":4853,"conditions":5570,"interventions":5571},[50],[17],[5535,5551,5552,5553],{"trials":5573,"activeCount":59},[],{"trials":5575,"activeCount":59},[],{"intervention":5552,"totalTrials":190,"cells":5577},{"EARLY_PHASE1":5578,"PHASE1":5580,"PHASE2":5582,"PHASE3":5584,"PHASE4":5590,"NA":5592},{"trials":5579,"activeCount":59},[],{"trials":5581,"activeCount":59},[],{"trials":5583,"activeCount":59},[],{"trials":5585,"activeCount":59},[5586],{"nctId":5546,"briefTitle":5547,"status":67,"phases":5587,"primaryCompletion":1529,"completion":1529,"start":1299,"enrollment":4853,"conditions":5588,"interventions":5589},[50],[17],[5535,5551,5552,5553],{"trials":5591,"activeCount":59},[],{"trials":5593,"activeCount":59},[],{"intervention":5553,"totalTrials":190,"cells":5595},{"EARLY_PHASE1":5596,"PHASE1":5598,"PHASE2":5600,"PHASE3":5602,"PHASE4":5608,"NA":5610},{"trials":5597,"activeCount":59},[],{"trials":5599,"activeCount":59},[],{"trials":5601,"activeCount":59},[],{"trials":5603,"activeCount":59},[5604],{"nctId":5546,"briefTitle":5547,"status":67,"phases":5605,"primaryCompletion":1529,"completion":1529,"start":1299,"enrollment":4853,"conditions":5606,"interventions":5607},[50],[17],[5535,5551,5552,5553],{"trials":5609,"activeCount":59},[],{"trials":5611,"activeCount":59},[],{"intervention":3616,"totalTrials":190,"cells":5613},{"EARLY_PHASE1":5614,"PHASE1":5616,"PHASE2":5618,"PHASE3":5620,"PHASE4":5626,"NA":5628},{"trials":5615,"activeCount":59},[],{"trials":5617,"activeCount":59},[],{"trials":5619,"activeCount":59},[],{"trials":5621,"activeCount":59},[5622],{"nctId":3610,"briefTitle":3611,"status":67,"phases":5623,"primaryCompletion":402,"completion":402,"start":359,"enrollment":3613,"conditions":5624,"interventions":5625},[50],[23],[3589,3616],{"trials":5627,"activeCount":59},[],{"trials":5629,"activeCount":59},[],{"intervention":5631,"totalTrials":190,"cells":5632},"MK0476, montelukast sodium \u002F Duration of Treatment: 1 Year",{"EARLY_PHASE1":5633,"PHASE1":5635,"PHASE2":5637,"PHASE3":5639,"PHASE4":5651,"NA":5653},{"trials":5634,"activeCount":59},[],{"trials":5636,"activeCount":59},[],{"trials":5638,"activeCount":59},[],{"trials":5640,"activeCount":59},[5641],{"nctId":5642,"briefTitle":5643,"status":67,"phases":5644,"primaryCompletion":5645,"completion":5645,"start":5646,"enrollment":5647,"conditions":5648,"interventions":5649},"NCT00489346","A Study to Evaluate MK0476 and Fluticasone to Control Asthma in Patients With Mild Persistent Asthma (0476-910)",[50],"2002-06","2001-10",994,[2003],[5631,5650],"Comparator : fluticasone propionate \u002F Duration of Treatment: 1 Year",{"trials":5652,"activeCount":59},[],{"trials":5654,"activeCount":59},[],{"intervention":5650,"totalTrials":190,"cells":5656},{"EARLY_PHASE1":5657,"PHASE1":5659,"PHASE2":5661,"PHASE3":5663,"PHASE4":5669,"NA":5671},{"trials":5658,"activeCount":59},[],{"trials":5660,"activeCount":59},[],{"trials":5662,"activeCount":59},[],{"trials":5664,"activeCount":59},[5665],{"nctId":5642,"briefTitle":5643,"status":67,"phases":5666,"primaryCompletion":5645,"completion":5645,"start":5646,"enrollment":5647,"conditions":5667,"interventions":5668},[50],[2003],[5631,5650],{"trials":5670,"activeCount":59},[],{"trials":5672,"activeCount":59},[],{"intervention":5674,"totalTrials":190,"cells":5675},"phenylephrine",{"EARLY_PHASE1":5676,"PHASE1":5678,"PHASE2":5680,"PHASE3":5682,"PHASE4":5693,"NA":5695},{"trials":5677,"activeCount":59},[],{"trials":5679,"activeCount":59},[],{"trials":5681,"activeCount":59},[],{"trials":5683,"activeCount":59},[5684],{"nctId":5685,"briefTitle":5686,"status":67,"phases":5687,"primaryCompletion":439,"completion":439,"start":5688,"enrollment":5689,"conditions":5690,"interventions":5691},"NCT00276016","The Effects of Phenylephrine Compared With Those of Placebo and Pseudoephedrine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis (SAR)(P04579)",[50],"2006-01",39,[33],[5674,5692],"pseudoephedrine",{"trials":5694,"activeCount":59},[],{"trials":5696,"activeCount":59},[],{"intervention":5692,"totalTrials":190,"cells":5698},{"EARLY_PHASE1":5699,"PHASE1":5701,"PHASE2":5703,"PHASE3":5705,"PHASE4":5711,"NA":5713},{"trials":5700,"activeCount":59},[],{"trials":5702,"activeCount":59},[],{"trials":5704,"activeCount":59},[],{"trials":5706,"activeCount":59},[5707],{"nctId":5685,"briefTitle":5686,"status":67,"phases":5708,"primaryCompletion":439,"completion":439,"start":5688,"enrollment":5689,"conditions":5709,"interventions":5710},[50],[33],[5674,5692],{"trials":5712,"activeCount":59},[],{"trials":5714,"activeCount":59},[],{"intervention":229,"totalTrials":190,"cells":5716},{"EARLY_PHASE1":5717,"PHASE1":5719,"PHASE2":5721,"PHASE3":5723,"PHASE4":5729,"NA":5731},{"trials":5718,"activeCount":59},[],{"trials":5720,"activeCount":59},[],{"trials":5722,"activeCount":59},[],{"trials":5724,"activeCount":59},[5725],{"nctId":220,"briefTitle":221,"status":67,"phases":5726,"primaryCompletion":223,"completion":223,"start":224,"enrollment":225,"conditions":5727,"interventions":5728},[50],[227],[196,229],{"trials":5730,"activeCount":59},[],{"trials":5732,"activeCount":59},[],{"intervention":3711,"totalTrials":190,"cells":5734},{"EARLY_PHASE1":5735,"PHASE1":5737,"PHASE2":5739,"PHASE3":5741,"PHASE4":5747,"NA":5749},{"trials":5736,"activeCount":59},[],{"trials":5738,"activeCount":59},[],{"trials":5740,"activeCount":59},[],{"trials":5742,"activeCount":59},[5743],{"nctId":3705,"briefTitle":3706,"status":67,"phases":5744,"primaryCompletion":1095,"completion":1095,"start":1082,"enrollment":3708,"conditions":5745,"interventions":5746},[50],[3701],[3703,3711,652,652],{"trials":5748,"activeCount":59},[],{"trials":5750,"activeCount":59},[],{"intervention":4550,"totalTrials":190,"cells":5752},{"EARLY_PHASE1":5753,"PHASE1":5755,"PHASE2":5757,"PHASE3":5759,"PHASE4":5765,"NA":5767},{"trials":5754,"activeCount":59},[],{"trials":5756,"activeCount":59},[],{"trials":5758,"activeCount":59},[],{"trials":5760,"activeCount":59},[5761],{"nctId":4541,"briefTitle":4542,"status":67,"phases":5762,"primaryCompletion":4544,"completion":4545,"start":4546,"enrollment":4547,"conditions":5763,"interventions":5764},[50],[3555],[4550,4530],{"trials":5766,"activeCount":59},[],{"trials":5768,"activeCount":59},[],{"intervention":4192,"totalTrials":190,"cells":5770},{"EARLY_PHASE1":5771,"PHASE1":5773,"PHASE2":5775,"PHASE3":5777,"PHASE4":5783,"NA":5785},{"trials":5772,"activeCount":59},[],{"trials":5774,"activeCount":59},[],{"trials":5776,"activeCount":59},[],{"trials":5778,"activeCount":59},[5779],{"nctId":4184,"briefTitle":4185,"status":67,"phases":5780,"primaryCompletion":4187,"completion":4188,"start":4189,"enrollment":791,"conditions":5781,"interventions":5782},[50],[26],[4173,4192],{"trials":5784,"activeCount":59},[],{"trials":5786,"activeCount":59},[],{"intervention":4591,"totalTrials":190,"cells":5788},{"EARLY_PHASE1":5789,"PHASE1":5791,"PHASE2":5793,"PHASE3":5795,"PHASE4":5801,"NA":5803},{"trials":5790,"activeCount":59},[],{"trials":5792,"activeCount":59},[],{"trials":5794,"activeCount":59},[],{"trials":5796,"activeCount":59},[5797],{"nctId":4583,"briefTitle":4584,"status":67,"phases":5798,"primaryCompletion":3677,"completion":4586,"start":312,"enrollment":4587,"conditions":5799,"interventions":5800},[50],[4589],[4565,4591,4592,3355],{"trials":5802,"activeCount":59},[],{"trials":5804,"activeCount":59},[],{"intervention":4592,"totalTrials":190,"cells":5806},{"EARLY_PHASE1":5807,"PHASE1":5809,"PHASE2":5811,"PHASE3":5813,"PHASE4":5819,"NA":5821},{"trials":5808,"activeCount":59},[],{"trials":5810,"activeCount":59},[],{"trials":5812,"activeCount":59},[],{"trials":5814,"activeCount":59},[5815],{"nctId":4583,"briefTitle":4584,"status":67,"phases":5816,"primaryCompletion":3677,"completion":4586,"start":312,"enrollment":4587,"conditions":5817,"interventions":5818},[50],[4589],[4565,4591,4592,3355],{"trials":5820,"activeCount":59},[],{"trials":5822,"activeCount":59},[],{"intervention":5824,"totalTrials":190,"cells":5825},"MK0476, montelukast sodium \u002F Duration of Treatment: 12 Weeks",{"EARLY_PHASE1":5826,"PHASE1":5828,"PHASE2":5830,"PHASE3":5832,"PHASE4":5842,"NA":5844},{"trials":5827,"activeCount":59},[],{"trials":5829,"activeCount":59},[],{"trials":5831,"activeCount":59},[],{"trials":5833,"activeCount":59},[5834],{"nctId":5835,"briefTitle":5836,"status":67,"phases":5837,"primaryCompletion":5838,"completion":5838,"start":5839,"enrollment":101,"conditions":5840,"interventions":5841},"NCT00398151","To Evaluate the Inflammatory Markers in Adult Patients With Asthma Associated With Allergic Rhinitis Receiving Montelukast Therapy (0476-366)",[50],"2006-01-18","2005-08-01",[17],[5824],{"trials":5843,"activeCount":59},[],{"trials":5845,"activeCount":59},[],{"intervention":5847,"totalTrials":190,"cells":5848},"Losartan 50 mg",{"EARLY_PHASE1":5849,"PHASE1":5851,"PHASE2":5853,"PHASE3":5855,"PHASE4":5869,"NA":5871},{"trials":5850,"activeCount":59},[],{"trials":5852,"activeCount":59},[],{"trials":5854,"activeCount":59},[],{"trials":5856,"activeCount":59},[5857],{"nctId":5858,"briefTitle":5859,"status":67,"phases":5860,"primaryCompletion":5861,"completion":5862,"start":5863,"enrollment":5864,"conditions":5865,"interventions":5867},"NCT00090259","Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)",[50],"2009-03-31","2009-05-13","2001-12-19",3834,[5866],"Heart Failure",[5847,5868],"Losartan 150 mg",{"trials":5870,"activeCount":59},[],{"trials":5872,"activeCount":59},[],{"intervention":5868,"totalTrials":190,"cells":5874},{"EARLY_PHASE1":5875,"PHASE1":5877,"PHASE2":5879,"PHASE3":5881,"PHASE4":5887,"NA":5889},{"trials":5876,"activeCount":59},[],{"trials":5878,"activeCount":59},[],{"trials":5880,"activeCount":59},[],{"trials":5882,"activeCount":59},[5883],{"nctId":5858,"briefTitle":5859,"status":67,"phases":5884,"primaryCompletion":5861,"completion":5862,"start":5863,"enrollment":5864,"conditions":5885,"interventions":5886},[50],[5866],[5847,5868],{"trials":5888,"activeCount":59},[],{"trials":5890,"activeCount":59},[],{"intervention":5892,"totalTrials":190,"cells":5893},"MK0663, etoricoxib \u002F Duration of Treatment 12 Weeks",{"EARLY_PHASE1":5894,"PHASE1":5896,"PHASE2":5898,"PHASE3":5900,"PHASE4":5912,"NA":5914},{"trials":5895,"activeCount":59},[],{"trials":5897,"activeCount":59},[],{"trials":5899,"activeCount":59},[],{"trials":5901,"activeCount":59},[5902],{"nctId":5903,"briefTitle":5904,"status":67,"phases":5905,"primaryCompletion":5906,"completion":5907,"start":5908,"enrollment":5909,"conditions":5910,"interventions":5911},"NCT00269191","A Study to Assess the Safety and Efficacy of an Investigational Drug in Patients With Osteoarthritis (0663-071)(COMPLETED)",[50],"2003-11-07","2003-11-21","2003-02-05",528,[2995],[5892],{"trials":5913,"activeCount":59},[],{"trials":5915,"activeCount":59},[],{"intervention":5917,"totalTrials":190,"cells":5918},"MK0954A, hydrochlorothiazide (+) losartan potassium \u002F Duration of Treatment: 12 Weeks",{"EARLY_PHASE1":5919,"PHASE1":5921,"PHASE2":5923,"PHASE3":5925,"PHASE4":5934,"NA":5936},{"trials":5920,"activeCount":59},[],{"trials":5922,"activeCount":59},[],{"trials":5924,"activeCount":59},[],{"trials":5926,"activeCount":59},[5927],{"nctId":5928,"briefTitle":5929,"status":67,"phases":5930,"primaryCompletion":2402,"completion":5931,"start":253,"enrollment":3716,"conditions":5932,"interventions":5933},"NCT00400218","Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)",[50],"2006-07-19",[26],[5917],{"trials":5935,"activeCount":59},[],{"trials":5937,"activeCount":59},[],{"intervention":5939,"totalTrials":190,"cells":5940},"SCH 32088 mometasone furoate (MF) metered-dose inhaler",{"EARLY_PHASE1":5941,"PHASE1":5943,"PHASE2":5945,"PHASE3":5947,"PHASE4":5956,"NA":5958},{"trials":5942,"activeCount":59},[],{"trials":5944,"activeCount":59},[],{"trials":5946,"activeCount":59},[],{"trials":5948,"activeCount":59},[5949],{"nctId":5950,"briefTitle":5951,"status":347,"phases":5952,"primaryCompletion":5953,"completion":5953,"start":3933,"enrollment":59,"conditions":5954,"interventions":5955},"NCT01026870","Efficacy and Safety of Mometasone Furoate for Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids (ICS) (Study P06115)",[50],"2013-12",[17],[5939],{"trials":5957,"activeCount":59},[],{"trials":5959,"activeCount":59},[],{"intervention":5961,"totalTrials":190,"cells":5962},"Comparator: ezetimibe\u002Fsimvastatin + niacin",{"EARLY_PHASE1":5963,"PHASE1":5965,"PHASE2":5967,"PHASE3":5969,"PHASE4":5985,"NA":5987},{"trials":5964,"activeCount":59},[],{"trials":5966,"activeCount":59},[],{"trials":5968,"activeCount":59},[],{"trials":5970,"activeCount":59},[5971],{"nctId":5972,"briefTitle":5973,"status":67,"phases":5974,"primaryCompletion":437,"completion":437,"start":1082,"enrollment":5975,"conditions":5976,"interventions":5977},"NCT00271817","To Evaluate Ezetimibe\u002FSimvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)",[50],1220,[14],[5961,5978,5979,5980,5981,5982,5983,5984],"Comparator: Placebo to ezetimibe\u002Fsimvastatin","Comparator: niacin (ER)","Comparator: ezetimibe (+) simvastatin","Comparator: Placebo to Niacin","Comparator: ezetimibe\u002Fsimvastatin and niacin","Comparator: ezetimibe and simvastatin","Comparator: Placebo to niacin",{"trials":5986,"activeCount":59},[],{"trials":5988,"activeCount":59},[],{"intervention":5978,"totalTrials":190,"cells":5990},{"EARLY_PHASE1":5991,"PHASE1":5993,"PHASE2":5995,"PHASE3":5997,"PHASE4":6003,"NA":6005},{"trials":5992,"activeCount":59},[],{"trials":5994,"activeCount":59},[],{"trials":5996,"activeCount":59},[],{"trials":5998,"activeCount":59},[5999],{"nctId":5972,"briefTitle":5973,"status":67,"phases":6000,"primaryCompletion":437,"completion":437,"start":1082,"enrollment":5975,"conditions":6001,"interventions":6002},[50],[14],[5961,5978,5979,5980,5981,5982,5983,5984],{"trials":6004,"activeCount":59},[],{"trials":6006,"activeCount":59},[],{"intervention":5979,"totalTrials":190,"cells":6008},{"EARLY_PHASE1":6009,"PHASE1":6011,"PHASE2":6013,"PHASE3":6015,"PHASE4":6021,"NA":6023},{"trials":6010,"activeCount":59},[],{"trials":6012,"activeCount":59},[],{"trials":6014,"activeCount":59},[],{"trials":6016,"activeCount":59},[6017],{"nctId":5972,"briefTitle":5973,"status":67,"phases":6018,"primaryCompletion":437,"completion":437,"start":1082,"enrollment":5975,"conditions":6019,"interventions":6020},[50],[14],[5961,5978,5979,5980,5981,5982,5983,5984],{"trials":6022,"activeCount":59},[],{"trials":6024,"activeCount":59},[],{"intervention":5980,"totalTrials":190,"cells":6026},{"EARLY_PHASE1":6027,"PHASE1":6029,"PHASE2":6031,"PHASE3":6033,"PHASE4":6039,"NA":6041},{"trials":6028,"activeCount":59},[],{"trials":6030,"activeCount":59},[],{"trials":6032,"activeCount":59},[],{"trials":6034,"activeCount":59},[6035],{"nctId":5972,"briefTitle":5973,"status":67,"phases":6036,"primaryCompletion":437,"completion":437,"start":1082,"enrollment":5975,"conditions":6037,"interventions":6038},[50],[14],[5961,5978,5979,5980,5981,5982,5983,5984],{"trials":6040,"activeCount":59},[],{"trials":6042,"activeCount":59},[],{"intervention":5981,"totalTrials":190,"cells":6044},{"EARLY_PHASE1":6045,"PHASE1":6047,"PHASE2":6049,"PHASE3":6051,"PHASE4":6057,"NA":6059},{"trials":6046,"activeCount":59},[],{"trials":6048,"activeCount":59},[],{"trials":6050,"activeCount":59},[],{"trials":6052,"activeCount":59},[6053],{"nctId":5972,"briefTitle":5973,"status":67,"phases":6054,"primaryCompletion":437,"completion":437,"start":1082,"enrollment":5975,"conditions":6055,"interventions":6056},[50],[14],[5961,5978,5979,5980,5981,5982,5983,5984],{"trials":6058,"activeCount":59},[],{"trials":6060,"activeCount":59},[],{"intervention":5982,"totalTrials":190,"cells":6062},{"EARLY_PHASE1":6063,"PHASE1":6065,"PHASE2":6067,"PHASE3":6069,"PHASE4":6075,"NA":6077},{"trials":6064,"activeCount":59},[],{"trials":6066,"activeCount":59},[],{"trials":6068,"activeCount":59},[],{"trials":6070,"activeCount":59},[6071],{"nctId":5972,"briefTitle":5973,"status":67,"phases":6072,"primaryCompletion":437,"completion":437,"start":1082,"enrollment":5975,"conditions":6073,"interventions":6074},[50],[14],[5961,5978,5979,5980,5981,5982,5983,5984],{"trials":6076,"activeCount":59},[],{"trials":6078,"activeCount":59},[],{"intervention":5983,"totalTrials":190,"cells":6080},{"EARLY_PHASE1":6081,"PHASE1":6083,"PHASE2":6085,"PHASE3":6087,"PHASE4":6093,"NA":6095},{"trials":6082,"activeCount":59},[],{"trials":6084,"activeCount":59},[],{"trials":6086,"activeCount":59},[],{"trials":6088,"activeCount":59},[6089],{"nctId":5972,"briefTitle":5973,"status":67,"phases":6090,"primaryCompletion":437,"completion":437,"start":1082,"enrollment":5975,"conditions":6091,"interventions":6092},[50],[14],[5961,5978,5979,5980,5981,5982,5983,5984],{"trials":6094,"activeCount":59},[],{"trials":6096,"activeCount":59},[],{"intervention":6098,"totalTrials":190,"cells":6099},"MK0217, alendronate sodium \u002F Duration of Treatment : 5 Years",{"EARLY_PHASE1":6100,"PHASE1":6102,"PHASE2":6104,"PHASE3":6106,"PHASE4":6117,"NA":6119},{"trials":6101,"activeCount":59},[],{"trials":6103,"activeCount":59},[],{"trials":6105,"activeCount":59},[],{"trials":6107,"activeCount":59},[6108],{"nctId":6109,"briefTitle":6110,"status":67,"phases":6111,"primaryCompletion":1290,"completion":1290,"start":6112,"enrollment":6113,"conditions":6114,"interventions":6115},"NCT00398931","FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051)",[50],"1998-02",1099,[2933],[6098,6116],"Comparator : placebo (unspecified) \u002FDuration of Treatment : 5 Years",{"trials":6118,"activeCount":59},[],{"trials":6120,"activeCount":59},[],{"intervention":6116,"totalTrials":190,"cells":6122},{"EARLY_PHASE1":6123,"PHASE1":6125,"PHASE2":6127,"PHASE3":6129,"PHASE4":6135,"NA":6137},{"trials":6124,"activeCount":59},[],{"trials":6126,"activeCount":59},[],{"trials":6128,"activeCount":59},[],{"trials":6130,"activeCount":59},[6131],{"nctId":6109,"briefTitle":6110,"status":67,"phases":6132,"primaryCompletion":1290,"completion":1290,"start":6112,"enrollment":6113,"conditions":6133,"interventions":6134},[50],[2933],[6098,6116],{"trials":6136,"activeCount":59},[],{"trials":6138,"activeCount":59},[],{"intervention":4661,"totalTrials":190,"cells":6140},{"EARLY_PHASE1":6141,"PHASE1":6143,"PHASE2":6145,"PHASE3":6147,"PHASE4":6153,"NA":6155},{"trials":6142,"activeCount":59},[],{"trials":6144,"activeCount":59},[],{"trials":6146,"activeCount":59},[],{"trials":6148,"activeCount":59},[6149],{"nctId":4652,"briefTitle":4653,"status":67,"phases":6150,"primaryCompletion":4655,"completion":4656,"start":4657,"enrollment":4658,"conditions":6151,"interventions":6152},[50],[14],[4661,1060],{"trials":6154,"activeCount":59},[],{"trials":6156,"activeCount":59},[],{"intervention":6158,"totalTrials":190,"cells":6159},"Simivastatin",{"EARLY_PHASE1":6160,"PHASE1":6162,"PHASE2":6164,"PHASE3":6166,"PHASE4":6177,"NA":6179},{"trials":6161,"activeCount":59},[],{"trials":6163,"activeCount":59},[],{"trials":6165,"activeCount":59},[],{"trials":6167,"activeCount":59},[6168],{"nctId":6169,"briefTitle":6170,"status":67,"phases":6171,"primaryCompletion":1506,"completion":1506,"start":6172,"enrollment":6173,"conditions":6174,"interventions":6175},"NCT03882905","A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)",[50],"2001-01-31",769,[563],[432,6158,6176],"Statin",{"trials":6178,"activeCount":59},[],{"trials":6180,"activeCount":59},[],{"intervention":6182,"totalTrials":190,"cells":6183},"Mometasone furoate\u002Fformoterol (MF\u002FF) MDI",{"EARLY_PHASE1":6184,"PHASE1":6186,"PHASE2":6188,"PHASE3":6190,"PHASE4":6199,"NA":6201},{"trials":6185,"activeCount":59},[],{"trials":6187,"activeCount":59},[],{"trials":6189,"activeCount":59},[],{"trials":6191,"activeCount":59},[6192],{"nctId":6193,"briefTitle":6194,"status":67,"phases":6195,"primaryCompletion":274,"completion":274,"start":3076,"enrollment":1360,"conditions":6196,"interventions":6197},"NCT00424008","Study of Inhaled Glucocorticosteroids\u002FLong-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)",[50],[17],[6182,6198],"Fluticasone propionate\u002Fsalmeterol (F\u002FSC) DPI",{"trials":6200,"activeCount":59},[],{"trials":6202,"activeCount":59},[],{"intervention":6198,"totalTrials":190,"cells":6204},{"EARLY_PHASE1":6205,"PHASE1":6207,"PHASE2":6209,"PHASE3":6211,"PHASE4":6217,"NA":6219},{"trials":6206,"activeCount":59},[],{"trials":6208,"activeCount":59},[],{"trials":6210,"activeCount":59},[],{"trials":6212,"activeCount":59},[6213],{"nctId":6193,"briefTitle":6194,"status":67,"phases":6214,"primaryCompletion":274,"completion":274,"start":3076,"enrollment":1360,"conditions":6215,"interventions":6216},[50],[17],[6182,6198],{"trials":6218,"activeCount":59},[],{"trials":6220,"activeCount":59},[],{"intervention":4405,"totalTrials":190,"cells":6222},{"EARLY_PHASE1":6223,"PHASE1":6225,"PHASE2":6227,"PHASE3":6229,"PHASE4":6235,"NA":6237},{"trials":6224,"activeCount":59},[],{"trials":6226,"activeCount":59},[],{"trials":6228,"activeCount":59},[],{"trials":6230,"activeCount":59},[6231],{"nctId":4395,"briefTitle":4396,"status":67,"phases":6232,"primaryCompletion":4398,"completion":4399,"start":4400,"enrollment":4401,"conditions":6233,"interventions":6234},[50],[4403],[4405,4369],{"trials":6236,"activeCount":59},[],{"trials":6238,"activeCount":59},[],{"intervention":6240,"totalTrials":190,"cells":6241},"Comparator: rizatriptan benzoate",{"EARLY_PHASE1":6242,"PHASE1":6244,"PHASE2":6246,"PHASE3":6248,"PHASE4":6259,"NA":6261},{"trials":6243,"activeCount":59},[],{"trials":6245,"activeCount":59},[],{"trials":6247,"activeCount":59},[],{"trials":6249,"activeCount":59},[6250],{"nctId":6251,"briefTitle":6252,"status":67,"phases":6253,"primaryCompletion":6254,"completion":6254,"start":6255,"enrollment":6256,"conditions":6257,"interventions":6258},"NCT00516737","Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)",[50],"2008-04-08","2007-10-03",207,[3555],[6240,652],{"trials":6260,"activeCount":59},[],{"trials":6262,"activeCount":59},[],{"intervention":4705,"totalTrials":190,"cells":6264},{"EARLY_PHASE1":6265,"PHASE1":6267,"PHASE2":6269,"PHASE3":6271,"PHASE4":6277,"NA":6279},{"trials":6266,"activeCount":59},[],{"trials":6268,"activeCount":59},[],{"trials":6270,"activeCount":59},[],{"trials":6272,"activeCount":59},[6273],{"nctId":4694,"briefTitle":4695,"status":67,"phases":6274,"primaryCompletion":4697,"completion":4698,"start":4699,"enrollment":975,"conditions":6275,"interventions":6276},[50],[4701,4702,4703],[4671,4705],{"trials":6278,"activeCount":59},[],{"trials":6280,"activeCount":59},[],{"intervention":6282,"totalTrials":190,"cells":6283},"MK0653, ezetimibe \u002F Duration of Treatment: 27 Weeks",{"EARLY_PHASE1":6284,"PHASE1":6286,"PHASE2":6288,"PHASE3":6290,"PHASE4":6301,"NA":6303},{"trials":6285,"activeCount":59},[],{"trials":6287,"activeCount":59},[],{"trials":6289,"activeCount":59},[],{"trials":6291,"activeCount":59},[6292],{"nctId":6293,"briefTitle":6294,"status":67,"phases":6295,"primaryCompletion":1375,"completion":1375,"start":2322,"enrollment":6296,"conditions":6297,"interventions":6298},"NCT00551447","A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patients at Risk for Heart Disease (0653-023)(COMPLETED)",[50],616,[1036],[6282,6299,6300],"MK0733, simvastatin \u002F Duration of Treatment: 27 Weeks","Comparator: simvastatin \u002F Duration of Treatment: 27 Weeks",{"trials":6302,"activeCount":59},[],{"trials":6304,"activeCount":59},[],{"intervention":6299,"totalTrials":190,"cells":6306},{"EARLY_PHASE1":6307,"PHASE1":6309,"PHASE2":6311,"PHASE3":6313,"PHASE4":6319,"NA":6321},{"trials":6308,"activeCount":59},[],{"trials":6310,"activeCount":59},[],{"trials":6312,"activeCount":59},[],{"trials":6314,"activeCount":59},[6315],{"nctId":6293,"briefTitle":6294,"status":67,"phases":6316,"primaryCompletion":1375,"completion":1375,"start":2322,"enrollment":6296,"conditions":6317,"interventions":6318},[50],[1036],[6282,6299,6300],{"trials":6320,"activeCount":59},[],{"trials":6322,"activeCount":59},[],{"intervention":6300,"totalTrials":190,"cells":6324},{"EARLY_PHASE1":6325,"PHASE1":6327,"PHASE2":6329,"PHASE3":6331,"PHASE4":6337,"NA":6339},{"trials":6326,"activeCount":59},[],{"trials":6328,"activeCount":59},[],{"trials":6330,"activeCount":59},[],{"trials":6332,"activeCount":59},[6333],{"nctId":6293,"briefTitle":6294,"status":67,"phases":6334,"primaryCompletion":1375,"completion":1375,"start":2322,"enrollment":6296,"conditions":6335,"interventions":6336},[50],[1036],[6282,6299,6300],{"trials":6338,"activeCount":59},[],{"trials":6340,"activeCount":59},[],{"intervention":3773,"totalTrials":190,"cells":6342},{"EARLY_PHASE1":6343,"PHASE1":6345,"PHASE2":6347,"PHASE3":6349,"PHASE4":6355,"NA":6357},{"trials":6344,"activeCount":59},[],{"trials":6346,"activeCount":59},[],{"trials":6348,"activeCount":59},[],{"trials":6350,"activeCount":59},[6351],{"nctId":3765,"briefTitle":3766,"status":67,"phases":6352,"primaryCompletion":3768,"completion":3768,"start":3769,"enrollment":3770,"conditions":6353,"interventions":6354},[50],[2995],[3744,3773],{"trials":6356,"activeCount":59},[],{"trials":6358,"activeCount":59},[],{"intervention":6360,"totalTrials":190,"cells":6361},"MK0217, \u002FDuration of Treatment : 12 Months",{"EARLY_PHASE1":6362,"PHASE1":6364,"PHASE2":6366,"PHASE3":6368,"PHASE4":6380,"NA":6382},{"trials":6363,"activeCount":59},[],{"trials":6365,"activeCount":59},[],{"trials":6367,"activeCount":59},[],{"trials":6369,"activeCount":59},[6370],{"nctId":6371,"briefTitle":6372,"status":67,"phases":6373,"primaryCompletion":6374,"completion":6374,"start":6375,"enrollment":6376,"conditions":6377,"interventions":6378},"NCT00389740","A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)",[50],"2003-01-16","2001-04-02",400,[2933],[6360,6379],"Comparator : raloxifene hydrochloride \u002FDuration of Treatment : 12 Months",{"trials":6381,"activeCount":59},[],{"trials":6383,"activeCount":59},[],{"intervention":6379,"totalTrials":190,"cells":6385},{"EARLY_PHASE1":6386,"PHASE1":6388,"PHASE2":6390,"PHASE3":6392,"PHASE4":6398,"NA":6400},{"trials":6387,"activeCount":59},[],{"trials":6389,"activeCount":59},[],{"trials":6391,"activeCount":59},[],{"trials":6393,"activeCount":59},[6394],{"nctId":6371,"briefTitle":6372,"status":67,"phases":6395,"primaryCompletion":6374,"completion":6374,"start":6375,"enrollment":6376,"conditions":6396,"interventions":6397},[50],[2933],[6360,6379],{"trials":6399,"activeCount":59},[],{"trials":6401,"activeCount":59},[],{"intervention":6403,"totalTrials":190,"cells":6404},"Asenapine - Open Label",{"EARLY_PHASE1":6405,"PHASE1":6407,"PHASE2":6409,"PHASE3":6411,"PHASE4":6420,"NA":6422},{"trials":6406,"activeCount":59},[],{"trials":6408,"activeCount":59},[],{"trials":6410,"activeCount":59},[],{"trials":6412,"activeCount":59},[6413],{"nctId":6414,"briefTitle":6415,"status":67,"phases":6416,"primaryCompletion":312,"completion":293,"start":1923,"enrollment":4459,"conditions":6417,"interventions":6418},"NCT00150176","To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)",[50],[28],[6403,6419],"Asenapine - Double Blind",{"trials":6421,"activeCount":59},[],{"trials":6423,"activeCount":59},[],{"intervention":6419,"totalTrials":190,"cells":6425},{"EARLY_PHASE1":6426,"PHASE1":6428,"PHASE2":6430,"PHASE3":6432,"PHASE4":6438,"NA":6440},{"trials":6427,"activeCount":59},[],{"trials":6429,"activeCount":59},[],{"trials":6431,"activeCount":59},[],{"trials":6433,"activeCount":59},[6434],{"nctId":6414,"briefTitle":6415,"status":67,"phases":6435,"primaryCompletion":312,"completion":293,"start":1923,"enrollment":4459,"conditions":6436,"interventions":6437},[50],[28],[6403,6419],{"trials":6439,"activeCount":59},[],{"trials":6441,"activeCount":59},[],{"intervention":499,"totalTrials":190,"cells":6443},{"EARLY_PHASE1":6444,"PHASE1":6446,"PHASE2":6448,"PHASE3":6450,"PHASE4":6456,"NA":6458},{"trials":6445,"activeCount":59},[],{"trials":6447,"activeCount":59},[],{"trials":6449,"activeCount":59},[],{"trials":6451,"activeCount":59},[6452],{"nctId":490,"briefTitle":491,"status":67,"phases":6453,"primaryCompletion":493,"completion":494,"start":495,"enrollment":496,"conditions":6454,"interventions":6455},[50],[14],[499,500,412],{"trials":6457,"activeCount":59},[],{"trials":6459,"activeCount":59},[],{"intervention":500,"totalTrials":190,"cells":6461},{"EARLY_PHASE1":6462,"PHASE1":6464,"PHASE2":6466,"PHASE3":6468,"PHASE4":6474,"NA":6476},{"trials":6463,"activeCount":59},[],{"trials":6465,"activeCount":59},[],{"trials":6467,"activeCount":59},[],{"trials":6469,"activeCount":59},[6470],{"nctId":490,"briefTitle":491,"status":67,"phases":6471,"primaryCompletion":493,"completion":494,"start":495,"enrollment":496,"conditions":6472,"interventions":6473},[50],[14],[499,500,412],{"trials":6475,"activeCount":59},[],{"trials":6477,"activeCount":59},[],{"intervention":3949,"totalTrials":190,"cells":6479},{"EARLY_PHASE1":6480,"PHASE1":6482,"PHASE2":6484,"PHASE3":6486,"PHASE4":6492,"NA":6494},{"trials":6481,"activeCount":59},[],{"trials":6483,"activeCount":59},[],{"trials":6485,"activeCount":59},[],{"trials":6487,"activeCount":59},[6488],{"nctId":3941,"briefTitle":3942,"status":610,"phases":6489,"primaryCompletion":3944,"completion":3944,"start":3945,"enrollment":3946,"conditions":6490,"interventions":6491},[50],[3923],[3949,3906],{"trials":6493,"activeCount":59},[],{"trials":6495,"activeCount":59},[],{"intervention":6497,"totalTrials":190,"cells":6498},"MK0653, ezetimibe \u002F Duration of Treatment: 6 Weeks",{"EARLY_PHASE1":6499,"PHASE1":6501,"PHASE2":6503,"PHASE3":6505,"PHASE4":6514,"NA":6516},{"trials":6500,"activeCount":59},[],{"trials":6502,"activeCount":59},[],{"trials":6504,"activeCount":59},[],{"trials":6506,"activeCount":59},[6507],{"nctId":6508,"briefTitle":6509,"status":67,"phases":6510,"primaryCompletion":570,"completion":570,"start":1180,"enrollment":6511,"conditions":6512,"interventions":6513},"NCT00395473","Ezetimibe Added to Statin Therapy (EASY) Study (0653-087)(COMPLETED)",[50],141,[14],[6497],{"trials":6515,"activeCount":59},[],{"trials":6517,"activeCount":59},[],{"intervention":3463,"totalTrials":190,"cells":6519},{"EARLY_PHASE1":6520,"PHASE1":6522,"PHASE2":6524,"PHASE3":6526,"PHASE4":6532,"NA":6534},{"trials":6521,"activeCount":59},[],{"trials":6523,"activeCount":59},[],{"trials":6525,"activeCount":59},[],{"trials":6527,"activeCount":59},[6528],{"nctId":3457,"briefTitle":3458,"status":67,"phases":6529,"primaryCompletion":1290,"completion":1290,"start":2730,"enrollment":3460,"conditions":6530,"interventions":6531},[50],[14],[3413,3463],{"trials":6533,"activeCount":59},[],{"trials":6535,"activeCount":59},[],{"intervention":6537,"totalTrials":190,"cells":6538},"Radiopaque Etonogestrel (ENG) Implant",{"EARLY_PHASE1":6539,"PHASE1":6541,"PHASE2":6543,"PHASE3":6545,"PHASE4":6556,"NA":6558},{"trials":6540,"activeCount":59},[],{"trials":6542,"activeCount":59},[],{"trials":6544,"activeCount":59},[],{"trials":6546,"activeCount":59},[6547],{"nctId":6548,"briefTitle":6549,"status":67,"phases":6550,"primaryCompletion":6551,"completion":6551,"start":6552,"enrollment":6553,"conditions":6554,"interventions":6555},"NCT04626596","A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060)",[50],"2024-12-30","2020-11-19",498,[23],[6537],{"trials":6557,"activeCount":59},[],{"trials":6559,"activeCount":59},[],{"intervention":1630,"totalTrials":190,"cells":6561},{"EARLY_PHASE1":6562,"PHASE1":6564,"PHASE2":6566,"PHASE3":6568,"PHASE4":6574,"NA":6576},{"trials":6563,"activeCount":59},[],{"trials":6565,"activeCount":59},[],{"trials":6567,"activeCount":59},[],{"trials":6569,"activeCount":59},[6570],{"nctId":1624,"briefTitle":1625,"status":67,"phases":6571,"primaryCompletion":1627,"completion":1627,"start":668,"enrollment":139,"conditions":6572,"interventions":6573},[50],[17],[1321,1630],{"trials":6575,"activeCount":59},[],{"trials":6577,"activeCount":59},[],{"intervention":6579,"totalTrials":190,"cells":6580},"FOSAVANCE 5600",{"EARLY_PHASE1":6581,"PHASE1":6583,"PHASE2":6585,"PHASE3":6587,"PHASE4":6595,"NA":6597},{"trials":6582,"activeCount":59},[],{"trials":6584,"activeCount":59},[],{"trials":6586,"activeCount":59},[],{"trials":6588,"activeCount":59},[6589],{"nctId":6590,"briefTitle":6591,"status":67,"phases":6592,"primaryCompletion":451,"completion":451,"start":312,"enrollment":165,"conditions":6593,"interventions":6594},"NCT00692913","A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262)",[50],[1120],[6579],{"trials":6596,"activeCount":59},[],{"trials":6598,"activeCount":59},[],{"intervention":6600,"totalTrials":190,"cells":6601},"MK0217, alendronate sodium\u002FDuration of Intervention: 12 mo",{"EARLY_PHASE1":6602,"PHASE1":6604,"PHASE2":6606,"PHASE3":6608,"PHASE4":6620,"NA":6622},{"trials":6603,"activeCount":59},[],{"trials":6605,"activeCount":59},[],{"trials":6607,"activeCount":59},[],{"trials":6609,"activeCount":59},[6610],{"nctId":6611,"briefTitle":6612,"status":67,"phases":6613,"primaryCompletion":6614,"completion":5250,"start":6615,"enrollment":6616,"conditions":6617,"interventions":6618},"NCT00092040","A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)",[50],"2004-10-18","2003-03-18",936,[2933],[6600,6619],"Comparator: risedronate \u002F Duration of Intervention: 12 mo",{"trials":6621,"activeCount":59},[],{"trials":6623,"activeCount":59},[],{"intervention":6619,"totalTrials":190,"cells":6625},{"EARLY_PHASE1":6626,"PHASE1":6628,"PHASE2":6630,"PHASE3":6632,"PHASE4":6638,"NA":6640},{"trials":6627,"activeCount":59},[],{"trials":6629,"activeCount":59},[],{"trials":6631,"activeCount":59},[],{"trials":6633,"activeCount":59},[6634],{"nctId":6611,"briefTitle":6612,"status":67,"phases":6635,"primaryCompletion":6614,"completion":5250,"start":6615,"enrollment":6616,"conditions":6636,"interventions":6637},[50],[2933],[6600,6619],{"trials":6639,"activeCount":59},[],{"trials":6641,"activeCount":59},[],{"intervention":6643,"totalTrials":190,"cells":6644},"beclomethasone",{"EARLY_PHASE1":6645,"PHASE1":6647,"PHASE2":6649,"PHASE3":6651,"PHASE4":6660,"NA":6662},{"trials":6646,"activeCount":59},[],{"trials":6648,"activeCount":59},[],{"trials":6650,"activeCount":59},[],{"trials":6652,"activeCount":59},[6653],{"nctId":6654,"briefTitle":6655,"status":67,"phases":6656,"primaryCompletion":3530,"completion":3540,"start":3580,"enrollment":6657,"conditions":6658,"interventions":6659},"NCT00911547","The Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients (0476-029)",[50],642,[17],[2626,6643],{"trials":6661,"activeCount":59},[],{"trials":6663,"activeCount":59},[],{"intervention":4936,"totalTrials":190,"cells":6665},{"EARLY_PHASE1":6666,"PHASE1":6668,"PHASE2":6670,"PHASE3":6672,"PHASE4":6678,"NA":6680},{"trials":6667,"activeCount":59},[],{"trials":6669,"activeCount":59},[],{"trials":6671,"activeCount":59},[],{"trials":6673,"activeCount":59},[6674],{"nctId":4928,"briefTitle":4929,"status":67,"phases":6675,"primaryCompletion":4931,"completion":4931,"start":4932,"enrollment":4933,"conditions":6676,"interventions":6677},[50],[26],[4917,4936],{"trials":6679,"activeCount":59},[],{"trials":6681,"activeCount":59},[],{"intervention":6683,"totalTrials":190,"cells":6684},"MK-0653, ezetimibe",{"EARLY_PHASE1":6685,"PHASE1":6687,"PHASE2":6689,"PHASE3":6691,"PHASE4":6702,"NA":6704},{"trials":6686,"activeCount":59},[],{"trials":6688,"activeCount":59},[],{"trials":6690,"activeCount":59},[],{"trials":6692,"activeCount":59},[6693],{"nctId":6694,"briefTitle":6695,"status":67,"phases":6696,"primaryCompletion":5688,"completion":5688,"start":1782,"enrollment":6697,"conditions":6698,"interventions":6700},"NCT00328523","TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)",[50],1496,[715,6699],"Hyperlipidaemia",[6683,6701],"Duration of Treatment: 3 months",{"trials":6703,"activeCount":59},[],{"trials":6705,"activeCount":59},[],{"intervention":6701,"totalTrials":190,"cells":6707},{"EARLY_PHASE1":6708,"PHASE1":6710,"PHASE2":6712,"PHASE3":6714,"PHASE4":6720,"NA":6722},{"trials":6709,"activeCount":59},[],{"trials":6711,"activeCount":59},[],{"trials":6713,"activeCount":59},[],{"trials":6715,"activeCount":59},[6716],{"nctId":6694,"briefTitle":6695,"status":67,"phases":6717,"primaryCompletion":5688,"completion":5688,"start":1782,"enrollment":6697,"conditions":6718,"interventions":6719},[50],[715,6699],[6683,6701],{"trials":6721,"activeCount":59},[],{"trials":6723,"activeCount":59},[],{"intervention":6725,"totalTrials":190,"cells":6726},"MK0733 \u002F Duration of Treatment: 18 Weeks",{"EARLY_PHASE1":6727,"PHASE1":6729,"PHASE2":6731,"PHASE3":6733,"PHASE4":6746,"NA":6748},{"trials":6728,"activeCount":59},[],{"trials":6730,"activeCount":59},[],{"trials":6732,"activeCount":59},[],{"trials":6734,"activeCount":59},[6735],{"nctId":6736,"briefTitle":6737,"status":67,"phases":6738,"primaryCompletion":6739,"completion":6739,"start":6740,"enrollment":6741,"conditions":6742,"interventions":6744},"NCT00389896","A Crossover Study to Evaluate the Efficacy of Simvastatin in Elevating HDL-C Levels in Patients With Type 2 Diabetes (0733-216)(COMPLETED)",[50],"2002-10-04","2001-07-26",150,[6743],"HDL Cholesterol",[6725,6745],"Comparator: placebo (unspecified) \u002F Duration of Treatment: 18 Weeks",{"trials":6747,"activeCount":59},[],{"trials":6749,"activeCount":59},[],{"intervention":6745,"totalTrials":190,"cells":6751},{"EARLY_PHASE1":6752,"PHASE1":6754,"PHASE2":6756,"PHASE3":6758,"PHASE4":6764,"NA":6766},{"trials":6753,"activeCount":59},[],{"trials":6755,"activeCount":59},[],{"trials":6757,"activeCount":59},[],{"trials":6759,"activeCount":59},[6760],{"nctId":6736,"briefTitle":6737,"status":67,"phases":6761,"primaryCompletion":6739,"completion":6739,"start":6740,"enrollment":6741,"conditions":6762,"interventions":6763},[50],[6743],[6725,6745],{"trials":6765,"activeCount":59},[],{"trials":6767,"activeCount":59},[],{"intervention":6769,"totalTrials":190,"cells":6770},"MK0476, montelukast sodium \u002F Duration of Treatment: 8 Weeks",{"EARLY_PHASE1":6771,"PHASE1":6773,"PHASE2":6775,"PHASE3":6777,"PHASE4":6787,"NA":6789},{"trials":6772,"activeCount":59},[],{"trials":6774,"activeCount":59},[],{"trials":6776,"activeCount":59},[],{"trials":6778,"activeCount":59},[6779],{"nctId":6780,"briefTitle":6781,"status":67,"phases":6782,"primaryCompletion":3622,"completion":6783,"start":761,"enrollment":6784,"conditions":6785,"interventions":6786},"NCT00445107","SINGULAIR (R) as Complementary Therapy to Fixed Association Regimen (0476-363)",[50],"2006-05-17",198,[17],[6769],{"trials":6788,"activeCount":59},[],{"trials":6790,"activeCount":59},[],{"intervention":1863,"totalTrials":190,"cells":6792},{"EARLY_PHASE1":6793,"PHASE1":6795,"PHASE2":6797,"PHASE3":6799,"PHASE4":6805,"NA":6807},{"trials":6794,"activeCount":59},[],{"trials":6796,"activeCount":59},[],{"trials":6798,"activeCount":59},[],{"trials":6800,"activeCount":59},[6801],{"nctId":1855,"briefTitle":1856,"status":67,"phases":6802,"primaryCompletion":1858,"completion":1858,"start":1859,"enrollment":1274,"conditions":6803,"interventions":6804},[50],[17],[1862,1863],{"trials":6806,"activeCount":59},[],{"trials":6808,"activeCount":59},[],{"intervention":6810,"totalTrials":190,"cells":6811},"MK0954, losartan potassium \u002F Duration of Treatment - 12 weeks",{"EARLY_PHASE1":6812,"PHASE1":6814,"PHASE2":6816,"PHASE3":6818,"PHASE4":6829,"NA":6831},{"trials":6813,"activeCount":59},[],{"trials":6815,"activeCount":59},[],{"trials":6817,"activeCount":59},[],{"trials":6819,"activeCount":59},[6820],{"nctId":6821,"briefTitle":6822,"status":610,"phases":6823,"primaryCompletion":6824,"completion":6824,"start":6825,"enrollment":6826,"conditions":6827,"interventions":6828},"NCT00449111","An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg\u002FHydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg\u002FHydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325)",[50],"2006-09-30","2006-03-13",11,[26],[6810],{"trials":6830,"activeCount":59},[],{"trials":6832,"activeCount":59},[],{"intervention":6834,"totalTrials":190,"cells":6835},"MK0653, ezetimibe \u002F Duration of Treatment: 30 Weeks",{"EARLY_PHASE1":6836,"PHASE1":6838,"PHASE2":6840,"PHASE3":6842,"PHASE4":6853,"NA":6855},{"trials":6837,"activeCount":59},[],{"trials":6839,"activeCount":59},[],{"trials":6841,"activeCount":59},[],{"trials":6843,"activeCount":59},[6844],{"nctId":6845,"briefTitle":6846,"status":67,"phases":6847,"primaryCompletion":3794,"completion":3794,"start":6848,"enrollment":6849,"conditions":6850,"interventions":6851},"NCT00551876","Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED)",[50],"2001-12",214,[3849],[6834,6852],"Comparator : ezetimibe (+) simvastatin \u002F Duration of Treatment: 30 Weeks",{"trials":6854,"activeCount":59},[],{"trials":6856,"activeCount":59},[],{"intervention":6852,"totalTrials":190,"cells":6858},{"EARLY_PHASE1":6859,"PHASE1":6861,"PHASE2":6863,"PHASE3":6865,"PHASE4":6871,"NA":6873},{"trials":6860,"activeCount":59},[],{"trials":6862,"activeCount":59},[],{"trials":6864,"activeCount":59},[],{"trials":6866,"activeCount":59},[6867],{"nctId":6845,"briefTitle":6846,"status":67,"phases":6868,"primaryCompletion":3794,"completion":3794,"start":6848,"enrollment":6849,"conditions":6869,"interventions":6870},[50],[3849],[6834,6852],{"trials":6872,"activeCount":59},[],{"trials":6874,"activeCount":59},[],{"intervention":6876,"totalTrials":190,"cells":6877},"Radiopaque Etonogestrel Implant",{"EARLY_PHASE1":6878,"PHASE1":6880,"PHASE2":6882,"PHASE3":6884,"PHASE4":6894,"NA":6896},{"trials":6879,"activeCount":59},[],{"trials":6881,"activeCount":59},[],{"trials":6883,"activeCount":59},[],{"trials":6885,"activeCount":59},[6886],{"nctId":6887,"briefTitle":6888,"status":67,"phases":6889,"primaryCompletion":6890,"completion":6890,"start":284,"enrollment":6891,"conditions":6892,"interventions":6893},"NCT00620035","A Multicenter Trial to Evaluate the Insertion Characteristics of the Radiopaque Etonogestrel Implant Using a Next Generation Applicator (34530)(P05702)",[50],"2010-10",301,[23],[6876],{"trials":6895,"activeCount":59},[],{"trials":6897,"activeCount":59},[],{"intervention":1514,"totalTrials":190,"cells":6899},{"EARLY_PHASE1":6900,"PHASE1":6902,"PHASE2":6904,"PHASE3":6906,"PHASE4":6912,"NA":6914},{"trials":6901,"activeCount":59},[],{"trials":6903,"activeCount":59},[],{"trials":6905,"activeCount":59},[],{"trials":6907,"activeCount":59},[6908],{"nctId":1503,"briefTitle":1504,"status":67,"phases":6909,"primaryCompletion":1506,"completion":1506,"start":1507,"enrollment":1508,"conditions":6910,"interventions":6911},[50],[14],[1511,1492,1512,1513,1514],{"trials":6913,"activeCount":59},[],{"trials":6915,"activeCount":59},[],{"intervention":6917,"totalTrials":190,"cells":6918},"Risedronate 35 mg",{"EARLY_PHASE1":6919,"PHASE1":6921,"PHASE2":6923,"PHASE3":6925,"PHASE4":6939,"NA":6941},{"trials":6920,"activeCount":59},[],{"trials":6922,"activeCount":59},[],{"trials":6924,"activeCount":59},[],{"trials":6926,"activeCount":59},[6927],{"nctId":6928,"briefTitle":6929,"status":67,"phases":6930,"primaryCompletion":6931,"completion":6931,"start":6932,"enrollment":541,"conditions":6933,"interventions":6935},"NCT00092014","A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)",[50],"2004-04-01","2002-09-01",[6934],"Postmenopausal Osteoporosis",[6936,6917,6937,6938],"Alendronate","Risendronate placebo","Alendronate placebo",{"trials":6940,"activeCount":59},[],{"trials":6942,"activeCount":59},[],{"intervention":6937,"totalTrials":190,"cells":6944},{"EARLY_PHASE1":6945,"PHASE1":6947,"PHASE2":6949,"PHASE3":6951,"PHASE4":6957,"NA":6959},{"trials":6946,"activeCount":59},[],{"trials":6948,"activeCount":59},[],{"trials":6950,"activeCount":59},[],{"trials":6952,"activeCount":59},[6953],{"nctId":6928,"briefTitle":6929,"status":67,"phases":6954,"primaryCompletion":6931,"completion":6931,"start":6932,"enrollment":541,"conditions":6955,"interventions":6956},[50],[6934],[6936,6917,6937,6938],{"trials":6958,"activeCount":59},[],{"trials":6960,"activeCount":59},[],{"intervention":6938,"totalTrials":190,"cells":6962},{"EARLY_PHASE1":6963,"PHASE1":6965,"PHASE2":6967,"PHASE3":6969,"PHASE4":6975,"NA":6977},{"trials":6964,"activeCount":59},[],{"trials":6966,"activeCount":59},[],{"trials":6968,"activeCount":59},[],{"trials":6970,"activeCount":59},[6971],{"nctId":6928,"briefTitle":6929,"status":67,"phases":6972,"primaryCompletion":6931,"completion":6931,"start":6932,"enrollment":541,"conditions":6973,"interventions":6974},[50],[6934],[6936,6917,6937,6938],{"trials":6976,"activeCount":59},[],{"trials":6978,"activeCount":59},[],{"intervention":6980,"totalTrials":190,"cells":6981},"Montelukast 10 mg\u002Floratadine 10 mg",{"EARLY_PHASE1":6982,"PHASE1":6984,"PHASE2":6986,"PHASE3":6988,"PHASE4":6999,"NA":7001},{"trials":6983,"activeCount":59},[],{"trials":6985,"activeCount":59},[],{"trials":6987,"activeCount":59},[],{"trials":6989,"activeCount":59},[6990],{"nctId":6991,"briefTitle":6992,"status":67,"phases":6993,"primaryCompletion":6994,"completion":6994,"start":6995,"enrollment":6996,"conditions":6997,"interventions":6998},"NCT01673620","A Study to Evaluate the Safety of Combination Montelukast\u002FLoratadine in Mexican Participants With Allergic Rhinitis (MK-0476A-484)",[50],"2012-10-10","2012-07-04",69,[31],[6980],{"trials":7000,"activeCount":59},[],{"trials":7002,"activeCount":59},[],{"intervention":7004,"totalTrials":190,"cells":7005},"Comparator: losartan +\u002F- HCTZ",{"EARLY_PHASE1":7006,"PHASE1":7008,"PHASE2":7010,"PHASE3":7012,"PHASE4":7021,"NA":7023},{"trials":7007,"activeCount":59},[],{"trials":7009,"activeCount":59},[],{"trials":7011,"activeCount":59},[],{"trials":7013,"activeCount":59},[7014],{"nctId":7015,"briefTitle":7016,"status":67,"phases":7017,"primaryCompletion":368,"completion":284,"start":439,"enrollment":7018,"conditions":7019,"interventions":7020},"NCT00289887","Obese Hypertension Study (0954-315)",[50],261,[26],[7004,652],{"trials":7022,"activeCount":59},[],{"trials":7024,"activeCount":59},[],{"intervention":7026,"totalTrials":190,"cells":7027},"MK0954A, hydrochlorothiazide (+) losartan potassium",{"EARLY_PHASE1":7028,"PHASE1":7030,"PHASE2":7032,"PHASE3":7034,"PHASE4":7045,"NA":7047},{"trials":7029,"activeCount":59},[],{"trials":7031,"activeCount":59},[],{"trials":7033,"activeCount":59},[],{"trials":7035,"activeCount":59},[7036],{"nctId":7037,"briefTitle":7038,"status":67,"phases":7039,"primaryCompletion":883,"completion":883,"start":7040,"enrollment":7041,"conditions":7042,"interventions":7043},"NCT00092209","Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)",[50],"2002-04",840,[26],[7026,7044],"Comparator: placebo, losartan, hydrochlorothiazide",{"trials":7046,"activeCount":59},[],{"trials":7048,"activeCount":59},[],{"intervention":7044,"totalTrials":190,"cells":7050},{"EARLY_PHASE1":7051,"PHASE1":7053,"PHASE2":7055,"PHASE3":7057,"PHASE4":7063,"NA":7065},{"trials":7052,"activeCount":59},[],{"trials":7054,"activeCount":59},[],{"trials":7056,"activeCount":59},[],{"trials":7058,"activeCount":59},[7059],{"nctId":7037,"briefTitle":7038,"status":67,"phases":7060,"primaryCompletion":883,"completion":883,"start":7040,"enrollment":7041,"conditions":7061,"interventions":7062},[50],[26],[7026,7044],{"trials":7064,"activeCount":59},[],{"trials":7066,"activeCount":59},[],{"intervention":7068,"totalTrials":190,"cells":7069},"Part I - etoricoxib 60 mg",{"EARLY_PHASE1":7070,"PHASE1":7072,"PHASE2":7074,"PHASE3":7076,"PHASE4":7098,"NA":7100},{"trials":7071,"activeCount":59},[],{"trials":7073,"activeCount":59},[],{"trials":7075,"activeCount":59},[],{"trials":7077,"activeCount":59},[7078],{"nctId":7079,"briefTitle":7080,"status":67,"phases":7081,"primaryCompletion":7082,"completion":7082,"start":4400,"enrollment":7083,"conditions":7084,"interventions":7086},"NCT01208207","A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)",[50],"2014-11-12",1015,[7085],"Spondylitis, Ankylosing",[7068,7087,7088,7089,7090,7091,7092,7093,7094,7095,7096,7097],"Part I - etoricoxib 90 mg","Part I- naproxen 1000 mg","Part I - Placebo to naproxen 500 mg","Part II- etoricoxib 60 mg","Part II- etoricoxib 90 mg","Part II- naproxen 1000 mg","Part I - Placebo to etoricoxib 60 mg","Part I - Placebo to etoricoxib 90 mg","Part II- Placebo to etoricoxib 60 mg","Part II - Placebo to etoricoxib 90 mg","Part II- Placebo to naproxen 500 mg",{"trials":7099,"activeCount":59},[],{"trials":7101,"activeCount":59},[],{"intervention":7087,"totalTrials":190,"cells":7103},{"EARLY_PHASE1":7104,"PHASE1":7106,"PHASE2":7108,"PHASE3":7110,"PHASE4":7116,"NA":7118},{"trials":7105,"activeCount":59},[],{"trials":7107,"activeCount":59},[],{"trials":7109,"activeCount":59},[],{"trials":7111,"activeCount":59},[7112],{"nctId":7079,"briefTitle":7080,"status":67,"phases":7113,"primaryCompletion":7082,"completion":7082,"start":4400,"enrollment":7083,"conditions":7114,"interventions":7115},[50],[7085],[7068,7087,7088,7089,7090,7091,7092,7093,7094,7095,7096,7097],{"trials":7117,"activeCount":59},[],{"trials":7119,"activeCount":59},[],{"intervention":7088,"totalTrials":190,"cells":7121},{"EARLY_PHASE1":7122,"PHASE1":7124,"PHASE2":7126,"PHASE3":7128,"PHASE4":7134,"NA":7136},{"trials":7123,"activeCount":59},[],{"trials":7125,"activeCount":59},[],{"trials":7127,"activeCount":59},[],{"trials":7129,"activeCount":59},[7130],{"nctId":7079,"briefTitle":7080,"status":67,"phases":7131,"primaryCompletion":7082,"completion":7082,"start":4400,"enrollment":7083,"conditions":7132,"interventions":7133},[50],[7085],[7068,7087,7088,7089,7090,7091,7092,7093,7094,7095,7096,7097],{"trials":7135,"activeCount":59},[],{"trials":7137,"activeCount":59},[],{"intervention":7089,"totalTrials":190,"cells":7139},{"EARLY_PHASE1":7140,"PHASE1":7142,"PHASE2":7144,"PHASE3":7146,"PHASE4":7152,"NA":7154},{"trials":7141,"activeCount":59},[],{"trials":7143,"activeCount":59},[],{"trials":7145,"activeCount":59},[],{"trials":7147,"activeCount":59},[7148],{"nctId":7079,"briefTitle":7080,"status":67,"phases":7149,"primaryCompletion":7082,"completion":7082,"start":4400,"enrollment":7083,"conditions":7150,"interventions":7151},[50],[7085],[7068,7087,7088,7089,7090,7091,7092,7093,7094,7095,7096,7097],{"trials":7153,"activeCount":59},[],{"trials":7155,"activeCount":59},[],{"intervention":7090,"totalTrials":190,"cells":7157},{"EARLY_PHASE1":7158,"PHASE1":7160,"PHASE2":7162,"PHASE3":7164,"PHASE4":7170,"NA":7172},{"trials":7159,"activeCount":59},[],{"trials":7161,"activeCount":59},[],{"trials":7163,"activeCount":59},[],{"trials":7165,"activeCount":59},[7166],{"nctId":7079,"briefTitle":7080,"status":67,"phases":7167,"primaryCompletion":7082,"completion":7082,"start":4400,"enrollment":7083,"conditions":7168,"interventions":7169},[50],[7085],[7068,7087,7088,7089,7090,7091,7092,7093,7094,7095,7096,7097],{"trials":7171,"activeCount":59},[],{"trials":7173,"activeCount":59},[],{"intervention":7091,"totalTrials":190,"cells":7175},{"EARLY_PHASE1":7176,"PHASE1":7178,"PHASE2":7180,"PHASE3":7182,"PHASE4":7188,"NA":7190},{"trials":7177,"activeCount":59},[],{"trials":7179,"activeCount":59},[],{"trials":7181,"activeCount":59},[],{"trials":7183,"activeCount":59},[7184],{"nctId":7079,"briefTitle":7080,"status":67,"phases":7185,"primaryCompletion":7082,"completion":7082,"start":4400,"enrollment":7083,"conditions":7186,"interventions":7187},[50],[7085],[7068,7087,7088,7089,7090,7091,7092,7093,7094,7095,7096,7097],{"trials":7189,"activeCount":59},[],{"trials":7191,"activeCount":59},[],{"intervention":7092,"totalTrials":190,"cells":7193},{"EARLY_PHASE1":7194,"PHASE1":7196,"PHASE2":7198,"PHASE3":7200,"PHASE4":7206,"NA":7208},{"trials":7195,"activeCount":59},[],{"trials":7197,"activeCount":59},[],{"trials":7199,"activeCount":59},[],{"trials":7201,"activeCount":59},[7202],{"nctId":7079,"briefTitle":7080,"status":67,"phases":7203,"primaryCompletion":7082,"completion":7082,"start":4400,"enrollment":7083,"conditions":7204,"interventions":7205},[50],[7085],[7068,7087,7088,7089,7090,7091,7092,7093,7094,7095,7096,7097],{"trials":7207,"activeCount":59},[],{"trials":7209,"activeCount":59},[],{"intervention":7093,"totalTrials":190,"cells":7211},{"EARLY_PHASE1":7212,"PHASE1":7214,"PHASE2":7216,"PHASE3":7218,"PHASE4":7224,"NA":7226},{"trials":7213,"activeCount":59},[],{"trials":7215,"activeCount":59},[],{"trials":7217,"activeCount":59},[],{"trials":7219,"activeCount":59},[7220],{"nctId":7079,"briefTitle":7080,"status":67,"phases":7221,"primaryCompletion":7082,"completion":7082,"start":4400,"enrollment":7083,"conditions":7222,"interventions":7223},[50],[7085],[7068,7087,7088,7089,7090,7091,7092,7093,7094,7095,7096,7097],{"trials":7225,"activeCount":59},[],{"trials":7227,"activeCount":59},[],{"intervention":7094,"totalTrials":190,"cells":7229},{"EARLY_PHASE1":7230,"PHASE1":7232,"PHASE2":7234,"PHASE3":7236,"PHASE4":7242,"NA":7244},{"trials":7231,"activeCount":59},[],{"trials":7233,"activeCount":59},[],{"trials":7235,"activeCount":59},[],{"trials":7237,"activeCount":59},[7238],{"nctId":7079,"briefTitle":7080,"status":67,"phases":7239,"primaryCompletion":7082,"completion":7082,"start":4400,"enrollment":7083,"conditions":7240,"interventions":7241},[50],[7085],[7068,7087,7088,7089,7090,7091,7092,7093,7094,7095,7096,7097],{"trials":7243,"activeCount":59},[],{"trials":7245,"activeCount":59},[],{"intervention":7095,"totalTrials":190,"cells":7247},{"EARLY_PHASE1":7248,"PHASE1":7250,"PHASE2":7252,"PHASE3":7254,"PHASE4":7260,"NA":7262},{"trials":7249,"activeCount":59},[],{"trials":7251,"activeCount":59},[],{"trials":7253,"activeCount":59},[],{"trials":7255,"activeCount":59},[7256],{"nctId":7079,"briefTitle":7080,"status":67,"phases":7257,"primaryCompletion":7082,"completion":7082,"start":4400,"enrollment":7083,"conditions":7258,"interventions":7259},[50],[7085],[7068,7087,7088,7089,7090,7091,7092,7093,7094,7095,7096,7097],{"trials":7261,"activeCount":59},[],{"trials":7263,"activeCount":59},[],{"intervention":7096,"totalTrials":190,"cells":7265},{"EARLY_PHASE1":7266,"PHASE1":7268,"PHASE2":7270,"PHASE3":7272,"PHASE4":7278,"NA":7280},{"trials":7267,"activeCount":59},[],{"trials":7269,"activeCount":59},[],{"trials":7271,"activeCount":59},[],{"trials":7273,"activeCount":59},[7274],{"nctId":7079,"briefTitle":7080,"status":67,"phases":7275,"primaryCompletion":7082,"completion":7082,"start":4400,"enrollment":7083,"conditions":7276,"interventions":7277},[50],[7085],[7068,7087,7088,7089,7090,7091,7092,7093,7094,7095,7096,7097],{"trials":7279,"activeCount":59},[],{"trials":7281,"activeCount":59},[],{"intervention":7097,"totalTrials":190,"cells":7283},{"EARLY_PHASE1":7284,"PHASE1":7286,"PHASE2":7288,"PHASE3":7290,"PHASE4":7296,"NA":7298},{"trials":7285,"activeCount":59},[],{"trials":7287,"activeCount":59},[],{"trials":7289,"activeCount":59},[],{"trials":7291,"activeCount":59},[7292],{"nctId":7079,"briefTitle":7080,"status":67,"phases":7293,"primaryCompletion":7082,"completion":7082,"start":4400,"enrollment":7083,"conditions":7294,"interventions":7295},[50],[7085],[7068,7087,7088,7089,7090,7091,7092,7093,7094,7095,7096,7097],{"trials":7297,"activeCount":59},[],{"trials":7299,"activeCount":59},[],{"intervention":7301,"totalTrials":190,"cells":7302},"gonadatropin releasing hormone",{"EARLY_PHASE1":7303,"PHASE1":7305,"PHASE2":7307,"PHASE3":7309,"PHASE4":7326,"NA":7328},{"trials":7304,"activeCount":59},[],{"trials":7306,"activeCount":59},[],{"trials":7308,"activeCount":59},[],{"trials":7310,"activeCount":59},[7311],{"nctId":7312,"briefTitle":7313,"status":67,"phases":7314,"primaryCompletion":7315,"completion":7316,"start":7317,"enrollment":7318,"conditions":7319,"interventions":7320},"NCT00702845","To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690\u002FMK-8962-001)",[50],"2007-07-07","2007-11-15","2006-12-28",397,[3128],[7321,7322,7301,7323,7324,7325],"corifollitropin alfa","recFSH","human chorion gonadatropin","progesterone","open-label recFSH",{"trials":7327,"activeCount":59},[],{"trials":7329,"activeCount":59},[],{"intervention":3642,"totalTrials":190,"cells":7331},{"EARLY_PHASE1":7332,"PHASE1":7334,"PHASE2":7336,"PHASE3":7338,"PHASE4":7344,"NA":7346},{"trials":7333,"activeCount":59},[],{"trials":7335,"activeCount":59},[],{"trials":7337,"activeCount":59},[],{"trials":7339,"activeCount":59},[7340],{"nctId":3635,"briefTitle":3636,"status":67,"phases":7341,"primaryCompletion":3638,"completion":3638,"start":1095,"enrollment":3639,"conditions":7342,"interventions":7343},[50],[23],[3589,3642],{"trials":7345,"activeCount":59},[],{"trials":7347,"activeCount":59},[],{"intervention":784,"totalTrials":190,"cells":7349},{"EARLY_PHASE1":7350,"PHASE1":7352,"PHASE2":7354,"PHASE3":7356,"PHASE4":7362,"NA":7364},{"trials":7351,"activeCount":59},[],{"trials":7353,"activeCount":59},[],{"trials":7355,"activeCount":59},[],{"trials":7357,"activeCount":59},[7358],{"nctId":776,"briefTitle":777,"status":67,"phases":7359,"primaryCompletion":779,"completion":779,"start":780,"enrollment":781,"conditions":7360,"interventions":7361},[50],[14],[574,784,652,652],{"trials":7363,"activeCount":59},[],{"trials":7365,"activeCount":59},[],{"intervention":7367,"totalTrials":190,"cells":7368},"MK0954, losartan \u002F Duration of Treatment: mean 3.4 years",{"EARLY_PHASE1":7369,"PHASE1":7371,"PHASE2":7373,"PHASE3":7375,"PHASE4":7387,"NA":7389},{"trials":7370,"activeCount":59},[],{"trials":7372,"activeCount":59},[],{"trials":7374,"activeCount":59},[],{"trials":7376,"activeCount":59},[7377],{"nctId":7378,"briefTitle":7379,"status":67,"phases":7380,"primaryCompletion":7381,"completion":3893,"start":3540,"enrollment":7382,"conditions":7383,"interventions":7386},"NCT00308347","A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED)",[50],"2001-02",1513,[7384,7385],"Type 2 Diabetes","Nephropathy",[7367],{"trials":7388,"activeCount":59},[],{"trials":7390,"activeCount":59},[],{"intervention":7392,"totalTrials":190,"cells":7393},"MK0954, \u002FDuration of Treatment : 16 Weeks",{"EARLY_PHASE1":7394,"PHASE1":7396,"PHASE2":7398,"PHASE3":7400,"PHASE4":7412,"NA":7414},{"trials":7395,"activeCount":59},[],{"trials":7397,"activeCount":59},[],{"trials":7399,"activeCount":59},[],{"trials":7401,"activeCount":59},[7402],{"nctId":7403,"briefTitle":7404,"status":67,"phases":7405,"primaryCompletion":7406,"completion":7406,"start":7407,"enrollment":7408,"conditions":7409,"interventions":7410},"NCT00541684","Health Assessment Study (0954-946)",[50],"2003-01-23","2001-07-11",143,[26],[7392,7411],"Comparator : atenolol \u002FDuration of Treatment : 16 Weeks",{"trials":7413,"activeCount":59},[],{"trials":7415,"activeCount":59},[],{"intervention":7411,"totalTrials":190,"cells":7417},{"EARLY_PHASE1":7418,"PHASE1":7420,"PHASE2":7422,"PHASE3":7424,"PHASE4":7430,"NA":7432},{"trials":7419,"activeCount":59},[],{"trials":7421,"activeCount":59},[],{"trials":7423,"activeCount":59},[],{"trials":7425,"activeCount":59},[7426],{"nctId":7403,"briefTitle":7404,"status":67,"phases":7427,"primaryCompletion":7406,"completion":7406,"start":7407,"enrollment":7408,"conditions":7428,"interventions":7429},[50],[26],[7392,7411],{"trials":7431,"activeCount":59},[],{"trials":7433,"activeCount":59},[],{"intervention":4353,"totalTrials":190,"cells":7435},{"EARLY_PHASE1":7436,"PHASE1":7438,"PHASE2":7440,"PHASE3":7442,"PHASE4":7448,"NA":7450},{"trials":7437,"activeCount":59},[],{"trials":7439,"activeCount":59},[],{"trials":7441,"activeCount":59},[],{"trials":7443,"activeCount":59},[7444],{"nctId":4344,"briefTitle":4345,"status":67,"phases":7445,"primaryCompletion":4347,"completion":4347,"start":4348,"enrollment":4349,"conditions":7446,"interventions":7447},[50],[33],[4352,4326,4353,4354],{"trials":7449,"activeCount":59},[],{"trials":7451,"activeCount":59},[],{"intervention":4354,"totalTrials":190,"cells":7453},{"EARLY_PHASE1":7454,"PHASE1":7456,"PHASE2":7458,"PHASE3":7460,"PHASE4":7466,"NA":7468},{"trials":7455,"activeCount":59},[],{"trials":7457,"activeCount":59},[],{"trials":7459,"activeCount":59},[],{"trials":7461,"activeCount":59},[7462],{"nctId":4344,"briefTitle":4345,"status":67,"phases":7463,"primaryCompletion":4347,"completion":4347,"start":4348,"enrollment":4349,"conditions":7464,"interventions":7465},[50],[33],[4352,4326,4353,4354],{"trials":7467,"activeCount":59},[],{"trials":7469,"activeCount":59},[],{"intervention":7471,"totalTrials":190,"cells":7472},"MK0217, alendronate sodium \u002F Duration of Treatment : 2 Years",{"EARLY_PHASE1":7473,"PHASE1":7475,"PHASE2":7477,"PHASE3":7479,"PHASE4":7489,"NA":7491},{"trials":7474,"activeCount":59},[],{"trials":7476,"activeCount":59},[],{"trials":7478,"activeCount":59},[],{"trials":7480,"activeCount":59},[7481],{"nctId":7482,"briefTitle":7483,"status":67,"phases":7484,"primaryCompletion":6112,"start":3531,"enrollment":7485,"conditions":7486,"interventions":7487},"NCT00398606","A Study to Compare the Efficacy of Alendronate With and Without Calcium or Calcium Alone In the Treatment of Osteoporosis in Postmenopausal Women (0217-088)(COMPLETED)",[50],650,[2933],[7471,7488],"Comparator : calcium carbonate \u002FDuration of Treatment : 2 Years",{"trials":7490,"activeCount":59},[],{"trials":7492,"activeCount":59},[],{"intervention":7488,"totalTrials":190,"cells":7494},{"EARLY_PHASE1":7495,"PHASE1":7497,"PHASE2":7499,"PHASE3":7501,"PHASE4":7507,"NA":7509},{"trials":7496,"activeCount":59},[],{"trials":7498,"activeCount":59},[],{"trials":7500,"activeCount":59},[],{"trials":7502,"activeCount":59},[7503],{"nctId":7482,"briefTitle":7483,"status":67,"phases":7504,"primaryCompletion":6112,"start":3531,"enrollment":7485,"conditions":7505,"interventions":7506},[50],[2933],[7471,7488],{"trials":7508,"activeCount":59},[],{"trials":7510,"activeCount":59},[],{"intervention":7512,"totalTrials":190,"cells":7513},"Etoricoxib 30 mg",{"EARLY_PHASE1":7514,"PHASE1":7516,"PHASE2":7518,"PHASE3":7520,"PHASE4":7532,"NA":7534},{"trials":7515,"activeCount":59},[],{"trials":7517,"activeCount":59},[],{"trials":7519,"activeCount":59},[],{"trials":7521,"activeCount":59},[7522],{"nctId":7523,"briefTitle":7524,"status":67,"phases":7525,"primaryCompletion":1899,"completion":1899,"start":7526,"enrollment":7527,"conditions":7528,"interventions":7530},"NCT01554163","Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Participants With Osteoarthritis",[50],"2012-03",239,[7529],"Osteoarthritis of the Knee",[7512,7531],"Celecoxib 200 mg",{"trials":7533,"activeCount":59},[],{"trials":7535,"activeCount":59},[],{"intervention":7531,"totalTrials":190,"cells":7537},{"EARLY_PHASE1":7538,"PHASE1":7540,"PHASE2":7542,"PHASE3":7544,"PHASE4":7550,"NA":7552},{"trials":7539,"activeCount":59},[],{"trials":7541,"activeCount":59},[],{"trials":7543,"activeCount":59},[],{"trials":7545,"activeCount":59},[7546],{"nctId":7523,"briefTitle":7524,"status":67,"phases":7547,"primaryCompletion":1899,"completion":1899,"start":7526,"enrollment":7527,"conditions":7548,"interventions":7549},[50],[7529],[7512,7531],{"trials":7551,"activeCount":59},[],{"trials":7553,"activeCount":59},[],{"intervention":1038,"totalTrials":190,"cells":7555},{"EARLY_PHASE1":7556,"PHASE1":7558,"PHASE2":7560,"PHASE3":7562,"PHASE4":7568,"NA":7570},{"trials":7557,"activeCount":59},[],{"trials":7559,"activeCount":59},[],{"trials":7561,"activeCount":59},[],{"trials":7563,"activeCount":59},[7564],{"nctId":1027,"briefTitle":1028,"status":67,"phases":7565,"primaryCompletion":1030,"completion":1031,"start":1032,"enrollment":1033,"conditions":7566,"interventions":7567},[50],[14,1035,1036],[1038,755,1039],{"trials":7569,"activeCount":59},[],{"trials":7571,"activeCount":59},[],{"intervention":1039,"totalTrials":190,"cells":7573},{"EARLY_PHASE1":7574,"PHASE1":7576,"PHASE2":7578,"PHASE3":7580,"PHASE4":7586,"NA":7588},{"trials":7575,"activeCount":59},[],{"trials":7577,"activeCount":59},[],{"trials":7579,"activeCount":59},[],{"trials":7581,"activeCount":59},[7582],{"nctId":1027,"briefTitle":1028,"status":67,"phases":7583,"primaryCompletion":1030,"completion":1031,"start":1032,"enrollment":1033,"conditions":7584,"interventions":7585},[50],[14,1035,1036],[1038,755,1039],{"trials":7587,"activeCount":59},[],{"trials":7589,"activeCount":59},[],{"intervention":1152,"totalTrials":190,"cells":7591},{"EARLY_PHASE1":7592,"PHASE1":7594,"PHASE2":7596,"PHASE3":7598,"PHASE4":7604,"NA":7606},{"trials":7593,"activeCount":59},[],{"trials":7595,"activeCount":59},[],{"trials":7597,"activeCount":59},[],{"trials":7599,"activeCount":59},[7600],{"nctId":1143,"briefTitle":1144,"status":67,"phases":7601,"primaryCompletion":1146,"completion":1146,"start":1147,"enrollment":1148,"conditions":7602,"interventions":7603},[50],[1150],[1102,1152,1153],{"trials":7605,"activeCount":59},[],{"trials":7607,"activeCount":59},[],{"intervention":1153,"totalTrials":190,"cells":7609},{"EARLY_PHASE1":7610,"PHASE1":7612,"PHASE2":7614,"PHASE3":7616,"PHASE4":7622,"NA":7624},{"trials":7611,"activeCount":59},[],{"trials":7613,"activeCount":59},[],{"trials":7615,"activeCount":59},[],{"trials":7617,"activeCount":59},[7618],{"nctId":1143,"briefTitle":1144,"status":67,"phases":7619,"primaryCompletion":1146,"completion":1146,"start":1147,"enrollment":1148,"conditions":7620,"interventions":7621},[50],[1150],[1102,1152,1153],{"trials":7623,"activeCount":59},[],{"trials":7625,"activeCount":59},[],{"intervention":795,"totalTrials":190,"cells":7627},{"EARLY_PHASE1":7628,"PHASE1":7630,"PHASE2":7632,"PHASE3":7634,"PHASE4":7640,"NA":7642},{"trials":7629,"activeCount":59},[],{"trials":7631,"activeCount":59},[],{"trials":7633,"activeCount":59},[],{"trials":7635,"activeCount":59},[7636],{"nctId":786,"briefTitle":787,"status":67,"phases":7637,"primaryCompletion":789,"completion":789,"start":790,"enrollment":791,"conditions":7638,"interventions":7639},[50],[703,793],[574,795,565,796],{"trials":7641,"activeCount":59},[],{"trials":7643,"activeCount":59},[],{"intervention":796,"totalTrials":190,"cells":7645},{"EARLY_PHASE1":7646,"PHASE1":7648,"PHASE2":7650,"PHASE3":7652,"PHASE4":7658,"NA":7660},{"trials":7647,"activeCount":59},[],{"trials":7649,"activeCount":59},[],{"trials":7651,"activeCount":59},[],{"trials":7653,"activeCount":59},[7654],{"nctId":786,"briefTitle":787,"status":67,"phases":7655,"primaryCompletion":789,"completion":789,"start":790,"enrollment":791,"conditions":7656,"interventions":7657},[50],[703,793],[574,795,565,796],{"trials":7659,"activeCount":59},[],{"trials":7661,"activeCount":59},[],{"intervention":306,"totalTrials":190,"cells":7663},{"EARLY_PHASE1":7664,"PHASE1":7666,"PHASE2":7668,"PHASE3":7670,"PHASE4":7676,"NA":7678},{"trials":7665,"activeCount":59},[],{"trials":7667,"activeCount":59},[],{"trials":7669,"activeCount":59},[],{"trials":7671,"activeCount":59},[7672],{"nctId":298,"briefTitle":299,"status":67,"phases":7673,"primaryCompletion":301,"completion":301,"start":302,"enrollment":303,"conditions":7674,"interventions":7675},[50],[33],[196,306,307],{"trials":7677,"activeCount":59},[],{"trials":7679,"activeCount":59},[],{"intervention":307,"totalTrials":190,"cells":7681},{"EARLY_PHASE1":7682,"PHASE1":7684,"PHASE2":7686,"PHASE3":7688,"PHASE4":7694,"NA":7696},{"trials":7683,"activeCount":59},[],{"trials":7685,"activeCount":59},[],{"trials":7687,"activeCount":59},[],{"trials":7689,"activeCount":59},[7690],{"nctId":298,"briefTitle":299,"status":67,"phases":7691,"primaryCompletion":301,"completion":301,"start":302,"enrollment":303,"conditions":7692,"interventions":7693},[50],[33],[196,306,307],{"trials":7695,"activeCount":59},[],{"trials":7697,"activeCount":59},[],{"intervention":4095,"totalTrials":190,"cells":7699},{"EARLY_PHASE1":7700,"PHASE1":7702,"PHASE2":7704,"PHASE3":7706,"PHASE4":7712,"NA":7714},{"trials":7701,"activeCount":59},[],{"trials":7703,"activeCount":59},[],{"trials":7705,"activeCount":59},[],{"trials":7707,"activeCount":59},[7708],{"nctId":4089,"briefTitle":4090,"status":67,"phases":7709,"primaryCompletion":1066,"completion":1066,"start":2730,"enrollment":4092,"conditions":7710,"interventions":7711},[50],[14],[1070,4095],{"trials":7713,"activeCount":59},[],{"trials":7715,"activeCount":59},[],{"intervention":7717,"totalTrials":190,"cells":7718},"MK0217\u002FDuration of Treatment : 12 Months",{"EARLY_PHASE1":7719,"PHASE1":7721,"PHASE2":7723,"PHASE3":7725,"PHASE4":7733,"NA":7735},{"trials":7720,"activeCount":59},[],{"trials":7722,"activeCount":59},[],{"trials":7724,"activeCount":59},[],{"trials":7726,"activeCount":59},[7727],{"nctId":7728,"briefTitle":7729,"status":67,"phases":7730,"primaryCompletion":892,"completion":892,"start":1117,"enrollment":813,"conditions":7731,"interventions":7732},"NCT00480766","A Research Study to Evaluate the Safety and Effectiveness of MK0217 to Prevent and Treat Bone Loss (0217-193)(COMPLETED)",[50],[1120],[7717],{"trials":7734,"activeCount":59},[],{"trials":7736,"activeCount":59},[],{"intervention":5000,"totalTrials":190,"cells":7738},{"EARLY_PHASE1":7739,"PHASE1":7741,"PHASE2":7743,"PHASE3":7745,"PHASE4":7751,"NA":7753},{"trials":7740,"activeCount":59},[],{"trials":7742,"activeCount":59},[],{"trials":7744,"activeCount":59},[],{"trials":7746,"activeCount":59},[7747],{"nctId":4994,"briefTitle":4995,"status":67,"phases":7748,"primaryCompletion":1260,"completion":1260,"start":1095,"enrollment":4997,"conditions":7749,"interventions":7750},[50],[17],[5000,5001,4983],{"trials":7752,"activeCount":59},[],{"trials":7754,"activeCount":59},[],{"intervention":5001,"totalTrials":190,"cells":7756},{"EARLY_PHASE1":7757,"PHASE1":7759,"PHASE2":7761,"PHASE3":7763,"PHASE4":7769,"NA":7771},{"trials":7758,"activeCount":59},[],{"trials":7760,"activeCount":59},[],{"trials":7762,"activeCount":59},[],{"trials":7764,"activeCount":59},[7765],{"nctId":4994,"briefTitle":4995,"status":67,"phases":7766,"primaryCompletion":1260,"completion":1260,"start":1095,"enrollment":4997,"conditions":7767,"interventions":7768},[50],[17],[5000,5001,4983],{"trials":7770,"activeCount":59},[],{"trials":7772,"activeCount":59},[],{"intervention":7774,"totalTrials":190,"cells":7775},"Rizatriptan 5 mg",{"EARLY_PHASE1":7776,"PHASE1":7778,"PHASE2":7780,"PHASE3":7782,"PHASE4":7794,"NA":7796},{"trials":7777,"activeCount":59},[],{"trials":7779,"activeCount":59},[],{"trials":7781,"activeCount":59},[],{"trials":7783,"activeCount":59},[7784],{"nctId":7785,"briefTitle":7786,"status":67,"phases":7787,"primaryCompletion":7788,"completion":7788,"start":3580,"enrollment":7789,"conditions":7790,"interventions":7791},"NCT01286207","Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029)",[50],"1997-05",1959,[3517],[7774,7792,7793],"Rizatriptan 10 mg","Standard Care",{"trials":7795,"activeCount":59},[],{"trials":7797,"activeCount":59},[],{"intervention":7792,"totalTrials":190,"cells":7799},{"EARLY_PHASE1":7800,"PHASE1":7802,"PHASE2":7804,"PHASE3":7806,"PHASE4":7812,"NA":7814},{"trials":7801,"activeCount":59},[],{"trials":7803,"activeCount":59},[],{"trials":7805,"activeCount":59},[],{"trials":7807,"activeCount":59},[7808],{"nctId":7785,"briefTitle":7786,"status":67,"phases":7809,"primaryCompletion":7788,"completion":7788,"start":3580,"enrollment":7789,"conditions":7810,"interventions":7811},[50],[3517],[7774,7792,7793],{"trials":7813,"activeCount":59},[],{"trials":7815,"activeCount":59},[],{"intervention":7793,"totalTrials":190,"cells":7817},{"EARLY_PHASE1":7818,"PHASE1":7820,"PHASE2":7822,"PHASE3":7824,"PHASE4":7830,"NA":7832},{"trials":7819,"activeCount":59},[],{"trials":7821,"activeCount":59},[],{"trials":7823,"activeCount":59},[],{"trials":7825,"activeCount":59},[7826],{"nctId":7785,"briefTitle":7786,"status":67,"phases":7827,"primaryCompletion":7788,"completion":7788,"start":3580,"enrollment":7789,"conditions":7828,"interventions":7829},[50],[3517],[7774,7792,7793],{"trials":7831,"activeCount":59},[],{"trials":7833,"activeCount":59},[],{"intervention":7835,"totalTrials":190,"cells":7836},"MK0653, ezetimibe \u002F Duration of Treatment: 28 weeks",{"EARLY_PHASE1":7837,"PHASE1":7839,"PHASE2":7841,"PHASE3":7843,"PHASE4":7853,"NA":7855},{"trials":7838,"activeCount":59},[],{"trials":7840,"activeCount":59},[],{"trials":7842,"activeCount":59},[],{"trials":7844,"activeCount":59},[7845],{"nctId":7846,"briefTitle":7847,"status":67,"phases":7848,"primaryCompletion":3495,"completion":3495,"start":1127,"enrollment":7849,"conditions":7850,"interventions":7851},"NCT00092716","Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)",[50],655,[14],[7835,7852],"Comparator: atorvastatin \u002F Duration of Treatment: 28 weeks",{"trials":7854,"activeCount":59},[],{"trials":7856,"activeCount":59},[],{"intervention":7852,"totalTrials":190,"cells":7858},{"EARLY_PHASE1":7859,"PHASE1":7861,"PHASE2":7863,"PHASE3":7865,"PHASE4":7871,"NA":7873},{"trials":7860,"activeCount":59},[],{"trials":7862,"activeCount":59},[],{"trials":7864,"activeCount":59},[],{"trials":7866,"activeCount":59},[7867],{"nctId":7846,"briefTitle":7847,"status":67,"phases":7868,"primaryCompletion":3495,"completion":3495,"start":1127,"enrollment":7849,"conditions":7869,"interventions":7870},[50],[14],[7835,7852],{"trials":7872,"activeCount":59},[],{"trials":7874,"activeCount":59},[],{"intervention":7876,"totalTrials":190,"cells":7877},"MK0653, ezetimibe \u002F Duration of Treatment: 4 Weeks",{"EARLY_PHASE1":7878,"PHASE1":7880,"PHASE2":7882,"PHASE3":7884,"PHASE4":7893,"NA":7895},{"trials":7879,"activeCount":59},[],{"trials":7881,"activeCount":59},[],{"trials":7883,"activeCount":59},[],{"trials":7885,"activeCount":59},[7886],{"nctId":7887,"briefTitle":7888,"status":67,"phases":7889,"primaryCompletion":570,"completion":570,"start":1923,"enrollment":7890,"conditions":7891,"interventions":7892},"NCT00457275","Observational Study to Evaluate LDL-C Lowering Effect of Ezetimibe (0653-070)",[50],440,[14],[7876],{"trials":7894,"activeCount":59},[],{"trials":7896,"activeCount":59},[],{"intervention":1048,"totalTrials":190,"cells":7898},{"EARLY_PHASE1":7899,"PHASE1":7901,"PHASE2":7903,"PHASE3":7905,"PHASE4":7911,"NA":7913},{"trials":7900,"activeCount":59},[],{"trials":7902,"activeCount":59},[],{"trials":7904,"activeCount":59},[],{"trials":7906,"activeCount":59},[7907],{"nctId":1041,"briefTitle":1042,"status":67,"phases":7908,"primaryCompletion":402,"completion":402,"start":439,"enrollment":1044,"conditions":7909,"interventions":7910},[50],[14],[755,652,1047,1048],{"trials":7912,"activeCount":59},[],{"trials":7914,"activeCount":59},[],{"intervention":7916,"totalTrials":190,"cells":7917},"Comparator: pranlukast",{"EARLY_PHASE1":7918,"PHASE1":7920,"PHASE2":7922,"PHASE3":7924,"PHASE4":7933,"NA":7935},{"trials":7919,"activeCount":59},[],{"trials":7921,"activeCount":59},[],{"trials":7923,"activeCount":59},[],{"trials":7925,"activeCount":59},[7926],{"nctId":7927,"briefTitle":7928,"status":67,"phases":7929,"primaryCompletion":1923,"completion":1923,"start":742,"enrollment":7930,"conditions":7931,"interventions":7932},"NCT00127647","An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)",[50],1375,[33],[2626,7916],{"trials":7934,"activeCount":59},[],{"trials":7936,"activeCount":59},[],{"intervention":5187,"totalTrials":190,"cells":7938},{"EARLY_PHASE1":7939,"PHASE1":7941,"PHASE2":7943,"PHASE3":7945,"PHASE4":7951,"NA":7953},{"trials":7940,"activeCount":59},[],{"trials":7942,"activeCount":59},[],{"trials":7944,"activeCount":59},[],{"trials":7946,"activeCount":59},[7947],{"nctId":5179,"briefTitle":5180,"status":67,"phases":7948,"primaryCompletion":5182,"completion":533,"start":5183,"enrollment":5184,"conditions":7949,"interventions":7950},[50],[3128],[5187,5168],{"trials":7952,"activeCount":59},[],{"trials":7954,"activeCount":59},[],{"intervention":7956,"totalTrials":190,"cells":7957},"MFNS and antibiotic",{"EARLY_PHASE1":7958,"PHASE1":7960,"PHASE2":7962,"PHASE3":7964,"PHASE4":7973,"NA":7975},{"trials":7959,"activeCount":59},[],{"trials":7961,"activeCount":59},[],{"trials":7963,"activeCount":59},[],{"trials":7965,"activeCount":59},[7966],{"nctId":7967,"briefTitle":7968,"status":610,"phases":7969,"primaryCompletion":312,"completion":312,"start":941,"enrollment":1924,"conditions":7970,"interventions":7972},"NCT00423176","The Study of Nasonex® Compared With Placebo for the Relief of Symptoms Associated With Acute Bacterial Sinusitis When Used With Antibiotics (Study P04824AM3)",[50],[7971],"Sinusitis",[7956],{"trials":7974,"activeCount":59},[],{"trials":7976,"activeCount":59},[],{"intervention":7978,"totalTrials":190,"cells":7979},"MK0217A, alendronate sodium (+) cholecalciferol \u002F Duration of Treatment: 15 weeks",{"EARLY_PHASE1":7980,"PHASE1":7982,"PHASE2":7984,"PHASE3":7986,"PHASE4":7997,"NA":7999},{"trials":7981,"activeCount":59},[],{"trials":7983,"activeCount":59},[],{"trials":7985,"activeCount":59},[],{"trials":7987,"activeCount":59},[7988],{"nctId":7989,"briefTitle":7990,"status":67,"phases":7991,"primaryCompletion":1804,"completion":1804,"start":7992,"enrollment":7993,"conditions":7994,"interventions":7996},"NCT00092066","A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)",[50],"2003-09-24",717,[1120,7995],"Vitamin D Deficiency",[7978],{"trials":7998,"activeCount":59},[],{"trials":8000,"activeCount":59},[],{"intervention":8002,"totalTrials":190,"cells":8003},"MK0954A, hydrochlorothiazide (+) losartan potassium \u002F Duration of Treatment: 6 weeks",{"EARLY_PHASE1":8004,"PHASE1":8006,"PHASE2":8008,"PHASE3":8010,"PHASE4":8022,"NA":8024},{"trials":8005,"activeCount":59},[],{"trials":8007,"activeCount":59},[],{"trials":8009,"activeCount":59},[],{"trials":8011,"activeCount":59},[8012],{"nctId":8013,"briefTitle":8014,"status":67,"phases":8015,"primaryCompletion":1406,"completion":8016,"start":377,"enrollment":8017,"conditions":8018,"interventions":8020},"NCT00307060","MK0954A-264 Filter Study (0954A-264)(COMPLETED)",[50],"2005-06-02",274,[8019],"Mild to Severe Hypertension",[8002,8021],"losartan \u002F Duration of Treatment: 6 weeks",{"trials":8023,"activeCount":59},[],{"trials":8025,"activeCount":59},[],{"intervention":8021,"totalTrials":190,"cells":8027},{"EARLY_PHASE1":8028,"PHASE1":8030,"PHASE2":8032,"PHASE3":8034,"PHASE4":8040,"NA":8042},{"trials":8029,"activeCount":59},[],{"trials":8031,"activeCount":59},[],{"trials":8033,"activeCount":59},[],{"trials":8035,"activeCount":59},[8036],{"nctId":8013,"briefTitle":8014,"status":67,"phases":8037,"primaryCompletion":1406,"completion":8016,"start":377,"enrollment":8017,"conditions":8038,"interventions":8039},[50],[8019],[8002,8021],{"trials":8041,"activeCount":59},[],{"trials":8043,"activeCount":59},[],{"intervention":8045,"totalTrials":190,"cells":8046},"MK0653; ezetimibe \u002F Duration of Treatment: 12 weeks",{"EARLY_PHASE1":8047,"PHASE1":8049,"PHASE2":8051,"PHASE3":8053,"PHASE4":8064,"NA":8066},{"trials":8048,"activeCount":59},[],{"trials":8050,"activeCount":59},[],{"trials":8052,"activeCount":59},[],{"trials":8054,"activeCount":59},[8055],{"nctId":8056,"briefTitle":8057,"status":67,"phases":8058,"primaryCompletion":1290,"completion":2479,"start":875,"enrollment":8059,"conditions":8060,"interventions":8062},"NCT00157911","A Study to Evaluate Ezetimibe in Korean Patients With Primary Hypercholesterolemia (0653-042)",[50],136,[8061],"Hypercholerolemia",[8045,8063],"Comparator: simvastatin \u002F Duration of Treatment: 12 weeks",{"trials":8065,"activeCount":59},[],{"trials":8067,"activeCount":59},[],{"intervention":8063,"totalTrials":190,"cells":8069},{"EARLY_PHASE1":8070,"PHASE1":8072,"PHASE2":8074,"PHASE3":8076,"PHASE4":8082,"NA":8084},{"trials":8071,"activeCount":59},[],{"trials":8073,"activeCount":59},[],{"trials":8075,"activeCount":59},[],{"trials":8077,"activeCount":59},[8078],{"nctId":8056,"briefTitle":8057,"status":67,"phases":8079,"primaryCompletion":1290,"completion":2479,"start":875,"enrollment":8059,"conditions":8080,"interventions":8081},[50],[8061],[8045,8063],{"trials":8083,"activeCount":59},[],{"trials":8085,"activeCount":59},[],{"intervention":1992,"totalTrials":190,"cells":8087},{"EARLY_PHASE1":8088,"PHASE1":8090,"PHASE2":8092,"PHASE3":8094,"PHASE4":8100,"NA":8102},{"trials":8089,"activeCount":59},[],{"trials":8091,"activeCount":59},[],{"trials":8093,"activeCount":59},[],{"trials":8095,"activeCount":59},[8096],{"nctId":1985,"briefTitle":1986,"status":67,"phases":8097,"primaryCompletion":1988,"completion":1988,"start":1989,"enrollment":1407,"conditions":8098,"interventions":8099},[50],[405],[1992,1993],{"trials":8101,"activeCount":59},[],{"trials":8103,"activeCount":59},[],{"intervention":3836,"totalTrials":190,"cells":8105},{"EARLY_PHASE1":8106,"PHASE1":8108,"PHASE2":8110,"PHASE3":8112,"PHASE4":8118,"NA":8120},{"trials":8107,"activeCount":59},[],{"trials":8109,"activeCount":59},[],{"trials":8111,"activeCount":59},[],{"trials":8113,"activeCount":59},[8114],{"nctId":3828,"briefTitle":3829,"status":67,"phases":8115,"primaryCompletion":3831,"completion":3831,"start":3832,"enrollment":3833,"conditions":8116,"interventions":8117},[50],[14],[1511,3836],{"trials":8119,"activeCount":59},[],{"trials":8121,"activeCount":59},[],{"intervention":8123,"totalTrials":190,"cells":8124},"loratadine; montelukast",{"EARLY_PHASE1":8125,"PHASE1":8127,"PHASE2":8129,"PHASE3":8131,"PHASE4":8143,"NA":8145},{"trials":8126,"activeCount":59},[],{"trials":8128,"activeCount":59},[],{"trials":8130,"activeCount":59},[],{"trials":8132,"activeCount":59},[8133],{"nctId":8134,"briefTitle":8135,"status":67,"phases":8136,"primaryCompletion":8137,"completion":8138,"start":8139,"enrollment":8140,"conditions":8141,"interventions":8142},"NCT00319995","Effects of Loratadine\u002FMontelukast vs Pseudoephedrine and Placebo in Patients With Seasonal Allergic Rhinitis (Study P04095) (COMPLETED)",[50],"2006-06-01","2006-06-28","2006-03-01",1095,[33],[8123],{"trials":8144,"activeCount":59},[],{"trials":8146,"activeCount":59},[],{"intervention":1533,"totalTrials":190,"cells":8148},{"EARLY_PHASE1":8149,"PHASE1":8151,"PHASE2":8153,"PHASE3":8155,"PHASE4":8161,"NA":8163},{"trials":8150,"activeCount":59},[],{"trials":8152,"activeCount":59},[],{"trials":8154,"activeCount":59},[],{"trials":8156,"activeCount":59},[8157],{"nctId":1525,"briefTitle":1526,"status":67,"phases":8158,"primaryCompletion":1528,"completion":1528,"start":1529,"enrollment":1530,"conditions":8159,"interventions":8160},[50],[14],[1492,1533,1512,1534,1513],{"trials":8162,"activeCount":59},[],{"trials":8164,"activeCount":59},[],{"intervention":1534,"totalTrials":190,"cells":8166},{"EARLY_PHASE1":8167,"PHASE1":8169,"PHASE2":8171,"PHASE3":8173,"PHASE4":8179,"NA":8181},{"trials":8168,"activeCount":59},[],{"trials":8170,"activeCount":59},[],{"trials":8172,"activeCount":59},[],{"trials":8174,"activeCount":59},[8175],{"nctId":1525,"briefTitle":1526,"status":67,"phases":8176,"primaryCompletion":1528,"completion":1528,"start":1529,"enrollment":1530,"conditions":8177,"interventions":8178},[50],[14],[1492,1533,1512,1534,1513],{"trials":8180,"activeCount":59},[],{"trials":8182,"activeCount":59},[],{"intervention":8184,"totalTrials":190,"cells":8185},"MK0954, \u002FDuration of Treatment : 5 Years",{"EARLY_PHASE1":8186,"PHASE1":8188,"PHASE2":8190,"PHASE3":8192,"PHASE4":8205,"NA":8207},{"trials":8187,"activeCount":59},[],{"trials":8189,"activeCount":59},[],{"trials":8191,"activeCount":59},[],{"trials":8193,"activeCount":59},[8194],{"nctId":8195,"briefTitle":8196,"status":67,"phases":8197,"primaryCompletion":8198,"completion":2906,"start":8199,"enrollment":8200,"conditions":8201,"interventions":8203},"NCT00338260","Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)",[50],"2001-09","1995-06",496,[8202],"Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart)",[8184,8204],"Comparator : atenolol \u002FDuration of Treatment : 5 Years",{"trials":8206,"activeCount":59},[],{"trials":8208,"activeCount":59},[],{"intervention":8204,"totalTrials":190,"cells":8210},{"EARLY_PHASE1":8211,"PHASE1":8213,"PHASE2":8215,"PHASE3":8217,"PHASE4":8223,"NA":8225},{"trials":8212,"activeCount":59},[],{"trials":8214,"activeCount":59},[],{"trials":8216,"activeCount":59},[],{"trials":8218,"activeCount":59},[8219],{"nctId":8195,"briefTitle":8196,"status":67,"phases":8220,"primaryCompletion":8198,"completion":2906,"start":8199,"enrollment":8200,"conditions":8221,"interventions":8222},[50],[8202],[8184,8204],{"trials":8224,"activeCount":59},[],{"trials":8226,"activeCount":59},[],{"intervention":1056,"totalTrials":190,"cells":8228},{"EARLY_PHASE1":8229,"PHASE1":8231,"PHASE2":8233,"PHASE3":8235,"PHASE4":8241,"NA":8243},{"trials":8230,"activeCount":59},[],{"trials":8232,"activeCount":59},[],{"trials":8234,"activeCount":59},[],{"trials":8236,"activeCount":59},[8237],{"nctId":1050,"briefTitle":1051,"status":67,"phases":8238,"primaryCompletion":974,"completion":974,"start":376,"enrollment":1053,"conditions":8239,"interventions":8240},[50],[14],[1056,755,1057,1058,1059,456,1060],{"trials":8242,"activeCount":59},[],{"trials":8244,"activeCount":59},[],{"intervention":1057,"totalTrials":190,"cells":8246},{"EARLY_PHASE1":8247,"PHASE1":8249,"PHASE2":8251,"PHASE3":8253,"PHASE4":8259,"NA":8261},{"trials":8248,"activeCount":59},[],{"trials":8250,"activeCount":59},[],{"trials":8252,"activeCount":59},[],{"trials":8254,"activeCount":59},[8255],{"nctId":1050,"briefTitle":1051,"status":67,"phases":8256,"primaryCompletion":974,"completion":974,"start":376,"enrollment":1053,"conditions":8257,"interventions":8258},[50],[14],[1056,755,1057,1058,1059,456,1060],{"trials":8260,"activeCount":59},[],{"trials":8262,"activeCount":59},[],{"intervention":1058,"totalTrials":190,"cells":8264},{"EARLY_PHASE1":8265,"PHASE1":8267,"PHASE2":8269,"PHASE3":8271,"PHASE4":8277,"NA":8279},{"trials":8266,"activeCount":59},[],{"trials":8268,"activeCount":59},[],{"trials":8270,"activeCount":59},[],{"trials":8272,"activeCount":59},[8273],{"nctId":1050,"briefTitle":1051,"status":67,"phases":8274,"primaryCompletion":974,"completion":974,"start":376,"enrollment":1053,"conditions":8275,"interventions":8276},[50],[14],[1056,755,1057,1058,1059,456,1060],{"trials":8278,"activeCount":59},[],{"trials":8280,"activeCount":59},[],{"intervention":1059,"totalTrials":190,"cells":8282},{"EARLY_PHASE1":8283,"PHASE1":8285,"PHASE2":8287,"PHASE3":8289,"PHASE4":8295,"NA":8297},{"trials":8284,"activeCount":59},[],{"trials":8286,"activeCount":59},[],{"trials":8288,"activeCount":59},[],{"trials":8290,"activeCount":59},[8291],{"nctId":1050,"briefTitle":1051,"status":67,"phases":8292,"primaryCompletion":974,"completion":974,"start":376,"enrollment":1053,"conditions":8293,"interventions":8294},[50],[14],[1056,755,1057,1058,1059,456,1060],{"trials":8296,"activeCount":59},[],{"trials":8298,"activeCount":59},[],{"intervention":8300,"totalTrials":190,"cells":8301},"MK0663, etoricoxib \u002F Duration of Treatment: 6 Weeks",{"EARLY_PHASE1":8302,"PHASE1":8304,"PHASE2":8306,"PHASE3":8308,"PHASE4":8320,"NA":8322},{"trials":8303,"activeCount":59},[],{"trials":8305,"activeCount":59},[],{"trials":8307,"activeCount":59},[],{"trials":8309,"activeCount":59},[8310],{"nctId":8311,"briefTitle":8312,"status":67,"phases":8313,"primaryCompletion":8314,"completion":8314,"start":8315,"enrollment":8316,"conditions":8317,"interventions":8318},"NCT00542087","Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED)",[50],"2002-12-20","2002-03-22",516,[2995],[8300,8319],"Comparator: diclofenac sodium \u002F Duration of Treatment: 6 Weeks",{"trials":8321,"activeCount":59},[],{"trials":8323,"activeCount":59},[],{"intervention":8319,"totalTrials":190,"cells":8325},{"EARLY_PHASE1":8326,"PHASE1":8328,"PHASE2":8330,"PHASE3":8332,"PHASE4":8338,"NA":8340},{"trials":8327,"activeCount":59},[],{"trials":8329,"activeCount":59},[],{"trials":8331,"activeCount":59},[],{"trials":8333,"activeCount":59},[8334],{"nctId":8311,"briefTitle":8312,"status":67,"phases":8335,"primaryCompletion":8314,"completion":8314,"start":8315,"enrollment":8316,"conditions":8336,"interventions":8337},[50],[2995],[8300,8319],{"trials":8339,"activeCount":59},[],{"trials":8341,"activeCount":59},[],{"intervention":8343,"totalTrials":190,"cells":8344},"Comparator: Usual Care",{"EARLY_PHASE1":8345,"PHASE1":8347,"PHASE2":8349,"PHASE3":8351,"PHASE4":8359,"NA":8361},{"trials":8346,"activeCount":59},[],{"trials":8348,"activeCount":59},[],{"trials":8350,"activeCount":59},[],{"trials":8352,"activeCount":59},[8353],{"nctId":8354,"briefTitle":8355,"status":67,"phases":8356,"primaryCompletion":5646,"completion":2906,"start":3893,"enrollment":590,"conditions":8357,"interventions":8358},"NCT00943397","Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma (0476-232)",[50],[17],[2626,8343],{"trials":8360,"activeCount":59},[],{"trials":8362,"activeCount":59},[],{"intervention":8364,"totalTrials":190,"cells":8365},"NOMAC-E2 COC",{"EARLY_PHASE1":8366,"PHASE1":8368,"PHASE2":8370,"PHASE3":8372,"PHASE4":8384,"NA":8386},{"trials":8367,"activeCount":59},[],{"trials":8369,"activeCount":59},[],{"trials":8371,"activeCount":59},[],{"trials":8373,"activeCount":59},[8374],{"nctId":8375,"briefTitle":8376,"status":610,"phases":8377,"primaryCompletion":8378,"completion":8379,"start":8380,"enrollment":8381,"conditions":8382,"interventions":8383},"NCT05264506","Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive",[50],"2024-01-12","2024-01-26","2022-02-17",3055,[23],[8364],{"trials":8385,"activeCount":59},[],{"trials":8387,"activeCount":59},[],{"intervention":8389,"totalTrials":190,"cells":8390},"Atovastatin",{"EARLY_PHASE1":8391,"PHASE1":8393,"PHASE2":8395,"PHASE3":8397,"PHASE4":8407,"NA":8409},{"trials":8392,"activeCount":59},[],{"trials":8394,"activeCount":59},[],{"trials":8396,"activeCount":59},[],{"trials":8398,"activeCount":59},[8399],{"nctId":8400,"briefTitle":8401,"status":67,"phases":8402,"primaryCompletion":8403,"completion":8403,"start":8404,"enrollment":6376,"conditions":8405,"interventions":8406},"NCT03882892","Long-Term Safety and Tolerability of Ezetimibe (SCH 58235, MK-0653) With Atovastatin (P02154, MK-0653-017)",[50],"2002-08-08","2001-02-02",[14],[432,8389],{"trials":8408,"activeCount":59},[],{"trials":8410,"activeCount":59},[],{"intervention":8412,"totalTrials":190,"cells":8413},"Comparator: cetirizine",{"EARLY_PHASE1":8414,"PHASE1":8416,"PHASE2":8418,"PHASE3":8420,"PHASE4":8429,"NA":8431},{"trials":8415,"activeCount":59},[],{"trials":8417,"activeCount":59},[],{"trials":8419,"activeCount":59},[],{"trials":8421,"activeCount":59},[8422],{"nctId":8423,"briefTitle":8424,"status":67,"phases":8425,"primaryCompletion":1127,"completion":1127,"start":2906,"enrollment":8426,"conditions":8427,"interventions":8428},"NCT00974571","Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)",[50],1365,[405],[2626,8412,3355],{"trials":8430,"activeCount":59},[],{"trials":8432,"activeCount":59},[],{"intervention":3659,"totalTrials":190,"cells":8434},{"EARLY_PHASE1":8435,"PHASE1":8437,"PHASE2":8439,"PHASE3":8441,"PHASE4":8447,"NA":8449},{"trials":8436,"activeCount":59},[],{"trials":8438,"activeCount":59},[],{"trials":8440,"activeCount":59},[],{"trials":8442,"activeCount":59},[8443],{"nctId":3651,"briefTitle":3652,"status":610,"phases":8444,"primaryCompletion":3654,"completion":3654,"start":3655,"enrollment":3656,"conditions":8445,"interventions":8446},[50],[23],[3589,3659,3660,3661],{"trials":8448,"activeCount":59},[],{"trials":8450,"activeCount":59},[],{"intervention":3660,"totalTrials":190,"cells":8452},{"EARLY_PHASE1":8453,"PHASE1":8455,"PHASE2":8457,"PHASE3":8459,"PHASE4":8465,"NA":8467},{"trials":8454,"activeCount":59},[],{"trials":8456,"activeCount":59},[],{"trials":8458,"activeCount":59},[],{"trials":8460,"activeCount":59},[8461],{"nctId":3651,"briefTitle":3652,"status":610,"phases":8462,"primaryCompletion":3654,"completion":3654,"start":3655,"enrollment":3656,"conditions":8463,"interventions":8464},[50],[23],[3589,3659,3660,3661],{"trials":8466,"activeCount":59},[],{"trials":8468,"activeCount":59},[],{"intervention":3661,"totalTrials":190,"cells":8470},{"EARLY_PHASE1":8471,"PHASE1":8473,"PHASE2":8475,"PHASE3":8477,"PHASE4":8483,"NA":8485},{"trials":8472,"activeCount":59},[],{"trials":8474,"activeCount":59},[],{"trials":8476,"activeCount":59},[],{"trials":8478,"activeCount":59},[8479],{"nctId":3651,"briefTitle":3652,"status":610,"phases":8480,"primaryCompletion":3654,"completion":3654,"start":3655,"enrollment":3656,"conditions":8481,"interventions":8482},[50],[23],[3589,3659,3660,3661],{"trials":8484,"activeCount":59},[],{"trials":8486,"activeCount":59},[],{"intervention":8488,"totalTrials":190,"cells":8489},"MK0653A, ezetimibe (+) simvastatin \u002F Duration of Treatment: 14 weeks",{"EARLY_PHASE1":8490,"PHASE1":8492,"PHASE2":8494,"PHASE3":8496,"PHASE4":8505,"NA":8507},{"trials":8491,"activeCount":59},[],{"trials":8493,"activeCount":59},[],{"trials":8495,"activeCount":59},[],{"trials":8497,"activeCount":59},[8498],{"nctId":8499,"briefTitle":8500,"status":67,"phases":8501,"primaryCompletion":691,"completion":691,"start":3794,"enrollment":8502,"conditions":8503,"interventions":8504},"NCT00092664","An Extension Study of An Investigational Drug in Patients With Hypercholesterolemia (0653A-038)(COMPLETED)",[50],1104,[14],[8488],{"trials":8506,"activeCount":59},[],{"trials":8508,"activeCount":59},[],{"intervention":8510,"totalTrials":190,"cells":8511},"ENG 120 µg + EE 15 µg intravaginal ring",{"EARLY_PHASE1":8512,"PHASE1":8514,"PHASE2":8516,"PHASE3":8518,"PHASE4":8530,"NA":8532},{"trials":8513,"activeCount":59},[],{"trials":8515,"activeCount":59},[],{"trials":8517,"activeCount":59},[],{"trials":8519,"activeCount":59},[8520],{"nctId":8521,"briefTitle":8522,"status":67,"phases":8523,"primaryCompletion":8524,"completion":8524,"start":8525,"enrollment":8526,"conditions":8527,"interventions":8528},"NCT01277211","A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)",[50],"2013-09-18","2011-09-19",983,[23],[8510,8529],"DRSP 3 mg + EE 30 µg",{"trials":8531,"activeCount":59},[],{"trials":8533,"activeCount":59},[],{"intervention":8529,"totalTrials":190,"cells":8535},{"EARLY_PHASE1":8536,"PHASE1":8538,"PHASE2":8540,"PHASE3":8542,"PHASE4":8548,"NA":8550},{"trials":8537,"activeCount":59},[],{"trials":8539,"activeCount":59},[],{"trials":8541,"activeCount":59},[],{"trials":8543,"activeCount":59},[8544],{"nctId":8521,"briefTitle":8522,"status":67,"phases":8545,"primaryCompletion":8524,"completion":8524,"start":8525,"enrollment":8526,"conditions":8546,"interventions":8547},[50],[23],[8510,8529],{"trials":8549,"activeCount":59},[],{"trials":8551,"activeCount":59},[],{"intervention":3959,"totalTrials":190,"cells":8553},{"EARLY_PHASE1":8554,"PHASE1":8556,"PHASE2":8558,"PHASE3":8560,"PHASE4":8566,"NA":8568},{"trials":8555,"activeCount":59},[],{"trials":8557,"activeCount":59},[],{"trials":8559,"activeCount":59},[],{"trials":8561,"activeCount":59},[8562],{"nctId":3951,"briefTitle":3952,"status":610,"phases":8563,"primaryCompletion":3954,"completion":3954,"start":3955,"enrollment":21,"conditions":8564,"interventions":8565},[50],[3957],[3959,3906],{"trials":8567,"activeCount":59},[],{"trials":8569,"activeCount":59},[],{"intervention":8571,"totalTrials":190,"cells":8572},"Comparator: rosuvastatin 5 mg + ezetimibe 10 mg",{"EARLY_PHASE1":8573,"PHASE1":8575,"PHASE2":8577,"PHASE3":8579,"PHASE4":8590,"NA":8592},{"trials":8574,"activeCount":59},[],{"trials":8576,"activeCount":59},[],{"trials":8578,"activeCount":59},[],{"trials":8580,"activeCount":59},[8581],{"nctId":8582,"briefTitle":8583,"status":67,"phases":8584,"primaryCompletion":2794,"completion":2794,"start":274,"enrollment":7890,"conditions":8585,"interventions":8586},"NCT00783263","A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)",[50],[14],[8571,8587,8588,8589],"Comparator: rosuvastatin 10 mg","Comparator: rosuvastatin 10 mg + ezetimibe 10 mg","Comparator: rosuvastatin 20 mg",{"trials":8591,"activeCount":59},[],{"trials":8593,"activeCount":59},[],{"intervention":8587,"totalTrials":190,"cells":8595},{"EARLY_PHASE1":8596,"PHASE1":8598,"PHASE2":8600,"PHASE3":8602,"PHASE4":8608,"NA":8610},{"trials":8597,"activeCount":59},[],{"trials":8599,"activeCount":59},[],{"trials":8601,"activeCount":59},[],{"trials":8603,"activeCount":59},[8604],{"nctId":8582,"briefTitle":8583,"status":67,"phases":8605,"primaryCompletion":2794,"completion":2794,"start":274,"enrollment":7890,"conditions":8606,"interventions":8607},[50],[14],[8571,8587,8588,8589],{"trials":8609,"activeCount":59},[],{"trials":8611,"activeCount":59},[],{"intervention":8588,"totalTrials":190,"cells":8613},{"EARLY_PHASE1":8614,"PHASE1":8616,"PHASE2":8618,"PHASE3":8620,"PHASE4":8626,"NA":8628},{"trials":8615,"activeCount":59},[],{"trials":8617,"activeCount":59},[],{"trials":8619,"activeCount":59},[],{"trials":8621,"activeCount":59},[8622],{"nctId":8582,"briefTitle":8583,"status":67,"phases":8623,"primaryCompletion":2794,"completion":2794,"start":274,"enrollment":7890,"conditions":8624,"interventions":8625},[50],[14],[8571,8587,8588,8589],{"trials":8627,"activeCount":59},[],{"trials":8629,"activeCount":59},[],{"intervention":8589,"totalTrials":190,"cells":8631},{"EARLY_PHASE1":8632,"PHASE1":8634,"PHASE2":8636,"PHASE3":8638,"PHASE4":8644,"NA":8646},{"trials":8633,"activeCount":59},[],{"trials":8635,"activeCount":59},[],{"trials":8637,"activeCount":59},[],{"trials":8639,"activeCount":59},[8640],{"nctId":8582,"briefTitle":8583,"status":67,"phases":8641,"primaryCompletion":2794,"completion":2794,"start":274,"enrollment":7890,"conditions":8642,"interventions":8643},[50],[14],[8571,8587,8588,8589],{"trials":8645,"activeCount":59},[],{"trials":8647,"activeCount":59},[],{"intervention":1736,"totalTrials":190,"cells":8649},{"EARLY_PHASE1":8650,"PHASE1":8652,"PHASE2":8654,"PHASE3":8656,"PHASE4":8662,"NA":8664},{"trials":8651,"activeCount":59},[],{"trials":8653,"activeCount":59},[],{"trials":8655,"activeCount":59},[],{"trials":8657,"activeCount":59},[8658],{"nctId":1728,"briefTitle":1729,"status":67,"phases":8659,"primaryCompletion":1731,"completion":1731,"start":1732,"enrollment":1733,"conditions":8660,"interventions":8661},[50],[17],[1736,1737,1736,1738,1739],{"trials":8663,"activeCount":59},[],{"trials":8665,"activeCount":59},[],{"intervention":1737,"totalTrials":190,"cells":8667},{"EARLY_PHASE1":8668,"PHASE1":8670,"PHASE2":8672,"PHASE3":8674,"PHASE4":8680,"NA":8682},{"trials":8669,"activeCount":59},[],{"trials":8671,"activeCount":59},[],{"trials":8673,"activeCount":59},[],{"trials":8675,"activeCount":59},[8676],{"nctId":1728,"briefTitle":1729,"status":67,"phases":8677,"primaryCompletion":1731,"completion":1731,"start":1732,"enrollment":1733,"conditions":8678,"interventions":8679},[50],[17],[1736,1737,1736,1738,1739],{"trials":8681,"activeCount":59},[],{"trials":8683,"activeCount":59},[],{"intervention":1738,"totalTrials":190,"cells":8685},{"EARLY_PHASE1":8686,"PHASE1":8688,"PHASE2":8690,"PHASE3":8692,"PHASE4":8698,"NA":8700},{"trials":8687,"activeCount":59},[],{"trials":8689,"activeCount":59},[],{"trials":8691,"activeCount":59},[],{"trials":8693,"activeCount":59},[8694],{"nctId":1728,"briefTitle":1729,"status":67,"phases":8695,"primaryCompletion":1731,"completion":1731,"start":1732,"enrollment":1733,"conditions":8696,"interventions":8697},[50],[17],[1736,1737,1736,1738,1739],{"trials":8699,"activeCount":59},[],{"trials":8701,"activeCount":59},[],{"intervention":3851,"totalTrials":190,"cells":8703},{"EARLY_PHASE1":8704,"PHASE1":8706,"PHASE2":8708,"PHASE3":8710,"PHASE4":8716,"NA":8718},{"trials":8705,"activeCount":59},[],{"trials":8707,"activeCount":59},[],{"trials":8709,"activeCount":59},[],{"trials":8711,"activeCount":59},[8712],{"nctId":3842,"briefTitle":3843,"status":67,"phases":8713,"primaryCompletion":3845,"completion":3845,"start":3846,"enrollment":3847,"conditions":8714,"interventions":8715},[50],[14,3849,1036],[1511,3851,3852,3851,3853],{"trials":8717,"activeCount":59},[],{"trials":8719,"activeCount":59},[],{"intervention":3852,"totalTrials":190,"cells":8721},{"EARLY_PHASE1":8722,"PHASE1":8724,"PHASE2":8726,"PHASE3":8728,"PHASE4":8734,"NA":8736},{"trials":8723,"activeCount":59},[],{"trials":8725,"activeCount":59},[],{"trials":8727,"activeCount":59},[],{"trials":8729,"activeCount":59},[8730],{"nctId":3842,"briefTitle":3843,"status":67,"phases":8731,"primaryCompletion":3845,"completion":3845,"start":3846,"enrollment":3847,"conditions":8732,"interventions":8733},[50],[14,3849,1036],[1511,3851,3852,3851,3853],{"trials":8735,"activeCount":59},[],{"trials":8737,"activeCount":59},[],{"intervention":3853,"totalTrials":190,"cells":8739},{"EARLY_PHASE1":8740,"PHASE1":8742,"PHASE2":8744,"PHASE3":8746,"PHASE4":8752,"NA":8754},{"trials":8741,"activeCount":59},[],{"trials":8743,"activeCount":59},[],{"trials":8745,"activeCount":59},[],{"trials":8747,"activeCount":59},[8748],{"nctId":3842,"briefTitle":3843,"status":67,"phases":8749,"primaryCompletion":3845,"completion":3845,"start":3846,"enrollment":3847,"conditions":8750,"interventions":8751},[50],[14,3849,1036],[1511,3851,3852,3851,3853],{"trials":8753,"activeCount":59},[],{"trials":8755,"activeCount":59},[],{"intervention":4292,"totalTrials":190,"cells":8757},{"EARLY_PHASE1":8758,"PHASE1":8760,"PHASE2":8762,"PHASE3":8764,"PHASE4":8770,"NA":8772},{"trials":8759,"activeCount":59},[],{"trials":8761,"activeCount":59},[],{"trials":8763,"activeCount":59},[],{"trials":8765,"activeCount":59},[8766],{"nctId":4285,"briefTitle":4286,"status":67,"phases":8767,"primaryCompletion":4288,"completion":4288,"start":274,"enrollment":4289,"conditions":8768,"interventions":8769},[50],[14],[4292,4293,4294],{"trials":8771,"activeCount":59},[],{"trials":8773,"activeCount":59},[],{"intervention":1164,"totalTrials":190,"cells":8775},{"EARLY_PHASE1":8776,"PHASE1":8778,"PHASE2":8780,"PHASE3":8782,"PHASE4":8788,"NA":8790},{"trials":8777,"activeCount":59},[],{"trials":8779,"activeCount":59},[],{"trials":8781,"activeCount":59},[],{"trials":8783,"activeCount":59},[8784],{"nctId":1155,"briefTitle":1156,"status":67,"phases":8785,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":1160,"conditions":8786,"interventions":8787},[50],[1162],[1102,1164],{"trials":8789,"activeCount":59},[],{"trials":8791,"activeCount":59},[],{"intervention":8793,"totalTrials":190,"cells":8794},"MK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) \u002F Duration of Treatment : 8 Weeks",{"EARLY_PHASE1":8795,"PHASE1":8797,"PHASE2":8799,"PHASE3":8801,"PHASE4":8814,"NA":8816},{"trials":8796,"activeCount":59},[],{"trials":8798,"activeCount":59},[],{"trials":8800,"activeCount":59},[],{"trials":8802,"activeCount":59},[8803],{"nctId":8804,"briefTitle":8805,"status":67,"phases":8806,"primaryCompletion":8807,"completion":8808,"start":8809,"enrollment":8810,"conditions":8811,"interventions":8812},"NCT00480805","HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)",[50],"2002-10-15","2002-10-16","2001-08-08",312,[1086,26],[8793,8813],"Comparator : ramipril \u002FDuration of Treatment : 8 Weeks",{"trials":8815,"activeCount":59},[],{"trials":8817,"activeCount":59},[],{"intervention":8813,"totalTrials":190,"cells":8819},{"EARLY_PHASE1":8820,"PHASE1":8822,"PHASE2":8824,"PHASE3":8826,"PHASE4":8832,"NA":8834},{"trials":8821,"activeCount":59},[],{"trials":8823,"activeCount":59},[],{"trials":8825,"activeCount":59},[],{"trials":8827,"activeCount":59},[8828],{"nctId":8804,"briefTitle":8805,"status":67,"phases":8829,"primaryCompletion":8807,"completion":8808,"start":8809,"enrollment":8810,"conditions":8830,"interventions":8831},[50],[1086,26],[8793,8813],{"trials":8833,"activeCount":59},[],{"trials":8835,"activeCount":59},[],{"intervention":8837,"totalTrials":190,"cells":8838},"Mometasone Furoate\u002FFormoterol Fumarate (MF\u002FF) 100\u002F5 mcg MDI",{"EARLY_PHASE1":8839,"PHASE1":8841,"PHASE2":8843,"PHASE3":8845,"PHASE4":8854,"NA":8856},{"trials":8840,"activeCount":59},[],{"trials":8842,"activeCount":59},[],{"trials":8844,"activeCount":59},[],{"trials":8846,"activeCount":59},[8847],{"nctId":8848,"briefTitle":8849,"status":67,"phases":8850,"primaryCompletion":449,"completion":449,"start":7526,"enrollment":4489,"conditions":8851,"interventions":8852},"NCT01566149","Study of Mometasone Furoate\u002FFormoterol Fumarate (MF\u002FF) Metered Dose Inhaler (MDI) in Adolescents & Adults With Persistent Asthma (P08212)",[50],[17],[8837,8853],"Mometasone Furoate\u002FFormoterol Fumarate (MF\u002FF) 200\u002F5 mcg MDI",{"trials":8855,"activeCount":59},[],{"trials":8857,"activeCount":59},[],{"intervention":8853,"totalTrials":190,"cells":8859},{"EARLY_PHASE1":8860,"PHASE1":8862,"PHASE2":8864,"PHASE3":8866,"PHASE4":8872,"NA":8874},{"trials":8861,"activeCount":59},[],{"trials":8863,"activeCount":59},[],{"trials":8865,"activeCount":59},[],{"trials":8867,"activeCount":59},[8868],{"nctId":8848,"briefTitle":8849,"status":67,"phases":8869,"primaryCompletion":449,"completion":449,"start":7526,"enrollment":4489,"conditions":8870,"interventions":8871},[50],[17],[8837,8853],{"trials":8873,"activeCount":59},[],{"trials":8875,"activeCount":59},[],{"intervention":8877,"totalTrials":190,"cells":8878},"EZ 10 mg\u002FAtorva 20 mg FDC",{"EARLY_PHASE1":8879,"PHASE1":8881,"PHASE2":8883,"PHASE3":8885,"PHASE4":8897,"NA":8899},{"trials":8880,"activeCount":59},[],{"trials":8882,"activeCount":59},[],{"trials":8884,"activeCount":59},[],{"trials":8886,"activeCount":59},[8887],{"nctId":8888,"briefTitle":8889,"status":67,"phases":8890,"primaryCompletion":8891,"completion":8891,"start":8892,"enrollment":1389,"conditions":8893,"interventions":8895},"NCT02460159","A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)",[50],"2016-12-22","2015-06-23",[14,8894],"Heterozygous Familial Hypercholesterolemia",[8877,8896],"EZ 10 mg\u002FAtorva 10 mg FDC",{"trials":8898,"activeCount":59},[],{"trials":8900,"activeCount":59},[],{"intervention":8896,"totalTrials":190,"cells":8902},{"EARLY_PHASE1":8903,"PHASE1":8905,"PHASE2":8907,"PHASE3":8909,"PHASE4":8915,"NA":8917},{"trials":8904,"activeCount":59},[],{"trials":8906,"activeCount":59},[],{"trials":8908,"activeCount":59},[],{"trials":8910,"activeCount":59},[8911],{"nctId":8888,"briefTitle":8889,"status":67,"phases":8912,"primaryCompletion":8891,"completion":8891,"start":8892,"enrollment":1389,"conditions":8913,"interventions":8914},[50],[14,8894],[8877,8896],{"trials":8916,"activeCount":59},[],{"trials":8918,"activeCount":59},[],{"intervention":8920,"totalTrials":190,"cells":8921},"A-Phase: tirofiban; Z-Phase simvastatin",{"EARLY_PHASE1":8922,"PHASE1":8924,"PHASE2":8926,"PHASE3":8928,"PHASE4":8943,"NA":8945},{"trials":8923,"activeCount":59},[],{"trials":8925,"activeCount":59},[],{"trials":8927,"activeCount":59},[],{"trials":8929,"activeCount":59},[8930],{"nctId":8931,"briefTitle":8932,"status":67,"phases":8933,"primaryCompletion":1159,"completion":1159,"start":8934,"enrollment":8935,"conditions":8936,"interventions":8938},"NCT00251576","Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180)",[50],"1999-11-01",4497,[8937],"Acute Coronary Syndrome",[8920,8939,8940,8941,8942],"Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years","Comparator: A-Phase: low molecular weight heparin, unfractionated heparin","Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours","Duration of Treatment: Z-Phase, 2 years.",{"trials":8944,"activeCount":59},[],{"trials":8946,"activeCount":59},[],{"intervention":8939,"totalTrials":190,"cells":8948},{"EARLY_PHASE1":8949,"PHASE1":8951,"PHASE2":8953,"PHASE3":8955,"PHASE4":8961,"NA":8963},{"trials":8950,"activeCount":59},[],{"trials":8952,"activeCount":59},[],{"trials":8954,"activeCount":59},[],{"trials":8956,"activeCount":59},[8957],{"nctId":8931,"briefTitle":8932,"status":67,"phases":8958,"primaryCompletion":1159,"completion":1159,"start":8934,"enrollment":8935,"conditions":8959,"interventions":8960},[50],[8937],[8920,8939,8940,8941,8942],{"trials":8962,"activeCount":59},[],{"trials":8964,"activeCount":59},[],{"intervention":8940,"totalTrials":190,"cells":8966},{"EARLY_PHASE1":8967,"PHASE1":8969,"PHASE2":8971,"PHASE3":8973,"PHASE4":8979,"NA":8981},{"trials":8968,"activeCount":59},[],{"trials":8970,"activeCount":59},[],{"trials":8972,"activeCount":59},[],{"trials":8974,"activeCount":59},[8975],{"nctId":8931,"briefTitle":8932,"status":67,"phases":8976,"primaryCompletion":1159,"completion":1159,"start":8934,"enrollment":8935,"conditions":8977,"interventions":8978},[50],[8937],[8920,8939,8940,8941,8942],{"trials":8980,"activeCount":59},[],{"trials":8982,"activeCount":59},[],{"intervention":8941,"totalTrials":190,"cells":8984},{"EARLY_PHASE1":8985,"PHASE1":8987,"PHASE2":8989,"PHASE3":8991,"PHASE4":8997,"NA":8999},{"trials":8986,"activeCount":59},[],{"trials":8988,"activeCount":59},[],{"trials":8990,"activeCount":59},[],{"trials":8992,"activeCount":59},[8993],{"nctId":8931,"briefTitle":8932,"status":67,"phases":8994,"primaryCompletion":1159,"completion":1159,"start":8934,"enrollment":8935,"conditions":8995,"interventions":8996},[50],[8937],[8920,8939,8940,8941,8942],{"trials":8998,"activeCount":59},[],{"trials":9000,"activeCount":59},[],{"intervention":8942,"totalTrials":190,"cells":9002},{"EARLY_PHASE1":9003,"PHASE1":9005,"PHASE2":9007,"PHASE3":9009,"PHASE4":9015,"NA":9017},{"trials":9004,"activeCount":59},[],{"trials":9006,"activeCount":59},[],{"trials":9008,"activeCount":59},[],{"trials":9010,"activeCount":59},[9011],{"nctId":8931,"briefTitle":8932,"status":67,"phases":9012,"primaryCompletion":1159,"completion":1159,"start":8934,"enrollment":8935,"conditions":9013,"interventions":9014},[50],[8937],[8920,8939,8940,8941,8942],{"trials":9016,"activeCount":59},[],{"trials":9018,"activeCount":59},[],{"intervention":9020,"totalTrials":190,"cells":9021},"Comparator: Rizatriptan",{"EARLY_PHASE1":9022,"PHASE1":9024,"PHASE2":9026,"PHASE3":9028,"PHASE4":9038,"NA":9040},{"trials":9023,"activeCount":59},[],{"trials":9025,"activeCount":59},[],{"trials":9027,"activeCount":59},[],{"trials":9029,"activeCount":59},[9030],{"nctId":9031,"briefTitle":9032,"status":67,"phases":9033,"primaryCompletion":359,"completion":359,"start":9034,"enrollment":9035,"conditions":9036,"interventions":9037},"NCT00250458","Study to Test a Marketed Product in the Treatment of Migraine-associated Nausea",[50],"2006-03",346,[3555],[9020,652],{"trials":9039,"activeCount":59},[],{"trials":9041,"activeCount":59},[],{"intervention":805,"totalTrials":190,"cells":9043},{"EARLY_PHASE1":9044,"PHASE1":9046,"PHASE2":9048,"PHASE3":9050,"PHASE4":9056,"NA":9058},{"trials":9045,"activeCount":59},[],{"trials":9047,"activeCount":59},[],{"trials":9049,"activeCount":59},[],{"trials":9051,"activeCount":59},[9052],{"nctId":798,"briefTitle":799,"status":67,"phases":9053,"primaryCompletion":293,"completion":293,"start":540,"enrollment":801,"conditions":9054,"interventions":9055},[50],[14,803],[574,805,652],{"trials":9057,"activeCount":59},[],{"trials":9059,"activeCount":59},[],{"intervention":544,"totalTrials":190,"cells":9061},{"EARLY_PHASE1":9062,"PHASE1":9064,"PHASE2":9066,"PHASE3":9068,"PHASE4":9074,"NA":9076},{"trials":9063,"activeCount":59},[],{"trials":9065,"activeCount":59},[],{"trials":9067,"activeCount":59},[],{"trials":9069,"activeCount":59},[9070],{"nctId":537,"briefTitle":538,"status":67,"phases":9071,"primaryCompletion":292,"completion":292,"start":540,"enrollment":541,"conditions":9072,"interventions":9073},[50],[14],[544,443],{"trials":9075,"activeCount":59},[],{"trials":9077,"activeCount":59},[],{"intervention":9079,"totalTrials":190,"cells":9080},"Comparator: naproxen sodium",{"EARLY_PHASE1":9081,"PHASE1":9083,"PHASE2":9085,"PHASE3":9087,"PHASE4":9098,"NA":9100},{"trials":9082,"activeCount":59},[],{"trials":9084,"activeCount":59},[],{"trials":9086,"activeCount":59},[],{"trials":9088,"activeCount":59},[9089],{"nctId":9090,"briefTitle":9091,"status":67,"phases":9092,"primaryCompletion":9093,"completion":9093,"start":9094,"enrollment":9095,"conditions":9096,"interventions":9097},"NCT00092729","An Investigational Drug Study in the Treatment of Primary Dysmenorrhea (0663-064)",[50],"2002-12-06","2002-06-07",129,[3923],[4577,3355,9079],{"trials":9099,"activeCount":59},[],{"trials":9101,"activeCount":59},[],{"intervention":9103,"totalTrials":190,"cells":9104},"MK0906, finasteride \u002F Duration of Treatment: 48 weeks",{"EARLY_PHASE1":9105,"PHASE1":9107,"PHASE2":9109,"PHASE3":9111,"PHASE4":9124,"NA":9126},{"trials":9106,"activeCount":59},[],{"trials":9108,"activeCount":59},[],{"trials":9110,"activeCount":59},[],{"trials":9112,"activeCount":59},[9113],{"nctId":9114,"briefTitle":9115,"status":67,"phases":9116,"primaryCompletion":4967,"completion":9117,"start":9118,"enrollment":9119,"conditions":9120,"interventions":9122},"NCT00127179","A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)",[50],"2005-07-25","2004-01-01",600,[9121],"Benign Prostatic Hyperplasia",[9103,9123],"Comparator: placebo \u002F Duration of Treatment: 48 weeks",{"trials":9125,"activeCount":59},[],{"trials":9127,"activeCount":59},[],{"intervention":9123,"totalTrials":190,"cells":9129},{"EARLY_PHASE1":9130,"PHASE1":9132,"PHASE2":9134,"PHASE3":9136,"PHASE4":9142,"NA":9144},{"trials":9131,"activeCount":59},[],{"trials":9133,"activeCount":59},[],{"trials":9135,"activeCount":59},[],{"trials":9137,"activeCount":59},[9138],{"nctId":9114,"briefTitle":9115,"status":67,"phases":9139,"primaryCompletion":4967,"completion":9117,"start":9118,"enrollment":9119,"conditions":9140,"interventions":9141},[50],[9121],[9103,9123],{"trials":9143,"activeCount":59},[],{"trials":9145,"activeCount":59},[],{"intervention":980,"totalTrials":190,"cells":9147},{"EARLY_PHASE1":9148,"PHASE1":9150,"PHASE2":9152,"PHASE3":9154,"PHASE4":9160,"NA":9162},{"trials":9149,"activeCount":59},[],{"trials":9151,"activeCount":59},[],{"trials":9153,"activeCount":59},[],{"trials":9155,"activeCount":59},[9156],{"nctId":969,"briefTitle":970,"status":67,"phases":9157,"primaryCompletion":972,"completion":973,"start":974,"enrollment":975,"conditions":9158,"interventions":9159},[50],[977],[979,980,981],{"trials":9161,"activeCount":59},[],{"trials":9163,"activeCount":59},[],{"intervention":981,"totalTrials":190,"cells":9165},{"EARLY_PHASE1":9166,"PHASE1":9168,"PHASE2":9170,"PHASE3":9172,"PHASE4":9178,"NA":9180},{"trials":9167,"activeCount":59},[],{"trials":9169,"activeCount":59},[],{"trials":9171,"activeCount":59},[],{"trials":9173,"activeCount":59},[9174],{"nctId":969,"briefTitle":970,"status":67,"phases":9175,"primaryCompletion":972,"completion":973,"start":974,"enrollment":975,"conditions":9176,"interventions":9177},[50],[977],[979,980,981],{"trials":9179,"activeCount":59},[],{"trials":9181,"activeCount":59},[],{"intervention":9183,"totalTrials":190,"cells":9184},"MK-8962",{"EARLY_PHASE1":9185,"PHASE1":9187,"PHASE2":9189,"PHASE3":9191,"PHASE4":9202,"NA":9204},{"trials":9186,"activeCount":59},[],{"trials":9188,"activeCount":59},[],{"trials":9190,"activeCount":59},[],{"trials":9192,"activeCount":59},[9193],{"nctId":9194,"briefTitle":9195,"status":347,"phases":9196,"primaryCompletion":5059,"completion":9197,"start":9198,"enrollment":59,"conditions":9199,"interventions":9200},"NCT01599494","An Efficacy and Safety Study of Corifollitropin Alfa (MK-8962) in Contrast to Recombinant FSH for Use in Controlled Ovarian Stimulation of Indian Women (P07056, Also Known as MK-8962-029)",[50],"2015-06","2014-03",[3128],[9183,7322,5201,9201,5203],"human Chorionic Gonadotropin",{"trials":9203,"activeCount":59},[],{"trials":9205,"activeCount":59},[],{"intervention":9201,"totalTrials":190,"cells":9207},{"EARLY_PHASE1":9208,"PHASE1":9210,"PHASE2":9212,"PHASE3":9214,"PHASE4":9220,"NA":9222},{"trials":9209,"activeCount":59},[],{"trials":9211,"activeCount":59},[],{"trials":9213,"activeCount":59},[],{"trials":9215,"activeCount":59},[9216],{"nctId":9194,"briefTitle":9195,"status":347,"phases":9217,"primaryCompletion":5059,"completion":9197,"start":9198,"enrollment":59,"conditions":9218,"interventions":9219},[50],[3128],[9183,7322,5201,9201,5203],{"trials":9221,"activeCount":59},[],{"trials":9223,"activeCount":59},[],{"intervention":9225,"totalTrials":190,"cells":9226},"MK0217, alendronate sodium\u002FDuration of Treatment: 6 months",{"EARLY_PHASE1":9227,"PHASE1":9229,"PHASE2":9231,"PHASE3":9233,"PHASE4":9244,"NA":9246},{"trials":9228,"activeCount":59},[],{"trials":9230,"activeCount":59},[],{"trials":9232,"activeCount":59},[],{"trials":9234,"activeCount":59},[9235],{"nctId":9236,"briefTitle":9237,"status":67,"phases":9238,"primaryCompletion":9239,"completion":9239,"start":9240,"enrollment":496,"conditions":9241,"interventions":9242},"NCT00092027","A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)",[50],"2004-03-15","2003-03-19",[6934],[9225,9243],"Comparator: placebo \u002F Duration of Treatment: 6 months",{"trials":9245,"activeCount":59},[],{"trials":9247,"activeCount":59},[],{"intervention":9243,"totalTrials":190,"cells":9249},{"EARLY_PHASE1":9250,"PHASE1":9252,"PHASE2":9254,"PHASE3":9256,"PHASE4":9262,"NA":9264},{"trials":9251,"activeCount":59},[],{"trials":9253,"activeCount":59},[],{"trials":9255,"activeCount":59},[],{"trials":9257,"activeCount":59},[9258],{"nctId":9236,"briefTitle":9237,"status":67,"phases":9259,"primaryCompletion":9239,"completion":9239,"start":9240,"enrollment":496,"conditions":9260,"interventions":9261},[50],[6934],[9225,9243],{"trials":9263,"activeCount":59},[],{"trials":9265,"activeCount":59},[],{"intervention":4071,"totalTrials":190,"cells":9267},{"EARLY_PHASE1":9268,"PHASE1":9270,"PHASE2":9272,"PHASE3":9274,"PHASE4":9280,"NA":9282},{"trials":9269,"activeCount":59},[],{"trials":9271,"activeCount":59},[],{"trials":9273,"activeCount":59},[],{"trials":9275,"activeCount":59},[9276],{"nctId":4065,"briefTitle":4066,"status":67,"phases":9277,"primaryCompletion":275,"completion":275,"start":1095,"enrollment":4068,"conditions":9278,"interventions":9279},[50],[17],[4071,4072,4073],{"trials":9281,"activeCount":59},[],{"trials":9283,"activeCount":59},[],{"intervention":9285,"totalTrials":190,"cells":9286},"Loratadine\u002Fmontelukast combination",{"EARLY_PHASE1":9287,"PHASE1":9289,"PHASE2":9291,"PHASE3":9293,"PHASE4":9305,"NA":9307},{"trials":9288,"activeCount":59},[],{"trials":9290,"activeCount":59},[],{"trials":9292,"activeCount":59},[],{"trials":9294,"activeCount":59},[9295],{"nctId":9296,"briefTitle":9297,"status":67,"phases":9298,"primaryCompletion":9299,"completion":9300,"start":9301,"enrollment":9302,"conditions":9303,"interventions":9304},"NCT00423995","Effect of Loratadine\u002FMontelukast Combination on Congestion in SAR Patients Exposed to Pollen in an EEU (Study P04822)",[50],"2007-03-01","2007-03-10","2006-11-01",379,[20],[9285],{"trials":9306,"activeCount":59},[],{"trials":9308,"activeCount":59},[],{"intervention":4559,"totalTrials":190,"cells":9310},{"EARLY_PHASE1":9311,"PHASE1":9313,"PHASE2":9315,"PHASE3":9317,"PHASE4":9323,"NA":9325},{"trials":9312,"activeCount":59},[],{"trials":9314,"activeCount":59},[],{"trials":9316,"activeCount":59},[],{"trials":9318,"activeCount":59},[9319],{"nctId":4552,"briefTitle":4553,"status":67,"phases":9320,"primaryCompletion":4555,"completion":4556,"start":4546,"enrollment":4547,"conditions":9321,"interventions":9322},[50],[3555],[4559,4530],{"trials":9324,"activeCount":59},[],{"trials":9326,"activeCount":59},[],{"intervention":1088,"totalTrials":190,"cells":9328},{"EARLY_PHASE1":9329,"PHASE1":9331,"PHASE2":9333,"PHASE3":9335,"PHASE4":9341,"NA":9343},{"trials":9330,"activeCount":59},[],{"trials":9332,"activeCount":59},[],{"trials":9334,"activeCount":59},[],{"trials":9336,"activeCount":59},[9337],{"nctId":1079,"briefTitle":1080,"status":67,"phases":9338,"primaryCompletion":1082,"completion":1082,"start":1083,"enrollment":1084,"conditions":9339,"interventions":9340},[50],[1086,14],[1070,1088,755],{"trials":9342,"activeCount":59},[],{"trials":9344,"activeCount":59},[],{"intervention":9346,"totalTrials":190,"cells":9347},"Radiopaque Implanon",{"EARLY_PHASE1":9348,"PHASE1":9350,"PHASE2":9352,"PHASE3":9354,"PHASE4":9363,"NA":9365},{"trials":9349,"activeCount":59},[],{"trials":9351,"activeCount":59},[],{"trials":9353,"activeCount":59},[],{"trials":9355,"activeCount":59},[9356],{"nctId":9357,"briefTitle":9358,"status":67,"phases":9359,"primaryCompletion":3688,"completion":3688,"start":1083,"enrollment":3553,"conditions":9360,"interventions":9361},"NCT00620464","A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720)",[50],[23],[9346,9362],"Implanon",{"trials":9364,"activeCount":59},[],{"trials":9366,"activeCount":59},[],{"intervention":9362,"totalTrials":190,"cells":9368},{"EARLY_PHASE1":9369,"PHASE1":9371,"PHASE2":9373,"PHASE3":9375,"PHASE4":9381,"NA":9383},{"trials":9370,"activeCount":59},[],{"trials":9372,"activeCount":59},[],{"trials":9374,"activeCount":59},[],{"trials":9376,"activeCount":59},[9377],{"nctId":9357,"briefTitle":9358,"status":67,"phases":9378,"primaryCompletion":3688,"completion":3688,"start":1083,"enrollment":3553,"conditions":9379,"interventions":9380},[50],[23],[9346,9362],{"trials":9382,"activeCount":59},[],{"trials":9384,"activeCount":59},[],{"intervention":9386,"totalTrials":190,"cells":9387},"Comparator: fluticasone",{"EARLY_PHASE1":9388,"PHASE1":9390,"PHASE2":9392,"PHASE3":9394,"PHASE4":9404,"NA":9406},{"trials":9389,"activeCount":59},[],{"trials":9391,"activeCount":59},[],{"trials":9393,"activeCount":59},[],{"trials":9395,"activeCount":59},[9396],{"nctId":9397,"briefTitle":9398,"status":67,"phases":9399,"primaryCompletion":9400,"completion":9400,"start":350,"enrollment":9401,"conditions":9402,"interventions":9403},"NCT00284856","Montelukast Asthmatic Smoker Study (0476-332)(COMPLETED)",[50],"2010-04",1640,[17],[2626,652,9386,652],{"trials":9405,"activeCount":59},[],{"trials":9407,"activeCount":59},[],{"intervention":990,"totalTrials":190,"cells":9409},{"EARLY_PHASE1":9410,"PHASE1":9412,"PHASE2":9414,"PHASE3":9416,"PHASE4":9422,"NA":9424},{"trials":9411,"activeCount":59},[],{"trials":9413,"activeCount":59},[],{"trials":9415,"activeCount":59},[],{"trials":9417,"activeCount":59},[9418],{"nctId":983,"briefTitle":984,"status":610,"phases":9419,"primaryCompletion":986,"completion":986,"start":987,"enrollment":648,"conditions":9420,"interventions":9421},[50],[26],[990,921],{"trials":9423,"activeCount":59},[],{"trials":9425,"activeCount":59},[],{"intervention":9427,"totalTrials":190,"cells":9428},"MK-217A\u002FAlendronate Sodium 70-mg\u002FVitamin D3 5600 IU Combination",{"EARLY_PHASE1":9429,"PHASE1":9431,"PHASE2":9433,"PHASE3":9435,"PHASE4":9445,"NA":9447},{"trials":9430,"activeCount":59},[],{"trials":9432,"activeCount":59},[],{"trials":9434,"activeCount":59},[],{"trials":9436,"activeCount":59},[9437],{"nctId":9438,"briefTitle":9439,"status":67,"phases":9440,"primaryCompletion":2238,"completion":2238,"start":9441,"enrollment":9442,"conditions":9443,"interventions":9444},"NCT01437111","Study of MK-217A\u002FAlendronate Sodium 70-mg\u002FVitamin D3 5600 IU Combination Tablet (MK-0217A-329)",[50],"2011-10-26",200,[1120],[9427],{"trials":9446,"activeCount":59},[],{"trials":9448,"activeCount":59},[],{"intervention":9450,"totalTrials":190,"cells":9451},"Eptifibatide",{"EARLY_PHASE1":9452,"PHASE1":9454,"PHASE2":9456,"PHASE3":9458,"PHASE4":9469,"NA":9471},{"trials":9453,"activeCount":59},[],{"trials":9455,"activeCount":59},[],{"trials":9457,"activeCount":59},[],{"trials":9459,"activeCount":59},[9460],{"nctId":9461,"briefTitle":9462,"status":67,"phases":9463,"primaryCompletion":5436,"completion":5436,"start":9464,"enrollment":9465,"conditions":9466,"interventions":9468},"NCT00089895","EARLY ACS: Early Glycoprotein IIb\u002FIIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)",[50],"2004-11-01",9406,[9467,8937],"Myocardial Ischemia",[9450],{"trials":9470,"activeCount":59},[],{"trials":9472,"activeCount":59},[],{"intervention":9474,"totalTrials":190,"cells":9475},"MK0906, finasteride \u002F Duration of Treatment : 48 Weeks",{"EARLY_PHASE1":9476,"PHASE1":9478,"PHASE2":9480,"PHASE3":9482,"PHASE4":9494,"NA":9496},{"trials":9477,"activeCount":59},[],{"trials":9479,"activeCount":59},[],{"trials":9481,"activeCount":59},[],{"trials":9483,"activeCount":59},[9484],{"nctId":9485,"briefTitle":9486,"status":67,"phases":9487,"primaryCompletion":9488,"start":1966,"enrollment":9489,"conditions":9490,"interventions":9492},"NCT00396175","Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111)",[50],"2000-01",355,[9491],"Androgenetic Alopecia",[9474,9493],"Comparator : placebo (unspecified) \u002F Duration of Treatment : 48 Weeks",{"trials":9495,"activeCount":59},[],{"trials":9497,"activeCount":59},[],{"intervention":9493,"totalTrials":190,"cells":9499},{"EARLY_PHASE1":9500,"PHASE1":9502,"PHASE2":9504,"PHASE3":9506,"PHASE4":9512,"NA":9514},{"trials":9501,"activeCount":59},[],{"trials":9503,"activeCount":59},[],{"trials":9505,"activeCount":59},[],{"trials":9507,"activeCount":59},[9508],{"nctId":9485,"briefTitle":9486,"status":67,"phases":9509,"primaryCompletion":9488,"start":1966,"enrollment":9489,"conditions":9510,"interventions":9511},[50],[9491],[9474,9493],{"trials":9513,"activeCount":59},[],{"trials":9515,"activeCount":59},[],{"intervention":4945,"totalTrials":190,"cells":9517},{"EARLY_PHASE1":9518,"PHASE1":9520,"PHASE2":9522,"PHASE3":9524,"PHASE4":9530,"NA":9532},{"trials":9519,"activeCount":59},[],{"trials":9521,"activeCount":59},[],{"trials":9523,"activeCount":59},[],{"trials":9525,"activeCount":59},[9526],{"nctId":4938,"briefTitle":4939,"status":67,"phases":9527,"primaryCompletion":4941,"completion":4941,"start":4932,"enrollment":4942,"conditions":9528,"interventions":9529},[50],[26],[4917,4945],{"trials":9531,"activeCount":59},[],{"trials":9533,"activeCount":59},[],{"intervention":4363,"totalTrials":190,"cells":9535},{"EARLY_PHASE1":9536,"PHASE1":9538,"PHASE2":9540,"PHASE3":9542,"PHASE4":9548,"NA":9550},{"trials":9537,"activeCount":59},[],{"trials":9539,"activeCount":59},[],{"trials":9541,"activeCount":59},[],{"trials":9543,"activeCount":59},[9544],{"nctId":4356,"briefTitle":4357,"status":67,"phases":9545,"primaryCompletion":274,"completion":274,"start":1082,"enrollment":4359,"conditions":9546,"interventions":9547},[50],[4361],[4342,4363,4326],{"trials":9549,"activeCount":59},[],{"trials":9551,"activeCount":59},[],{"intervention":9553,"totalTrials":8,"cells":9554},"E6005",{"EARLY_PHASE1":9555,"PHASE1":9557,"PHASE2":9559,"PHASE3":9579,"PHASE4":9581,"NA":9583},{"trials":9556,"activeCount":59},[],{"trials":9558,"activeCount":59},[],{"trials":9560,"activeCount":59},[9561,9568],{"nctId":9562,"briefTitle":9563,"status":67,"phases":9564,"primaryCompletion":9565,"completion":9565,"start":4288,"enrollment":648,"conditions":9566,"interventions":9567},"NCT01179880","A Study of E6005 in Japanese Patients With Atopic Dermatitis",[48,49],"2012-12",[83],[9553],{"nctId":9569,"briefTitle":9570,"status":67,"phases":9571,"primaryCompletion":9572,"completion":9573,"start":9574,"enrollment":9575,"conditions":9576,"interventions":9577},"NCT01461941","A Phase 2 Study of E6005 in Patients With Atopic Dermatitis",[49],"2012-11","2013-01","2011-12",78,[83],[9553,9578],"E6005 ointment",{"trials":9580,"activeCount":59},[],{"trials":9582,"activeCount":59},[],{"trials":9584,"activeCount":59},[],{"intervention":9586,"totalTrials":8,"cells":9587},"etonogestrel",{"EARLY_PHASE1":9588,"PHASE1":9590,"PHASE2":9592,"PHASE3":9606,"PHASE4":9608,"NA":9610},{"trials":9589,"activeCount":59},[],{"trials":9591,"activeCount":59},[],{"trials":9593,"activeCount":59},[9594,9602],{"nctId":9595,"briefTitle":9596,"status":610,"phases":9597,"primaryCompletion":275,"completion":275,"start":438,"enrollment":9598,"conditions":9599,"interventions":9601},"NCT00651807","A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)",[49],16,[9600],"Benign Prostatic Hyperplasia (BPH)",[9586],{"nctId":5042,"briefTitle":5043,"status":67,"phases":9603,"primaryCompletion":5045,"completion":5045,"start":5046,"enrollment":5047,"conditions":9604,"interventions":9605},[49],[23],[5033,5050,5051,5052],{"trials":9607,"activeCount":59},[],{"trials":9609,"activeCount":59},[],{"trials":9611,"activeCount":59},[],{"intervention":9613,"totalTrials":190,"cells":9614},"E6005 0.05%",{"EARLY_PHASE1":9615,"PHASE1":9617,"PHASE2":9619,"PHASE3":9631,"PHASE4":9633,"NA":9635},{"trials":9616,"activeCount":59},[],{"trials":9618,"activeCount":59},[],{"trials":9620,"activeCount":59},[9621],{"nctId":9622,"briefTitle":9623,"status":67,"phases":9624,"primaryCompletion":9625,"completion":9626,"start":9627,"enrollment":3716,"conditions":9628,"interventions":9629},"NCT02094235","A Phase 1\u002F2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis",[48,49],"2014-12","2015-01","2014-01",[83],[9613,9630],"E6005 0.2%",{"trials":9632,"activeCount":59},[],{"trials":9634,"activeCount":59},[],{"trials":9636,"activeCount":59},[],{"intervention":9630,"totalTrials":190,"cells":9638},{"EARLY_PHASE1":9639,"PHASE1":9641,"PHASE2":9643,"PHASE3":9649,"PHASE4":9651,"NA":9653},{"trials":9640,"activeCount":59},[],{"trials":9642,"activeCount":59},[],{"trials":9644,"activeCount":59},[9645],{"nctId":9622,"briefTitle":9623,"status":67,"phases":9646,"primaryCompletion":9625,"completion":9626,"start":9627,"enrollment":3716,"conditions":9647,"interventions":9648},[48,49],[83],[9613,9630],{"trials":9650,"activeCount":59},[],{"trials":9652,"activeCount":59},[],{"trials":9654,"activeCount":59},[],{"intervention":9656,"totalTrials":190,"cells":9657},"MK0663, etoricoxib \u002F Duration of Treatment: Part I",{"EARLY_PHASE1":9658,"PHASE1":9660,"PHASE2":9662,"PHASE3":9673,"PHASE4":9675,"NA":9677},{"trials":9659,"activeCount":59},[],{"trials":9661,"activeCount":59},[],{"trials":9663,"activeCount":59},[9664],{"nctId":9665,"briefTitle":9666,"status":67,"phases":9667,"primaryCompletion":9668,"completion":4488,"start":9669,"enrollment":9670,"conditions":9671,"interventions":9672},"NCT00242489","Etoricoxib in the Treatment of Osteoarthritis (MK-0663-007)",[49],"1999-02","1998-06",1167,[2995],[9656],{"trials":9674,"activeCount":59},[],{"trials":9676,"activeCount":59},[],{"trials":9678,"activeCount":59},[],{"intervention":9680,"totalTrials":190,"cells":9681},"Comparator: diclofenac",{"EARLY_PHASE1":9682,"PHASE1":9684,"PHASE2":9686,"PHASE3":9695,"PHASE4":9697,"NA":9699},{"trials":9683,"activeCount":59},[],{"trials":9685,"activeCount":59},[],{"trials":9687,"activeCount":59},[9688],{"nctId":9689,"briefTitle":9690,"status":67,"phases":9691,"primaryCompletion":438,"completion":438,"start":5688,"enrollment":9692,"conditions":9693,"interventions":9694},"NCT00264147","Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)",[49],761,[3761],[4577,4577,4577,4577,3355,4577,9680],{"trials":9696,"activeCount":59},[],{"trials":9698,"activeCount":59},[],{"trials":9700,"activeCount":59},[],{"intervention":3692,"totalTrials":190,"cells":9702},{"EARLY_PHASE1":9703,"PHASE1":9705,"PHASE2":9707,"PHASE3":9713,"PHASE4":9715,"NA":9717},{"trials":9704,"activeCount":59},[],{"trials":9706,"activeCount":59},[],{"trials":9708,"activeCount":59},[9709],{"nctId":3685,"briefTitle":3686,"status":67,"phases":9710,"primaryCompletion":3688,"completion":3688,"start":338,"enrollment":3689,"conditions":9711,"interventions":9712},[49],[17],[3692,3667,3355],{"trials":9714,"activeCount":59},[],{"trials":9716,"activeCount":59},[],{"trials":9718,"activeCount":59},[],{"intervention":9720,"totalTrials":190,"cells":9721},"mometasone furoate\u002Fformoterol 100\u002F10 mcg",{"EARLY_PHASE1":9722,"PHASE1":9724,"PHASE2":9726,"PHASE3":9739,"PHASE4":9741,"NA":9743},{"trials":9723,"activeCount":59},[],{"trials":9725,"activeCount":59},[],{"trials":9727,"activeCount":59},[9728],{"nctId":9729,"briefTitle":9730,"status":67,"phases":9731,"primaryCompletion":3638,"completion":3638,"start":437,"enrollment":3847,"conditions":9732,"interventions":9734},"NCT00635882","Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate\u002FFormoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)",[49],[17,9733],"Airway Inflammation",[9720,9735,9736,9737,9738],"mometasone furoate\u002Fformoterol 200\u002F10 mcg","mometasone furoate\u002Fformoterol 400\u002F10 mcg","MF DPI 200 mcg","MF MDI 200 mcg",{"trials":9740,"activeCount":59},[],{"trials":9742,"activeCount":59},[],{"trials":9744,"activeCount":59},[],{"intervention":9735,"totalTrials":190,"cells":9746},{"EARLY_PHASE1":9747,"PHASE1":9749,"PHASE2":9751,"PHASE3":9757,"PHASE4":9759,"NA":9761},{"trials":9748,"activeCount":59},[],{"trials":9750,"activeCount":59},[],{"trials":9752,"activeCount":59},[9753],{"nctId":9729,"briefTitle":9730,"status":67,"phases":9754,"primaryCompletion":3638,"completion":3638,"start":437,"enrollment":3847,"conditions":9755,"interventions":9756},[49],[17,9733],[9720,9735,9736,9737,9738],{"trials":9758,"activeCount":59},[],{"trials":9760,"activeCount":59},[],{"trials":9762,"activeCount":59},[],{"intervention":9736,"totalTrials":190,"cells":9764},{"EARLY_PHASE1":9765,"PHASE1":9767,"PHASE2":9769,"PHASE3":9775,"PHASE4":9777,"NA":9779},{"trials":9766,"activeCount":59},[],{"trials":9768,"activeCount":59},[],{"trials":9770,"activeCount":59},[9771],{"nctId":9729,"briefTitle":9730,"status":67,"phases":9772,"primaryCompletion":3638,"completion":3638,"start":437,"enrollment":3847,"conditions":9773,"interventions":9774},[49],[17,9733],[9720,9735,9736,9737,9738],{"trials":9776,"activeCount":59},[],{"trials":9778,"activeCount":59},[],{"trials":9780,"activeCount":59},[],{"intervention":9737,"totalTrials":190,"cells":9782},{"EARLY_PHASE1":9783,"PHASE1":9785,"PHASE2":9787,"PHASE3":9793,"PHASE4":9795,"NA":9797},{"trials":9784,"activeCount":59},[],{"trials":9786,"activeCount":59},[],{"trials":9788,"activeCount":59},[9789],{"nctId":9729,"briefTitle":9730,"status":67,"phases":9790,"primaryCompletion":3638,"completion":3638,"start":437,"enrollment":3847,"conditions":9791,"interventions":9792},[49],[17,9733],[9720,9735,9736,9737,9738],{"trials":9794,"activeCount":59},[],{"trials":9796,"activeCount":59},[],{"trials":9798,"activeCount":59},[],{"intervention":9738,"totalTrials":190,"cells":9800},{"EARLY_PHASE1":9801,"PHASE1":9803,"PHASE2":9805,"PHASE3":9811,"PHASE4":9813,"NA":9815},{"trials":9802,"activeCount":59},[],{"trials":9804,"activeCount":59},[],{"trials":9806,"activeCount":59},[9807],{"nctId":9729,"briefTitle":9730,"status":67,"phases":9808,"primaryCompletion":3638,"completion":3638,"start":437,"enrollment":3847,"conditions":9809,"interventions":9810},[49],[17,9733],[9720,9735,9736,9737,9738],{"trials":9812,"activeCount":59},[],{"trials":9814,"activeCount":59},[],{"trials":9816,"activeCount":59},[],{"intervention":3925,"totalTrials":190,"cells":9818},{"EARLY_PHASE1":9819,"PHASE1":9821,"PHASE2":9823,"PHASE3":9829,"PHASE4":9831,"NA":9833},{"trials":9820,"activeCount":59},[],{"trials":9822,"activeCount":59},[],{"trials":9824,"activeCount":59},[9825],{"nctId":3915,"briefTitle":3916,"status":67,"phases":9826,"primaryCompletion":3918,"completion":3919,"start":3920,"enrollment":3921,"conditions":9827,"interventions":9828},[49],[3923],[3925,3926,3906],{"trials":9830,"activeCount":59},[],{"trials":9832,"activeCount":59},[],{"trials":9834,"activeCount":59},[],{"intervention":3926,"totalTrials":190,"cells":9836},{"EARLY_PHASE1":9837,"PHASE1":9839,"PHASE2":9841,"PHASE3":9847,"PHASE4":9849,"NA":9851},{"trials":9838,"activeCount":59},[],{"trials":9840,"activeCount":59},[],{"trials":9842,"activeCount":59},[9843],{"nctId":3915,"briefTitle":3916,"status":67,"phases":9844,"primaryCompletion":3918,"completion":3919,"start":3920,"enrollment":3921,"conditions":9845,"interventions":9846},[49],[3923],[3925,3926,3906],{"trials":9848,"activeCount":59},[],{"trials":9850,"activeCount":59},[],{"trials":9852,"activeCount":59},[],{"intervention":9854,"totalTrials":190,"cells":9855},"MK0476, Montelukast Sodium \u002FDuration of Treatment : 14 Days",{"EARLY_PHASE1":9856,"PHASE1":9858,"PHASE2":9860,"PHASE3":9869,"PHASE4":9871,"NA":9873},{"trials":9857,"activeCount":59},[],{"trials":9859,"activeCount":59},[],{"trials":9861,"activeCount":59},[9862],{"nctId":9863,"briefTitle":9864,"status":67,"phases":9865,"primaryCompletion":581,"completion":581,"start":461,"enrollment":34,"conditions":9866,"interventions":9868},"NCT00394160","Safety and Pk Study in 1- to 3- Month-Old Children With Bronchiolitis (0476-297)",[49],[9867],"Bronchiolitis",[9854],{"trials":9870,"activeCount":59},[],{"trials":9872,"activeCount":59},[],{"trials":9874,"activeCount":59},[],{"intervention":9876,"totalTrials":190,"cells":9877},"etonogestrel with testosterone undecanoate",{"EARLY_PHASE1":9878,"PHASE1":9880,"PHASE2":9882,"PHASE3":9891,"PHASE4":9893,"NA":9895},{"trials":9879,"activeCount":59},[],{"trials":9881,"activeCount":59},[],{"trials":9883,"activeCount":59},[9884],{"nctId":9885,"briefTitle":9886,"status":67,"phases":9887,"primaryCompletion":941,"completion":941,"start":1290,"enrollment":9888,"conditions":9889,"interventions":9890},"NCT00403793","Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057)",[49],350,[23],[9876],{"trials":9892,"activeCount":59},[],{"trials":9894,"activeCount":59},[],{"trials":9896,"activeCount":59},[],{"intervention":9898,"totalTrials":190,"cells":9899},"Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg",{"EARLY_PHASE1":9900,"PHASE1":9902,"PHASE2":9904,"PHASE3":9918,"PHASE4":9920,"NA":9922},{"trials":9901,"activeCount":59},[],{"trials":9903,"activeCount":59},[],{"trials":9905,"activeCount":59},[9906],{"nctId":9907,"briefTitle":9908,"status":67,"phases":9909,"primaryCompletion":9910,"completion":9910,"start":9911,"enrollment":9912,"conditions":9913,"interventions":9914},"NCT01502371","A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223)",[49],"2015-01-29","2012-01-25",583,[17],[9898,9915,9916,9917],"Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg","Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg","Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg",{"trials":9919,"activeCount":59},[],{"trials":9921,"activeCount":59},[],{"trials":9923,"activeCount":59},[],{"intervention":9915,"totalTrials":190,"cells":9925},{"EARLY_PHASE1":9926,"PHASE1":9928,"PHASE2":9930,"PHASE3":9936,"PHASE4":9938,"NA":9940},{"trials":9927,"activeCount":59},[],{"trials":9929,"activeCount":59},[],{"trials":9931,"activeCount":59},[9932],{"nctId":9907,"briefTitle":9908,"status":67,"phases":9933,"primaryCompletion":9910,"completion":9910,"start":9911,"enrollment":9912,"conditions":9934,"interventions":9935},[49],[17],[9898,9915,9916,9917],{"trials":9937,"activeCount":59},[],{"trials":9939,"activeCount":59},[],{"trials":9941,"activeCount":59},[],{"intervention":9916,"totalTrials":190,"cells":9943},{"EARLY_PHASE1":9944,"PHASE1":9946,"PHASE2":9948,"PHASE3":9954,"PHASE4":9956,"NA":9958},{"trials":9945,"activeCount":59},[],{"trials":9947,"activeCount":59},[],{"trials":9949,"activeCount":59},[9950],{"nctId":9907,"briefTitle":9908,"status":67,"phases":9951,"primaryCompletion":9910,"completion":9910,"start":9911,"enrollment":9912,"conditions":9952,"interventions":9953},[49],[17],[9898,9915,9916,9917],{"trials":9955,"activeCount":59},[],{"trials":9957,"activeCount":59},[],{"trials":9959,"activeCount":59},[],{"intervention":9917,"totalTrials":190,"cells":9961},{"EARLY_PHASE1":9962,"PHASE1":9964,"PHASE2":9966,"PHASE3":9972,"PHASE4":9974,"NA":9976},{"trials":9963,"activeCount":59},[],{"trials":9965,"activeCount":59},[],{"trials":9967,"activeCount":59},[9968],{"nctId":9907,"briefTitle":9908,"status":67,"phases":9969,"primaryCompletion":9910,"completion":9910,"start":9911,"enrollment":9912,"conditions":9970,"interventions":9971},[49],[17],[9898,9915,9916,9917],{"trials":9973,"activeCount":59},[],{"trials":9975,"activeCount":59},[],{"trials":9977,"activeCount":59},[],{"intervention":9979,"totalTrials":190,"cells":9980},"Asenapine WHITE raspberry flavor",{"EARLY_PHASE1":9981,"PHASE1":9983,"PHASE2":9985,"PHASE3":9998,"PHASE4":10000,"NA":10002},{"trials":9982,"activeCount":59},[],{"trials":9984,"activeCount":59},[],{"trials":9986,"activeCount":59},[9987],{"nctId":9988,"briefTitle":9989,"status":67,"phases":9990,"primaryCompletion":9991,"completion":9991,"start":9992,"enrollment":1242,"conditions":9993,"interventions":9995},"NCT00878462","An Acceptability Study of Unflavored Asenapine Versus Raspberry Flavored Asenapine in Stable Patients With a Psychotic Disorder (P07010)(COMPLETED)",[49],"2005-10-15","2005-06-29",[9994],"Psychosis",[9979,9996,9997],"Asenapine RED raspberry flavor","Asenapine WHITE UNFLAVORED",{"trials":9999,"activeCount":59},[],{"trials":10001,"activeCount":59},[],{"trials":10003,"activeCount":59},[],{"intervention":9996,"totalTrials":190,"cells":10005},{"EARLY_PHASE1":10006,"PHASE1":10008,"PHASE2":10010,"PHASE3":10016,"PHASE4":10018,"NA":10020},{"trials":10007,"activeCount":59},[],{"trials":10009,"activeCount":59},[],{"trials":10011,"activeCount":59},[10012],{"nctId":9988,"briefTitle":9989,"status":67,"phases":10013,"primaryCompletion":9991,"completion":9991,"start":9992,"enrollment":1242,"conditions":10014,"interventions":10015},[49],[9994],[9979,9996,9997],{"trials":10017,"activeCount":59},[],{"trials":10019,"activeCount":59},[],{"trials":10021,"activeCount":59},[],{"intervention":9997,"totalTrials":190,"cells":10023},{"EARLY_PHASE1":10024,"PHASE1":10026,"PHASE2":10028,"PHASE3":10034,"PHASE4":10036,"NA":10038},{"trials":10025,"activeCount":59},[],{"trials":10027,"activeCount":59},[],{"trials":10029,"activeCount":59},[10030],{"nctId":9988,"briefTitle":9989,"status":67,"phases":10031,"primaryCompletion":9991,"completion":9991,"start":9992,"enrollment":1242,"conditions":10032,"interventions":10033},[49],[9994],[9979,9996,9997],{"trials":10035,"activeCount":59},[],{"trials":10037,"activeCount":59},[],{"trials":10039,"activeCount":59},[],{"intervention":10041,"totalTrials":190,"cells":10042},"OG-6219",{"EARLY_PHASE1":10043,"PHASE1":10045,"PHASE2":10047,"PHASE3":10059,"PHASE4":10061,"NA":10063},{"trials":10044,"activeCount":59},[],{"trials":10046,"activeCount":59},[],{"trials":10048,"activeCount":59},[10049],{"nctId":10050,"briefTitle":10051,"status":67,"phases":10052,"primaryCompletion":10053,"completion":10053,"start":10054,"enrollment":10055,"conditions":10056,"interventions":10058},"NCT05560646","A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain",[49],"2025-05-28","2022-10-25",354,[10057],"Endometriosis",[10041],{"trials":10060,"activeCount":59},[],{"trials":10062,"activeCount":59},[],{"trials":10064,"activeCount":59},[],{"intervention":10066,"totalTrials":190,"cells":10067},"Etonogestrel-releasing IUS",{"EARLY_PHASE1":10068,"PHASE1":10070,"PHASE2":10072,"PHASE3":10082,"PHASE4":10084,"NA":10086},{"trials":10069,"activeCount":59},[],{"trials":10071,"activeCount":59},[],{"trials":10073,"activeCount":59},[10074],{"nctId":10075,"briefTitle":10076,"status":67,"phases":10077,"primaryCompletion":10078,"completion":5182,"start":10079,"enrollment":1310,"conditions":10080,"interventions":10081},"NCT00967746","An Explorative Trial to Explore the Safety, Acceptability and Vaginal Bleeding Pattern of Three Etonogestrel-releasing Medicated Intrauterine Systems (Study P06060)",[49],"2010-11","2009-11",[23],[10066,10066,10066],{"trials":10083,"activeCount":59},[],{"trials":10085,"activeCount":59},[],{"trials":10087,"activeCount":59},[],{"intervention":10089,"totalTrials":190,"cells":10090},"Asenapine 3x5mg followed by 1x15mg",{"EARLY_PHASE1":10091,"PHASE1":10093,"PHASE2":10095,"PHASE3":10105,"PHASE4":10107,"NA":10109},{"trials":10092,"activeCount":59},[],{"trials":10094,"activeCount":59},[],{"trials":10096,"activeCount":59},[10097],{"nctId":10098,"briefTitle":10099,"status":67,"phases":10100,"primaryCompletion":875,"completion":875,"start":2000,"enrollment":55,"conditions":10101,"interventions":10103},"NCT01101464","A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)",[49],[28,10102],"Schizoaffective Disorder",[10089,10104],"Asenapine 1x15mg followed by 3x5mg",{"trials":10106,"activeCount":59},[],{"trials":10108,"activeCount":59},[],{"trials":10110,"activeCount":59},[],{"intervention":10104,"totalTrials":190,"cells":10112},{"EARLY_PHASE1":10113,"PHASE1":10115,"PHASE2":10117,"PHASE3":10123,"PHASE4":10125,"NA":10127},{"trials":10114,"activeCount":59},[],{"trials":10116,"activeCount":59},[],{"trials":10118,"activeCount":59},[10119],{"nctId":10098,"briefTitle":10099,"status":67,"phases":10120,"primaryCompletion":875,"completion":875,"start":2000,"enrollment":55,"conditions":10121,"interventions":10122},[49],[28,10102],[10089,10104],{"trials":10124,"activeCount":59},[],{"trials":10126,"activeCount":59},[],{"trials":10128,"activeCount":59},[],{"intervention":9578,"totalTrials":190,"cells":10130},{"EARLY_PHASE1":10131,"PHASE1":10133,"PHASE2":10135,"PHASE3":10141,"PHASE4":10143,"NA":10145},{"trials":10132,"activeCount":59},[],{"trials":10134,"activeCount":59},[],{"trials":10136,"activeCount":59},[10137],{"nctId":9569,"briefTitle":9570,"status":67,"phases":10138,"primaryCompletion":9572,"completion":9573,"start":9574,"enrollment":9575,"conditions":10139,"interventions":10140},[49],[83],[9553,9578],{"trials":10142,"activeCount":59},[],{"trials":10144,"activeCount":59},[],{"trials":10146,"activeCount":59},[],{"intervention":10148,"totalTrials":190,"cells":10149},"MK0476, montelukast sodium \u002F Duration of Treatment: 2 Weeks",{"EARLY_PHASE1":10150,"PHASE1":10152,"PHASE2":10154,"PHASE3":10165,"PHASE4":10167,"NA":10169},{"trials":10151,"activeCount":59},[],{"trials":10153,"activeCount":59},[],{"trials":10155,"activeCount":59},[10156],{"nctId":10157,"briefTitle":10158,"status":67,"phases":10159,"primaryCompletion":1065,"completion":1065,"start":10160,"enrollment":10161,"conditions":10162,"interventions":10163},"NCT00446186","MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378)",[49],"2004-02",945,[3103],[10148,10164],"Comparator: placebo \u002F Duration of Treatment: 2 Weeks",{"trials":10166,"activeCount":59},[],{"trials":10168,"activeCount":59},[],{"trials":10170,"activeCount":59},[],{"intervention":10164,"totalTrials":190,"cells":10172},{"EARLY_PHASE1":10173,"PHASE1":10175,"PHASE2":10177,"PHASE3":10183,"PHASE4":10185,"NA":10187},{"trials":10174,"activeCount":59},[],{"trials":10176,"activeCount":59},[],{"trials":10178,"activeCount":59},[10179],{"nctId":10157,"briefTitle":10158,"status":67,"phases":10180,"primaryCompletion":1065,"completion":1065,"start":10160,"enrollment":10161,"conditions":10181,"interventions":10182},[49],[3103],[10148,10164],{"trials":10184,"activeCount":59},[],{"trials":10186,"activeCount":59},[],{"trials":10188,"activeCount":59},[],{"intervention":10190,"totalTrials":190,"cells":10191},"Desloratadine 2.5 mg",{"EARLY_PHASE1":10192,"PHASE1":10194,"PHASE2":10196,"PHASE3":10208,"PHASE4":10210,"NA":10212},{"trials":10193,"activeCount":59},[],{"trials":10195,"activeCount":59},[],{"trials":10197,"activeCount":59},[10198],{"nctId":10199,"briefTitle":10200,"status":67,"phases":10201,"primaryCompletion":1955,"completion":1955,"start":1923,"enrollment":10202,"conditions":10203,"interventions":10206},"NCT00816972","Desloratadine With Oxybutynin for the Treatment of Seasonal Allergic Rhinitis and Post-Nasal Drip (Study P04258)(COMPLETED)",[49],540,[10204,20,10205],"Post-nasal Drip","Rhinorrhea",[10190,10207],"Oxybutynin 2.5 mg",{"trials":10209,"activeCount":59},[],{"trials":10211,"activeCount":59},[],{"trials":10213,"activeCount":59},[],{"intervention":10207,"totalTrials":190,"cells":10215},{"EARLY_PHASE1":10216,"PHASE1":10218,"PHASE2":10220,"PHASE3":10226,"PHASE4":10228,"NA":10230},{"trials":10217,"activeCount":59},[],{"trials":10219,"activeCount":59},[],{"trials":10221,"activeCount":59},[10222],{"nctId":10199,"briefTitle":10200,"status":67,"phases":10223,"primaryCompletion":1955,"completion":1955,"start":1923,"enrollment":10202,"conditions":10224,"interventions":10225},[49],[10204,20,10205],[10190,10207],{"trials":10227,"activeCount":59},[],{"trials":10229,"activeCount":59},[],{"trials":10231,"activeCount":59},[],{"intervention":10233,"totalTrials":190,"cells":10234},"OXY combination: mometasone furoate nasal spray",{"EARLY_PHASE1":10235,"PHASE1":10237,"PHASE2":10239,"PHASE3":10250,"PHASE4":10252,"NA":10254},{"trials":10236,"activeCount":59},[],{"trials":10238,"activeCount":59},[],{"trials":10240,"activeCount":59},[10241],{"nctId":10242,"briefTitle":10243,"status":67,"phases":10244,"primaryCompletion":437,"completion":437,"start":283,"enrollment":10245,"conditions":10246,"interventions":10247},"NCT00552110","Study of Mometasone Furoate Nasal Spray and Oxymetazoline Nasal Spray Given Together Once A Day To Treat Seasonal Allergic Rhinitis (P04500)",[49],707,[20],[10233,10233,10248,10249],"mometasone furoate nasal spray (MFNS) once daily","oxymetazoline nasal spray (OXY) twice daily",{"trials":10251,"activeCount":59},[],{"trials":10253,"activeCount":59},[],{"trials":10255,"activeCount":59},[],{"intervention":10248,"totalTrials":190,"cells":10257},{"EARLY_PHASE1":10258,"PHASE1":10260,"PHASE2":10262,"PHASE3":10268,"PHASE4":10270,"NA":10272},{"trials":10259,"activeCount":59},[],{"trials":10261,"activeCount":59},[],{"trials":10263,"activeCount":59},[10264],{"nctId":10242,"briefTitle":10243,"status":67,"phases":10265,"primaryCompletion":437,"completion":437,"start":283,"enrollment":10245,"conditions":10266,"interventions":10267},[49],[20],[10233,10233,10248,10249],{"trials":10269,"activeCount":59},[],{"trials":10271,"activeCount":59},[],{"trials":10273,"activeCount":59},[],{"intervention":10249,"totalTrials":190,"cells":10275},{"EARLY_PHASE1":10276,"PHASE1":10278,"PHASE2":10280,"PHASE3":10286,"PHASE4":10288,"NA":10290},{"trials":10277,"activeCount":59},[],{"trials":10279,"activeCount":59},[],{"trials":10281,"activeCount":59},[10282],{"nctId":10242,"briefTitle":10243,"status":67,"phases":10283,"primaryCompletion":437,"completion":437,"start":283,"enrollment":10245,"conditions":10284,"interventions":10285},[49],[20],[10233,10233,10248,10249],{"trials":10287,"activeCount":59},[],{"trials":10289,"activeCount":59},[],{"trials":10291,"activeCount":59},[],{"intervention":5051,"totalTrials":190,"cells":10293},{"EARLY_PHASE1":10294,"PHASE1":10296,"PHASE2":10298,"PHASE3":10304,"PHASE4":10306,"NA":10308},{"trials":10295,"activeCount":59},[],{"trials":10297,"activeCount":59},[],{"trials":10299,"activeCount":59},[10300],{"nctId":5042,"briefTitle":5043,"status":67,"phases":10301,"primaryCompletion":5045,"completion":5045,"start":5046,"enrollment":5047,"conditions":10302,"interventions":10303},[49],[23],[5033,5050,5051,5052],{"trials":10305,"activeCount":59},[],{"trials":10307,"activeCount":59},[],{"trials":10309,"activeCount":59},[],{"intervention":10311,"totalTrials":190,"cells":10312},"Etoricoxib 75 mg 4% DMSO Gel",{"EARLY_PHASE1":10313,"PHASE1":10315,"PHASE2":10317,"PHASE3":10334,"PHASE4":10336,"NA":10338},{"trials":10314,"activeCount":59},[],{"trials":10316,"activeCount":59},[],{"trials":10318,"activeCount":59},[10319],{"nctId":10320,"briefTitle":10321,"status":67,"phases":10322,"primaryCompletion":10323,"completion":10323,"start":10324,"enrollment":10325,"conditions":10326,"interventions":10328},"NCT01980940","The Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Participants With Osteoarthritis (MK-0663-168)",[48,49],"2014-11-26","2013-12-23",70,[10327],"Osteoarthritis Pain",[10311,10329,10330,10331,10332,10333],"Etoricoxib 75 mg 4% PG Gel","Etoricoxib 150 mg 4% DMSO Gel","Etoricoxib 150 mg 4% PG Gel","Etoricoxib 163 mg 4% DMSO gel","Etoricoxib 50 mg 4% DMSO",{"trials":10335,"activeCount":59},[],{"trials":10337,"activeCount":59},[],{"trials":10339,"activeCount":59},[],{"intervention":10329,"totalTrials":190,"cells":10341},{"EARLY_PHASE1":10342,"PHASE1":10344,"PHASE2":10346,"PHASE3":10352,"PHASE4":10354,"NA":10356},{"trials":10343,"activeCount":59},[],{"trials":10345,"activeCount":59},[],{"trials":10347,"activeCount":59},[10348],{"nctId":10320,"briefTitle":10321,"status":67,"phases":10349,"primaryCompletion":10323,"completion":10323,"start":10324,"enrollment":10325,"conditions":10350,"interventions":10351},[48,49],[10327],[10311,10329,10330,10331,10332,10333],{"trials":10353,"activeCount":59},[],{"trials":10355,"activeCount":59},[],{"trials":10357,"activeCount":59},[],{"intervention":10330,"totalTrials":190,"cells":10359},{"EARLY_PHASE1":10360,"PHASE1":10362,"PHASE2":10364,"PHASE3":10370,"PHASE4":10372,"NA":10374},{"trials":10361,"activeCount":59},[],{"trials":10363,"activeCount":59},[],{"trials":10365,"activeCount":59},[10366],{"nctId":10320,"briefTitle":10321,"status":67,"phases":10367,"primaryCompletion":10323,"completion":10323,"start":10324,"enrollment":10325,"conditions":10368,"interventions":10369},[48,49],[10327],[10311,10329,10330,10331,10332,10333],{"trials":10371,"activeCount":59},[],{"trials":10373,"activeCount":59},[],{"trials":10375,"activeCount":59},[],{"intervention":10331,"totalTrials":190,"cells":10377},{"EARLY_PHASE1":10378,"PHASE1":10380,"PHASE2":10382,"PHASE3":10388,"PHASE4":10390,"NA":10392},{"trials":10379,"activeCount":59},[],{"trials":10381,"activeCount":59},[],{"trials":10383,"activeCount":59},[10384],{"nctId":10320,"briefTitle":10321,"status":67,"phases":10385,"primaryCompletion":10323,"completion":10323,"start":10324,"enrollment":10325,"conditions":10386,"interventions":10387},[48,49],[10327],[10311,10329,10330,10331,10332,10333],{"trials":10389,"activeCount":59},[],{"trials":10391,"activeCount":59},[],{"trials":10393,"activeCount":59},[],{"intervention":10332,"totalTrials":190,"cells":10395},{"EARLY_PHASE1":10396,"PHASE1":10398,"PHASE2":10400,"PHASE3":10406,"PHASE4":10408,"NA":10410},{"trials":10397,"activeCount":59},[],{"trials":10399,"activeCount":59},[],{"trials":10401,"activeCount":59},[10402],{"nctId":10320,"briefTitle":10321,"status":67,"phases":10403,"primaryCompletion":10323,"completion":10323,"start":10324,"enrollment":10325,"conditions":10404,"interventions":10405},[48,49],[10327],[10311,10329,10330,10331,10332,10333],{"trials":10407,"activeCount":59},[],{"trials":10409,"activeCount":59},[],{"trials":10411,"activeCount":59},[],{"intervention":10333,"totalTrials":190,"cells":10413},{"EARLY_PHASE1":10414,"PHASE1":10416,"PHASE2":10418,"PHASE3":10424,"PHASE4":10426,"NA":10428},{"trials":10415,"activeCount":59},[],{"trials":10417,"activeCount":59},[],{"trials":10419,"activeCount":59},[10420],{"nctId":10320,"briefTitle":10321,"status":67,"phases":10421,"primaryCompletion":10323,"completion":10323,"start":10324,"enrollment":10325,"conditions":10422,"interventions":10423},[48,49],[10327],[10311,10329,10330,10331,10332,10333],{"trials":10425,"activeCount":59},[],{"trials":10427,"activeCount":59},[],{"trials":10429,"activeCount":59},[],{"intervention":10431,"totalTrials":190,"cells":10432},"Puregon®",{"EARLY_PHASE1":10433,"PHASE1":10435,"PHASE2":10437,"PHASE3":10450,"PHASE4":10452,"NA":10454},{"trials":10434,"activeCount":59},[],{"trials":10436,"activeCount":59},[],{"trials":10438,"activeCount":59},[10439],{"nctId":10440,"briefTitle":10441,"status":67,"phases":10442,"primaryCompletion":8807,"completion":8807,"start":10443,"enrollment":10444,"conditions":10445,"interventions":10446},"NCT00702806","Investigate Dose of Org 36286 to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF\u002FICSI (P07015)",[49],"2001-07-01",99,[3128,5197],[10447,10431,10448,10449],"Org 36286","Orgalutran®","Pregnyl®",{"trials":10451,"activeCount":59},[],{"trials":10453,"activeCount":59},[],{"trials":10455,"activeCount":59},[],{"intervention":10448,"totalTrials":190,"cells":10457},{"EARLY_PHASE1":10458,"PHASE1":10460,"PHASE2":10462,"PHASE3":10468,"PHASE4":10470,"NA":10472},{"trials":10459,"activeCount":59},[],{"trials":10461,"activeCount":59},[],{"trials":10463,"activeCount":59},[10464],{"nctId":10440,"briefTitle":10441,"status":67,"phases":10465,"primaryCompletion":8807,"completion":8807,"start":10443,"enrollment":10444,"conditions":10466,"interventions":10467},[49],[3128,5197],[10447,10431,10448,10449],{"trials":10469,"activeCount":59},[],{"trials":10471,"activeCount":59},[],{"trials":10473,"activeCount":59},[],{"intervention":10449,"totalTrials":190,"cells":10475},{"EARLY_PHASE1":10476,"PHASE1":10478,"PHASE2":10480,"PHASE3":10486,"PHASE4":10488,"NA":10490},{"trials":10477,"activeCount":59},[],{"trials":10479,"activeCount":59},[],{"trials":10481,"activeCount":59},[10482],{"nctId":10440,"briefTitle":10441,"status":67,"phases":10483,"primaryCompletion":8807,"completion":8807,"start":10443,"enrollment":10444,"conditions":10484,"interventions":10485},[49],[3128,5197],[10447,10431,10448,10449],{"trials":10487,"activeCount":59},[],{"trials":10489,"activeCount":59},[],{"trials":10491,"activeCount":59},[],{"intervention":10493,"totalTrials":190,"cells":10494},"MK-0476, montelukast sodium",{"EARLY_PHASE1":10495,"PHASE1":10497,"PHASE2":10499,"PHASE3":10507,"PHASE4":10509,"NA":10511},{"trials":10496,"activeCount":59},[],{"trials":10498,"activeCount":59},[],{"trials":10500,"activeCount":59},[10501],{"nctId":10502,"briefTitle":10503,"status":67,"phases":10504,"primaryCompletion":2479,"completion":2479,"start":647,"enrollment":597,"conditions":10505,"interventions":10506},"NCT00394069","PK Study in 3- to 6- Month-Old Children (0476-268)(COMPLETED)",[49],[9867],[10493],{"trials":10508,"activeCount":59},[],{"trials":10510,"activeCount":59},[],{"trials":10512,"activeCount":59},[],{"intervention":10514,"totalTrials":190,"cells":10515},"MF\u002FF Metered Dose Inhaler (MDI) 25\u002F5 mcg",{"EARLY_PHASE1":10516,"PHASE1":10518,"PHASE2":10520,"PHASE3":10535,"PHASE4":10537,"NA":10539},{"trials":10517,"activeCount":59},[],{"trials":10519,"activeCount":59},[],{"trials":10521,"activeCount":59},[10522],{"nctId":10523,"briefTitle":10524,"status":347,"phases":10525,"primaryCompletion":10526,"completion":10526,"start":9573,"enrollment":59,"conditions":10527,"interventions":10528},"NCT01615874","Study of the Effect of Mometasone Furoate\u002FFormoterol (MF\u002FF), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)",[49],"2013-09",[17],[10514,10529,10530,10531,10532,10533,10534],"MF\u002FF MDI 50\u002F5 mcg","MF\u002FF MDI 100\u002F5 mcg","BDP hydrofluoroalkane (HFA) 80 mcg","Montelukast tablets 5 mg","Rescue medication: short-acting beta-2 agonist (SABA) MDI","Rescue medication: Prednisone\u002FPrednisolone",{"trials":10536,"activeCount":59},[],{"trials":10538,"activeCount":59},[],{"trials":10540,"activeCount":59},[],{"intervention":10529,"totalTrials":190,"cells":10542},{"EARLY_PHASE1":10543,"PHASE1":10545,"PHASE2":10547,"PHASE3":10553,"PHASE4":10555,"NA":10557},{"trials":10544,"activeCount":59},[],{"trials":10546,"activeCount":59},[],{"trials":10548,"activeCount":59},[10549],{"nctId":10523,"briefTitle":10524,"status":347,"phases":10550,"primaryCompletion":10526,"completion":10526,"start":9573,"enrollment":59,"conditions":10551,"interventions":10552},[49],[17],[10514,10529,10530,10531,10532,10533,10534],{"trials":10554,"activeCount":59},[],{"trials":10556,"activeCount":59},[],{"trials":10558,"activeCount":59},[],{"intervention":10530,"totalTrials":190,"cells":10560},{"EARLY_PHASE1":10561,"PHASE1":10563,"PHASE2":10565,"PHASE3":10571,"PHASE4":10573,"NA":10575},{"trials":10562,"activeCount":59},[],{"trials":10564,"activeCount":59},[],{"trials":10566,"activeCount":59},[10567],{"nctId":10523,"briefTitle":10524,"status":347,"phases":10568,"primaryCompletion":10526,"completion":10526,"start":9573,"enrollment":59,"conditions":10569,"interventions":10570},[49],[17],[10514,10529,10530,10531,10532,10533,10534],{"trials":10572,"activeCount":59},[],{"trials":10574,"activeCount":59},[],{"trials":10576,"activeCount":59},[],{"intervention":10531,"totalTrials":190,"cells":10578},{"EARLY_PHASE1":10579,"PHASE1":10581,"PHASE2":10583,"PHASE3":10589,"PHASE4":10591,"NA":10593},{"trials":10580,"activeCount":59},[],{"trials":10582,"activeCount":59},[],{"trials":10584,"activeCount":59},[10585],{"nctId":10523,"briefTitle":10524,"status":347,"phases":10586,"primaryCompletion":10526,"completion":10526,"start":9573,"enrollment":59,"conditions":10587,"interventions":10588},[49],[17],[10514,10529,10530,10531,10532,10533,10534],{"trials":10590,"activeCount":59},[],{"trials":10592,"activeCount":59},[],{"trials":10594,"activeCount":59},[],{"intervention":10532,"totalTrials":190,"cells":10596},{"EARLY_PHASE1":10597,"PHASE1":10599,"PHASE2":10601,"PHASE3":10607,"PHASE4":10609,"NA":10611},{"trials":10598,"activeCount":59},[],{"trials":10600,"activeCount":59},[],{"trials":10602,"activeCount":59},[10603],{"nctId":10523,"briefTitle":10524,"status":347,"phases":10604,"primaryCompletion":10526,"completion":10526,"start":9573,"enrollment":59,"conditions":10605,"interventions":10606},[49],[17],[10514,10529,10530,10531,10532,10533,10534],{"trials":10608,"activeCount":59},[],{"trials":10610,"activeCount":59},[],{"trials":10612,"activeCount":59},[],{"intervention":10533,"totalTrials":190,"cells":10614},{"EARLY_PHASE1":10615,"PHASE1":10617,"PHASE2":10619,"PHASE3":10625,"PHASE4":10627,"NA":10629},{"trials":10616,"activeCount":59},[],{"trials":10618,"activeCount":59},[],{"trials":10620,"activeCount":59},[10621],{"nctId":10523,"briefTitle":10524,"status":347,"phases":10622,"primaryCompletion":10526,"completion":10526,"start":9573,"enrollment":59,"conditions":10623,"interventions":10624},[49],[17],[10514,10529,10530,10531,10532,10533,10534],{"trials":10626,"activeCount":59},[],{"trials":10628,"activeCount":59},[],{"trials":10630,"activeCount":59},[],{"intervention":10534,"totalTrials":190,"cells":10632},{"EARLY_PHASE1":10633,"PHASE1":10635,"PHASE2":10637,"PHASE3":10643,"PHASE4":10645,"NA":10647},{"trials":10634,"activeCount":59},[],{"trials":10636,"activeCount":59},[],{"trials":10638,"activeCount":59},[10639],{"nctId":10523,"briefTitle":10524,"status":347,"phases":10640,"primaryCompletion":10526,"completion":10526,"start":9573,"enrollment":59,"conditions":10641,"interventions":10642},[49],[17],[10514,10529,10530,10531,10532,10533,10534],{"trials":10644,"activeCount":59},[],{"trials":10646,"activeCount":59},[],{"trials":10648,"activeCount":59},[],{"intervention":10650,"totalTrials":190,"cells":10651},"Formoterol Fumarate DPI",{"EARLY_PHASE1":10652,"PHASE1":10654,"PHASE2":10656,"PHASE3":10670,"PHASE4":10672,"NA":10674},{"trials":10653,"activeCount":59},[],{"trials":10655,"activeCount":59},[],{"trials":10657,"activeCount":59},[10658],{"nctId":10659,"briefTitle":10660,"status":67,"phases":10661,"primaryCompletion":10662,"completion":10662,"start":10663,"enrollment":10664,"conditions":10665,"interventions":10666},"NCT01258803","A Study of the Bronchodilator Effect of Formoterol Fumarate Used in Combination With Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P06476 AM2)",[49],"2011-10","2010-12",92,[17],[10650,10667,10668,10669],"Mometasone Furoate\u002FFormoterol Fumarate MDI (ex-actuator) without spacer","Mometasone Furoate\u002FFormoterol Fumarate MDI (ex-actuator) with spacer","Mometasone Furoate DPI",{"trials":10671,"activeCount":59},[],{"trials":10673,"activeCount":59},[],{"trials":10675,"activeCount":59},[],{"intervention":10667,"totalTrials":190,"cells":10677},{"EARLY_PHASE1":10678,"PHASE1":10680,"PHASE2":10682,"PHASE3":10688,"PHASE4":10690,"NA":10692},{"trials":10679,"activeCount":59},[],{"trials":10681,"activeCount":59},[],{"trials":10683,"activeCount":59},[10684],{"nctId":10659,"briefTitle":10660,"status":67,"phases":10685,"primaryCompletion":10662,"completion":10662,"start":10663,"enrollment":10664,"conditions":10686,"interventions":10687},[49],[17],[10650,10667,10668,10669],{"trials":10689,"activeCount":59},[],{"trials":10691,"activeCount":59},[],{"trials":10693,"activeCount":59},[],{"intervention":10668,"totalTrials":190,"cells":10695},{"EARLY_PHASE1":10696,"PHASE1":10698,"PHASE2":10700,"PHASE3":10706,"PHASE4":10708,"NA":10710},{"trials":10697,"activeCount":59},[],{"trials":10699,"activeCount":59},[],{"trials":10701,"activeCount":59},[10702],{"nctId":10659,"briefTitle":10660,"status":67,"phases":10703,"primaryCompletion":10662,"completion":10662,"start":10663,"enrollment":10664,"conditions":10704,"interventions":10705},[49],[17],[10650,10667,10668,10669],{"trials":10707,"activeCount":59},[],{"trials":10709,"activeCount":59},[],{"trials":10711,"activeCount":59},[],{"intervention":10669,"totalTrials":190,"cells":10713},{"EARLY_PHASE1":10714,"PHASE1":10716,"PHASE2":10718,"PHASE3":10724,"PHASE4":10726,"NA":10728},{"trials":10715,"activeCount":59},[],{"trials":10717,"activeCount":59},[],{"trials":10719,"activeCount":59},[10720],{"nctId":10659,"briefTitle":10660,"status":67,"phases":10721,"primaryCompletion":10662,"completion":10662,"start":10663,"enrollment":10664,"conditions":10722,"interventions":10723},[49],[17],[10650,10667,10668,10669],{"trials":10725,"activeCount":59},[],{"trials":10727,"activeCount":59},[],{"trials":10729,"activeCount":59},[],{"intervention":1670,"totalTrials":8,"cells":10731},{"EARLY_PHASE1":10732,"PHASE1":10734,"PHASE2":10748,"PHASE3":10750,"PHASE4":10752,"NA":10754},{"trials":10733,"activeCount":59},[],{"trials":10735,"activeCount":59},[10736,10744],{"nctId":10737,"briefTitle":10738,"status":67,"phases":10739,"primaryCompletion":313,"completion":313,"start":350,"enrollment":10740,"conditions":10741,"interventions":10742},"NCT00803790","A Study of the Bioequivalence of 70-mg Alendronate and 70-mg Alendronate in Combination With 5600 IU Vitamin D (MK0217A-253)",[48],318,[1120],[10743,1670],"alendronate sodium+vitamin D combination",{"nctId":1663,"briefTitle":1664,"status":67,"phases":10745,"primaryCompletion":892,"completion":1666,"start":462,"enrollment":1667,"conditions":10746,"interventions":10747},[48],[1120],[1649,1670],{"trials":10749,"activeCount":59},[],{"trials":10751,"activeCount":59},[],{"trials":10753,"activeCount":59},[],{"trials":10755,"activeCount":59},[],{"intervention":10757,"totalTrials":190,"cells":10758},"Commercial NOMAC-E2",{"EARLY_PHASE1":10759,"PHASE1":10761,"PHASE2":10773,"PHASE3":10775,"PHASE4":10777,"NA":10779},{"trials":10760,"activeCount":59},[],{"trials":10762,"activeCount":59},[10763],{"nctId":10764,"briefTitle":10765,"status":67,"phases":10766,"primaryCompletion":5183,"completion":5183,"start":10079,"enrollment":10767,"conditions":10768,"interventions":10770},"NCT01345786","Bioequivalence of Nomegestrol Acetate (NOMAC) and Estradiol (E2) in Commercial Versus Phase 3 Pivotal Clinical Batches of NOMAC-E2 Tablets (P06328)",[48],158,[10769],"Healthy Postmenopausal Females",[10757,10771,10772],"Phase 3 NOMAC-E2 \"Batch A\"","Phase 3 NOMAC-E2 \"Batch B\"",{"trials":10774,"activeCount":59},[],{"trials":10776,"activeCount":59},[],{"trials":10778,"activeCount":59},[],{"trials":10780,"activeCount":59},[],{"intervention":10771,"totalTrials":190,"cells":10782},{"EARLY_PHASE1":10783,"PHASE1":10785,"PHASE2":10791,"PHASE3":10793,"PHASE4":10795,"NA":10797},{"trials":10784,"activeCount":59},[],{"trials":10786,"activeCount":59},[10787],{"nctId":10764,"briefTitle":10765,"status":67,"phases":10788,"primaryCompletion":5183,"completion":5183,"start":10079,"enrollment":10767,"conditions":10789,"interventions":10790},[48],[10769],[10757,10771,10772],{"trials":10792,"activeCount":59},[],{"trials":10794,"activeCount":59},[],{"trials":10796,"activeCount":59},[],{"trials":10798,"activeCount":59},[],{"intervention":10772,"totalTrials":190,"cells":10800},{"EARLY_PHASE1":10801,"PHASE1":10803,"PHASE2":10809,"PHASE3":10811,"PHASE4":10813,"NA":10815},{"trials":10802,"activeCount":59},[],{"trials":10804,"activeCount":59},[10805],{"nctId":10764,"briefTitle":10765,"status":67,"phases":10806,"primaryCompletion":5183,"completion":5183,"start":10079,"enrollment":10767,"conditions":10807,"interventions":10808},[48],[10769],[10757,10771,10772],{"trials":10810,"activeCount":59},[],{"trials":10812,"activeCount":59},[],{"trials":10814,"activeCount":59},[],{"trials":10816,"activeCount":59},[],{"intervention":936,"totalTrials":190,"cells":10818},{"EARLY_PHASE1":10819,"PHASE1":10821,"PHASE2":10827,"PHASE3":10829,"PHASE4":10831,"NA":10833},{"trials":10820,"activeCount":59},[],{"trials":10822,"activeCount":59},[10823],{"nctId":928,"briefTitle":929,"status":67,"phases":10824,"primaryCompletion":931,"completion":932,"start":646,"enrollment":933,"conditions":10825,"interventions":10826},[48],[26],[921,921,936],{"trials":10828,"activeCount":59},[],{"trials":10830,"activeCount":59},[],{"trials":10832,"activeCount":59},[],{"trials":10834,"activeCount":59},[],{"intervention":10836,"totalTrials":190,"cells":10837},"Comparator: cyclosporine",{"EARLY_PHASE1":10838,"PHASE1":10840,"PHASE2":10848,"PHASE3":10850,"PHASE4":10852,"NA":10854},{"trials":10839,"activeCount":59},[],{"trials":10841,"activeCount":59},[10842],{"nctId":10843,"briefTitle":10844,"status":67,"phases":10845,"primaryCompletion":1666,"completion":1666,"start":3699,"enrollment":943,"conditions":10846,"interventions":10847},"NCT00653276","MD Ezetimibe Cyclosporine Interaction (0653-057)",[48],[650],[444,10836],{"trials":10849,"activeCount":59},[],{"trials":10851,"activeCount":59},[],{"trials":10853,"activeCount":59},[],{"trials":10855,"activeCount":59},[],{"intervention":3602,"totalTrials":190,"cells":10857},{"EARLY_PHASE1":10858,"PHASE1":10860,"PHASE2":10866,"PHASE3":10868,"PHASE4":10870,"NA":10872},{"trials":10859,"activeCount":59},[],{"trials":10861,"activeCount":59},[10862],{"nctId":3596,"briefTitle":3597,"status":67,"phases":10863,"primaryCompletion":274,"completion":274,"start":338,"enrollment":3599,"conditions":10864,"interventions":10865},[48],[23],[3602,3589,3603,3604],{"trials":10867,"activeCount":59},[],{"trials":10869,"activeCount":59},[],{"trials":10871,"activeCount":59},[],{"trials":10873,"activeCount":59},[],{"intervention":3603,"totalTrials":190,"cells":10875},{"EARLY_PHASE1":10876,"PHASE1":10878,"PHASE2":10884,"PHASE3":10886,"PHASE4":10888,"NA":10890},{"trials":10877,"activeCount":59},[],{"trials":10879,"activeCount":59},[10880],{"nctId":3596,"briefTitle":3597,"status":67,"phases":10881,"primaryCompletion":274,"completion":274,"start":338,"enrollment":3599,"conditions":10882,"interventions":10883},[48],[23],[3602,3589,3603,3604],{"trials":10885,"activeCount":59},[],{"trials":10887,"activeCount":59},[],{"trials":10889,"activeCount":59},[],{"trials":10891,"activeCount":59},[],{"intervention":3604,"totalTrials":190,"cells":10893},{"EARLY_PHASE1":10894,"PHASE1":10896,"PHASE2":10902,"PHASE3":10904,"PHASE4":10906,"NA":10908},{"trials":10895,"activeCount":59},[],{"trials":10897,"activeCount":59},[10898],{"nctId":3596,"briefTitle":3597,"status":67,"phases":10899,"primaryCompletion":274,"completion":274,"start":338,"enrollment":3599,"conditions":10900,"interventions":10901},[48],[23],[3602,3589,3603,3604],{"trials":10903,"activeCount":59},[],{"trials":10905,"activeCount":59},[],{"trials":10907,"activeCount":59},[],{"trials":10909,"activeCount":59},[],{"intervention":3519,"totalTrials":190,"cells":10911},{"EARLY_PHASE1":10912,"PHASE1":10914,"PHASE2":10920,"PHASE3":10922,"PHASE4":10924,"NA":10926},{"trials":10913,"activeCount":59},[],{"trials":10915,"activeCount":59},[10916],{"nctId":3511,"briefTitle":3512,"status":67,"phases":10917,"primaryCompletion":3514,"completion":3514,"start":3515,"enrollment":1957,"conditions":10918,"interventions":10919},[48],[3517],[3504,3504,3519,3520],{"trials":10921,"activeCount":59},[],{"trials":10923,"activeCount":59},[],{"trials":10925,"activeCount":59},[],{"trials":10927,"activeCount":59},[],{"intervention":3520,"totalTrials":190,"cells":10929},{"EARLY_PHASE1":10930,"PHASE1":10932,"PHASE2":10938,"PHASE3":10940,"PHASE4":10942,"NA":10944},{"trials":10931,"activeCount":59},[],{"trials":10933,"activeCount":59},[10934],{"nctId":3511,"briefTitle":3512,"status":67,"phases":10935,"primaryCompletion":3514,"completion":3514,"start":3515,"enrollment":1957,"conditions":10936,"interventions":10937},[48],[3517],[3504,3504,3519,3520],{"trials":10939,"activeCount":59},[],{"trials":10941,"activeCount":59},[],{"trials":10943,"activeCount":59},[],{"trials":10945,"activeCount":59},[],{"intervention":10947,"totalTrials":190,"cells":10948},"SCH 58235",{"EARLY_PHASE1":10949,"PHASE1":10951,"PHASE2":10961,"PHASE3":10963,"PHASE4":10965,"NA":10967},{"trials":10950,"activeCount":59},[],{"trials":10952,"activeCount":59},[10953],{"nctId":10954,"briefTitle":10955,"status":67,"phases":10956,"primaryCompletion":10957,"completion":10957,"start":1065,"enrollment":3946,"conditions":10958,"interventions":10959},"NCT00653913","Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and Pitavastatin (Study P03962)(COMPLETED)",[48],"2004-09",[14],[10947,10960],"pitavastatin",{"trials":10962,"activeCount":59},[],{"trials":10964,"activeCount":59},[],{"trials":10966,"activeCount":59},[],{"trials":10968,"activeCount":59},[],{"intervention":10960,"totalTrials":190,"cells":10970},{"EARLY_PHASE1":10971,"PHASE1":10973,"PHASE2":10979,"PHASE3":10981,"PHASE4":10983,"NA":10985},{"trials":10972,"activeCount":59},[],{"trials":10974,"activeCount":59},[10975],{"nctId":10954,"briefTitle":10955,"status":67,"phases":10976,"primaryCompletion":10957,"completion":10957,"start":1065,"enrollment":3946,"conditions":10977,"interventions":10978},[48],[14],[10947,10960],{"trials":10980,"activeCount":59},[],{"trials":10982,"activeCount":59},[],{"trials":10984,"activeCount":59},[],{"trials":10986,"activeCount":59},[],{"intervention":10988,"totalTrials":190,"cells":10989},"Vytorin + Niaspan",{"EARLY_PHASE1":10990,"PHASE1":10992,"PHASE2":11002,"PHASE3":11004,"PHASE4":11006,"NA":11008},{"trials":10991,"activeCount":59},[],{"trials":10993,"activeCount":59},[10994],{"nctId":10995,"briefTitle":10996,"status":67,"phases":10997,"primaryCompletion":283,"completion":283,"start":1637,"enrollment":3946,"conditions":10998,"interventions":10999},"NCT00652431","Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)",[48],[14,745],[10988,11000,11001],"Vytorin","Niaspan",{"trials":11003,"activeCount":59},[],{"trials":11005,"activeCount":59},[],{"trials":11007,"activeCount":59},[],{"trials":11009,"activeCount":59},[],{"intervention":11001,"totalTrials":190,"cells":11011},{"EARLY_PHASE1":11012,"PHASE1":11014,"PHASE2":11020,"PHASE3":11022,"PHASE4":11024,"NA":11026},{"trials":11013,"activeCount":59},[],{"trials":11015,"activeCount":59},[11016],{"nctId":10995,"briefTitle":10996,"status":67,"phases":11017,"primaryCompletion":283,"completion":283,"start":1637,"enrollment":3946,"conditions":11018,"interventions":11019},[48],[14,745],[10988,11000,11001],{"trials":11021,"activeCount":59},[],{"trials":11023,"activeCount":59},[],{"trials":11025,"activeCount":59},[],{"trials":11027,"activeCount":59},[],{"intervention":1378,"totalTrials":190,"cells":11029},{"EARLY_PHASE1":11030,"PHASE1":11032,"PHASE2":11038,"PHASE3":11040,"PHASE4":11042,"NA":11044},{"trials":11031,"activeCount":59},[],{"trials":11033,"activeCount":59},[11034],{"nctId":1372,"briefTitle":1373,"status":67,"phases":11035,"primaryCompletion":462,"completion":462,"start":1375,"enrollment":648,"conditions":11036,"interventions":11037},[48],[14,465],[1378,565,432],{"trials":11039,"activeCount":59},[],{"trials":11041,"activeCount":59},[],{"trials":11043,"activeCount":59},[],{"trials":11045,"activeCount":59},[],{"intervention":10743,"totalTrials":190,"cells":11047},{"EARLY_PHASE1":11048,"PHASE1":11050,"PHASE2":11056,"PHASE3":11058,"PHASE4":11060,"NA":11062},{"trials":11049,"activeCount":59},[],{"trials":11051,"activeCount":59},[11052],{"nctId":10737,"briefTitle":10738,"status":67,"phases":11053,"primaryCompletion":313,"completion":313,"start":350,"enrollment":10740,"conditions":11054,"interventions":11055},[48],[1120],[10743,1670],{"trials":11057,"activeCount":59},[],{"trials":11059,"activeCount":59},[],{"trials":11061,"activeCount":59},[],{"trials":11063,"activeCount":59},[],{"intervention":11065,"totalTrials":190,"cells":11066},"Ezetimibe\u002Fatorvastatin 10mg\u002F10mg FDC",{"EARLY_PHASE1":11067,"PHASE1":11069,"PHASE2":11082,"PHASE3":11084,"PHASE4":11086,"NA":11088},{"trials":11068,"activeCount":59},[],{"trials":11070,"activeCount":59},[11071],{"nctId":11072,"briefTitle":11073,"status":67,"phases":11074,"primaryCompletion":3934,"completion":11075,"start":11076,"enrollment":9442,"conditions":11077,"interventions":11078},"NCT01236430","A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)",[48],"2012-02","2011-02",[745],[432,11065,11079,11080,11081],"Atorvastatin 10mg","Atorvastatin 80mg","Ezetimibe\u002Fatorvastatin 10mg\u002F80mg FDC",{"trials":11083,"activeCount":59},[],{"trials":11085,"activeCount":59},[],{"trials":11087,"activeCount":59},[],{"trials":11089,"activeCount":59},[],{"intervention":11079,"totalTrials":190,"cells":11091},{"EARLY_PHASE1":11092,"PHASE1":11094,"PHASE2":11100,"PHASE3":11102,"PHASE4":11104,"NA":11106},{"trials":11093,"activeCount":59},[],{"trials":11095,"activeCount":59},[11096],{"nctId":11072,"briefTitle":11073,"status":67,"phases":11097,"primaryCompletion":3934,"completion":11075,"start":11076,"enrollment":9442,"conditions":11098,"interventions":11099},[48],[745],[432,11065,11079,11080,11081],{"trials":11101,"activeCount":59},[],{"trials":11103,"activeCount":59},[],{"trials":11105,"activeCount":59},[],{"trials":11107,"activeCount":59},[],{"intervention":11080,"totalTrials":190,"cells":11109},{"EARLY_PHASE1":11110,"PHASE1":11112,"PHASE2":11118,"PHASE3":11120,"PHASE4":11122,"NA":11124},{"trials":11111,"activeCount":59},[],{"trials":11113,"activeCount":59},[11114],{"nctId":11072,"briefTitle":11073,"status":67,"phases":11115,"primaryCompletion":3934,"completion":11075,"start":11076,"enrollment":9442,"conditions":11116,"interventions":11117},[48],[745],[432,11065,11079,11080,11081],{"trials":11119,"activeCount":59},[],{"trials":11121,"activeCount":59},[],{"trials":11123,"activeCount":59},[],{"trials":11125,"activeCount":59},[],{"intervention":11081,"totalTrials":190,"cells":11127},{"EARLY_PHASE1":11128,"PHASE1":11130,"PHASE2":11136,"PHASE3":11138,"PHASE4":11140,"NA":11142},{"trials":11129,"activeCount":59},[],{"trials":11131,"activeCount":59},[11132],{"nctId":11072,"briefTitle":11073,"status":67,"phases":11133,"primaryCompletion":3934,"completion":11075,"start":11076,"enrollment":9442,"conditions":11134,"interventions":11135},[48],[745],[432,11065,11079,11080,11081],{"trials":11137,"activeCount":59},[],{"trials":11139,"activeCount":59},[],{"trials":11141,"activeCount":59},[],{"trials":11143,"activeCount":59},[],{"intervention":946,"totalTrials":190,"cells":11145},{"EARLY_PHASE1":11146,"PHASE1":11148,"PHASE2":11154,"PHASE3":11156,"PHASE4":11158,"NA":11160},{"trials":11147,"activeCount":59},[],{"trials":11149,"activeCount":59},[11150],{"nctId":938,"briefTitle":939,"status":67,"phases":11151,"primaryCompletion":941,"completion":941,"start":942,"enrollment":943,"conditions":11152,"interventions":11153},[48],[26],[921,946,947,947,652],{"trials":11155,"activeCount":59},[],{"trials":11157,"activeCount":59},[],{"trials":11159,"activeCount":59},[],{"trials":11161,"activeCount":59},[],{"intervention":947,"totalTrials":190,"cells":11163},{"EARLY_PHASE1":11164,"PHASE1":11166,"PHASE2":11172,"PHASE3":11174,"PHASE4":11176,"NA":11178},{"trials":11165,"activeCount":59},[],{"trials":11167,"activeCount":59},[11168],{"nctId":938,"briefTitle":939,"status":67,"phases":11169,"primaryCompletion":941,"completion":941,"start":942,"enrollment":943,"conditions":11170,"interventions":11171},[48],[26],[921,946,947,947,652],{"trials":11173,"activeCount":59},[],{"trials":11175,"activeCount":59},[],{"trials":11177,"activeCount":59},[],{"trials":11179,"activeCount":59},[],{"intervention":11181,"totalTrials":190,"cells":11182},"nomegestrol acetate and estradiol",{"EARLY_PHASE1":11183,"PHASE1":11185,"PHASE2":11195,"PHASE3":11197,"PHASE4":11199,"NA":11201},{"trials":11184,"activeCount":59},[],{"trials":11186,"activeCount":59},[11187],{"nctId":11188,"briefTitle":11189,"status":67,"phases":11190,"primaryCompletion":11191,"completion":11191,"start":4189,"enrollment":21,"conditions":11192,"interventions":11194},"NCT00711607","A Trial to Assess the Pharmacokinetic Profile (e.g., Uptake, Distribution and Excretion of a Substance in the Body) of Nomegestrol Acetate (NOMAC), Estradiol (E2) and Estrone (E1) After Multiple and Single Dose Administration of the Combined Oral Contraception NOMAC-E2 (COMPLETED)(P05822)",[48],"2007-09-01",[11193],"Healthy",[11181],{"trials":11196,"activeCount":59},[],{"trials":11198,"activeCount":59},[],{"trials":11200,"activeCount":59},[],{"trials":11202,"activeCount":59},[],{"intervention":11204,"totalTrials":190,"cells":11205},"Lyndiol®",{"EARLY_PHASE1":11206,"PHASE1":11208,"PHASE2":11217,"PHASE3":11219,"PHASE4":11221,"NA":11223},{"trials":11207,"activeCount":59},[],{"trials":11209,"activeCount":59},[11210],{"nctId":11211,"briefTitle":11212,"status":67,"phases":11213,"primaryCompletion":11214,"completion":11214,"start":2480,"enrollment":2262,"conditions":11215,"interventions":11216},"NCT00647933","An Open-label, Single Center Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Org 36286 (P07004)",[48],"2000-12",[3128],[10447,11204],{"trials":11218,"activeCount":59},[],{"trials":11220,"activeCount":59},[],{"trials":11222,"activeCount":59},[],{"trials":11224,"activeCount":59},[],{"intervention":652,"totalTrials":11226,"cells":11227},52,{"EARLY_PHASE1":11228,"PHASE1":11230,"PHASE2":11251,"PHASE3":11261,"PHASE4":11462,"NA":11476},{"trials":11229,"activeCount":59},[],{"trials":11231,"activeCount":59},[11232,11239,11243,11247],{"nctId":11233,"briefTitle":11234,"status":67,"phases":11235,"primaryCompletion":292,"completion":292,"start":1637,"enrollment":2262,"conditions":11236,"interventions":11238},"NCT00664937","Exercise Induced Bronchoconstriction (0476-359)",[48],[11237],"Asthma, Exercise-induced",[2626,3355],{"nctId":3674,"briefTitle":3675,"status":67,"phases":11240,"primaryCompletion":3677,"completion":3677,"start":293,"enrollment":3678,"conditions":11241,"interventions":11242},[48],[3680],[3667,3355],{"nctId":938,"briefTitle":939,"status":67,"phases":11244,"primaryCompletion":941,"completion":941,"start":942,"enrollment":943,"conditions":11245,"interventions":11246},[48],[26],[921,946,947,947,652],{"nctId":1656,"briefTitle":1657,"status":67,"phases":11248,"primaryCompletion":669,"completion":669,"start":931,"enrollment":1659,"conditions":11249,"interventions":11250},[48],[1120],[1649,652],{"trials":11252,"activeCount":59},[11253,11257],{"nctId":9689,"briefTitle":9690,"status":67,"phases":11254,"primaryCompletion":438,"completion":438,"start":5688,"enrollment":9692,"conditions":11255,"interventions":11256},[49],[3761],[4577,4577,4577,4577,3355,4577,9680],{"nctId":3685,"briefTitle":3686,"status":67,"phases":11258,"primaryCompletion":3688,"completion":3688,"start":338,"enrollment":3689,"conditions":11259,"interventions":11260},[49],[17],[3692,3667,3355],{"trials":11262,"activeCount":59},[11263,11272,11276,11280,11284,11288,11292,11296,11300,11304,11308,11316,11320,11324,11328,11332,11341,11345,11349,11353,11360,11364,11368,11372,11376,11383,11387,11391,11395,11399,11407,11411,11418,11422,11426,11434,11438,11442,11446,11450,11454,11458],{"nctId":11264,"briefTitle":11265,"status":67,"phases":11266,"primaryCompletion":11267,"completion":11267,"start":11268,"enrollment":11269,"conditions":11270,"interventions":11271},"NCT00968201","Chronic Asthma Study in 2- to 5-Year-Old Patients (MK0476-072 )",[50],"2001-03","1997-12",689,[17],[2626,652],{"nctId":4456,"briefTitle":4457,"status":67,"phases":11273,"primaryCompletion":1290,"completion":1290,"start":1375,"enrollment":4459,"conditions":11274,"interventions":11275},[50],[33,2003],[4445,3355],{"nctId":3869,"briefTitle":3870,"status":67,"phases":11277,"primaryCompletion":1965,"completion":3872,"start":3873,"enrollment":3874,"conditions":11278,"interventions":11279},[50],[20],[2626,3728,3355],{"nctId":5504,"briefTitle":5505,"status":67,"phases":11281,"primaryCompletion":451,"completion":451,"start":292,"enrollment":5507,"conditions":11282,"interventions":11283},[50],[5509],[5493,652,5511],{"nctId":3526,"briefTitle":3527,"status":67,"phases":11285,"primaryCompletion":3529,"completion":3530,"start":3531,"enrollment":3532,"conditions":11286,"interventions":11287},[50],[3534],[3504,652],{"nctId":3537,"briefTitle":3538,"status":67,"phases":11289,"primaryCompletion":3540,"completion":3541,"start":3542,"enrollment":3543,"conditions":11290,"interventions":11291},[50],[3534],[3504,3546,652],{"nctId":3696,"briefTitle":3697,"status":67,"phases":11293,"primaryCompletion":3699,"completion":3699,"start":1066,"enrollment":339,"conditions":11294,"interventions":11295},[50],[3701],[3703,652],{"nctId":3432,"briefTitle":3433,"status":67,"phases":11297,"primaryCompletion":741,"completion":581,"start":3435,"enrollment":403,"conditions":11298,"interventions":11299},[50],[3437,3438],[3413,3355],{"nctId":3441,"briefTitle":3442,"status":67,"phases":11301,"primaryCompletion":3444,"completion":3445,"start":3446,"enrollment":3447,"conditions":11302,"interventions":11303},[50],[3437,3438],[3413,3355],{"nctId":3878,"briefTitle":3879,"status":67,"phases":11305,"primaryCompletion":2906,"completion":2906,"start":3881,"enrollment":3882,"conditions":11306,"interventions":11307},[50],[20],[2626,3728,3355],{"nctId":11309,"briefTitle":11310,"status":67,"phases":11311,"primaryCompletion":11312,"completion":1117,"start":11267,"enrollment":11313,"conditions":11314,"interventions":11315},"NCT00968149","A Study Comparing Montelukast With Placebo in Children With Seasonal Allergic Rhinitis (0476-219)(COMPLETED)",[50],"2001-06",413,[20],[2626,652],{"nctId":3705,"briefTitle":3706,"status":67,"phases":11317,"primaryCompletion":1095,"completion":1095,"start":1082,"enrollment":3708,"conditions":11318,"interventions":11319},[50],[3701],[3703,3711,652,652],{"nctId":4463,"briefTitle":4464,"status":67,"phases":11321,"primaryCompletion":209,"completion":4466,"start":4467,"enrollment":101,"conditions":11322,"interventions":11323},[50],[2003,1293],[4445,3355],{"nctId":4583,"briefTitle":4584,"status":67,"phases":11325,"primaryCompletion":3677,"completion":4586,"start":312,"enrollment":4587,"conditions":11326,"interventions":11327},[50],[4589],[4565,4591,4592,3355],{"nctId":3713,"briefTitle":3714,"status":67,"phases":11329,"primaryCompletion":3435,"completion":3435,"start":931,"enrollment":3716,"conditions":11330,"interventions":11331},[50],[3701],[3703,652],{"nctId":11333,"briefTitle":11334,"status":67,"phases":11335,"primaryCompletion":11336,"completion":11337,"start":11338,"enrollment":101,"conditions":11339,"interventions":11340},"NCT00101439","A Study to Evaluate the Effects of Ezetimibe (MK-0653) on the Postprandial (Following a Meal) Lipoprotein Response in Participants With Primary Hypercholesterolemia (High Cholesterol) (MK-0653-072)(COMPLETED)",[50],"2006-10-24","2006-11-08","2005-11-10",[14],[444,3355],{"nctId":6251,"briefTitle":6252,"status":67,"phases":11342,"primaryCompletion":6254,"completion":6254,"start":6255,"enrollment":6256,"conditions":11343,"interventions":11344},[50],[3555],[6240,652],{"nctId":643,"briefTitle":644,"status":67,"phases":11346,"primaryCompletion":646,"completion":646,"start":647,"enrollment":648,"conditions":11347,"interventions":11348},[50],[650],[444,652,575],{"nctId":3720,"briefTitle":3721,"status":67,"phases":11350,"primaryCompletion":3723,"completion":3723,"start":3724,"enrollment":3725,"conditions":11351,"interventions":11352},[50],[20],[3667,3728,3355,3729],{"nctId":11354,"briefTitle":11355,"status":67,"phases":11356,"primaryCompletion":283,"completion":283,"start":9034,"enrollment":11357,"conditions":11358,"interventions":11359},"NCT00289874","Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED)",[50],421,[17],[2626,652],{"nctId":3890,"briefTitle":3891,"status":67,"phases":11361,"primaryCompletion":1117,"completion":1117,"start":3893,"enrollment":3894,"conditions":11362,"interventions":11363},[50],[20],[2626,3728,652],{"nctId":766,"briefTitle":767,"status":67,"phases":11365,"primaryCompletion":769,"completion":769,"start":770,"enrollment":771,"conditions":11366,"interventions":11367},[50],[773],[574,652],{"nctId":4127,"briefTitle":4128,"status":67,"phases":11369,"primaryCompletion":4130,"completion":4130,"start":4131,"enrollment":4132,"conditions":11370,"interventions":11371},[50],[4134],[4136,652,4137],{"nctId":3548,"briefTitle":3549,"status":67,"phases":11373,"primaryCompletion":3551,"completion":3551,"start":3552,"enrollment":3553,"conditions":11374,"interventions":11375},[50],[3555],[3504,3355],{"nctId":11377,"briefTitle":11378,"status":67,"phases":11379,"primaryCompletion":1299,"completion":359,"start":892,"enrollment":11380,"conditions":11381,"interventions":11382},"NCT00076973","An Investigational Drug Study to Treat Respiratory Symptoms Associated With Respiratory Syncytial Virus (RSV) Bronchiolitis (0476-272)",[50],1125,[9867],[2626,3355],{"nctId":7015,"briefTitle":7016,"status":67,"phases":11384,"primaryCompletion":368,"completion":284,"start":439,"enrollment":7018,"conditions":11385,"interventions":11386},[50],[26],[7004,652],{"nctId":776,"briefTitle":777,"status":67,"phases":11388,"primaryCompletion":779,"completion":779,"start":780,"enrollment":781,"conditions":11389,"interventions":11390},[50],[14],[574,784,652,652],{"nctId":3558,"briefTitle":3559,"status":67,"phases":11392,"primaryCompletion":3540,"completion":3541,"start":3561,"enrollment":3562,"conditions":11393,"interventions":11394},[50],[3534],[3504,3504,3546,652],{"nctId":1041,"briefTitle":1042,"status":67,"phases":11396,"primaryCompletion":402,"completion":402,"start":439,"enrollment":1044,"conditions":11397,"interventions":11398},[50],[14],[755,652,1047,1048],{"nctId":11400,"briefTitle":11401,"status":67,"phases":11402,"primaryCompletion":438,"completion":438,"start":11403,"enrollment":11404,"conditions":11405,"interventions":11406},"NCT00117338","A Study of an Intravenous Drug in Pediatric Patients With Acute Asthma (0476-301)",[50],"2005-07",276,[17],[2626,3355],{"nctId":3471,"briefTitle":3472,"status":67,"phases":11408,"primaryCompletion":3444,"completion":3445,"start":3446,"enrollment":101,"conditions":11409,"interventions":11410},[50],[3437,3438],[3413,3355],{"nctId":11412,"briefTitle":11413,"status":67,"phases":11414,"primaryCompletion":359,"completion":668,"start":741,"enrollment":11415,"conditions":11416,"interventions":11417},"NCT00229970","MK0476 Study in Adult Patients With Acute Asthma (0476-322)",[50],225,[17],[2626,652],{"nctId":8423,"briefTitle":8424,"status":67,"phases":11419,"primaryCompletion":1127,"completion":1127,"start":2906,"enrollment":8426,"conditions":11420,"interventions":11421},[50],[405],[2626,8412,3355],{"nctId":3731,"briefTitle":3732,"status":67,"phases":11423,"primaryCompletion":3734,"completion":3734,"start":3735,"enrollment":3736,"conditions":11424,"interventions":11425},[50],[20],[3729,3667,3728,3355],{"nctId":11427,"briefTitle":11428,"status":67,"phases":11429,"primaryCompletion":11430,"completion":11430,"start":359,"enrollment":11431,"conditions":11432,"interventions":11433},"NCT00337675","Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)",[50],"2009-08",1771,[17],[2626,652,2626],{"nctId":1287,"briefTitle":1288,"status":67,"phases":11435,"primaryCompletion":931,"completion":931,"start":1290,"enrollment":1291,"conditions":11436,"interventions":11437},[50],[1293],[1265,652],{"nctId":1296,"briefTitle":1297,"status":67,"phases":11439,"primaryCompletion":360,"completion":360,"start":1299,"enrollment":1300,"conditions":11440,"interventions":11441},[50],[17],[1250,652],{"nctId":9031,"briefTitle":9032,"status":67,"phases":11443,"primaryCompletion":359,"completion":359,"start":9034,"enrollment":9035,"conditions":11444,"interventions":11445},[50],[3555],[9020,652],{"nctId":798,"briefTitle":799,"status":67,"phases":11447,"primaryCompletion":293,"completion":293,"start":540,"enrollment":801,"conditions":11448,"interventions":11449},[50],[14,803],[574,805,652],{"nctId":9090,"briefTitle":9091,"status":67,"phases":11451,"primaryCompletion":9093,"completion":9093,"start":9094,"enrollment":9095,"conditions":11452,"interventions":11453},[50],[3923],[4577,3355,9079],{"nctId":3576,"briefTitle":3577,"status":67,"phases":11455,"primaryCompletion":3529,"completion":3579,"start":3580,"enrollment":3581,"conditions":11456,"interventions":11457},[50],[3534],[3504,3355],{"nctId":9397,"briefTitle":9398,"status":67,"phases":11459,"primaryCompletion":9400,"completion":9400,"start":350,"enrollment":9401,"conditions":11460,"interventions":11461},[50],[17],[2626,652,9386,652],{"trials":11463,"activeCount":59},[11464,11468,11472],{"nctId":677,"briefTitle":678,"status":610,"phases":11465,"primaryCompletion":680,"completion":680,"start":681,"enrollment":682,"conditions":11466,"interventions":11467},[51],[684],[575,652],{"nctId":3348,"briefTitle":3349,"status":67,"phases":11469,"primaryCompletion":3351,"completion":3351,"start":3352,"enrollment":1283,"conditions":11470,"interventions":11471},[51],[17],[3335,3355],{"nctId":1003,"briefTitle":1004,"status":67,"phases":11473,"primaryCompletion":376,"completion":376,"start":1006,"enrollment":571,"conditions":11474,"interventions":11475},[51],[1008],[921,652],{"trials":11477,"activeCount":59},[11478],{"nctId":11479,"briefTitle":11480,"status":67,"phases":11481,"primaryCompletion":7381,"completion":7381,"start":3873,"enrollment":1075,"conditions":11482,"interventions":11483},"NCT00943683","Montelukast in Pediatric Patients Aged 6 to 24 Months With Asthma--Safety Study (0476-176)",[52],[17],[2626,652],{"intervention":432,"totalTrials":3447,"cells":11485},{"EARLY_PHASE1":11486,"PHASE1":11488,"PHASE2":11502,"PHASE3":11504,"PHASE4":11591,"NA":11652},{"trials":11487,"activeCount":59},[],{"trials":11489,"activeCount":59},[11490,11494,11498],{"nctId":10843,"briefTitle":10844,"status":67,"phases":11491,"primaryCompletion":1666,"completion":1666,"start":3699,"enrollment":943,"conditions":11492,"interventions":11493},[48],[650],[444,10836],{"nctId":1372,"briefTitle":1373,"status":67,"phases":11495,"primaryCompletion":462,"completion":462,"start":1375,"enrollment":648,"conditions":11496,"interventions":11497},[48],[14,465],[1378,565,432],{"nctId":11072,"briefTitle":11073,"status":67,"phases":11499,"primaryCompletion":3934,"completion":11075,"start":11076,"enrollment":9442,"conditions":11500,"interventions":11501},[48],[745],[432,11065,11079,11080,11081],{"trials":11503,"activeCount":59},[],{"trials":11505,"activeCount":59},[11506,11510,11514,11518,11522,11526,11530,11534,11538,11542,11546,11550,11559,11563,11567,11571,11577,11587],{"nctId":424,"briefTitle":425,"status":67,"phases":11507,"primaryCompletion":427,"completion":427,"start":428,"enrollment":429,"conditions":11508,"interventions":11509},[50],[14],[412,432],{"nctId":434,"briefTitle":435,"status":67,"phases":11511,"primaryCompletion":437,"completion":438,"start":439,"enrollment":440,"conditions":11512,"interventions":11513},[50],[14],[443,443,444],{"nctId":11333,"briefTitle":11334,"status":67,"phases":11515,"primaryCompletion":11336,"completion":11337,"start":11338,"enrollment":101,"conditions":11516,"interventions":11517},[50],[14],[444,3355],{"nctId":6169,"briefTitle":6170,"status":67,"phases":11519,"primaryCompletion":1506,"completion":1506,"start":6172,"enrollment":6173,"conditions":11520,"interventions":11521},[50],[563],[432,6158,6176],{"nctId":630,"briefTitle":631,"status":67,"phases":11523,"primaryCompletion":633,"completion":633,"start":634,"enrollment":635,"conditions":11524,"interventions":11525},[50],[14],[617,478,432],{"nctId":470,"briefTitle":471,"status":67,"phases":11527,"primaryCompletion":473,"completion":473,"start":474,"enrollment":475,"conditions":11528,"interventions":11529},[50],[14],[432,412,478],{"nctId":643,"briefTitle":644,"status":67,"phases":11531,"primaryCompletion":646,"completion":646,"start":647,"enrollment":648,"conditions":11532,"interventions":11533},[50],[650],[444,652,575],{"nctId":1384,"briefTitle":1385,"status":67,"phases":11535,"primaryCompletion":1387,"completion":1387,"start":1388,"enrollment":1389,"conditions":11536,"interventions":11537},[50],[14,487],[432,565],{"nctId":480,"briefTitle":481,"status":67,"phases":11539,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":11540,"interventions":11541},[50],[487],[412,478,432],{"nctId":502,"briefTitle":503,"status":67,"phases":11543,"primaryCompletion":505,"completion":505,"start":506,"enrollment":507,"conditions":11544,"interventions":11545},[50],[14],[432,412],{"nctId":658,"briefTitle":659,"status":67,"phases":11547,"primaryCompletion":524,"completion":524,"start":525,"enrollment":661,"conditions":11548,"interventions":11549},[50],[14],[432,478],{"nctId":11551,"briefTitle":11552,"status":67,"phases":11553,"primaryCompletion":11554,"completion":11554,"start":11555,"enrollment":11556,"conditions":11557,"interventions":11558},"NCT00867165","Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)",[50],"2012-04-13","2009-05-21",138,[563],[444],{"nctId":511,"briefTitle":512,"status":67,"phases":11560,"primaryCompletion":514,"completion":514,"start":515,"enrollment":516,"conditions":11561,"interventions":11562},[50],[14],[412,432,519],{"nctId":521,"briefTitle":522,"status":67,"phases":11564,"primaryCompletion":524,"completion":524,"start":525,"enrollment":526,"conditions":11565,"interventions":11566},[50],[14],[432,443],{"nctId":8400,"briefTitle":8401,"status":67,"phases":11568,"primaryCompletion":8403,"completion":8403,"start":8404,"enrollment":6376,"conditions":11569,"interventions":11570},[50],[14],[432,8389],{"nctId":11572,"briefTitle":11573,"status":67,"phases":11574,"primaryCompletion":461,"completion":461,"start":1666,"enrollment":2822,"conditions":11575,"interventions":11576},"NCT00651404","Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)",[50],[14,465],[432],{"nctId":11578,"briefTitle":11579,"status":67,"phases":11580,"primaryCompletion":11581,"completion":11581,"start":11582,"enrollment":11583,"conditions":11584,"interventions":11586},"NCT00552097","Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578)",[50],"2006-04-25","2002-06-01",720,[465,14,11585],"Hyperlipoproteinemia Type II",[444],{"nctId":530,"briefTitle":531,"status":67,"phases":11588,"primaryCompletion":533,"completion":533,"start":515,"enrollment":131,"conditions":11589,"interventions":11590},[50],[14],[412,432,519],{"trials":11592,"activeCount":59},[11593,11601,11610,11614,11623,11627,11633,11637,11644,11648],{"nctId":11594,"briefTitle":11595,"status":67,"phases":11596,"primaryCompletion":1180,"completion":1180,"start":10957,"enrollment":11597,"conditions":11598,"interventions":11600},"NCT00651963","Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia (0653-141)(COMPLETED)",[51],80,[11599],"Lipid Metabolism Disorder",[444],{"nctId":11602,"briefTitle":11603,"status":67,"phases":11604,"primaryCompletion":11605,"completion":11605,"start":11606,"enrollment":11607,"conditions":11608,"interventions":11609},"NCT01611883","A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)",[51],"2014-01-16","2012-07-02",152,[14],[432],{"nctId":687,"briefTitle":688,"status":67,"phases":11611,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":11612,"interventions":11613},[51],[14],[444,575],{"nctId":11615,"briefTitle":11616,"status":67,"phases":11617,"primaryCompletion":551,"completion":551,"start":11618,"enrollment":11619,"conditions":11620,"interventions":11622},"NCT00651274","Comparison of Co-administration of Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Primary Hypercholesterolemia (P03476)",[51],"2003-04-01",144,[465,14,11621],"Coronary Heart Disease",[432],{"nctId":556,"briefTitle":557,"status":67,"phases":11624,"primaryCompletion":559,"completion":559,"start":560,"enrollment":561,"conditions":11625,"interventions":11626},[51],[563],[432,412,412,565],{"nctId":11628,"briefTitle":11629,"status":67,"phases":11630,"primaryCompletion":359,"completion":359,"start":1083,"enrollment":1805,"conditions":11631,"interventions":11632},"NCT00202904","Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With High Cholesterol and Coronary Heart Disease (Study P03740)",[51],[14,11621],[444],{"nctId":696,"briefTitle":697,"status":67,"phases":11634,"primaryCompletion":699,"completion":700,"start":633,"enrollment":701,"conditions":11635,"interventions":11636},[51],[703],[432,575],{"nctId":11638,"briefTitle":11639,"status":610,"phases":11640,"primaryCompletion":1299,"completion":1299,"start":1666,"enrollment":11641,"conditions":11642,"interventions":11643},"NCT00651014","Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)",[51],82,[14,465],[432],{"nctId":3326,"briefTitle":3327,"status":67,"phases":11645,"primaryCompletion":1637,"completion":1637,"start":1083,"enrollment":3329,"conditions":11646,"interventions":11647},[51],[14],[444,3313],{"nctId":1538,"briefTitle":1539,"status":67,"phases":11649,"primaryCompletion":359,"completion":359,"start":741,"enrollment":1541,"conditions":11650,"interventions":11651},[51],[14,1543],[432,1492],{"trials":11653,"activeCount":59},[11654,11661,11671,11679,11688,11695],{"nctId":11655,"briefTitle":11656,"status":67,"phases":11657,"primaryCompletion":11430,"completion":11430,"start":402,"enrollment":11658,"conditions":11659,"interventions":11660},"NCT00730132","Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease \u003C\u003CTreat to Goal>> (Study P05464)",[],712,[11621,14],[432,6176],{"nctId":11662,"briefTitle":11663,"status":67,"phases":11664,"primaryCompletion":11665,"completion":11665,"start":668,"enrollment":11666,"conditions":11667,"interventions":11669},"NCT00704444","A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244)",[],"2009-09",11332,[14,487,11668],"Homozygous Sitosterolemia",[432,11670],"Ezetimibe + other lipid-lowering medication",{"nctId":11672,"briefTitle":11673,"status":67,"phases":11674,"primaryCompletion":769,"completion":769,"start":9034,"enrollment":11675,"conditions":11676,"interventions":11678},"NCT00704535","Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)",[],4105,[563,11677],"Homozygous Familial Hypercholesterolemia",[432],{"nctId":11680,"briefTitle":11681,"status":67,"phases":11682,"primaryCompletion":11683,"completion":11683,"start":5688,"enrollment":11684,"conditions":11685,"interventions":11686},"NCT00705081","Evaluation of the LDL-C Lowering Effects of Ezetimibe Achieved in Co-administration Therapy With Statins in an Indonesian Population (Study P04276)(COMPLETED)",[],"2007-12",453,[14],[444,11687],"statin",{"nctId":11689,"briefTitle":11690,"status":67,"phases":11691,"primaryCompletion":10663,"completion":10663,"start":337,"enrollment":11692,"conditions":11693,"interventions":11694},"NCT01381679","Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)",[],1682,[14],[432],{"nctId":11696,"briefTitle":11697,"status":67,"phases":11698,"primaryCompletion":11699,"completion":11699,"start":668,"enrollment":11700,"conditions":11701,"interventions":11702},"NCT00705211","A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)",[],"2009-12",1794,[14,487,11668],[432,11670],{"intervention":2626,"totalTrials":3077,"cells":11704},{"EARLY_PHASE1":11705,"PHASE1":11707,"PHASE2":11713,"PHASE3":11715,"PHASE4":11809,"NA":11829},{"trials":11706,"activeCount":59},[],{"trials":11708,"activeCount":59},[11709],{"nctId":11233,"briefTitle":11234,"status":67,"phases":11710,"primaryCompletion":292,"completion":292,"start":1637,"enrollment":2262,"conditions":11711,"interventions":11712},[48],[11237],[2626,3355],{"trials":11714,"activeCount":59},[],{"trials":11716,"activeCount":59},[11717,11721,11725,11729,11733,11737,11741,11745,11752,11756,11762,11766,11770,11774,11778,11785,11789,11793,11797,11801,11805],{"nctId":11264,"briefTitle":11265,"status":67,"phases":11718,"primaryCompletion":11267,"completion":11267,"start":11268,"enrollment":11269,"conditions":11719,"interventions":11720},[50],[17],[2626,652],{"nctId":3869,"briefTitle":3870,"status":67,"phases":11722,"primaryCompletion":1965,"completion":3872,"start":3873,"enrollment":3874,"conditions":11723,"interventions":11724},[50],[20],[2626,3728,3355],{"nctId":5483,"briefTitle":5484,"status":67,"phases":11726,"primaryCompletion":1261,"completion":1261,"start":284,"enrollment":3101,"conditions":11727,"interventions":11728},[50],[17],[2626,2626,5472],{"nctId":3878,"briefTitle":3879,"status":67,"phases":11730,"primaryCompletion":2906,"completion":2906,"start":3881,"enrollment":3882,"conditions":11731,"interventions":11732},[50],[20],[2626,3728,3355],{"nctId":11309,"briefTitle":11310,"status":67,"phases":11734,"primaryCompletion":11312,"completion":1117,"start":11267,"enrollment":11313,"conditions":11735,"interventions":11736},[50],[20],[2626,652],{"nctId":11354,"briefTitle":11355,"status":67,"phases":11738,"primaryCompletion":283,"completion":283,"start":9034,"enrollment":11357,"conditions":11739,"interventions":11740},[50],[17],[2626,652],{"nctId":3890,"briefTitle":3891,"status":67,"phases":11742,"primaryCompletion":1117,"completion":1117,"start":3893,"enrollment":3894,"conditions":11743,"interventions":11744},[50],[20],[2626,3728,652],{"nctId":11746,"briefTitle":11747,"status":67,"phases":11748,"primaryCompletion":11749,"completion":11749,"start":10957,"enrollment":692,"conditions":11750,"interventions":11751},"NCT00771160","MK0476 Study in Adult Patients With Perennial Allergic Rhinitis (0476-397)(COMPLETED)",[50],"2005-02",[227],[2626],{"nctId":6654,"briefTitle":6655,"status":67,"phases":11753,"primaryCompletion":3530,"completion":3540,"start":3580,"enrollment":6657,"conditions":11754,"interventions":11755},[50],[17],[2626,6643],{"nctId":11757,"briefTitle":11758,"status":67,"phases":11759,"primaryCompletion":284,"completion":284,"start":932,"enrollment":7485,"conditions":11760,"interventions":11761},"NCT00092989","Investigation of Intravenous (IV) Administration of an Approved Drug (MK-0476, Montelukast Sodium) for Acute Asthma (MK-0476-288)",[50],[17],[2626],{"nctId":11377,"briefTitle":11378,"status":67,"phases":11763,"primaryCompletion":1299,"completion":359,"start":892,"enrollment":11380,"conditions":11764,"interventions":11765},[50],[9867],[2626,3355],{"nctId":4337,"briefTitle":4338,"status":347,"phases":11767,"primaryCompletion":438,"start":1529,"enrollment":59,"conditions":11768,"interventions":11769},[50],[2003],[4342,4326],{"nctId":7927,"briefTitle":7928,"status":67,"phases":11771,"primaryCompletion":1923,"completion":1923,"start":742,"enrollment":7930,"conditions":11772,"interventions":11773},[50],[33],[2626,7916],{"nctId":11400,"briefTitle":11401,"status":67,"phases":11775,"primaryCompletion":438,"completion":438,"start":11403,"enrollment":11404,"conditions":11776,"interventions":11777},[50],[17],[2626,3355],{"nctId":11779,"briefTitle":11780,"status":67,"phases":11781,"primaryCompletion":589,"completion":589,"start":1299,"enrollment":11782,"conditions":11783,"interventions":11784},"NCT00755794","The Singulair® add-on Study Effectiveness of Adding Montelukast to Inhaled Corticosteroids in Adult Subjects With Uncontrolled Asthma (0476-384)",[50],800,[17],[2626],{"nctId":8354,"briefTitle":8355,"status":67,"phases":11786,"primaryCompletion":5646,"completion":2906,"start":3893,"enrollment":590,"conditions":11787,"interventions":11788},[50],[17],[2626,8343],{"nctId":11412,"briefTitle":11413,"status":67,"phases":11790,"primaryCompletion":359,"completion":668,"start":741,"enrollment":11415,"conditions":11791,"interventions":11792},[50],[17],[2626,652],{"nctId":8423,"briefTitle":8424,"status":67,"phases":11794,"primaryCompletion":1127,"completion":1127,"start":2906,"enrollment":8426,"conditions":11795,"interventions":11796},[50],[405],[2626,8412,3355],{"nctId":11427,"briefTitle":11428,"status":67,"phases":11798,"primaryCompletion":11430,"completion":11430,"start":359,"enrollment":11431,"conditions":11799,"interventions":11800},[50],[17],[2626,652,2626],{"nctId":9397,"briefTitle":9398,"status":67,"phases":11802,"primaryCompletion":9400,"completion":9400,"start":350,"enrollment":9401,"conditions":11803,"interventions":11804},[50],[17],[2626,652,9386,652],{"nctId":4356,"briefTitle":4357,"status":67,"phases":11806,"primaryCompletion":274,"completion":274,"start":1082,"enrollment":4359,"conditions":11807,"interventions":11808},[50],[4361],[4342,4363,4326],{"trials":11810,"activeCount":59},[11811,11815,11822],{"nctId":2619,"briefTitle":2620,"status":67,"phases":11812,"primaryCompletion":580,"completion":580,"start":2622,"enrollment":2623,"conditions":11813,"interventions":11814},[51],[17,31],[2626,2606],{"nctId":11816,"briefTitle":11817,"status":67,"phases":11818,"primaryCompletion":292,"completion":292,"start":1299,"enrollment":11819,"conditions":11820,"interventions":11821},"NCT00832455","Pediatric ACTION3 (Identify, Treat, Control): Effectiveness of Adding Montelukast in Pediatric Subjects With Uncontrolled Asthma (0476-385)",[51],445,[17],[2626],{"nctId":11823,"briefTitle":11824,"status":67,"phases":11825,"primaryCompletion":4043,"completion":4043,"start":11826,"enrollment":4349,"conditions":11827,"interventions":11828},"NCT00545844","Singulair(R) In Asthma And Allergic Rhinitis (0476-383)",[51],"2007-04-01",[17],[2626],{"trials":11830,"activeCount":59},[11831],{"nctId":11479,"briefTitle":11480,"status":67,"phases":11832,"primaryCompletion":7381,"completion":7381,"start":3873,"enrollment":1075,"conditions":11833,"interventions":11834},[52],[17],[2626,652],{"intervention":4846,"totalTrials":3077,"cells":11836},{"EARLY_PHASE1":11837,"PHASE1":11839,"PHASE2":11841,"PHASE3":11843,"PHASE4":12027,"NA":12029},{"trials":11838,"activeCount":59},[],{"trials":11840,"activeCount":59},[],{"trials":11842,"activeCount":59},[],{"trials":11844,"activeCount":59},[11845,11854,11863,11867,11878,11885,11895,11905,11911,11915,11922,11930,11937,11946,11952,11959,11968,11974,11978,11982,11988,11997,12006,12013,12019],{"nctId":11846,"briefTitle":11847,"status":67,"phases":11848,"primaryCompletion":11849,"completion":11850,"start":8016,"enrollment":11851,"conditions":11852,"interventions":11853},"NCT00145470","12 Week Study of the Safety\u002FEfficacy of Asenapine When Added to Lithium\u002FValproate in the Treatment of Bipolar Disorder (A7501008 \u002F P05844 \u002F MK-8274-017)",[50],"2007-02-28","2007-03-22",326,[4844],[4846],{"nctId":11855,"briefTitle":11856,"status":67,"phases":11857,"primaryCompletion":11858,"completion":11859,"start":4941,"enrollment":2481,"conditions":11860,"interventions":11861},"NCT01617187","A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)",[50],"2014-08-11","2014-09-09",[28],[4846,11862],"Olanzapine",{"nctId":4837,"briefTitle":4838,"status":67,"phases":11864,"primaryCompletion":4840,"completion":4840,"start":4841,"enrollment":4842,"conditions":11865,"interventions":11866},[50],[4844],[4846,4826],{"nctId":11868,"briefTitle":11869,"status":67,"phases":11870,"primaryCompletion":11871,"completion":11872,"start":11873,"enrollment":11874,"conditions":11875,"interventions":11876},"NCT00212836","Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)",[50],"2007-06-15","2007-08-02","2005-04-21",481,[28],[4857,11877],"olanzapine",{"nctId":11879,"briefTitle":11880,"status":67,"phases":11881,"primaryCompletion":274,"completion":3677,"start":461,"enrollment":11882,"conditions":11883,"interventions":11884},"NCT00145496","Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)",[50],468,[28],[4846,11862],{"nctId":11886,"briefTitle":11887,"status":67,"phases":11888,"primaryCompletion":11889,"completion":11890,"start":11891,"enrollment":11892,"conditions":11893,"interventions":11894},"NCT00156117","Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)",[50],"2006-04-28","2006-05-30","2005-05-12",417,[28],[4857,11877],{"nctId":11896,"briefTitle":11897,"status":67,"phases":11898,"primaryCompletion":11899,"completion":11900,"start":11901,"enrollment":571,"conditions":11902,"interventions":11904},"NCT00764478","Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691)",[50],"2014-04-30","2014-05-28","2012-04-06",[11903],"Bipolar 1 Disorder",[4846,4846],{"nctId":11906,"briefTitle":11907,"status":67,"phases":11908,"primaryCompletion":11683,"completion":402,"start":1082,"enrollment":975,"conditions":11909,"interventions":11910},"NCT00265343","6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)",[50],[28],[4857,11877],{"nctId":4962,"briefTitle":4963,"status":67,"phases":11912,"primaryCompletion":4965,"completion":4966,"start":4967,"enrollment":4968,"conditions":11913,"interventions":11914},[50],[28],[4846,4846,4951],{"nctId":11916,"briefTitle":11917,"status":67,"phases":11918,"primaryCompletion":3076,"completion":3076,"start":11403,"enrollment":11919,"conditions":11920,"interventions":11921},"NCT00159783","40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)",[50],218,[4844],[4857,11862],{"nctId":11923,"briefTitle":11924,"status":67,"phases":11925,"primaryCompletion":11926,"completion":11926,"start":3445,"enrollment":11927,"conditions":11928,"interventions":11929},"NCT00159744","3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)",[50],"2006-04-29",488,[4844],[4846,11862],{"nctId":11931,"briefTitle":11932,"status":67,"phases":11933,"primaryCompletion":11934,"completion":11934,"start":4699,"enrollment":1210,"conditions":11935,"interventions":11936},"NCT01190267","Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)",[50],"2013-10-07",[4701,4702,4703],[4857],{"nctId":11938,"briefTitle":11939,"status":67,"phases":11940,"primaryCompletion":11941,"completion":11889,"start":11942,"enrollment":11943,"conditions":11944,"interventions":11945},"NCT00159796","3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)",[50],"2006-03-28","2004-12-14",489,[4844],[4846,11862],{"nctId":11947,"briefTitle":11948,"status":67,"phases":11949,"primaryCompletion":790,"completion":337,"start":11403,"enrollment":1044,"conditions":11950,"interventions":11951},"NCT00174265","6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)",[50],[28],[4857,11877],{"nctId":11953,"briefTitle":11954,"status":67,"phases":11955,"primaryCompletion":668,"completion":668,"start":1923,"enrollment":11956,"conditions":11957,"interventions":11958},"NCT00156091","Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)",[50],260,[28],[11862,4846],{"nctId":11960,"briefTitle":11961,"status":67,"phases":11962,"primaryCompletion":11963,"completion":11963,"start":11964,"enrollment":11965,"conditions":11966,"interventions":11967},"NCT01244828","Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or\u002Fand High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)",[50],"2014-08-21","2011-04-05",157,[28],[4846],{"nctId":11969,"briefTitle":11970,"status":67,"phases":11971,"primaryCompletion":1095,"completion":359,"start":10957,"enrollment":7890,"conditions":11972,"interventions":11973},"NCT00212771","Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)",[50],[28,10102],[4857,11877],{"nctId":4972,"briefTitle":4973,"status":67,"phases":11975,"primaryCompletion":589,"completion":580,"start":741,"enrollment":4975,"conditions":11976,"interventions":11977},[50],[28],[4951,4846,4846],{"nctId":4848,"briefTitle":4849,"status":67,"phases":11979,"primaryCompletion":4851,"completion":4852,"start":4841,"enrollment":4853,"conditions":11980,"interventions":11981},[50],[4855],[4857,4826],{"nctId":11983,"briefTitle":11984,"status":67,"phases":11985,"primaryCompletion":11683,"completion":11683,"start":669,"enrollment":933,"conditions":11986,"interventions":11987},"NCT00145509","40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)",[50],[4844],[4846],{"nctId":11989,"briefTitle":11990,"status":67,"phases":11991,"primaryCompletion":11992,"completion":11992,"start":11993,"enrollment":11994,"conditions":11995,"interventions":11996},"NCT00212784","Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)",[50],"2006-03-15","2003-09-04",1225,[28,10102],[4857,11877],{"nctId":11998,"briefTitle":11999,"status":67,"phases":12000,"primaryCompletion":12001,"completion":12002,"start":699,"enrollment":12003,"conditions":12004,"interventions":12005},"NCT00151424","Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)",[50],"2006-01-06","2006-02-06",277,[28],[4857,11862],{"nctId":12007,"briefTitle":12008,"status":67,"phases":12009,"primaryCompletion":12010,"completion":12010,"start":4773,"enrollment":237,"conditions":12011,"interventions":12012},"NCT01142596","Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)",[50],"2015-04-22",[28],[4846],{"nctId":12014,"briefTitle":12015,"status":67,"phases":12016,"primaryCompletion":3677,"completion":3677,"start":439,"enrollment":463,"conditions":12017,"interventions":12018},"NCT00281320","Study of Asenapine in Elderly Subjects With Psychosis (A7501021)(P05717)",[50],[9994],[4846],{"nctId":12020,"briefTitle":12021,"status":67,"phases":12022,"primaryCompletion":8138,"completion":8138,"start":12023,"enrollment":12024,"conditions":12025,"interventions":12026},"NCT00143182","9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)",[50],"2005-01-07",504,[4844],[4846,11862],{"trials":12028,"activeCount":59},[],{"trials":12030,"activeCount":59},[12031],{"nctId":12032,"briefTitle":12033,"status":67,"phases":12034,"primaryCompletion":12035,"completion":12035,"start":4698,"enrollment":12036,"conditions":12037,"interventions":12038},"NCT01498770","An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)",[],"2017-12-21",42,[4844],[4846,12039,12040,12041,11862,12042,12043,12044,12045,12046,12047,12048,12049],"Aripiprazole","Quetiapine","Risperidone","Ziprasidone","Iloperidone","Paliperidone","Lurasidone","Clozapine","Amisulpride","Sertindole","Zotepine",{"intervention":1205,"totalTrials":2262,"cells":12051},{"EARLY_PHASE1":12052,"PHASE1":12054,"PHASE2":12056,"PHASE3":12058,"PHASE4":12107,"NA":12182},{"trials":12053,"activeCount":59},[],{"trials":12055,"activeCount":59},[],{"trials":12057,"activeCount":59},[],{"trials":12059,"activeCount":59},[12060,12067,12071,12078,12082,12088,12092,12099],{"nctId":12061,"briefTitle":12062,"status":67,"phases":12063,"primaryCompletion":892,"completion":892,"start":462,"enrollment":12064,"conditions":12065,"interventions":12066},"NCT00805324","Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Hayfever With or Without Asthma (P03472)",[50],54,[33,17],[1205],{"nctId":1801,"briefTitle":1802,"status":67,"phases":12068,"primaryCompletion":1804,"completion":1804,"start":246,"enrollment":1805,"conditions":12069,"interventions":12070},[50],[31],[1245,1790],{"nctId":12072,"briefTitle":12073,"status":67,"phases":12074,"primaryCompletion":613,"completion":613,"start":907,"enrollment":2324,"conditions":12075,"interventions":12077},"NCT00757562","Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)",[50],[1581,12076],"Atopy",[1245],{"nctId":1199,"briefTitle":1200,"status":67,"phases":12079,"primaryCompletion":742,"completion":742,"start":742,"enrollment":1202,"conditions":12080,"interventions":12081},[50],[31],[1205,878],{"nctId":12083,"briefTitle":12084,"status":67,"phases":12085,"primaryCompletion":647,"completion":647,"start":1375,"enrollment":648,"conditions":12086,"interventions":12087},"NCT00817076","Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Allergic Skin Inflammation (P03475)",[50],[2796],[1245],{"nctId":1207,"briefTitle":1208,"status":67,"phases":12089,"primaryCompletion":742,"completion":742,"start":742,"enrollment":1210,"conditions":12090,"interventions":12091},[50],[31],[1205,878],{"nctId":12093,"briefTitle":12094,"status":67,"phases":12095,"primaryCompletion":1666,"completion":1666,"start":883,"enrollment":12096,"conditions":12097,"interventions":12098},"NCT00795158","How Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With Chronic Idiopathic Urticaria (Have Had Hives for 6 Weeks or Longer)(Study P02988)",[50],282,[1227],[1245],{"nctId":12100,"briefTitle":12101,"status":67,"phases":12102,"primaryCompletion":12103,"completion":12104,"start":844,"enrollment":7527,"conditions":12105,"interventions":12106},"NCT01916967","An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)",[50],"2014-02-28","2014-03-13",[1227],[1205],{"trials":12108,"activeCount":59},[12109,12113,12117,12123,12131,12135,12142,12146,12150,12159,12166,12170,12174],{"nctId":1220,"briefTitle":1221,"status":610,"phases":12110,"primaryCompletion":1223,"completion":1223,"start":1224,"enrollment":1225,"conditions":12111,"interventions":12112},[51],[1227],[1205,878],{"nctId":1811,"briefTitle":1812,"status":67,"phases":12114,"primaryCompletion":350,"completion":350,"start":439,"enrollment":81,"conditions":12115,"interventions":12116},[51],[1815],[1245,1790,1817,1818],{"nctId":12118,"briefTitle":12119,"status":67,"phases":12120,"primaryCompletion":11749,"completion":1180,"start":647,"enrollment":339,"conditions":12121,"interventions":12122},"NCT00795522","An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540)",[51],[1227],[1205],{"nctId":12124,"briefTitle":12125,"status":67,"phases":12126,"primaryCompletion":11618,"completion":11618,"start":12127,"enrollment":12128,"conditions":12129,"interventions":12130},"NCT00867191","Comparison of the Effects of Desloratadine and Placebo in the Relief of Nasal Symptom Scores in Subjects With Seasonal Allergic Rhinitis to Cypress Pollen (Study P02836)",[51],"2002-02-01",233,[20],[1205],{"nctId":2044,"briefTitle":2045,"status":67,"phases":12132,"primaryCompletion":581,"completion":581,"start":669,"enrollment":1283,"conditions":12133,"interventions":12134},[51],[2048],[1205,2031],{"nctId":12136,"briefTitle":12137,"status":67,"phases":12138,"primaryCompletion":12139,"completion":6931,"start":11618,"enrollment":9095,"conditions":12140,"interventions":12141},"NCT00783354","A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)",[51],"2004-02-01",[1227,1581],[1245,1245],{"nctId":1350,"briefTitle":1351,"status":67,"phases":12143,"primaryCompletion":1353,"completion":1353,"start":551,"enrollment":94,"conditions":12144,"interventions":12145},[51],[20],[1245,887],{"nctId":1238,"briefTitle":1239,"status":67,"phases":12147,"primaryCompletion":1241,"completion":1241,"start":244,"enrollment":1242,"conditions":12148,"interventions":12149},[51],[1227],[1245,1246],{"nctId":12151,"briefTitle":12152,"status":67,"phases":12153,"primaryCompletion":9464,"completion":9464,"start":12154,"enrollment":12155,"conditions":12156,"interventions":12158},"NCT00779636","Effectiveness and Safety of Desloratadine in Patients With Allergic Airway Disease During the Pollen Season (Study P03284)",[51],"2003-07-01",506,[12157],"Allergic Airway Disease",[1205],{"nctId":12160,"briefTitle":12161,"status":67,"phases":12162,"primaryCompletion":1066,"completion":1066,"start":462,"enrollment":12163,"conditions":12164,"interventions":12165},"NCT00805584","Study of Nasal Symptom Relief and Side Effects in Hayfever Patients Treated With Aerius (Desloratadine)(P03442)",[51],311,[33],[1245],{"nctId":2051,"briefTitle":2052,"status":67,"phases":12167,"primaryCompletion":581,"completion":581,"start":741,"enrollment":2054,"conditions":12168,"interventions":12169},[51],[2048],[1205,2031],{"nctId":1357,"briefTitle":1358,"status":67,"phases":12171,"primaryCompletion":1353,"completion":1353,"start":551,"enrollment":1360,"conditions":12172,"interventions":12173},[51],[20],[1245,887],{"nctId":12175,"briefTitle":12176,"status":67,"phases":12177,"primaryCompletion":12178,"completion":12178,"start":4206,"enrollment":4207,"conditions":12179,"interventions":12181},"NCT00311844","A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209)",[51],"2005-05-28",[12180],"Conjunctivitis, Allergic",[1245],{"trials":12183,"activeCount":59},[12184,12192,12199],{"nctId":12185,"briefTitle":12186,"status":67,"phases":12187,"primaryCompletion":11683,"completion":11683,"start":1083,"enrollment":12188,"conditions":12189,"interventions":12191},"NCT00704769","Response of Desloratadine Syrup in the Relief of Symptoms Associated With Perennial Allergic Rhinitis in Pediatric Patients (Study P04299)",[],591,[12190],"Rhinitis",[1205],{"nctId":12193,"briefTitle":12194,"status":67,"phases":12195,"primaryCompletion":11683,"completion":11683,"start":581,"enrollment":12196,"conditions":12197,"interventions":12198},"NCT00724698","Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria",[],3011,[12190,1227],[1205],{"nctId":12200,"briefTitle":12201,"status":67,"phases":12202,"primaryCompletion":312,"completion":312,"start":11683,"enrollment":378,"conditions":12203,"interventions":12204},"NCT00723736","Safety of Aerius Syrup in Pediatric Patients Aged 1-5 Years Old With Allergic Rhinitis or Chronic Idiopathic Urticaria (Study P04446AM1)(COMPLETED)",[],[12190,1227],[1205],{"intervention":11862,"totalTrials":11,"cells":12206},{"EARLY_PHASE1":12207,"PHASE1":12209,"PHASE2":12211,"PHASE3":12213,"PHASE4":12271,"NA":12273},{"trials":12208,"activeCount":59},[],{"trials":12210,"activeCount":59},[],{"trials":12212,"activeCount":59},[],{"trials":12214,"activeCount":59},[12215,12219,12223,12227,12231,12235,12239,12243,12247,12251,12255,12259,12263,12267],{"nctId":11855,"briefTitle":11856,"status":67,"phases":12216,"primaryCompletion":11858,"completion":11859,"start":4941,"enrollment":2481,"conditions":12217,"interventions":12218},[50],[28],[4846,11862],{"nctId":11868,"briefTitle":11869,"status":67,"phases":12220,"primaryCompletion":11871,"completion":11872,"start":11873,"enrollment":11874,"conditions":12221,"interventions":12222},[50],[28],[4857,11877],{"nctId":11879,"briefTitle":11880,"status":67,"phases":12224,"primaryCompletion":274,"completion":3677,"start":461,"enrollment":11882,"conditions":12225,"interventions":12226},[50],[28],[4846,11862],{"nctId":11886,"briefTitle":11887,"status":67,"phases":12228,"primaryCompletion":11889,"completion":11890,"start":11891,"enrollment":11892,"conditions":12229,"interventions":12230},[50],[28],[4857,11877],{"nctId":11906,"briefTitle":11907,"status":67,"phases":12232,"primaryCompletion":11683,"completion":402,"start":1082,"enrollment":975,"conditions":12233,"interventions":12234},[50],[28],[4857,11877],{"nctId":11916,"briefTitle":11917,"status":67,"phases":12236,"primaryCompletion":3076,"completion":3076,"start":11403,"enrollment":11919,"conditions":12237,"interventions":12238},[50],[4844],[4857,11862],{"nctId":11923,"briefTitle":11924,"status":67,"phases":12240,"primaryCompletion":11926,"completion":11926,"start":3445,"enrollment":11927,"conditions":12241,"interventions":12242},[50],[4844],[4846,11862],{"nctId":11938,"briefTitle":11939,"status":67,"phases":12244,"primaryCompletion":11941,"completion":11889,"start":11942,"enrollment":11943,"conditions":12245,"interventions":12246},[50],[4844],[4846,11862],{"nctId":11947,"briefTitle":11948,"status":67,"phases":12248,"primaryCompletion":790,"completion":337,"start":11403,"enrollment":1044,"conditions":12249,"interventions":12250},[50],[28],[4857,11877],{"nctId":11953,"briefTitle":11954,"status":67,"phases":12252,"primaryCompletion":668,"completion":668,"start":1923,"enrollment":11956,"conditions":12253,"interventions":12254},[50],[28],[11862,4846],{"nctId":11969,"briefTitle":11970,"status":67,"phases":12256,"primaryCompletion":1095,"completion":359,"start":10957,"enrollment":7890,"conditions":12257,"interventions":12258},[50],[28,10102],[4857,11877],{"nctId":11989,"briefTitle":11990,"status":67,"phases":12260,"primaryCompletion":11992,"completion":11992,"start":11993,"enrollment":11994,"conditions":12261,"interventions":12262},[50],[28,10102],[4857,11877],{"nctId":11998,"briefTitle":11999,"status":67,"phases":12264,"primaryCompletion":12001,"completion":12002,"start":699,"enrollment":12003,"conditions":12265,"interventions":12266},[50],[28],[4857,11862],{"nctId":12020,"briefTitle":12021,"status":67,"phases":12268,"primaryCompletion":8138,"completion":8138,"start":12023,"enrollment":12024,"conditions":12269,"interventions":12270},[50],[4844],[4846,11862],{"trials":12272,"activeCount":59},[],{"trials":12274,"activeCount":59},[12275],{"nctId":12032,"briefTitle":12033,"status":67,"phases":12276,"primaryCompletion":12035,"completion":12035,"start":4698,"enrollment":12036,"conditions":12277,"interventions":12278},[],[4844],[4846,12039,12040,12041,11862,12042,12043,12044,12045,12046,12047,12048,12049],{"intervention":5199,"totalTrials":943,"cells":12280},{"EARLY_PHASE1":12281,"PHASE1":12283,"PHASE2":12285,"PHASE3":12309,"PHASE4":12360,"NA":12362},{"trials":12282,"activeCount":59},[],{"trials":12284,"activeCount":59},[],{"trials":12286,"activeCount":59},[12287,12296],{"nctId":12288,"briefTitle":12289,"status":67,"phases":12290,"primaryCompletion":9239,"completion":9239,"start":12291,"enrollment":4878,"conditions":12292,"interventions":12294},"NCT00598208","A Phase 2, Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian (Study 38826)(P06055)(COMPLETED)",[49],"2003-05-19",[12293],"Fertilization",[7321,12295],"Follitropin beta",{"nctId":12297,"briefTitle":12298,"status":610,"phases":12299,"primaryCompletion":12300,"completion":12301,"start":12302,"enrollment":55,"conditions":12303,"interventions":12305},"NCT00697255","A Phase 2 Trial to Evaluate if Corifollitropin Alfa (Org 36286), Followed by a Low Daily Dose of hCG or Recombinant FSH Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility (P05693)",[49],"2008-04-03","2008-05-15","2007-05-15",[12304],"Ovulation Induction",[7321,12306,12307,12308],"recombinant Follicle Stimulating Hormone","human Chorion Gonadotropin","hCG Bolus",{"trials":12310,"activeCount":59},[12311,12320,12333,12337,12347,12351],{"nctId":12312,"briefTitle":12313,"status":67,"phases":12314,"primaryCompletion":12315,"completion":12315,"start":12316,"enrollment":413,"conditions":12317,"interventions":12319},"NCT03019575","Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043)",[50],"2020-05-05","2017-02-02",[12318],"Hypogonadotropic Hypogonadism",[5199,5202],{"nctId":12321,"briefTitle":12322,"status":67,"phases":12323,"primaryCompletion":12324,"completion":12325,"start":12326,"enrollment":12327,"conditions":12328,"interventions":12329},"NCT00696878","Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714)",[50],"2009-02-17","2009-05-15","2006-09-26",682,[5197],[5199,12330,12331,12332,5203],"FSH","GnRH antagonist","(rec)hCG",{"nctId":7312,"briefTitle":7313,"status":67,"phases":12334,"primaryCompletion":7315,"completion":7316,"start":7317,"enrollment":7318,"conditions":12335,"interventions":12336},[50],[3128],[7321,7322,7301,7323,7324,7325],{"nctId":12338,"briefTitle":12339,"status":67,"phases":12340,"primaryCompletion":12341,"completion":12342,"start":12343,"enrollment":12344,"conditions":12345,"interventions":12346},"NCT01146418","Frozen-thawed Embryo Transfer (FTET) Cycle Follow-up Protocol (P06031)",[50],"2013-07-24","2014-04-29","2010-06-02",307,[3128],[5199,7322],{"nctId":5189,"briefTitle":5190,"status":67,"phases":12348,"primaryCompletion":5192,"completion":5193,"start":5194,"enrollment":5195,"conditions":12349,"interventions":12350},[50],[5197],[5199,5200,5200,5201,5202,5203],{"nctId":12352,"briefTitle":12353,"status":67,"phases":12354,"primaryCompletion":12355,"completion":12355,"start":12356,"enrollment":3946,"conditions":12357,"interventions":12359},"NCT01709331","A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)",[50],"2015-04-08","2013-02-11",[12358,12318],"Hypogonadism",[5199,5202],{"trials":12361,"activeCount":59},[],{"trials":12363,"activeCount":59},[12364,12375,12385,12392,12401],{"nctId":12365,"briefTitle":12366,"status":67,"phases":12367,"primaryCompletion":769,"completion":312,"start":3076,"enrollment":12368,"conditions":12369,"interventions":12372},"NCT00702624","Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05690 (Care Program) (P05710)",[],113,[12370,12371],"Pregnancy","Neonates",[5199,7322,12373,12374,7324,7325],"gonadatropin releasing hormone (GnRH) antagonist ganirelix","human chorion gonadotropin",{"nctId":12376,"briefTitle":12377,"status":67,"phases":12378,"primaryCompletion":12379,"completion":12379,"start":12380,"enrollment":12381,"conditions":12382,"interventions":12384},"NCT01408615","A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)",[],"2016-11-18","2011-09-20",472,[12383],"Infertility, Female",[7321],{"nctId":12386,"briefTitle":12387,"status":67,"phases":12388,"primaryCompletion":12389,"completion":4385,"start":12301,"enrollment":190,"conditions":12390,"interventions":12391},"NCT00702338","Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05693 (P05713)",[],"2008-08-09",[12370,12371],[7321,12306,12307,12308],{"nctId":12393,"briefTitle":12394,"status":67,"phases":12395,"primaryCompletion":3551,"completion":12396,"start":12397,"enrollment":12398,"conditions":12399,"interventions":12400},"NCT00702234","Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05714 (Care Program)(P05715)",[],"2010-01-15","2007-02-15",268,[12370,12371],[5199,12331,12332,12330,5203],{"nctId":12402,"briefTitle":12403,"status":67,"phases":12404,"primaryCompletion":3677,"completion":3677,"start":941,"enrollment":1139,"conditions":12405,"interventions":12406},"NCT00702546","Follow-up Protocol on the Outcome of Frozen-thawed Embryo Transfer Cycles From Clinical Trial P05690 (P05711)",[],[5197],[7321,7322,12373,7323,7324,7325],{"intervention":4352,"totalTrials":6826,"cells":12408},{"EARLY_PHASE1":12409,"PHASE1":12411,"PHASE2":12413,"PHASE3":12424,"PHASE4":12468,"NA":12484},{"trials":12410,"activeCount":59},[],{"trials":12412,"activeCount":59},[],{"trials":12414,"activeCount":59},[12415],{"nctId":12416,"briefTitle":12417,"status":67,"phases":12418,"primaryCompletion":12419,"completion":12419,"start":12420,"enrollment":12421,"conditions":12422,"interventions":12423},"NCT00779545","A Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis (Study P03748)(COMPLETED)",[49],"2004-08-06","2004-04-08",455,[1293],[4352,4352,4352,4352,4352],{"trials":12425,"activeCount":59},[12426,12433,12437,12441,12449,12456,12462],{"nctId":12427,"briefTitle":12428,"status":67,"phases":12429,"primaryCompletion":5126,"completion":5126,"start":633,"enrollment":1139,"conditions":12430,"interventions":12431},"NCT00779740","Equivalency Study of Two Formulations of Mometasone Furoate Nasal Spray (Study P04419)",[50],[1293],[12432,12432],"mometasone furoate",{"nctId":5457,"briefTitle":5458,"status":67,"phases":12434,"primaryCompletion":5460,"completion":5461,"start":5462,"enrollment":5463,"conditions":12435,"interventions":12436},[50],[20],[5466,5446],{"nctId":4344,"briefTitle":4345,"status":67,"phases":12438,"primaryCompletion":4347,"completion":4347,"start":4348,"enrollment":4349,"conditions":12439,"interventions":12440},[50],[33],[4352,4326,4353,4354],{"nctId":12442,"briefTitle":12443,"status":67,"phases":12444,"primaryCompletion":12445,"completion":12445,"start":1223,"enrollment":12446,"conditions":12447,"interventions":12448},"NCT00732368","A Long-term Study of Mometasone Furoate in Patients With Perennial Allergic Rhinitis (Study P04459)",[50],"2006-01-01",98,[405],[4352],{"nctId":12450,"briefTitle":12451,"status":67,"phases":12452,"primaryCompletion":668,"completion":668,"start":284,"enrollment":12453,"conditions":12454,"interventions":12455},"NCT00453063","Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg Once Daily (QD) in the Treatment of Seasonal Allergic Rhinitis (Study P05067)(COMPLETED)",[50],426,[20],[12432],{"nctId":12457,"briefTitle":12458,"status":67,"phases":12459,"primaryCompletion":10663,"completion":10663,"start":9400,"enrollment":11597,"conditions":12460,"interventions":12461},"NCT01165424","A Study of Long-term Administration of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06333AM1)",[50],[1293],[12432],{"nctId":12463,"briefTitle":12464,"status":67,"phases":12465,"primaryCompletion":6890,"completion":6890,"start":5183,"enrollment":330,"conditions":12466,"interventions":12467},"NCT01135134","Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06332)",[50],[1293],[4352],{"trials":12469,"activeCount":59},[12470,12477],{"nctId":12471,"briefTitle":12472,"status":67,"phases":12473,"primaryCompletion":6931,"completion":6931,"start":208,"enrollment":12474,"conditions":12475,"interventions":12476},"NCT00834119","Assessment of Intranasal Steroids in Allergic Rhinitis When Used Alone or in Combination With an Oral Antihistamine (Study P03270)",[51],72,[227],[4352,4352],{"nctId":12478,"briefTitle":12479,"status":610,"phases":12480,"primaryCompletion":11665,"completion":11665,"start":360,"enrollment":12481,"conditions":12482,"interventions":12483},"NCT00687531","Clinical Trial to Assess Efficacy, Safety, Treatment Adherence and Quality of Life Impact of Mometasone Furoate in Asthmatic Patients (Study P04879)(TERMINATED)",[51],385,[17],[5466],{"trials":12485,"activeCount":59},[12486],{"nctId":12487,"briefTitle":12488,"status":67,"phases":12489,"primaryCompletion":450,"completion":450,"start":274,"enrollment":12490,"conditions":12491,"interventions":12492},"NCT00903721","Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation (Study P05876)",[],3806,[31],[12432],{"intervention":4577,"totalTrials":828,"cells":12494},{"EARLY_PHASE1":12495,"PHASE1":12497,"PHASE2":12503,"PHASE3":12509,"PHASE4":12519,"NA":12534},{"trials":12496,"activeCount":59},[],{"trials":12498,"activeCount":59},[12499],{"nctId":4572,"briefTitle":4573,"status":67,"phases":12500,"primaryCompletion":875,"completion":875,"start":883,"enrollment":81,"conditions":12501,"interventions":12502},[48],[1926],[4577,4565],{"trials":12504,"activeCount":59},[12505],{"nctId":9689,"briefTitle":9690,"status":67,"phases":12506,"primaryCompletion":438,"completion":438,"start":5688,"enrollment":9692,"conditions":12507,"interventions":12508},[49],[3761],[4577,4577,4577,4577,3355,4577,9680],{"trials":12510,"activeCount":59},[12511,12515],{"nctId":3930,"briefTitle":3931,"status":67,"phases":12512,"primaryCompletion":3933,"completion":3933,"start":3934,"enrollment":3935,"conditions":12513,"interventions":12514},[50],[3923],[3938,3906,3939],{"nctId":9090,"briefTitle":9091,"status":67,"phases":12516,"primaryCompletion":9093,"completion":9093,"start":9094,"enrollment":9095,"conditions":12517,"interventions":12518},[50],[3923],[4577,3355,9079],{"trials":12520,"activeCount":59},[12521,12527],{"nctId":12522,"briefTitle":12523,"status":67,"phases":12524,"primaryCompletion":3677,"completion":3677,"start":11683,"enrollment":1274,"conditions":12525,"interventions":12526},"NCT00757627","Patient-Reported Effectiveness and Safety of Etoricoxib in Osteoarthritis (OA)(0663-113)",[51],[1926],[4577],{"nctId":12528,"briefTitle":12529,"status":347,"phases":12530,"primaryCompletion":12531,"completion":12531,"start":10662,"enrollment":59,"conditions":12532,"interventions":12533},"NCT01429168","A Study of Etoricoxib in Participants With Osteoarthritis Not Responding to Analgesic Drugs (MK-0663-142)",[51],"2012-08",[2995],[3938],{"trials":12535,"activeCount":59},[12536,12549,12561],{"nctId":12537,"briefTitle":12538,"status":67,"phases":12539,"primaryCompletion":12540,"completion":12541,"start":12542,"enrollment":12543,"conditions":12544,"interventions":12546},"NCT01327638","Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)\u002FAnkylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)",[],"2018-09-24","2018-12-06","2011-02-15",21108,[12545],"Spondylarthropathies; Spondylitis, Ankylosing",[4577,12547,12548],"Other COX-2 inhibitor","nsNSAIDs",{"nctId":12550,"briefTitle":12551,"status":67,"phases":12552,"primaryCompletion":12553,"completion":12553,"start":12554,"enrollment":12555,"conditions":12556,"interventions":12560},"NCT01685424","Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)",[],"2015-03-01","2006-06-30",79189,[2995,3761,12557,12558,12559],"Ankylosing Spondylitis","Gout","Arthritis",[3938],{"nctId":12562,"briefTitle":12563,"status":67,"phases":12564,"primaryCompletion":12565,"completion":12565,"start":12566,"enrollment":12567,"conditions":12568,"interventions":12569},"NCT01077843","Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)",[],"2015-07-01","2009-08-17",27381,[12557],[3938,12570,12571],"Other Cox-2 inhibitors","Other Non-selective NSAIDs",{"intervention":5203,"totalTrials":828,"cells":12573},{"EARLY_PHASE1":12574,"PHASE1":12576,"PHASE2":12578,"PHASE3":12580,"PHASE4":12598,"NA":12600},{"trials":12575,"activeCount":59},[],{"trials":12577,"activeCount":59},[],{"trials":12579,"activeCount":59},[],{"trials":12581,"activeCount":59},[12582,12586,12590,12594],{"nctId":12321,"briefTitle":12322,"status":67,"phases":12583,"primaryCompletion":12324,"completion":12325,"start":12326,"enrollment":12327,"conditions":12584,"interventions":12585},[50],[5197],[5199,12330,12331,12332,5203],{"nctId":7312,"briefTitle":7313,"status":67,"phases":12587,"primaryCompletion":7315,"completion":7316,"start":7317,"enrollment":7318,"conditions":12588,"interventions":12589},[50],[3128],[7321,7322,7301,7323,7324,7325],{"nctId":5189,"briefTitle":5190,"status":67,"phases":12591,"primaryCompletion":5192,"completion":5193,"start":5194,"enrollment":5195,"conditions":12592,"interventions":12593},[50],[5197],[5199,5200,5200,5201,5202,5203],{"nctId":9194,"briefTitle":9195,"status":347,"phases":12595,"primaryCompletion":5059,"completion":9197,"start":9198,"enrollment":59,"conditions":12596,"interventions":12597},[50],[3128],[9183,7322,5201,9201,5203],{"trials":12599,"activeCount":59},[],{"trials":12601,"activeCount":59},[12602,12606,12618,12622,12626],{"nctId":12365,"briefTitle":12366,"status":67,"phases":12603,"primaryCompletion":769,"completion":312,"start":3076,"enrollment":12368,"conditions":12604,"interventions":12605},[],[12370,12371],[5199,7322,12373,12374,7324,7325],{"nctId":12607,"briefTitle":12608,"status":67,"phases":12609,"primaryCompletion":12610,"completion":12611,"start":12612,"enrollment":12613,"conditions":12614,"interventions":12615},"NCT00703014","Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05787 (P05712)",[],"2008-04-18","2009-03-15","2006-07-13",541,[12370,12371],[12616,12617,12617,5201,5202,5203],"Corifollitropin Alfa 150 μg","200 IU RecFSH\u002FFollitropin beta",{"nctId":12393,"briefTitle":12394,"status":67,"phases":12619,"primaryCompletion":3551,"completion":12396,"start":12397,"enrollment":12398,"conditions":12620,"interventions":12621},[],[12370,12371],[5199,12331,12332,12330,5203],{"nctId":12402,"briefTitle":12403,"status":67,"phases":12623,"primaryCompletion":3677,"completion":3677,"start":941,"enrollment":1139,"conditions":12624,"interventions":12625},[],[5197],[7321,7322,12373,7323,7324,7325],{"nctId":12627,"briefTitle":12628,"status":67,"phases":12629,"primaryCompletion":12630,"completion":12631,"start":12632,"enrollment":12633,"conditions":12634,"interventions":12635},"NCT00702273","Follow-up Study of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Trial P05787 (P05716)",[],"2009-05-19","2009-05-31","2006-04-19",344,[5197],[12636,12617,12617,5201,5202,5203],"150 µg Corifollitropin Alfa",{"intervention":7322,"totalTrials":1103,"cells":12638},{"EARLY_PHASE1":12639,"PHASE1":12641,"PHASE2":12643,"PHASE3":12645,"PHASE4":12659,"NA":12661},{"trials":12640,"activeCount":59},[],{"trials":12642,"activeCount":59},[],{"trials":12644,"activeCount":59},[],{"trials":12646,"activeCount":59},[12647,12651,12655],{"nctId":7312,"briefTitle":7313,"status":67,"phases":12648,"primaryCompletion":7315,"completion":7316,"start":7317,"enrollment":7318,"conditions":12649,"interventions":12650},[50],[3128],[7321,7322,7301,7323,7324,7325],{"nctId":12338,"briefTitle":12339,"status":67,"phases":12652,"primaryCompletion":12341,"completion":12342,"start":12343,"enrollment":12344,"conditions":12653,"interventions":12654},[50],[3128],[5199,7322],{"nctId":9194,"briefTitle":9195,"status":347,"phases":12656,"primaryCompletion":5059,"completion":9197,"start":9198,"enrollment":59,"conditions":12657,"interventions":12658},[50],[3128],[9183,7322,5201,9201,5203],{"trials":12660,"activeCount":59},[],{"trials":12662,"activeCount":59},[12663,12667,12674,12678],{"nctId":12365,"briefTitle":12366,"status":67,"phases":12664,"primaryCompletion":769,"completion":312,"start":3076,"enrollment":12368,"conditions":12665,"interventions":12666},[],[12370,12371],[5199,7322,12373,12374,7324,7325],{"nctId":12668,"briefTitle":12669,"status":67,"phases":12670,"primaryCompletion":12671,"completion":12671,"start":613,"enrollment":475,"conditions":12672,"interventions":12673},"NCT00702988","Pregnancy & Neonatal Follow-up of Ongoing Pregnancies Established During Clinical Trial 38826 (Study 38827)(P06056)(COMPLETED)",[],"2005-02-28",[12370,12371],[10447,7322],{"nctId":12402,"briefTitle":12403,"status":67,"phases":12675,"primaryCompletion":3677,"completion":3677,"start":941,"enrollment":1139,"conditions":12676,"interventions":12677},[],[5197],[7321,7322,12373,7323,7324,7325],{"nctId":12679,"briefTitle":12680,"status":67,"phases":12681,"primaryCompletion":12682,"completion":12682,"start":12683,"enrollment":12684,"conditions":12685,"interventions":12686},"NCT00702195","Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established During Phase II Clinical Trials of Org 36286 (Study 38817)(P06054)(COMPLETED)",[],"2003-09-15","2002-01-01",29,[12370],[10447,7322],{"intervention":5201,"totalTrials":1103,"cells":12688},{"EARLY_PHASE1":12689,"PHASE1":12691,"PHASE2":12693,"PHASE3":12705,"PHASE4":12724,"NA":12726},{"trials":12690,"activeCount":59},[],{"trials":12692,"activeCount":59},[],{"trials":12694,"activeCount":59},[12695],{"nctId":12696,"briefTitle":12697,"status":67,"phases":12698,"primaryCompletion":12699,"completion":12699,"start":12700,"enrollment":12701,"conditions":12702,"interventions":12704},"NCT00988260","Japanese Bridging Trial of Org 37462 (Study P05969)(COMPLETED)",[49],"2004-04-12","2003-02-03",266,[12703],"Controlled Ovarian Stimulation",[5201,5201,5201],{"trials":12706,"activeCount":59},[12707,12716,12720],{"nctId":12708,"briefTitle":12709,"status":67,"phases":12710,"primaryCompletion":3677,"completion":3677,"start":1637,"enrollment":12711,"conditions":12712,"interventions":12713},"NCT00725491","A Study to Assess the Efficacy and Safety of Ganirelix (Orgalutran®) Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for in Vitro Fertilization (IVF) or Intra Cytoplasmatic Sperm Injection (ICSI) (Study 38651)(P05703)",[50],259,[12703],[12714,12715],"ganirelix","triptorelin",{"nctId":5189,"briefTitle":5190,"status":67,"phases":12717,"primaryCompletion":5192,"completion":5193,"start":5194,"enrollment":5195,"conditions":12718,"interventions":12719},[50],[5197],[5199,5200,5200,5201,5202,5203],{"nctId":9194,"briefTitle":9195,"status":347,"phases":12721,"primaryCompletion":5059,"completion":9197,"start":9198,"enrollment":59,"conditions":12722,"interventions":12723},[50],[3128],[9183,7322,5201,9201,5203],{"trials":12725,"activeCount":59},[],{"trials":12727,"activeCount":59},[12728,12732,12740],{"nctId":12607,"briefTitle":12608,"status":67,"phases":12729,"primaryCompletion":12610,"completion":12611,"start":12612,"enrollment":12613,"conditions":12730,"interventions":12731},[],[12370,12371],[12616,12617,12617,5201,5202,5203],{"nctId":12733,"briefTitle":12734,"status":67,"phases":12735,"primaryCompletion":570,"completion":570,"start":3872,"enrollment":12736,"conditions":12737,"interventions":12738},"NCT00724789","Monitor the Incidence of Congenital Malformations in Infants of Women Who Have Been Treated With Ganirelix (Orgalutran®)(Study 38644)(P05966)(COMPLETED)",[],2066,[12370,12371],[12714,12739],"GnRH agonist",{"nctId":12627,"briefTitle":12628,"status":67,"phases":12741,"primaryCompletion":12630,"completion":12631,"start":12632,"enrollment":12633,"conditions":12742,"interventions":12743},[],[5197],[12636,12617,12617,5201,5202,5203],{"intervention":10447,"totalTrials":3745,"cells":12745},{"EARLY_PHASE1":12746,"PHASE1":12748,"PHASE2":12754,"PHASE3":12776,"PHASE4":12778,"NA":12780},{"trials":12747,"activeCount":59},[],{"trials":12749,"activeCount":59},[12750],{"nctId":11211,"briefTitle":11212,"status":67,"phases":12751,"primaryCompletion":11214,"completion":11214,"start":2480,"enrollment":2262,"conditions":12752,"interventions":12753},[48],[3128],[10447,11204],{"trials":12755,"activeCount":59},[12756,12765,12772],{"nctId":12757,"briefTitle":12758,"status":67,"phases":12759,"primaryCompletion":12760,"completion":12761,"start":12762,"enrollment":485,"conditions":12763,"interventions":12764},"NCT00702351","A Trial of Single Dose Corifollitropin Alfa's Ability to Induce Multiple Follicular Growth During the First Week of Controlled Ovarian Stimulation for IVF or ICSI (38833)(P05788)",[49],"2007-03-26","2007-07-11","2005-12-09",[5197],[10447],{"nctId":12766,"briefTitle":12767,"status":67,"phases":12768,"primaryCompletion":8807,"completion":8807,"start":12769,"enrollment":18,"conditions":12770,"interventions":12771},"NCT00702585","Study to Investigate the Optimal Dose of Org 36286 to Induce Monofollicular Ovulation in Women With WHO Group II Anovulatory Infertility (P07016)",[49],"2001-08-01",[3128],[10447],{"nctId":10440,"briefTitle":10441,"status":67,"phases":12773,"primaryCompletion":8807,"completion":8807,"start":10443,"enrollment":10444,"conditions":12774,"interventions":12775},[49],[3128,5197],[10447,10431,10448,10449],{"trials":12777,"activeCount":59},[],{"trials":12779,"activeCount":59},[],{"trials":12781,"activeCount":59},[12782,12786],{"nctId":12668,"briefTitle":12669,"status":67,"phases":12783,"primaryCompletion":12671,"completion":12671,"start":613,"enrollment":475,"conditions":12784,"interventions":12785},[],[12370,12371],[10447,7322],{"nctId":12679,"briefTitle":12680,"status":67,"phases":12787,"primaryCompletion":12682,"completion":12682,"start":12683,"enrollment":12684,"conditions":12788,"interventions":12789},[],[12370],[10447,7322],{"intervention":5202,"totalTrials":148,"cells":12791},{"EARLY_PHASE1":12792,"PHASE1":12794,"PHASE2":12796,"PHASE3":12798,"PHASE4":12812,"NA":12814},{"trials":12793,"activeCount":59},[],{"trials":12795,"activeCount":59},[],{"trials":12797,"activeCount":59},[],{"trials":12799,"activeCount":59},[12800,12804,12808],{"nctId":12312,"briefTitle":12313,"status":67,"phases":12801,"primaryCompletion":12315,"completion":12315,"start":12316,"enrollment":413,"conditions":12802,"interventions":12803},[50],[12318],[5199,5202],{"nctId":5189,"briefTitle":5190,"status":67,"phases":12805,"primaryCompletion":5192,"completion":5193,"start":5194,"enrollment":5195,"conditions":12806,"interventions":12807},[50],[5197],[5199,5200,5200,5201,5202,5203],{"nctId":12352,"briefTitle":12353,"status":67,"phases":12809,"primaryCompletion":12355,"completion":12355,"start":12356,"enrollment":3946,"conditions":12810,"interventions":12811},[50],[12358,12318],[5199,5202],{"trials":12813,"activeCount":59},[],{"trials":12815,"activeCount":59},[12816,12820],{"nctId":12607,"briefTitle":12608,"status":67,"phases":12817,"primaryCompletion":12610,"completion":12611,"start":12612,"enrollment":12613,"conditions":12818,"interventions":12819},[],[12370,12371],[12616,12617,12617,5201,5202,5203],{"nctId":12627,"briefTitle":12628,"status":67,"phases":12821,"primaryCompletion":12630,"completion":12631,"start":12632,"enrollment":12633,"conditions":12822,"interventions":12823},[],[5197],[12636,12617,12617,5201,5202,5203],{"intervention":6176,"totalTrials":682,"cells":12825},{"EARLY_PHASE1":12826,"PHASE1":12828,"PHASE2":12830,"PHASE3":12832,"PHASE4":12838,"NA":12840},{"trials":12827,"activeCount":59},[],{"trials":12829,"activeCount":59},[],{"trials":12831,"activeCount":59},[],{"trials":12833,"activeCount":59},[12834],{"nctId":6169,"briefTitle":6170,"status":67,"phases":12835,"primaryCompletion":1506,"completion":1506,"start":6172,"enrollment":6173,"conditions":12836,"interventions":12837},[50],[563],[432,6158,6176],{"trials":12839,"activeCount":59},[],{"trials":12841,"activeCount":59},[12842,12849,12853],{"nctId":12843,"briefTitle":12844,"status":67,"phases":12845,"primaryCompletion":3638,"completion":3638,"start":402,"enrollment":12846,"conditions":12847,"interventions":12848},"NCT00723723","Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)",[],555,[11621,14,745],[6176],{"nctId":11655,"briefTitle":11656,"status":67,"phases":12850,"primaryCompletion":11430,"completion":11430,"start":402,"enrollment":11658,"conditions":12851,"interventions":12852},[],[11621,14],[432,6176],{"nctId":11680,"briefTitle":11681,"status":67,"phases":12854,"primaryCompletion":11683,"completion":11683,"start":5688,"enrollment":11684,"conditions":12855,"interventions":12856},[],[14],[444,11687],{"intervention":12295,"totalTrials":1549,"cells":12858},{"EARLY_PHASE1":12859,"PHASE1":12861,"PHASE2":12863,"PHASE3":12869,"PHASE4":12871,"NA":12873},{"trials":12860,"activeCount":59},[],{"trials":12862,"activeCount":59},[],{"trials":12864,"activeCount":59},[12865],{"nctId":12288,"briefTitle":12289,"status":67,"phases":12866,"primaryCompletion":9239,"completion":9239,"start":12291,"enrollment":4878,"conditions":12867,"interventions":12868},[49],[12293],[7321,12295],{"trials":12870,"activeCount":59},[],{"trials":12872,"activeCount":59},[],{"trials":12874,"activeCount":59},[12875,12883],{"nctId":12876,"briefTitle":12877,"status":67,"phases":12878,"primaryCompletion":1528,"completion":1528,"start":283,"enrollment":12879,"conditions":12880,"interventions":12882},"NCT00920634","Protocol for Drug Use Investigation of Follistim Injection (Study P06132)(COMPLETED)",[],384,[12881],"Anovulation",[12295],{"nctId":12884,"briefTitle":12885,"status":67,"phases":12886,"primaryCompletion":1528,"completion":1528,"start":570,"enrollment":12887,"conditions":12888,"interventions":12890},"NCT00920361","Designated Drug Use Investigation 1 of Follistim Injection (Study P06130)(COMPLETED)",[],1664,[12889],"Fertilization in Vitro",[12295],{"intervention":12307,"totalTrials":1549,"cells":12892},{"EARLY_PHASE1":12893,"PHASE1":12895,"PHASE2":12897,"PHASE3":12903,"PHASE4":12905,"NA":12907},{"trials":12894,"activeCount":59},[],{"trials":12896,"activeCount":59},[],{"trials":12898,"activeCount":59},[12899],{"nctId":12297,"briefTitle":12298,"status":610,"phases":12900,"primaryCompletion":12300,"completion":12301,"start":12302,"enrollment":55,"conditions":12901,"interventions":12902},[49],[12304],[7321,12306,12307,12308],{"trials":12904,"activeCount":59},[],{"trials":12906,"activeCount":59},[],{"trials":12908,"activeCount":59},[12909,12913],{"nctId":12365,"briefTitle":12366,"status":67,"phases":12910,"primaryCompletion":769,"completion":312,"start":3076,"enrollment":12368,"conditions":12911,"interventions":12912},[],[12370,12371],[5199,7322,12373,12374,7324,7325],{"nctId":12386,"briefTitle":12387,"status":67,"phases":12914,"primaryCompletion":12389,"completion":4385,"start":12301,"enrollment":190,"conditions":12915,"interventions":12916},[],[12370,12371],[7321,12306,12307,12308],{"intervention":7325,"totalTrials":1549,"cells":12918},{"EARLY_PHASE1":12919,"PHASE1":12921,"PHASE2":12923,"PHASE3":12925,"PHASE4":12931,"NA":12933},{"trials":12920,"activeCount":59},[],{"trials":12922,"activeCount":59},[],{"trials":12924,"activeCount":59},[],{"trials":12926,"activeCount":59},[12927],{"nctId":7312,"briefTitle":7313,"status":67,"phases":12928,"primaryCompletion":7315,"completion":7316,"start":7317,"enrollment":7318,"conditions":12929,"interventions":12930},[50],[3128],[7321,7322,7301,7323,7324,7325],{"trials":12932,"activeCount":59},[],{"trials":12934,"activeCount":59},[12935,12939],{"nctId":12365,"briefTitle":12366,"status":67,"phases":12936,"primaryCompletion":769,"completion":312,"start":3076,"enrollment":12368,"conditions":12937,"interventions":12938},[],[12370,12371],[5199,7322,12373,12374,7324,7325],{"nctId":12402,"briefTitle":12403,"status":67,"phases":12940,"primaryCompletion":3677,"completion":3677,"start":941,"enrollment":1139,"conditions":12941,"interventions":12942},[],[5197],[7321,7322,12373,7323,7324,7325],{"intervention":12306,"totalTrials":1549,"cells":12944},{"EARLY_PHASE1":12945,"PHASE1":12947,"PHASE2":12949,"PHASE3":12955,"PHASE4":12957,"NA":12959},{"trials":12946,"activeCount":59},[],{"trials":12948,"activeCount":59},[],{"trials":12950,"activeCount":59},[12951],{"nctId":12297,"briefTitle":12298,"status":610,"phases":12952,"primaryCompletion":12300,"completion":12301,"start":12302,"enrollment":55,"conditions":12953,"interventions":12954},[49],[12304],[7321,12306,12307,12308],{"trials":12956,"activeCount":59},[],{"trials":12958,"activeCount":59},[],{"trials":12960,"activeCount":59},[12961,12974],{"nctId":12962,"briefTitle":12963,"status":67,"phases":12964,"primaryCompletion":12965,"completion":5193,"start":12966,"enrollment":11,"conditions":12967,"interventions":12968},"NCT00702520","Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)",[],"2007-11-07","2006-04-01",[12370,12371],[12969,12970,12971,12972,12973],"Corifollitropin alpha (MK-8962, Org 36286) 100 ug","Corifollitropin alpha (MK-8962, Org 36286) 150 ug","Triptorelin","Recombinant follicle stimulating hormone","Human chorionic gonadotprophin (hCG).",{"nctId":12386,"briefTitle":12387,"status":67,"phases":12975,"primaryCompletion":12389,"completion":4385,"start":12301,"enrollment":190,"conditions":12976,"interventions":12977},[],[12370,12371],[7321,12306,12307,12308],{"intervention":6936,"totalTrials":1549,"cells":12979},{"EARLY_PHASE1":12980,"PHASE1":12982,"PHASE2":12984,"PHASE3":12986,"PHASE4":13001,"NA":13003},{"trials":12981,"activeCount":59},[],{"trials":12983,"activeCount":59},[],{"trials":12985,"activeCount":59},[],{"trials":12987,"activeCount":59},[12988,12992],{"nctId":6928,"briefTitle":6929,"status":67,"phases":12989,"primaryCompletion":6931,"completion":6931,"start":6932,"enrollment":541,"conditions":12990,"interventions":12991},[50],[6934],[6936,6917,6937,6938],{"nctId":12993,"briefTitle":12994,"status":67,"phases":12995,"primaryCompletion":2000,"completion":2000,"start":5646,"enrollment":12996,"conditions":12997,"interventions":12999},"NCT00480662","A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)",[50],60,[12998],"Paget's Disease of Bone",[13000],"alendronate",{"trials":13002,"activeCount":59},[],{"trials":13004,"activeCount":59},[13005],{"nctId":13006,"briefTitle":13007,"status":67,"phases":13008,"primaryCompletion":13009,"completion":13009,"start":13010,"enrollment":13011,"conditions":13012,"interventions":13016},"NCT01077817","Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)",[],"2012-02-16","2010-02-26",684815,[13013,13014,13015],"Esophageal Cancer","Squamous Cell Carcinoma","Adenocarcinoma",[6936,13017,13018,13019,13020],"Etidronate","Ibandronate","Risedronate","Raloxifene",{"intervention":12373,"totalTrials":8,"cells":13022},{"EARLY_PHASE1":13023,"PHASE1":13025,"PHASE2":13027,"PHASE3":13029,"PHASE4":13031,"NA":13033},{"trials":13024,"activeCount":59},[],{"trials":13026,"activeCount":59},[],{"trials":13028,"activeCount":59},[],{"trials":13030,"activeCount":59},[],{"trials":13032,"activeCount":59},[],{"trials":13034,"activeCount":59},[13035,13039],{"nctId":12365,"briefTitle":12366,"status":67,"phases":13036,"primaryCompletion":769,"completion":312,"start":3076,"enrollment":12368,"conditions":13037,"interventions":13038},[],[12370,12371],[5199,7322,12373,12374,7324,7325],{"nctId":12402,"briefTitle":12403,"status":67,"phases":13040,"primaryCompletion":3677,"completion":3677,"start":941,"enrollment":1139,"conditions":13041,"interventions":13042},[],[5197],[7321,7322,12373,7323,7324,7325],{"intervention":13044,"totalTrials":8,"cells":13045},"ibandronate",{"EARLY_PHASE1":13046,"PHASE1":13048,"PHASE2":13050,"PHASE3":13052,"PHASE4":13060,"NA":13062},{"trials":13047,"activeCount":59},[],{"trials":13049,"activeCount":59},[],{"trials":13051,"activeCount":59},[],{"trials":13053,"activeCount":59},[13054],{"nctId":13055,"briefTitle":13056,"status":67,"phases":13057,"primaryCompletion":11403,"completion":11403,"start":461,"enrollment":582,"conditions":13058,"interventions":13059},"NCT00092053","Study of Investigational Drug in Osteoporosis (MK-0217-908)",[50],[6934],[13044],{"trials":13061,"activeCount":59},[],{"trials":13063,"activeCount":59},[13064],{"nctId":13006,"briefTitle":13007,"status":67,"phases":13065,"primaryCompletion":13009,"completion":13009,"start":13010,"enrollment":13011,"conditions":13066,"interventions":13067},[],[13013,13014,13015],[6936,13017,13018,13019,13020],{"intervention":12971,"totalTrials":8,"cells":13069},{"EARLY_PHASE1":13070,"PHASE1":13072,"PHASE2":13074,"PHASE3":13076,"PHASE4":13082,"NA":13084},{"trials":13071,"activeCount":59},[],{"trials":13073,"activeCount":59},[],{"trials":13075,"activeCount":59},[],{"trials":13077,"activeCount":59},[13078],{"nctId":12708,"briefTitle":12709,"status":67,"phases":13079,"primaryCompletion":3677,"completion":3677,"start":1637,"enrollment":12711,"conditions":13080,"interventions":13081},[50],[12703],[12714,12715],{"trials":13083,"activeCount":59},[],{"trials":13085,"activeCount":59},[13086],{"nctId":12962,"briefTitle":12963,"status":67,"phases":13087,"primaryCompletion":12965,"completion":5193,"start":12966,"enrollment":11,"conditions":13088,"interventions":13089},[],[12370,12371],[12969,12970,12971,12972,12973],{"intervention":12330,"totalTrials":8,"cells":13091},{"EARLY_PHASE1":13092,"PHASE1":13094,"PHASE2":13096,"PHASE3":13098,"PHASE4":13104,"NA":13106},{"trials":13093,"activeCount":59},[],{"trials":13095,"activeCount":59},[],{"trials":13097,"activeCount":59},[],{"trials":13099,"activeCount":59},[13100],{"nctId":12321,"briefTitle":12322,"status":67,"phases":13101,"primaryCompletion":12324,"completion":12325,"start":12326,"enrollment":12327,"conditions":13102,"interventions":13103},[50],[5197],[5199,12330,12331,12332,5203],{"trials":13105,"activeCount":59},[],{"trials":13107,"activeCount":59},[13108],{"nctId":12393,"briefTitle":12394,"status":67,"phases":13109,"primaryCompletion":3551,"completion":12396,"start":12397,"enrollment":12398,"conditions":13110,"interventions":13111},[],[12370,12371],[5199,12331,12332,12330,5203],{"intervention":12331,"totalTrials":8,"cells":13113},{"EARLY_PHASE1":13114,"PHASE1":13116,"PHASE2":13118,"PHASE3":13120,"PHASE4":13126,"NA":13128},{"trials":13115,"activeCount":59},[],{"trials":13117,"activeCount":59},[],{"trials":13119,"activeCount":59},[],{"trials":13121,"activeCount":59},[13122],{"nctId":12321,"briefTitle":12322,"status":67,"phases":13123,"primaryCompletion":12324,"completion":12325,"start":12326,"enrollment":12327,"conditions":13124,"interventions":13125},[50],[5197],[5199,12330,12331,12332,5203],{"trials":13127,"activeCount":59},[],{"trials":13129,"activeCount":59},[13130],{"nctId":12393,"briefTitle":12394,"status":67,"phases":13131,"primaryCompletion":3551,"completion":12396,"start":12397,"enrollment":12398,"conditions":13132,"interventions":13133},[],[12370,12371],[5199,12331,12332,12330,5203],{"intervention":12332,"totalTrials":8,"cells":13135},{"EARLY_PHASE1":13136,"PHASE1":13138,"PHASE2":13140,"PHASE3":13142,"PHASE4":13148,"NA":13150},{"trials":13137,"activeCount":59},[],{"trials":13139,"activeCount":59},[],{"trials":13141,"activeCount":59},[],{"trials":13143,"activeCount":59},[13144],{"nctId":12321,"briefTitle":12322,"status":67,"phases":13145,"primaryCompletion":12324,"completion":12325,"start":12326,"enrollment":12327,"conditions":13146,"interventions":13147},[50],[5197],[5199,12330,12331,12332,5203],{"trials":13149,"activeCount":59},[],{"trials":13151,"activeCount":59},[13152],{"nctId":12393,"briefTitle":12394,"status":67,"phases":13153,"primaryCompletion":3551,"completion":12396,"start":12397,"enrollment":12398,"conditions":13154,"interventions":13155},[],[12370,12371],[5199,12331,12332,12330,5203],{"intervention":11000,"totalTrials":8,"cells":13157},{"EARLY_PHASE1":13158,"PHASE1":13160,"PHASE2":13166,"PHASE3":13168,"PHASE4":13170,"NA":13172},{"trials":13159,"activeCount":59},[],{"trials":13161,"activeCount":59},[13162],{"nctId":10995,"briefTitle":10996,"status":67,"phases":13163,"primaryCompletion":283,"completion":283,"start":1637,"enrollment":3946,"conditions":13164,"interventions":13165},[48],[14,745],[10988,11000,11001],{"trials":13167,"activeCount":59},[],{"trials":13169,"activeCount":59},[],{"trials":13171,"activeCount":59},[],{"trials":13173,"activeCount":59},[13174],{"nctId":13175,"briefTitle":13176,"status":67,"phases":13177,"primaryCompletion":274,"completion":274,"start":360,"enrollment":13178,"conditions":13179,"interventions":13180},"NCT00909389","Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647)",[],4748,[14],[11000],{"intervention":12308,"totalTrials":8,"cells":13182},{"EARLY_PHASE1":13183,"PHASE1":13185,"PHASE2":13187,"PHASE3":13193,"PHASE4":13195,"NA":13197},{"trials":13184,"activeCount":59},[],{"trials":13186,"activeCount":59},[],{"trials":13188,"activeCount":59},[13189],{"nctId":12297,"briefTitle":12298,"status":610,"phases":13190,"primaryCompletion":12300,"completion":12301,"start":12302,"enrollment":55,"conditions":13191,"interventions":13192},[49],[12304],[7321,12306,12307,12308],{"trials":13194,"activeCount":59},[],{"trials":13196,"activeCount":59},[],{"trials":13198,"activeCount":59},[13199],{"nctId":12386,"briefTitle":12387,"status":67,"phases":13200,"primaryCompletion":12389,"completion":4385,"start":12301,"enrollment":190,"conditions":13201,"interventions":13202},[],[12370,12371],[7321,12306,12307,12308],{"intervention":11670,"totalTrials":8,"cells":13204},{"EARLY_PHASE1":13205,"PHASE1":13207,"PHASE2":13209,"PHASE3":13211,"PHASE4":13213,"NA":13215},{"trials":13206,"activeCount":59},[],{"trials":13208,"activeCount":59},[],{"trials":13210,"activeCount":59},[],{"trials":13212,"activeCount":59},[],{"trials":13214,"activeCount":59},[],{"trials":13216,"activeCount":59},[13217,13221],{"nctId":11662,"briefTitle":11663,"status":67,"phases":13218,"primaryCompletion":11665,"completion":11665,"start":668,"enrollment":11666,"conditions":13219,"interventions":13220},[],[14,487,11668],[432,11670],{"nctId":11696,"briefTitle":11697,"status":67,"phases":13222,"primaryCompletion":11699,"completion":11699,"start":668,"enrollment":11700,"conditions":13223,"interventions":13224},[],[14,487,11668],[432,11670],{"intervention":12617,"totalTrials":8,"cells":13226},{"EARLY_PHASE1":13227,"PHASE1":13229,"PHASE2":13231,"PHASE3":13233,"PHASE4":13235,"NA":13237},{"trials":13228,"activeCount":59},[],{"trials":13230,"activeCount":59},[],{"trials":13232,"activeCount":59},[],{"trials":13234,"activeCount":59},[],{"trials":13236,"activeCount":59},[],{"trials":13238,"activeCount":59},[13239,13243],{"nctId":12607,"briefTitle":12608,"status":67,"phases":13240,"primaryCompletion":12610,"completion":12611,"start":12612,"enrollment":12613,"conditions":13241,"interventions":13242},[],[12370,12371],[12616,12617,12617,5201,5202,5203],{"nctId":12627,"briefTitle":12628,"status":67,"phases":13244,"primaryCompletion":12630,"completion":12631,"start":12632,"enrollment":12633,"conditions":13245,"interventions":13246},[],[5197],[12636,12617,12617,5201,5202,5203],{"intervention":7323,"totalTrials":8,"cells":13248},{"EARLY_PHASE1":13249,"PHASE1":13251,"PHASE2":13253,"PHASE3":13255,"PHASE4":13261,"NA":13263},{"trials":13250,"activeCount":59},[],{"trials":13252,"activeCount":59},[],{"trials":13254,"activeCount":59},[],{"trials":13256,"activeCount":59},[13257],{"nctId":7312,"briefTitle":7313,"status":67,"phases":13258,"primaryCompletion":7315,"completion":7316,"start":7317,"enrollment":7318,"conditions":13259,"interventions":13260},[50],[3128],[7321,7322,7301,7323,7324,7325],{"trials":13262,"activeCount":59},[],{"trials":13264,"activeCount":59},[13265],{"nctId":12402,"briefTitle":12403,"status":67,"phases":13266,"primaryCompletion":3677,"completion":3677,"start":941,"enrollment":1139,"conditions":13267,"interventions":13268},[],[5197],[7321,7322,12373,7323,7324,7325],{"intervention":12547,"totalTrials":190,"cells":13270},{"EARLY_PHASE1":13271,"PHASE1":13273,"PHASE2":13275,"PHASE3":13277,"PHASE4":13279,"NA":13281},{"trials":13272,"activeCount":59},[],{"trials":13274,"activeCount":59},[],{"trials":13276,"activeCount":59},[],{"trials":13278,"activeCount":59},[],{"trials":13280,"activeCount":59},[],{"trials":13282,"activeCount":59},[13283],{"nctId":12537,"briefTitle":12538,"status":67,"phases":13284,"primaryCompletion":12540,"completion":12541,"start":12542,"enrollment":12543,"conditions":13285,"interventions":13286},[],[12545],[4577,12547,12548],{"intervention":12548,"totalTrials":190,"cells":13288},{"EARLY_PHASE1":13289,"PHASE1":13291,"PHASE2":13293,"PHASE3":13295,"PHASE4":13297,"NA":13299},{"trials":13290,"activeCount":59},[],{"trials":13292,"activeCount":59},[],{"trials":13294,"activeCount":59},[],{"trials":13296,"activeCount":59},[],{"trials":13298,"activeCount":59},[],{"trials":13300,"activeCount":59},[13301],{"nctId":12537,"briefTitle":12538,"status":67,"phases":13302,"primaryCompletion":12540,"completion":12541,"start":12542,"enrollment":12543,"conditions":13303,"interventions":13304},[],[12545],[4577,12547,12548],{"intervention":13306,"totalTrials":190,"cells":13307},"Hypolipemics",{"EARLY_PHASE1":13308,"PHASE1":13310,"PHASE2":13312,"PHASE3":13314,"PHASE4":13316,"NA":13318},{"trials":13309,"activeCount":59},[],{"trials":13311,"activeCount":59},[],{"trials":13313,"activeCount":59},[],{"trials":13315,"activeCount":59},[],{"trials":13317,"activeCount":59},[],{"trials":13319,"activeCount":59},[13320],{"nctId":13321,"briefTitle":13322,"status":67,"phases":13323,"primaryCompletion":321,"completion":321,"start":3677,"enrollment":13324,"conditions":13325,"interventions":13326},"NCT01436253","Study of Lipid Control in Hyperlipidemic Participants (MK-0653-179)",[],2196,[1901],[13306],{"intervention":13328,"totalTrials":190,"cells":13329},"Orgalutran",{"EARLY_PHASE1":13330,"PHASE1":13332,"PHASE2":13334,"PHASE3":13336,"PHASE4":13338,"NA":13340},{"trials":13331,"activeCount":59},[],{"trials":13333,"activeCount":59},[],{"trials":13335,"activeCount":59},[],{"trials":13337,"activeCount":59},[],{"trials":13339,"activeCount":59},[],{"trials":13341,"activeCount":59},[13342],{"nctId":13343,"briefTitle":13344,"status":67,"phases":13345,"primaryCompletion":11683,"completion":11683,"start":11749,"enrollment":13346,"conditions":13347,"interventions":13348},"NCT01304511","Post-Marketing Surveillance of the Safety and Efficacy of Orgalutran (Ganirelix)®",[],711,[12889],[13328],{"intervention":13350,"totalTrials":190,"cells":13351},"FOSAMAX PLUS",{"EARLY_PHASE1":13352,"PHASE1":13354,"PHASE2":13356,"PHASE3":13358,"PHASE4":13360,"NA":13362},{"trials":13353,"activeCount":59},[],{"trials":13355,"activeCount":59},[],{"trials":13357,"activeCount":59},[],{"trials":13359,"activeCount":59},[],{"trials":13361,"activeCount":59},[],{"trials":13363,"activeCount":59},[13364],{"nctId":13365,"briefTitle":13366,"status":67,"phases":13367,"primaryCompletion":451,"completion":451,"start":9034,"enrollment":13368,"conditions":13369,"interventions":13370},"NCT01065779","FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267)",[],880,[1120],[13350,13371],"FOSAMAX PLUS D",{"intervention":13371,"totalTrials":190,"cells":13373},{"EARLY_PHASE1":13374,"PHASE1":13376,"PHASE2":13378,"PHASE3":13380,"PHASE4":13382,"NA":13384},{"trials":13375,"activeCount":59},[],{"trials":13377,"activeCount":59},[],{"trials":13379,"activeCount":59},[],{"trials":13381,"activeCount":59},[],{"trials":13383,"activeCount":59},[],{"trials":13385,"activeCount":59},[13386],{"nctId":13365,"briefTitle":13366,"status":67,"phases":13387,"primaryCompletion":451,"completion":451,"start":9034,"enrollment":13368,"conditions":13388,"interventions":13389},[],[1120],[13350,13371],{"intervention":12969,"totalTrials":190,"cells":13391},{"EARLY_PHASE1":13392,"PHASE1":13394,"PHASE2":13396,"PHASE3":13398,"PHASE4":13400,"NA":13402},{"trials":13393,"activeCount":59},[],{"trials":13395,"activeCount":59},[],{"trials":13397,"activeCount":59},[],{"trials":13399,"activeCount":59},[],{"trials":13401,"activeCount":59},[],{"trials":13403,"activeCount":59},[13404],{"nctId":12962,"briefTitle":12963,"status":67,"phases":13405,"primaryCompletion":12965,"completion":5193,"start":12966,"enrollment":11,"conditions":13406,"interventions":13407},[],[12370,12371],[12969,12970,12971,12972,12973],{"intervention":12970,"totalTrials":190,"cells":13409},{"EARLY_PHASE1":13410,"PHASE1":13412,"PHASE2":13414,"PHASE3":13416,"PHASE4":13418,"NA":13420},{"trials":13411,"activeCount":59},[],{"trials":13413,"activeCount":59},[],{"trials":13415,"activeCount":59},[],{"trials":13417,"activeCount":59},[],{"trials":13419,"activeCount":59},[],{"trials":13421,"activeCount":59},[13422],{"nctId":12962,"briefTitle":12963,"status":67,"phases":13423,"primaryCompletion":12965,"completion":5193,"start":12966,"enrollment":11,"conditions":13424,"interventions":13425},[],[12370,12371],[12969,12970,12971,12972,12973],{"intervention":12973,"totalTrials":190,"cells":13427},{"EARLY_PHASE1":13428,"PHASE1":13430,"PHASE2":13432,"PHASE3":13434,"PHASE4":13436,"NA":13438},{"trials":13429,"activeCount":59},[],{"trials":13431,"activeCount":59},[],{"trials":13433,"activeCount":59},[],{"trials":13435,"activeCount":59},[],{"trials":13437,"activeCount":59},[],{"trials":13439,"activeCount":59},[13440],{"nctId":12962,"briefTitle":12963,"status":67,"phases":13441,"primaryCompletion":12965,"completion":5193,"start":12966,"enrollment":11,"conditions":13442,"interventions":13443},[],[12370,12371],[12969,12970,12971,12972,12973],{"intervention":12039,"totalTrials":190,"cells":13445},{"EARLY_PHASE1":13446,"PHASE1":13448,"PHASE2":13450,"PHASE3":13452,"PHASE4":13454,"NA":13456},{"trials":13447,"activeCount":59},[],{"trials":13449,"activeCount":59},[],{"trials":13451,"activeCount":59},[],{"trials":13453,"activeCount":59},[],{"trials":13455,"activeCount":59},[],{"trials":13457,"activeCount":59},[13458],{"nctId":12032,"briefTitle":12033,"status":67,"phases":13459,"primaryCompletion":12035,"completion":12035,"start":4698,"enrollment":12036,"conditions":13460,"interventions":13461},[],[4844],[4846,12039,12040,12041,11862,12042,12043,12044,12045,12046,12047,12048,12049],{"intervention":12040,"totalTrials":190,"cells":13463},{"EARLY_PHASE1":13464,"PHASE1":13466,"PHASE2":13468,"PHASE3":13470,"PHASE4":13472,"NA":13474},{"trials":13465,"activeCount":59},[],{"trials":13467,"activeCount":59},[],{"trials":13469,"activeCount":59},[],{"trials":13471,"activeCount":59},[],{"trials":13473,"activeCount":59},[],{"trials":13475,"activeCount":59},[13476],{"nctId":12032,"briefTitle":12033,"status":67,"phases":13477,"primaryCompletion":12035,"completion":12035,"start":4698,"enrollment":12036,"conditions":13478,"interventions":13479},[],[4844],[4846,12039,12040,12041,11862,12042,12043,12044,12045,12046,12047,12048,12049],{"intervention":12041,"totalTrials":190,"cells":13481},{"EARLY_PHASE1":13482,"PHASE1":13484,"PHASE2":13486,"PHASE3":13488,"PHASE4":13490,"NA":13492},{"trials":13483,"activeCount":59},[],{"trials":13485,"activeCount":59},[],{"trials":13487,"activeCount":59},[],{"trials":13489,"activeCount":59},[],{"trials":13491,"activeCount":59},[],{"trials":13493,"activeCount":59},[13494],{"nctId":12032,"briefTitle":12033,"status":67,"phases":13495,"primaryCompletion":12035,"completion":12035,"start":4698,"enrollment":12036,"conditions":13496,"interventions":13497},[],[4844],[4846,12039,12040,12041,11862,12042,12043,12044,12045,12046,12047,12048,12049],{"intervention":12042,"totalTrials":190,"cells":13499},{"EARLY_PHASE1":13500,"PHASE1":13502,"PHASE2":13504,"PHASE3":13506,"PHASE4":13508,"NA":13510},{"trials":13501,"activeCount":59},[],{"trials":13503,"activeCount":59},[],{"trials":13505,"activeCount":59},[],{"trials":13507,"activeCount":59},[],{"trials":13509,"activeCount":59},[],{"trials":13511,"activeCount":59},[13512],{"nctId":12032,"briefTitle":12033,"status":67,"phases":13513,"primaryCompletion":12035,"completion":12035,"start":4698,"enrollment":12036,"conditions":13514,"interventions":13515},[],[4844],[4846,12039,12040,12041,11862,12042,12043,12044,12045,12046,12047,12048,12049],{"intervention":12043,"totalTrials":190,"cells":13517},{"EARLY_PHASE1":13518,"PHASE1":13520,"PHASE2":13522,"PHASE3":13524,"PHASE4":13526,"NA":13528},{"trials":13519,"activeCount":59},[],{"trials":13521,"activeCount":59},[],{"trials":13523,"activeCount":59},[],{"trials":13525,"activeCount":59},[],{"trials":13527,"activeCount":59},[],{"trials":13529,"activeCount":59},[13530],{"nctId":12032,"briefTitle":12033,"status":67,"phases":13531,"primaryCompletion":12035,"completion":12035,"start":4698,"enrollment":12036,"conditions":13532,"interventions":13533},[],[4844],[4846,12039,12040,12041,11862,12042,12043,12044,12045,12046,12047,12048,12049],{"intervention":12044,"totalTrials":190,"cells":13535},{"EARLY_PHASE1":13536,"PHASE1":13538,"PHASE2":13540,"PHASE3":13542,"PHASE4":13544,"NA":13546},{"trials":13537,"activeCount":59},[],{"trials":13539,"activeCount":59},[],{"trials":13541,"activeCount":59},[],{"trials":13543,"activeCount":59},[],{"trials":13545,"activeCount":59},[],{"trials":13547,"activeCount":59},[13548],{"nctId":12032,"briefTitle":12033,"status":67,"phases":13549,"primaryCompletion":12035,"completion":12035,"start":4698,"enrollment":12036,"conditions":13550,"interventions":13551},[],[4844],[4846,12039,12040,12041,11862,12042,12043,12044,12045,12046,12047,12048,12049],{"intervention":12045,"totalTrials":190,"cells":13553},{"EARLY_PHASE1":13554,"PHASE1":13556,"PHASE2":13558,"PHASE3":13560,"PHASE4":13562,"NA":13564},{"trials":13555,"activeCount":59},[],{"trials":13557,"activeCount":59},[],{"trials":13559,"activeCount":59},[],{"trials":13561,"activeCount":59},[],{"trials":13563,"activeCount":59},[],{"trials":13565,"activeCount":59},[13566],{"nctId":12032,"briefTitle":12033,"status":67,"phases":13567,"primaryCompletion":12035,"completion":12035,"start":4698,"enrollment":12036,"conditions":13568,"interventions":13569},[],[4844],[4846,12039,12040,12041,11862,12042,12043,12044,12045,12046,12047,12048,12049],{"intervention":12046,"totalTrials":190,"cells":13571},{"EARLY_PHASE1":13572,"PHASE1":13574,"PHASE2":13576,"PHASE3":13578,"PHASE4":13580,"NA":13582},{"trials":13573,"activeCount":59},[],{"trials":13575,"activeCount":59},[],{"trials":13577,"activeCount":59},[],{"trials":13579,"activeCount":59},[],{"trials":13581,"activeCount":59},[],{"trials":13583,"activeCount":59},[13584],{"nctId":12032,"briefTitle":12033,"status":67,"phases":13585,"primaryCompletion":12035,"completion":12035,"start":4698,"enrollment":12036,"conditions":13586,"interventions":13587},[],[4844],[4846,12039,12040,12041,11862,12042,12043,12044,12045,12046,12047,12048,12049],{"intervention":12047,"totalTrials":190,"cells":13589},{"EARLY_PHASE1":13590,"PHASE1":13592,"PHASE2":13594,"PHASE3":13596,"PHASE4":13598,"NA":13600},{"trials":13591,"activeCount":59},[],{"trials":13593,"activeCount":59},[],{"trials":13595,"activeCount":59},[],{"trials":13597,"activeCount":59},[],{"trials":13599,"activeCount":59},[],{"trials":13601,"activeCount":59},[13602],{"nctId":12032,"briefTitle":12033,"status":67,"phases":13603,"primaryCompletion":12035,"completion":12035,"start":4698,"enrollment":12036,"conditions":13604,"interventions":13605},[],[4844],[4846,12039,12040,12041,11862,12042,12043,12044,12045,12046,12047,12048,12049],{"intervention":12048,"totalTrials":190,"cells":13607},{"EARLY_PHASE1":13608,"PHASE1":13610,"PHASE2":13612,"PHASE3":13614,"PHASE4":13616,"NA":13618},{"trials":13609,"activeCount":59},[],{"trials":13611,"activeCount":59},[],{"trials":13613,"activeCount":59},[],{"trials":13615,"activeCount":59},[],{"trials":13617,"activeCount":59},[],{"trials":13619,"activeCount":59},[13620],{"nctId":12032,"briefTitle":12033,"status":67,"phases":13621,"primaryCompletion":12035,"completion":12035,"start":4698,"enrollment":12036,"conditions":13622,"interventions":13623},[],[4844],[4846,12039,12040,12041,11862,12042,12043,12044,12045,12046,12047,12048,12049],{"intervention":12049,"totalTrials":190,"cells":13625},{"EARLY_PHASE1":13626,"PHASE1":13628,"PHASE2":13630,"PHASE3":13632,"PHASE4":13634,"NA":13636},{"trials":13627,"activeCount":59},[],{"trials":13629,"activeCount":59},[],{"trials":13631,"activeCount":59},[],{"trials":13633,"activeCount":59},[],{"trials":13635,"activeCount":59},[],{"trials":13637,"activeCount":59},[13638],{"nctId":12032,"briefTitle":12033,"status":67,"phases":13639,"primaryCompletion":12035,"completion":12035,"start":4698,"enrollment":12036,"conditions":13640,"interventions":13641},[],[4844],[4846,12039,12040,12041,11862,12042,12043,12044,12045,12046,12047,12048,12049],{"intervention":12570,"totalTrials":190,"cells":13643},{"EARLY_PHASE1":13644,"PHASE1":13646,"PHASE2":13648,"PHASE3":13650,"PHASE4":13652,"NA":13654},{"trials":13645,"activeCount":59},[],{"trials":13647,"activeCount":59},[],{"trials":13649,"activeCount":59},[],{"trials":13651,"activeCount":59},[],{"trials":13653,"activeCount":59},[],{"trials":13655,"activeCount":59},[13656],{"nctId":12562,"briefTitle":12563,"status":67,"phases":13657,"primaryCompletion":12565,"completion":12565,"start":12566,"enrollment":12567,"conditions":13658,"interventions":13659},[],[12557],[3938,12570,12571],{"intervention":12571,"totalTrials":190,"cells":13661},{"EARLY_PHASE1":13662,"PHASE1":13664,"PHASE2":13666,"PHASE3":13668,"PHASE4":13670,"NA":13672},{"trials":13663,"activeCount":59},[],{"trials":13665,"activeCount":59},[],{"trials":13667,"activeCount":59},[],{"trials":13669,"activeCount":59},[],{"trials":13671,"activeCount":59},[],{"trials":13673,"activeCount":59},[13674],{"nctId":12562,"briefTitle":12563,"status":67,"phases":13675,"primaryCompletion":12565,"completion":12565,"start":12566,"enrollment":12567,"conditions":13676,"interventions":13677},[],[12557],[3938,12570,12571],{"intervention":12616,"totalTrials":190,"cells":13679},{"EARLY_PHASE1":13680,"PHASE1":13682,"PHASE2":13684,"PHASE3":13686,"PHASE4":13688,"NA":13690},{"trials":13681,"activeCount":59},[],{"trials":13683,"activeCount":59},[],{"trials":13685,"activeCount":59},[],{"trials":13687,"activeCount":59},[],{"trials":13689,"activeCount":59},[],{"trials":13691,"activeCount":59},[13692],{"nctId":12607,"briefTitle":12608,"status":67,"phases":13693,"primaryCompletion":12610,"completion":12611,"start":12612,"enrollment":12613,"conditions":13694,"interventions":13695},[],[12370,12371],[12616,12617,12617,5201,5202,5203],{"intervention":13017,"totalTrials":190,"cells":13697},{"EARLY_PHASE1":13698,"PHASE1":13700,"PHASE2":13702,"PHASE3":13704,"PHASE4":13706,"NA":13708},{"trials":13699,"activeCount":59},[],{"trials":13701,"activeCount":59},[],{"trials":13703,"activeCount":59},[],{"trials":13705,"activeCount":59},[],{"trials":13707,"activeCount":59},[],{"trials":13709,"activeCount":59},[13710],{"nctId":13006,"briefTitle":13007,"status":67,"phases":13711,"primaryCompletion":13009,"completion":13009,"start":13010,"enrollment":13011,"conditions":13712,"interventions":13713},[],[13013,13014,13015],[6936,13017,13018,13019,13020],{"intervention":13019,"totalTrials":190,"cells":13715},{"EARLY_PHASE1":13716,"PHASE1":13718,"PHASE2":13720,"PHASE3":13722,"PHASE4":13724,"NA":13726},{"trials":13717,"activeCount":59},[],{"trials":13719,"activeCount":59},[],{"trials":13721,"activeCount":59},[],{"trials":13723,"activeCount":59},[],{"trials":13725,"activeCount":59},[],{"trials":13727,"activeCount":59},[13728],{"nctId":13006,"briefTitle":13007,"status":67,"phases":13729,"primaryCompletion":13009,"completion":13009,"start":13010,"enrollment":13011,"conditions":13730,"interventions":13731},[],[13013,13014,13015],[6936,13017,13018,13019,13020],{"intervention":13020,"totalTrials":190,"cells":13733},{"EARLY_PHASE1":13734,"PHASE1":13736,"PHASE2":13738,"PHASE3":13740,"PHASE4":13742,"NA":13744},{"trials":13735,"activeCount":59},[],{"trials":13737,"activeCount":59},[],{"trials":13739,"activeCount":59},[],{"trials":13741,"activeCount":59},[],{"trials":13743,"activeCount":59},[],{"trials":13745,"activeCount":59},[13746],{"nctId":13006,"briefTitle":13007,"status":67,"phases":13747,"primaryCompletion":13009,"completion":13009,"start":13010,"enrollment":13011,"conditions":13748,"interventions":13749},[],[13013,13014,13015],[6936,13017,13018,13019,13020],{"intervention":12739,"totalTrials":190,"cells":13751},{"EARLY_PHASE1":13752,"PHASE1":13754,"PHASE2":13756,"PHASE3":13758,"PHASE4":13760,"NA":13762},{"trials":13753,"activeCount":59},[],{"trials":13755,"activeCount":59},[],{"trials":13757,"activeCount":59},[],{"trials":13759,"activeCount":59},[],{"trials":13761,"activeCount":59},[],{"trials":13763,"activeCount":59},[13764],{"nctId":12733,"briefTitle":12734,"status":67,"phases":13765,"primaryCompletion":570,"completion":570,"start":3872,"enrollment":12736,"conditions":13766,"interventions":13767},[],[12370,12371],[12714,12739],{"intervention":13769,"totalTrials":190,"cells":13770},"Standard of care for treatment of osteoarthritis",{"EARLY_PHASE1":13771,"PHASE1":13773,"PHASE2":13775,"PHASE3":13777,"PHASE4":13779,"NA":13781},{"trials":13772,"activeCount":59},[],{"trials":13774,"activeCount":59},[],{"trials":13776,"activeCount":59},[],{"trials":13778,"activeCount":59},[],{"trials":13780,"activeCount":59},[],{"trials":13782,"activeCount":59},[13783],{"nctId":13784,"briefTitle":13785,"status":67,"phases":13786,"primaryCompletion":9573,"completion":9573,"start":6890,"enrollment":13787,"conditions":13788,"interventions":13789},"NCT01294696","Survey of Osteoarthritis Real World Therapies (MK-0663-140)",[],1261,[2995],[13769],{"intervention":13791,"totalTrials":190,"cells":13792},"Ethinylestradiol + Desogestrel",{"EARLY_PHASE1":13793,"PHASE1":13795,"PHASE2":13797,"PHASE3":13799,"PHASE4":13801,"NA":13803},{"trials":13794,"activeCount":59},[],{"trials":13796,"activeCount":59},[],{"trials":13798,"activeCount":59},[],{"trials":13800,"activeCount":59},[],{"trials":13802,"activeCount":59},[],{"trials":13804,"activeCount":59},[13805],{"nctId":13806,"briefTitle":13807,"status":67,"phases":13808,"primaryCompletion":1528,"completion":1528,"start":1083,"enrollment":13809,"conditions":13810,"interventions":13811},"NCT01005056","Post-marketing, Observational Study to Confirm the Safety and Efficacy of MARVELON (Study P06083)",[],3838,[23],[13791],{"intervention":13813,"totalTrials":190,"cells":13814},"Ezetimibe 10 mg plus statin or ezetimibe 10 mg plus fenofibrate",{"EARLY_PHASE1":13815,"PHASE1":13817,"PHASE2":13819,"PHASE3":13821,"PHASE4":13823,"NA":13825},{"trials":13816,"activeCount":59},[],{"trials":13818,"activeCount":59},[],{"trials":13820,"activeCount":59},[],{"trials":13822,"activeCount":59},[],{"trials":13824,"activeCount":59},[],{"trials":13826,"activeCount":59},[13827],{"nctId":13828,"briefTitle":13829,"status":67,"phases":13830,"primaryCompletion":283,"completion":283,"start":1637,"enrollment":13831,"conditions":13832,"interventions":13833},"NCT00726856","Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition Lipid-lowering in the Treatment of Dyslipidemia (Study P05171)(COMPLETED)",[],1200,[1901],[13813],{"intervention":13835,"totalTrials":190,"cells":13836},"INEGY",{"EARLY_PHASE1":13837,"PHASE1":13839,"PHASE2":13841,"PHASE3":13843,"PHASE4":13845,"NA":13847},{"trials":13838,"activeCount":59},[],{"trials":13840,"activeCount":59},[],{"trials":13842,"activeCount":59},[],{"trials":13844,"activeCount":59},[],{"trials":13846,"activeCount":59},[],{"trials":13848,"activeCount":59},[13849],{"nctId":13850,"briefTitle":13851,"status":67,"phases":13852,"primaryCompletion":275,"completion":275,"start":580,"enrollment":13853,"conditions":13854,"interventions":13855},"NCT00724477","Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their LDL-C Objectives After Treatment With INEGY (Study P05103)(COMPLETED)",[],1663,[563],[13835],{"intervention":13857,"totalTrials":190,"cells":13858},"amlodipine\u002Flosartan",{"EARLY_PHASE1":13859,"PHASE1":13861,"PHASE2":13863,"PHASE3":13865,"PHASE4":13867,"NA":13869},{"trials":13860,"activeCount":59},[],{"trials":13862,"activeCount":59},[],{"trials":13864,"activeCount":59},[],{"trials":13866,"activeCount":59},[],{"trials":13868,"activeCount":59},[],{"trials":13870,"activeCount":59},[13871],{"nctId":13872,"briefTitle":13873,"status":67,"phases":13874,"primaryCompletion":13875,"completion":13875,"start":13876,"enrollment":13877,"conditions":13878,"interventions":13879},"NCT01041807","Cozaar XQ Re-examination Study (MK-0954-349)",[],"2015-03","2010-02",669,[26],[13857],{"intervention":12636,"totalTrials":190,"cells":13881},{"EARLY_PHASE1":13882,"PHASE1":13884,"PHASE2":13886,"PHASE3":13888,"PHASE4":13890,"NA":13892},{"trials":13883,"activeCount":59},[],{"trials":13885,"activeCount":59},[],{"trials":13887,"activeCount":59},[],{"trials":13889,"activeCount":59},[],{"trials":13891,"activeCount":59},[],{"trials":13893,"activeCount":59},[13894],{"nctId":12627,"briefTitle":12628,"status":67,"phases":13895,"primaryCompletion":12630,"completion":12631,"start":12632,"enrollment":12633,"conditions":13896,"interventions":13897},[],[5197],[12636,12617,12617,5201,5202,5203],{"intervention":13899,"totalTrials":190,"cells":13900},"Desloratadine Syrup",{"EARLY_PHASE1":13901,"PHASE1":13903,"PHASE2":13905,"PHASE3":13907,"PHASE4":13909,"NA":13911},{"trials":13902,"activeCount":59},[],{"trials":13904,"activeCount":59},[],{"trials":13906,"activeCount":59},[],{"trials":13908,"activeCount":59},[],{"trials":13910,"activeCount":59},[],{"trials":13912,"activeCount":59},[13913],{"nctId":13914,"briefTitle":13915,"status":67,"phases":13916,"primaryCompletion":2794,"completion":2794,"start":438,"enrollment":13917,"conditions":13918,"interventions":13919},"NCT00761527","Observation of Side Effects and Effectiveness of Desloratadine (Aerius) Syrup in Filipino Children (Study P05634)",[],2980,[33,1293,1227],[13899],{"intervention":13921,"totalTrials":190,"cells":13922},"etorocoxib",{"EARLY_PHASE1":13923,"PHASE1":13925,"PHASE2":13927,"PHASE3":13929,"PHASE4":13931,"NA":13933},{"trials":13924,"activeCount":59},[],{"trials":13926,"activeCount":59},[],{"trials":13928,"activeCount":59},[],{"trials":13930,"activeCount":59},[],{"trials":13932,"activeCount":59},[],{"trials":13934,"activeCount":59},[13935],{"nctId":13936,"briefTitle":13937,"status":67,"phases":13938,"primaryCompletion":13875,"completion":13875,"start":3933,"enrollment":1563,"conditions":13939,"interventions":13940},"NCT01572675","A Study of the Patterns of Use of Etoricoxib in France (MK-0663-148)",[],[2995],[13921,13941],"celecoxib",{"intervention":13941,"totalTrials":190,"cells":13943},{"EARLY_PHASE1":13944,"PHASE1":13946,"PHASE2":13948,"PHASE3":13950,"PHASE4":13952,"NA":13954},{"trials":13945,"activeCount":59},[],{"trials":13947,"activeCount":59},[],{"trials":13949,"activeCount":59},[],{"trials":13951,"activeCount":59},[],{"trials":13953,"activeCount":59},[],{"trials":13955,"activeCount":59},[13956],{"nctId":13936,"briefTitle":13937,"status":67,"phases":13957,"primaryCompletion":13875,"completion":13875,"start":3933,"enrollment":1563,"conditions":13958,"interventions":13959},[],[2995],[13921,13941]]